data_6lmr_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6lmr _Structure_validation_residue.Date_analyzed 2020-07-17 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 79.9 t . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.46 ' HB ' HG11 ' A' ' 113' ' ' VAL . 96.0 mt -61.92 -44.21 98.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.037 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.85 159.34 43.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.117 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.8 p -107.81 -140.7 0.38 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.661 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt -50.93 102.52 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.262 -0.575 . . . . 0.0 110.505 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.3 t -128.49 130.19 69.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.712 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 87.1 mt -82.12 137.01 35.08 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.93 -179.88 22.47 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 89.8 m -127.29 136.18 51.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.792 0.329 . . . . 0.0 110.501 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 89.3 t -76.67 112.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.74 -178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.552 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.45 -48.15 80.93 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.552 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -178.76 143.66 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.961 177.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -138.73 118.73 13.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -98.77 120.89 39.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.987 0.422 . . . . 0.0 110.81 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.402 HG21 ' N ' ' A' ' 139' ' ' ALA . 69.9 t -64.16 -45.1 97.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.42 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.1 ttp85 -61.31 -44.46 97.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.41 -38.36 89.4 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.843 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.36 3.96 66.67 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 121.091 -0.575 . . . . 0.0 112.401 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -149.28 161.38 42.16 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.441 0.621 . . . . 0.0 110.137 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.75 -177.08 35.46 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 120.554 -0.831 . . . . 0.0 111.577 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -131.56 147.7 52.55 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.107 0.48 . . . . 0.0 112.233 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.2 mt -120.24 127.68 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.856 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -93.32 109.83 21.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.849 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.9 mtm180 -65.6 131.78 47.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.093 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.9 p30 -86.91 -0.21 56.13 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.278 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -100.32 -32.7 10.72 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.892 0.377 . . . . 0.0 110.098 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.75 -10.59 11.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.674 -179.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 56.9 mtmt 55.37 32.34 18.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 109.996 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -121.25 132.37 54.77 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.319 0.58 . . . . 0.0 111.222 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -67.04 146.47 54.3 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.049 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.0 p -134.03 148.03 30.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.931 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -73.45 138.46 45.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.354 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -143.01 145.56 22.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 121.112 0.482 . . . . 0.0 110.947 178.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -137.4 158.85 43.52 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.868 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -61.28 -39.19 89.49 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.5 p -67.27 -15.7 63.85 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.469 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.02 0.75 54.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.5 mt -98.65 104.97 16.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.038 0.447 . . . . 0.0 111.136 -178.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -62.67 -44.93 95.01 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.331 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.431 ' HB2' HG23 ' A' ' 126' ' ' THR . 75.9 mmtt -125.62 145.39 50.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.002 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -150.98 176.59 10.98 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.399 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -63.71 121.14 68.92 Favored Pre-proline 0 CA--C 1.54 0.589 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.38 -25.61 63.69 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.999 1.799 . . . . 0.0 112.535 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.0 mmm180 -69.96 -17.95 63.33 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.436 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -95.78 123.85 39.54 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.689 0.28 . . . . 0.0 110.632 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -66.02 -39.8 90.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.858 0.361 . . . . 0.0 110.752 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -103.66 136.68 42.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.219 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.1 mtm180 -65.1 137.18 57.51 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.316 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 86.1 p -160.05 164.0 33.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 59.4 t -123.43 128.37 74.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.21 145.73 44.95 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.309 -179.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -83.0 137.91 33.96 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.49 2.78 88.29 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -93.57 132.13 38.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.88 0.371 . . . . 0.0 110.465 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -69.59 133.19 47.32 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.611 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.68 159.67 40.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.522 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -120.95 131.07 54.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -160.75 167.31 27.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.507 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -100.55 138.05 38.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.284 178.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.46 HG11 ' HB ' ' A' ' 55' ' ' ILE . 55.4 t -95.87 124.79 48.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 120.523 -0.471 . . . . 0.0 109.863 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.1 t . . . . . 0 C--N 1.326 -0.418 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.461 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 120.918 0.39 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.7 145.83 24.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.033 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.8 155.7 39.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.159 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 54.28 50.45 16.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.999 0.428 . . . . 0.0 110.131 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -78.4 119.62 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.112 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.431 HG23 ' HB2' ' A' ' 93' ' ' LYS . 82.3 p -138.41 164.58 28.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.769 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.05 171.27 51.1 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.18 137.64 37.66 Favored 'Trans proline' 0 C--N 1.3 -1.994 0 C-N-CA 122.0 1.8 . . . . 0.0 112.122 -179.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.11 19.43 79.79 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.5 0.58 89.35 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 76.0 t -61.2 137.77 94.35 Favored Pre-proline 0 CA--C 1.535 0.391 0 O-C-N 122.802 -0.234 . . . . 0.0 110.51 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.15 150.3 87.86 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 121.61 1.54 . . . . 0.0 111.351 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.05 132.39 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.588 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -61.66 -40.27 94.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.616 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.01 -176.98 53.91 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 72.6 m -103.19 153.78 20.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.82 0.343 . . . . 0.0 110.56 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -59.89 -37.75 80.28 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.401 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -62.31 -15.56 48.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.12 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.402 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.331 -0.233 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.569 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.2 t . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.427 ' HB ' HG11 ' A' ' 113' ' ' VAL . 95.3 mt -62.29 -44.17 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.061 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.77 164.95 33.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.098 0.475 . . . . 0.0 111.061 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 10.9 t -98.05 -151.4 0.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.647 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 22.5 pttp -47.03 116.0 1.24 Allowed 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.453 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 93.9 t -129.79 128.08 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.688 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.6 mt -75.18 136.5 41.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.12 0.486 . . . . 0.0 109.827 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -152.86 -175.87 24.8 Favored Glycine 0 CA--C 1.52 0.363 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.5 m -130.54 136.76 49.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.81 0.338 . . . . 0.0 110.503 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.427 HG22 HG11 ' A' ' 103' ' ' VAL . 77.5 t -73.21 115.57 14.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.752 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.445 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.2 ttpt -63.73 -47.05 82.63 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.445 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 56.5 p-90 -176.43 148.18 0.73 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 114.673 -1.148 . . . . 0.0 109.901 177.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -143.4 115.62 8.44 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -101.0 123.29 44.96 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.88 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.3 t -63.33 -46.08 96.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.461 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -60.29 -45.49 93.15 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.53 88.33 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.894 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.93 2.61 66.53 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.01 161.87 41.49 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 117.456 0.628 . . . . 0.0 110.064 179.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.74 -177.92 31.3 Favored Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.601 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -131.72 146.5 52.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.152 0.501 . . . . 0.0 112.157 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.492 HD11 HG23 ' A' ' 109' ' ' VAL . 86.8 mt -120.55 127.25 75.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.838 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -92.94 109.84 21.29 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.879 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.4 mtm180 -62.75 133.39 54.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.109 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 p30 -87.74 -0.15 56.52 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.279 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.9 -32.12 11.14 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 120.974 0.416 . . . . 0.0 110.113 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 75.2 p -113.44 -11.03 13.17 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.698 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt 57.69 31.44 20.41 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 0.0 110.007 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -120.1 142.66 48.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.356 0.598 . . . . 0.0 111.198 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.36 144.82 51.5 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.051 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 87.3 t -128.21 128.2 68.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.972 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -72.8 130.1 39.7 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.341 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.91 159.42 43.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.215 0.531 . . . . 0.0 110.917 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.34 155.93 47.36 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.936 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -60.86 -23.05 64.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.2 p -81.85 -11.94 58.71 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.421 178.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.22 0.9 56.98 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.156 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.4 mt -96.8 100.3 10.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.943 0.401 . . . . 0.0 111.168 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -63.36 -44.12 95.72 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.298 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -122.33 144.88 48.74 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.954 0.406 . . . . 0.0 111.031 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.5 p-10 -155.07 175.69 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.38 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -66.63 120.55 71.77 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -64.81 -25.66 60.42 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.039 1.826 . . . . 0.0 112.552 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -65.47 -20.73 66.48 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.395 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.82 128.68 40.19 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.696 0.284 . . . . 0.0 110.633 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -66.13 -38.67 88.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.754 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.9 mt -108.89 149.7 28.77 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.214 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -69.68 129.94 41.0 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.384 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.425 ' HG ' ' HB3' ' A' ' 139' ' ' ALA . 65.8 m -143.46 157.9 44.07 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.474 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.427 HG11 HG22 ' A' ' 63' ' ' VAL . 48.8 t -126.41 131.69 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.18 49.21 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.361 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.56 115.18 26.77 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 95.14 -8.42 69.85 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -72.21 156.11 39.5 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.921 0.391 . . . . 0.0 110.492 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.3 m -86.96 129.47 34.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.653 178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.492 HG23 HD11 ' A' ' 75' ' ' ILE . 33.0 m -129.86 158.98 42.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.431 -177.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -119.91 129.44 54.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -158.11 161.03 37.92 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.783 -0.767 . . . . 0.0 112.567 -177.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -85.36 152.98 22.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.336 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.427 HG11 ' HB ' ' A' ' 55' ' ' ILE . 59.8 t -107.18 124.67 63.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 120.473 -0.491 . . . . 0.0 109.985 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 83.3 t . . . . . 0 C--N 1.327 -0.409 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.776 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 . . . . . 0 C--O 1.228 -0.03 0 CA-C-O 120.89 0.376 . . . . 0.0 110.621 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.33 154.66 21.74 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.034 179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.36 151.9 32.38 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.297 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 53.35 46.52 26.18 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.161 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.9 t -70.75 124.09 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.126 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -140.91 165.55 27.21 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.76 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.78 172.93 52.61 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.6 136.77 31.54 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.061 1.841 . . . . 0.0 112.102 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.25 20.25 79.67 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 3.04 90.67 Favored Glycine 0 CA--C 1.532 1.146 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 75.4 t -63.68 138.09 97.28 Favored Pre-proline 0 CA--C 1.536 0.416 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.66 152.42 81.95 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.579 1.519 . . . . 0.0 111.337 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 94.7 t -68.92 131.31 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.563 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -61.11 -45.4 94.87 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.518 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.92 159.1 26.42 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -74.9 162.49 28.58 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.82 0.343 . . . . 0.0 110.581 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -72.35 -24.91 61.35 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.528 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -69.83 -15.4 63.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.052 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.425 ' HB3' ' HG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.268 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.433 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 98.1 t . . . . . 0 N--CA 1.452 -0.374 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.1 mt -62.43 -43.32 98.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.036 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.84 160.8 42.89 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.08 0.467 . . . . 0.0 111.107 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 p -99.22 -146.21 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.646 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -50.06 108.01 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.451 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.72 129.83 71.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.721 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.3 mt -74.83 137.1 41.64 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.22 -179.42 24.17 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.562 ' HG1' HD21 ' A' ' 78' ' ' ASN . 93.8 m -128.15 135.87 50.36 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.856 0.36 . . . . 0.0 110.451 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.7 t -75.99 109.25 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.708 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.538 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.04 -49.65 75.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.538 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 60.9 p-90 -174.72 146.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.979 178.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -142.58 121.16 12.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -103.47 123.12 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.592 -0.443 . . . . 0.0 110.868 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.0 t -63.79 -45.88 95.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.477 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.04 -44.77 96.89 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -62.2 -38.14 87.99 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 91.86 2.26 69.56 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.423 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -148.77 161.3 42.07 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-N 117.454 0.627 . . . . 0.0 110.057 179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.5 178.36 36.55 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.536 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -126.12 143.39 51.14 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.201 0.524 . . . . 0.0 112.118 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 86.2 mt -120.02 127.23 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.828 178.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -89.0 118.08 28.48 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.2 mtm180 -72.51 131.9 43.13 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.212 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.562 HD21 ' HG1' ' A' ' 62' ' ' THR . 98.7 m-20 -83.36 -6.35 59.44 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.267 179.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.87 -33.25 11.7 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.002 0.429 . . . . 0.0 110.086 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -114.06 -11.68 12.69 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.861 -0.608 . . . . 0.0 111.734 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.8 mttp 55.62 33.02 20.36 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.641 -0.424 . . . . 0.0 109.964 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -122.51 137.83 54.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.289 0.566 . . . . 0.0 111.248 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.24 142.27 57.8 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.046 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 80.0 t -127.79 131.16 70.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.876 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -69.08 138.8 54.62 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.328 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.21 149.31 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.163 0.506 . . . . 0.0 110.979 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -136.13 159.31 42.11 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.855 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -61.3 -39.49 90.65 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.2 p -66.6 -18.31 65.3 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.4 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.95 -0.79 55.48 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.095 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.0 mt -95.74 103.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.97 0.414 . . . . 0.0 111.091 -178.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -63.25 -43.96 96.53 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.292 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -127.27 147.38 50.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.088 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -154.44 177.55 11.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.336 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -65.6 120.8 71.32 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.09 -22.16 62.17 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.069 1.846 . . . . 0.0 112.515 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.3 mmm180 -67.46 -21.75 65.52 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -100.87 122.62 43.77 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-O 120.701 0.286 . . . . 0.0 110.534 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -61.0 -48.43 81.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.74 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 -60.95 132.48 54.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.999 0.428 . . . . 0.0 110.37 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 66.8 m -148.39 159.9 43.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.547 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 52.6 t -121.33 127.8 75.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -69.2 149.53 49.02 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.403 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -85.81 134.68 33.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.56 4.02 90.13 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -91.44 130.47 37.27 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.989 0.423 . . . . 0.0 110.465 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.4 m -69.15 132.71 46.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.651 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.4 m -129.99 157.53 42.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.471 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -117.59 126.74 53.07 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -156.57 163.6 39.17 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.718 -0.793 . . . . 0.0 112.537 -177.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -88.52 149.64 23.52 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.238 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.9 t -106.86 124.93 62.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.429 -0.508 . . . . 0.0 109.964 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 97.7 t . . . . . 0 C--N 1.327 -0.402 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.346 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 C--O 1.227 -0.117 0 CA-C-O 120.928 0.394 . . . . 0.0 110.645 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -119.89 143.22 48.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.076 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.1 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.261 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 53.5 45.84 27.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.977 0.418 . . . . 0.0 110.147 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.4 t -72.99 120.44 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.136 -179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.49 164.2 30.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.877 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.54 172.46 50.57 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.13 136.9 33.16 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 122.041 1.827 . . . . 0.0 112.162 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.33 19.68 79.78 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.03 1.26 89.73 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 71.0 t -62.0 138.06 95.66 Favored Pre-proline 0 CA--C 1.536 0.408 0 O-C-N 122.776 -0.25 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.91 150.3 88.31 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 121.687 1.591 . . . . 0.0 111.335 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.54 133.95 30.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.561 -179.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -60.48 -41.75 94.84 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.589 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.96 179.54 52.71 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.4 m -106.03 160.88 14.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.927 0.394 . . . . 0.0 110.552 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -61.09 -37.43 82.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.535 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -65.21 -14.6 61.03 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.118 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.233 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.479 -179.684 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t . . . . . 0 N--CA 1.45 -0.432 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.45 ' HB ' HG11 ' A' ' 113' ' ' VAL . 96.1 mt -63.17 -44.78 99.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.039 -178.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.1 163.57 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.086 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.416 HG23 ' N ' ' A' ' 58' ' ' LYS . 13.7 t -102.68 -148.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.658 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.416 ' N ' HG23 ' A' ' 57' ' ' THR . 59.1 mtmt -52.67 115.43 1.8 Allowed 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.388 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -132.3 130.38 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.755 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.1 mt -75.3 131.23 40.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.12 0.486 . . . . 0.0 109.771 178.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.66 -177.03 20.95 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.4 m -128.38 137.41 51.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.868 0.366 . . . . 0.0 110.478 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.1 t -73.82 115.06 14.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.552 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.4 tttt -62.88 -48.95 76.79 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 179.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.552 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 53.6 p-90 -179.31 140.28 0.15 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.99 178.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -135.96 117.26 14.59 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -102.67 123.67 46.8 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.876 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.4 t -62.84 -45.64 98.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.487 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -61.08 -45.37 95.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -62.74 -38.61 91.2 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.493 -0.483 . . . . 0.0 110.836 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.13 2.24 68.88 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.37 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -148.44 161.44 41.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.394 0.597 . . . . 0.0 110.14 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.22 -179.5 32.19 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.571 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -129.37 146.47 51.23 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 79.2 mt -125.7 128.22 72.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.79 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -94.26 126.22 39.38 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.857 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . 0.504 ' HE ' ' HG1' ' A' ' 80' ' ' THR . 95.1 mtm-85 -74.9 131.47 40.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.092 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -84.07 -0.16 50.69 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.305 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -100.79 -33.31 10.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.945 0.403 . . . . 0.0 110.112 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.504 ' HG1' ' HE ' ' A' ' 77' ' ' ARG . 81.4 p -116.5 -8.57 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.758 -0.656 . . . . 0.0 111.647 -179.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt 56.22 30.86 17.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.397 . . . . 0.0 110.006 -179.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -117.08 137.14 52.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.21 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.5 p-10 -74.25 158.05 34.76 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.113 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.23 148.51 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.947 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -77.94 136.68 38.04 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.375 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.2 p -143.96 148.1 19.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.159 0.504 . . . . 0.0 110.976 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -133.28 159.11 41.18 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.945 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.85 -25.56 65.13 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.8 p -74.86 -16.15 60.69 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.478 179.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.24 0.46 55.33 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.142 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -95.13 100.47 11.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.12 -178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -64.65 -41.8 95.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.298 179.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.15 138.4 52.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.123 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -148.54 153.73 38.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.342 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -58.62 120.83 48.67 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.31 -19.19 61.93 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 121.92 1.746 . . . . 0.0 112.557 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.0 mmm-85 -63.31 -23.96 67.64 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.408 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -101.39 133.24 46.31 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 120.686 0.279 . . . . 0.0 110.652 -179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -68.62 -38.46 80.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.745 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.9 mt -103.92 142.8 33.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.244 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.5 mtt85 -66.87 137.98 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.303 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.2 t -156.59 153.25 28.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.471 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 42.3 t -119.58 131.96 70.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -59.16 143.09 46.18 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.344 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -81.96 120.24 24.98 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.14 2.39 89.37 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.6 tp10 -81.71 137.42 35.39 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.903 0.383 . . . . 0.0 110.554 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 88.1 m -68.83 132.46 46.8 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.726 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.0 157.78 42.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.413 -178.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -117.43 126.99 53.58 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -154.82 162.09 41.24 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 119.807 -0.757 . . . . 0.0 112.565 -177.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -93.14 149.13 21.44 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.246 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.45 HG11 ' HB ' ' A' ' 55' ' ' ILE . 62.0 t -107.47 126.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.469 -0.492 . . . . 0.0 109.956 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 C--N 1.327 -0.407 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.945 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.226 -0.139 0 CA-C-O 120.827 0.346 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.15 152.67 29.1 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.973 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.97 157.12 43.18 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.193 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 53.4 44.88 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.436 . . . . 0.0 110.215 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.1 t -72.05 124.07 27.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.073 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.4 p -136.67 168.48 19.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.789 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.65 171.07 54.45 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -66.61 138.97 51.5 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 C-N-CA 121.929 1.753 . . . . 0.0 112.175 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.27 16.8 79.66 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.89 2.45 90.55 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 1.3 p -68.4 147.95 98.18 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-O 119.704 -0.189 . . . . 0.0 110.55 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.48 150.73 73.79 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.582 1.521 . . . . 0.0 111.309 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t -66.36 131.34 32.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.622 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -61.74 -39.97 93.45 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.497 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.47 -173.64 54.85 Favored Glycine 0 CA--C 1.524 0.623 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.66 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 71.1 m -112.5 157.96 20.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.822 0.344 . . . . 0.0 110.59 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -60.55 -37.69 82.08 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.384 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -60.87 -19.5 60.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.111 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.449 -179.849 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.45 -42.94 97.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.108 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.11 157.32 43.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.9 p -102.47 -149.99 0.4 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.609 179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -48.25 104.66 0.06 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.497 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.7 t -125.04 129.37 73.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.696 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.0 mt -75.37 138.59 41.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.132 0.492 . . . . 0.0 109.762 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.39 -178.15 25.0 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.564 ' HG1' HD22 ' A' ' 78' ' ' ASN . 93.9 m -129.05 137.76 51.48 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.878 0.37 . . . . 0.0 110.491 -179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.11 109.86 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.754 -179.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.529 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 61.9 tttm -61.16 -50.93 71.18 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.529 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.3 p-90 -176.65 139.55 0.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.016 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -137.92 116.57 12.17 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -99.34 121.72 41.49 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.964 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.26 -45.82 97.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.426 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -62.71 -42.1 99.48 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -62.2 -39.06 91.49 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.835 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.4 2.23 65.87 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.354 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -149.56 162.19 40.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 117.464 0.632 . . . . 0.0 109.984 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.33 -179.28 35.95 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.499 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -130.33 144.9 51.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.213 0.53 . . . . 0.0 112.127 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.4 mt -120.11 126.33 75.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.839 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -93.16 119.76 32.71 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -72.85 133.79 44.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.161 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.564 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.4 m-20 -83.23 -8.58 59.45 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.29 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -93.04 -33.18 14.2 Favored 'General case' 0 C--O 1.231 0.121 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.092 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 79.1 p -115.31 -9.13 12.23 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.75 -178.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.4 mttt 53.37 32.7 14.25 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.972 -179.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -120.39 134.74 55.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.332 0.587 . . . . 0.0 111.219 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -64.36 144.2 57.34 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.03 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 95.0 t -130.05 133.1 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.878 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -65.51 138.29 57.97 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.396 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.18 147.76 18.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.251 0.548 . . . . 0.0 110.855 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -137.73 160.2 39.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.926 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -61.73 -39.03 90.13 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -178.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.7 p -67.99 -16.07 63.88 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.453 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.84 2.41 51.48 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.0 mt -98.6 107.73 20.91 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.885 0.374 . . . . 0.0 111.245 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -65.63 -42.65 91.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.349 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.038 -178.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -144.11 168.78 19.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.388 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -55.12 121.14 34.54 Favored Pre-proline 0 CA--C 1.539 0.553 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.96 -41.69 72.5 Favored 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 121.933 1.756 . . . . 0.0 112.597 -178.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -63.86 -14.63 54.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.527 ' HD2' ' HB2' ' A' ' 139' ' ' ALA . 14.8 tppt? -104.39 118.03 35.61 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 120.688 0.28 . . . . 0.0 110.616 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -77.26 -22.83 51.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.915 0.388 . . . . 0.0 110.785 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.4 tp -100.72 125.61 47.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.173 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.64 133.8 56.46 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.584 -0.447 . . . . 0.0 110.31 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.3 t -160.79 151.92 18.93 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.495 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 56.6 t -118.59 127.13 75.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.68 145.85 46.02 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.334 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -83.56 135.42 34.64 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.3 4.06 89.86 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -92.43 131.87 37.24 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 120.958 0.409 . . . . 0.0 110.461 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.6 m -69.47 133.66 47.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.64 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.8 m -131.8 158.47 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.462 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.67 130.52 55.09 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -156.57 164.12 38.57 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 119.778 -0.769 . . . . 0.0 112.541 -177.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -97.3 140.28 32.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.368 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.3 t -100.86 125.65 54.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.066 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.326 -0.44 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.673 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 . . . . . 0 C--O 1.226 -0.147 0 CA-C-O 121.008 0.432 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -105.19 145.16 30.99 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.14 162.93 39.49 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.195 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 54.06 45.23 27.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.985 0.421 . . . . 0.0 110.173 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.7 t -74.25 123.91 30.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.048 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.9 p -138.32 167.93 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.806 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.96 174.38 53.05 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.86 137.6 38.58 Favored 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.065 1.844 . . . . 0.0 112.121 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.02 20.19 78.81 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.92 2.11 90.65 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 94.5 t -63.37 137.21 97.01 Favored Pre-proline 0 CA--C 1.537 0.449 0 O-C-N 122.78 -0.247 . . . . 0.0 110.56 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.94 145.42 91.32 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.561 1.507 . . . . 0.0 111.314 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.58 132.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -60.84 -43.1 98.73 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.456 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.99 -179.93 52.83 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 37.9 t -106.19 141.07 38.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.849 0.357 . . . . 0.0 110.589 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.5 ptmt -59.26 -21.88 60.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.44 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 70.1 m-85 -66.07 -22.62 66.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.139 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.527 ' HB2' ' HD2' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.331 -0.199 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.47 -179.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.4 t . . . . . 0 N--CA 1.45 -0.473 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.442 ' HB ' HG11 ' A' ' 113' ' ' VAL . 97.4 mt -63.14 -44.28 99.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.033 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.01 164.08 35.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.434 HG23 ' N ' ' A' ' 58' ' ' LYS . 15.0 t -101.99 -149.05 0.38 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.648 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 57' ' ' THR . 58.4 mtmt -52.3 117.01 2.52 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.431 -178.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.8 t -133.21 131.37 58.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.687 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.3 mt -76.01 136.07 39.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.084 0.469 . . . . 0.0 109.776 178.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.55 -179.36 24.42 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.602 ' HG1' HD22 ' A' ' 78' ' ' ASN . 94.5 m -127.06 140.67 52.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.937 0.398 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.0 t -82.21 111.24 18.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.739 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.467 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 64.9 tttp -62.77 -49.93 73.03 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 63.2 p-90 -169.81 154.41 5.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.645 -1.161 . . . . 0.0 109.927 177.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -142.5 118.68 10.75 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 -98.23 112.1 24.2 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.993 0.425 . . . . 0.0 110.892 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.423 HG21 ' N ' ' A' ' 139' ' ' ALA . 73.9 t -61.75 -45.05 99.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.381 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.2 ttt85 -61.09 -44.5 97.26 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.08 -38.71 92.27 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.444 -0.503 . . . . 0.0 110.821 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.15 4.49 59.87 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.387 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.466 ' HB3' ' HD1' ' A' ' 87' ' ' HIS . 47.7 p90 -152.37 162.0 41.8 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 117.43 0.615 . . . . 0.0 110.102 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.04 -176.05 27.73 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.56 -179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -126.3 145.14 50.55 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.155 0.502 . . . . 0.0 112.138 -179.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 83.3 mt -120.12 125.45 74.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.896 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -90.66 109.59 20.76 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.479 -0.488 . . . . 0.0 110.813 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -62.87 135.32 57.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.13 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.602 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.9 m-20 -86.37 -2.3 58.3 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.316 179.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -100.14 -34.05 10.2 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.973 0.416 . . . . 0.0 110.144 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.7 p -115.44 -9.25 12.13 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.679 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mmtm 55.43 29.96 14.15 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -115.18 133.62 55.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.375 0.607 . . . . 0.0 111.299 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.9 142.52 58.26 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.985 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.7 t -124.83 133.27 69.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -70.77 138.18 50.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.313 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.73 148.69 15.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.183 0.516 . . . . 0.0 110.954 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.466 ' HD1' ' HB3' ' A' ' 72' ' ' TYR . 94.8 m-70 -132.79 155.77 48.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.886 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -60.15 -23.67 64.1 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 80.5 p -83.33 -10.41 58.5 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.591 -0.443 . . . . 0.0 110.401 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.91 3.61 55.39 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.116 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.1 mt -99.13 106.1 18.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-O 120.994 0.426 . . . . 0.0 111.228 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -63.31 -44.78 94.02 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.327 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -122.3 141.21 51.76 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.125 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -150.23 176.34 10.95 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.349 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -64.95 120.42 66.56 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.69 -23.35 63.4 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.01 1.807 . . . . 0.0 112.578 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.9 mmm-85 -68.5 -19.62 64.54 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.412 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -98.93 129.33 45.25 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 120.678 0.275 . . . . 0.0 110.661 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -67.52 -37.86 83.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.966 0.412 . . . . 0.0 110.731 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.2 mt -105.6 141.34 37.22 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.258 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.28 138.76 57.87 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.319 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -156.96 162.75 39.61 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.532 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 45.6 t -125.88 130.97 72.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.38 143.8 37.94 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.294 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . 0.4 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 41.0 p-10 -75.92 132.75 40.46 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.65 4.83 89.45 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -86.93 129.48 34.86 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.007 0.432 . . . . 0.0 110.488 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 99.6 m -71.1 131.2 43.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.67 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.3 158.49 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.455 -177.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.91 129.0 54.95 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 178.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.412 ' HB3' HG22 ' A' ' 125' ' ' VAL . 45.9 p90 -155.68 162.82 40.5 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.582 -177.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -92.4 149.46 21.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.375 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.442 HG11 ' HB ' ' A' ' 55' ' ' ILE . 60.5 t -108.19 126.35 64.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.937 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.624 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 C--O 1.226 -0.154 0 CA-C-O 120.973 0.416 . . . . 0.0 110.672 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -109.96 147.75 32.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.989 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.43 161.08 41.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.145 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 54.51 44.37 28.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.984 0.421 . . . . 0.0 110.125 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 111' ' ' PHE . 91.8 t -72.81 122.77 26.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.092 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 62.7 p -136.91 163.79 29.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.783 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.43 168.57 54.8 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.099 -1.601 . . . . 0.0 109.099 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.52 138.09 81.69 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 121.903 1.736 . . . . 0.0 112.094 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.21 19.04 75.45 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.77 4.42 90.34 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.4 t -62.63 136.94 96.35 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 122.699 -0.295 . . . . 0.0 110.484 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -58.44 146.96 88.24 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.552 1.502 . . . . 0.0 111.335 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.4 132.37 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.645 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 11.8 tp-100 -61.34 -41.41 96.99 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.549 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.23 -176.59 50.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.2 m -105.49 157.85 17.08 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.75 0.31 . . . . 0.0 110.64 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -60.84 -37.39 81.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.51 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -63.88 -17.3 63.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.055 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--O 1.233 0.202 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.435 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.6 t . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.25 -44.42 99.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.071 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.52 157.25 43.1 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.4 p -102.41 -147.42 0.37 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.668 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -51.93 107.44 0.2 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.441 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 76.1 t -125.11 131.24 72.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.745 -179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.434 HD22 ' OE2' ' A' ' 110' ' ' GLU . 68.8 mt -69.09 134.98 50.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.069 0.462 . . . . 0.0 109.838 178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.77 178.23 30.82 Favored Glycine 0 CA--C 1.519 0.341 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.681 ' HG1' HD22 ' A' ' 78' ' ' ASN . 97.6 m -130.77 137.77 49.62 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.866 0.365 . . . . 0.0 110.466 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 88.1 t -70.45 112.39 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.813 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.527 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.45 -48.59 80.44 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.527 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.8 p-90 -177.32 140.06 0.27 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 114.564 -1.198 . . . . 0.0 109.95 177.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -138.14 115.28 10.96 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -100.21 124.44 45.64 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.934 -178.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -63.3 -46.08 96.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.452 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -61.19 -44.44 97.29 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.91 -39.21 93.84 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.872 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.42 4.78 65.83 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.365 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -151.75 162.59 40.77 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 117.442 0.621 . . . . 0.0 110.078 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.65 -178.4 34.6 Favored Glycine 0 CA--C 1.525 0.689 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.557 -179.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -129.64 148.67 51.56 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.124 0.488 . . . . 0.0 112.095 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 82.4 mt -118.67 126.79 75.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.428 -0.806 . . . . 0.0 109.863 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -91.54 110.24 21.55 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.876 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -65.72 130.36 43.0 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.085 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.681 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.7 m-20 -87.54 -3.58 58.99 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.331 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -97.74 -31.5 12.22 Favored 'General case' 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.393 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.0 p -113.28 -9.89 13.38 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.686 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp 57.77 32.14 21.48 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.024 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -126.23 148.88 49.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.34 0.59 . . . . 0.0 111.168 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -82.3 158.87 23.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -142.93 150.6 17.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -78.15 135.79 37.72 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.352 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.5 p -146.52 147.99 17.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.104 0.478 . . . . 0.0 110.864 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -136.21 159.1 42.76 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.9 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.6 pt20 -59.19 -25.02 63.6 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -74.44 -16.05 60.88 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.468 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.459 ' HB1' ' HA ' ' A' ' 123' ' ' ALA . . . -89.32 2.96 53.63 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.155 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.5 mt -95.87 103.12 14.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.905 0.383 . . . . 0.0 111.153 -178.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -65.19 -43.67 90.9 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.314 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -119.17 144.23 46.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.134 -178.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.0 t30 -144.1 171.18 14.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.439 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -61.07 122.87 72.6 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.64 -23.12 57.04 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 121.906 1.737 . . . . 0.0 112.522 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.4 mmm-85 -73.38 -14.06 61.21 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.399 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -114.2 142.22 46.54 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 120.746 0.308 . . . . 0.0 110.658 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -98.35 4.91 48.61 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.694 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.7 mt -119.42 142.4 48.25 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.156 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -81.15 125.98 30.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.416 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 87.9 p -156.38 162.44 40.05 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.507 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.7 t -131.53 134.63 60.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.38 147.98 50.36 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.338 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -84.91 120.82 26.91 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.25 -5.61 82.8 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.04 135.21 41.27 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-O 121.069 0.462 . . . . 0.0 110.44 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.2 m -70.88 131.46 43.79 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.636 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 19.9 m -135.93 159.38 39.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.39 -178.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.434 ' OE2' HD22 ' A' ' 60' ' ' LEU . 98.2 mt-10 -116.11 138.54 51.16 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 178.028 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.6 p90 -159.44 164.04 34.87 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.523 -177.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -98.59 138.49 35.71 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.218 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.0 t -107.02 127.21 62.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 120.463 -0.495 . . . . 0.0 110.033 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.326 -0.422 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.15 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 . . . . . 0 C--O 1.227 -0.128 0 CA-C-O 120.952 0.406 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.16 143.41 43.25 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.966 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.459 ' HA ' ' HB1' ' A' ' 90' ' ' ALA . . . -153.22 161.07 42.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.231 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 56.84 47.17 18.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 110.125 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.7 t -77.61 121.08 29.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.114 -179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 59.2 p -137.88 169.04 18.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.797 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.26 167.73 54.84 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.63 138.12 77.84 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.99 1.793 . . . . 0.0 112.146 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.5 20.58 78.48 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 178.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.47 89.84 Favored Glycine 0 CA--C 1.532 1.108 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.02 138.21 94.15 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-O 119.667 -0.206 . . . . 0.0 110.556 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -61.56 148.37 93.15 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 121.662 1.575 . . . . 0.0 111.233 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.5 t -63.81 130.77 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.653 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -62.31 -40.11 95.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.615 -179.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.77 157.42 33.15 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 81.5 p -76.19 160.2 29.93 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 120.921 0.391 . . . . 0.0 110.539 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -70.32 -23.48 62.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.513 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -80.09 -2.96 46.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.144 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.242 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.465 -179.967 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 97.0 t . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.4 mt -63.77 -45.9 95.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.002 -179.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -158.21 162.2 37.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.478 HG22 ' N ' ' A' ' 58' ' ' LYS . 11.7 t -96.38 -142.86 0.28 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.57 179.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.478 ' N ' HG22 ' A' ' 57' ' ' THR . 76.0 mmtt -50.34 103.28 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.291 -0.563 . . . . 0.0 110.416 -179.38 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.0 t -119.28 128.59 75.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 80.0 mt -64.33 130.75 45.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.082 0.468 . . . . 0.0 109.776 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.16 174.45 23.75 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -129.22 134.31 47.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.941 0.4 . . . . 0.0 110.488 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.6 t -75.43 108.48 7.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.723 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 22.0 ttmm -63.2 -48.22 79.23 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 62.4 p-90 -176.14 143.82 0.55 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.616 -1.174 . . . . 0.0 109.925 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -138.53 115.65 10.98 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.403 HD21 ' ND2' ' A' ' 70' ' ' ASN . 99.5 m-20 -100.0 119.21 37.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.978 0.418 . . . . 0.0 110.922 -179.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.58 -46.7 94.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.509 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -62.46 -41.49 98.8 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.406 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 96.2 m-20 -62.82 -38.61 91.39 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.494 -0.482 . . . . 0.0 110.809 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.37 4.54 64.2 Favored Glycine 0 CA--C 1.531 1.042 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.382 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.406 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 40.9 p90 -148.88 160.18 43.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 117.528 0.664 . . . . 0.0 110.107 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.66 173.22 37.16 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.515 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -128.12 146.88 50.56 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.096 0.474 . . . . 0.0 112.232 -179.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.3 mt -120.61 125.86 74.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.855 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -91.4 111.15 22.53 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.509 -0.477 . . . . 0.0 110.899 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.7 mtm180 -61.5 133.35 55.62 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.113 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -86.29 -12.16 50.26 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.311 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -89.49 -29.87 18.67 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-O 121.022 0.439 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.6 p -116.46 -11.42 11.15 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.694 -178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 58.0 mtpt 57.04 32.11 21.1 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -119.77 134.04 55.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.22 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -64.72 143.19 58.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.058 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.0 t -127.78 130.98 70.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -70.99 130.04 40.55 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.425 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.04 149.55 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.163 0.506 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -131.14 164.99 24.28 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.889 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.64 -39.75 94.82 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -69.69 -17.2 63.46 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.443 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.36 -2.63 53.49 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.169 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.7 mt -96.77 106.48 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.949 0.404 . . . . 0.0 111.112 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.75 -43.06 97.56 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.296 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -125.11 142.42 51.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.129 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -148.88 176.18 10.63 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.437 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.5 t-20 -66.23 117.33 42.21 Favored Pre-proline 0 CA--C 1.54 0.569 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.91 -31.34 95.3 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.979 1.786 . . . . 0.0 112.588 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.8 mmm-85 -64.23 -19.96 65.71 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.294 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -93.14 129.0 39.28 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 120.671 0.272 . . . . 0.0 110.613 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -67.68 -37.96 83.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.873 0.368 . . . . 0.0 110.785 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.1 mt -110.1 144.63 38.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.257 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -65.82 137.67 57.38 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.329 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.409 ' HG ' ' HB1' ' A' ' 139' ' ' ALA . 90.2 p -156.86 163.07 39.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.455 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 46.9 t -128.82 130.39 68.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.56 149.0 49.22 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.384 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -86.56 134.47 33.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.62 1.68 90.55 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -91.75 130.27 37.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-O 120.888 0.375 . . . . 0.0 110.526 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -70.16 134.36 48.05 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.69 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.93 161.2 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.433 -178.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -120.54 136.35 54.81 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 178.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.432 ' HB3' HG22 ' A' ' 125' ' ' VAL . 29.2 p90 -157.58 161.06 38.71 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.563 -178.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -83.35 122.07 27.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.21 179.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.3 t -88.83 122.26 39.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.491 -0.484 . . . . 0.0 109.998 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 59.4 t . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.546 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 . . . . . 0 C--O 1.227 -0.08 0 CA-C-O 120.822 0.344 . . . . 0.0 110.676 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -100.55 141.04 33.96 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.956 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.92 157.72 43.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.185 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 54.59 43.76 29.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.96 0.409 . . . . 0.0 110.076 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.432 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.7 t -70.18 125.43 28.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.09 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.0 p -138.92 164.76 28.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.775 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.91 164.35 54.24 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.02 136.73 71.3 Favored 'Trans proline' 0 C--N 1.301 -1.942 0 C-N-CA 122.001 1.801 . . . . 0.0 112.06 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 76.89 13.64 83.42 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.96 -0.56 89.1 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.488 HG23 ' HD2' ' A' ' 132' ' ' PRO . 9.4 p -64.82 141.38 98.32 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-O 119.679 -0.2 . . . . 0.0 110.586 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.488 ' HD2' HG23 ' A' ' 131' ' ' VAL . 18.4 Cg_endo -58.03 147.69 81.15 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.66 1.573 . . . . 0.0 111.349 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -69.9 134.46 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.585 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -60.94 -43.67 98.35 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.515 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.16 158.32 30.92 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -72.92 157.01 38.26 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.84 0.352 . . . . 0.0 110.619 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -69.3 -19.65 63.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.455 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -79.87 -7.7 58.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.128 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.409 ' HB1' ' HG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.259 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.504 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.421 ' CG1' ' O ' ' A' ' 54' ' ' VAL . 7.2 p . . . . . 0 N--CA 1.45 -0.426 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.431 ' HB ' HG11 ' A' ' 113' ' ' VAL . 97.9 mt -62.06 -44.61 99.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.098 -179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -143.68 160.37 40.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 14.4 p -98.02 -150.97 0.36 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -51.32 116.87 2.25 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.466 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.7 t -132.59 131.2 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.681 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.8 mt -75.33 134.71 40.96 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.043 0.449 . . . . 0.0 109.849 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.29 -179.48 23.38 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.4 m -129.11 135.86 49.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 110.483 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.4 t -73.54 113.1 11.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.731 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.467 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.6 ttpt -62.34 -46.77 87.21 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.9 p-90 -176.14 146.19 0.66 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.001 177.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -140.5 115.51 9.75 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -103.02 121.44 42.57 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.936 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.3 t -63.07 -44.56 99.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.452 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.42 ' HG3' ' N ' ' A' ' 70' ' ' ASN . 17.7 ptm180 -63.08 -35.11 79.18 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.42 ' N ' ' HG3' ' A' ' 69' ' ' ARG . 97.2 m-20 -69.36 -35.15 75.58 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.822 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 90.14 0.87 76.64 Favored Glycine 0 CA--C 1.531 1.057 0 C-N-CA 121.06 -0.591 . . . . 0.0 112.361 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -150.26 161.51 42.3 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 117.544 0.672 . . . . 0.0 110.086 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -154.98 179.43 31.02 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.603 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.16 145.64 51.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.144 0.497 . . . . 0.0 112.131 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 84.9 mt -119.74 123.58 71.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.849 178.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.64 109.16 20.57 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.817 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -63.14 130.93 46.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.115 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.3 p30 -85.43 -0.08 53.79 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.406 -0.518 . . . . 0.0 111.37 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -99.07 -34.48 10.38 Favored 'General case' 0 C--O 1.231 0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.127 178.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 77.9 p -114.4 -10.95 12.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.687 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 58.09 29.99 18.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.95 0.405 . . . . 0.0 110.025 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -116.2 132.96 56.52 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 121.362 0.601 . . . . 0.0 111.247 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -62.67 142.25 58.17 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.089 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 76.6 t -128.1 131.01 69.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -65.92 141.12 58.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.394 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.8 p -146.92 148.45 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.182 0.515 . . . . 0.0 110.935 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -137.63 159.04 43.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.784 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -60.33 -41.93 94.58 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.5 t -64.98 -16.63 63.61 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.478 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.16 -2.97 57.79 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.123 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -93.45 101.45 12.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.987 0.422 . . . . 0.0 111.152 -178.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -63.55 -43.31 97.44 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.305 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -120.63 140.65 51.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.151 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -149.73 156.36 41.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -60.48 121.45 60.46 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.49 -22.18 65.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 121.995 1.797 . . . . 0.0 112.478 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.52 -21.55 66.17 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.35 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -86.34 130.83 34.37 Favored 'General case' 0 N--CA 1.456 -0.127 0 CA-C-O 120.748 0.308 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 84.8 t80 -61.23 -48.5 81.2 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -116.43 139.98 49.85 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.206 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -55.71 138.01 48.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.075 0.464 . . . . 0.0 110.291 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.2 p -158.84 165.08 35.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.511 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 46.3 t -124.04 129.61 74.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.0 147.76 51.17 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -80.66 121.04 25.36 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.14 -0.86 88.93 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.16 135.11 41.11 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 120.941 0.401 . . . . 0.0 110.463 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 91.1 m -70.07 131.57 44.52 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.637 179.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.77 159.18 43.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.37 -0.532 . . . . 0.0 111.511 -178.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -120.74 129.87 53.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.42 ' HB3' HG23 ' A' ' 125' ' ' VAL . 44.7 p90 -157.64 163.86 37.81 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 112.549 -177.589 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -93.68 144.85 25.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.205 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.431 HG11 ' HB ' ' A' ' 55' ' ' ILE . 58.9 t -97.07 125.65 50.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.592 -0.443 . . . . 0.0 109.942 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 99.3 t . . . . . 0 C--N 1.326 -0.445 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 -179.53 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 120.985 0.421 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -105.45 146.73 29.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.973 -179.647 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.1 157.86 43.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.255 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 54.42 45.32 27.34 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.118 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.42 HG23 ' HB3' ' A' ' 111' ' ' PHE . 97.0 t -71.51 122.15 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.08 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.6 p -138.75 161.64 36.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.796 179.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 162.48 54.43 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.96 138.0 83.11 Favored 'Trans proline' 0 C--N 1.301 -1.926 0 C-N-CA 122.005 1.803 . . . . 0.0 112.149 -178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.23 19.24 78.55 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 178.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.89 3.01 89.54 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.0 t -60.72 137.63 93.12 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 122.811 -0.229 . . . . 0.0 110.472 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 153.06 79.84 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 121.64 1.56 . . . . 0.0 111.309 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -70.65 129.11 34.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.617 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.3 tp60 -60.72 -44.34 96.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.55 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.39 162.0 28.28 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 179.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.525 ' O ' ' HB3' ' A' ' 139' ' ' ALA . 84.0 p -81.4 163.06 23.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.933 0.397 . . . . 0.0 110.56 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.51 -37.13 86.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.502 179.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -66.67 -7.63 22.0 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.137 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 136' ' ' SER . . . . . . . . 0 C--N 1.33 -0.278 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.495 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.1 t . . . . . 0 N--CA 1.45 -0.45 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.54 -44.13 99.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.087 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.08 43.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.45 ' HG1' ' HG2' ' A' ' 58' ' ' LYS . 4.2 p -104.41 -147.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.632 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.45 ' HG2' ' HG1' ' A' ' 57' ' ' THR . 21.4 pttm -48.11 106.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.452 -179.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.2 t -127.53 130.58 70.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.718 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 93.1 mt -74.88 135.82 41.52 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 109.824 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.36 178.33 25.05 Favored Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.713 ' HG1' HD22 ' A' ' 78' ' ' ASN . 98.1 m -128.32 137.94 52.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 120.853 0.359 . . . . 0.0 110.547 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 94.0 t -77.1 109.79 12.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.689 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.463 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.5 ttpt -62.79 -46.96 85.58 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.463 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 51.5 p-90 -176.67 146.87 0.6 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.954 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -141.35 125.0 16.81 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.4 m-20 -107.48 122.53 46.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.992 0.425 . . . . 0.0 110.941 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.9 t -63.22 -46.71 95.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.462 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -62.02 -43.29 99.16 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.45 88.04 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.807 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.48 0.99 69.25 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.374 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -148.3 163.52 36.81 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 117.503 0.652 . . . . 0.0 110.076 179.16 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.21 -179.67 32.32 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.538 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -126.45 143.08 51.31 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.095 0.474 . . . . 0.0 112.111 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.1 mt -121.8 126.52 74.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.859 178.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -94.09 109.97 21.71 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.93 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -63.62 134.57 55.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.073 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.713 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.6 m-20 -88.62 -9.89 50.6 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.275 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.3 p-10 -96.71 -12.9 23.17 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.146 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 55.7 p -133.84 -10.51 2.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.709 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.5 mttp 51.61 35.51 14.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.952 0.406 . . . . 0.0 109.976 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -120.11 134.11 55.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.223 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -67.81 130.03 41.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.118 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 96.2 t -119.21 131.77 70.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.52 139.49 55.63 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.293 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.11 148.34 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 CA-C-O 121.133 0.492 . . . . 0.0 110.948 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -131.74 155.59 47.43 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.9 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -59.35 -28.46 66.87 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.8 p -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.431 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.99 0.25 55.48 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.198 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.2 mt -93.83 103.11 14.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.013 0.435 . . . . 0.0 111.128 -178.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -64.96 -42.22 94.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.281 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -125.69 136.1 52.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.074 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -146.76 176.47 9.84 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.375 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -62.2 121.2 64.64 Favored Pre-proline 0 CA--C 1.539 0.54 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.31 -26.12 64.0 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 121.965 1.777 . . . . 0.0 112.65 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.1 -14.45 61.85 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.426 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 4.0 mptp? -99.34 113.93 26.52 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 120.717 0.294 . . . . 0.0 110.647 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.21 -47.83 84.3 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.889 0.376 . . . . 0.0 110.758 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.3 tp -94.09 130.83 40.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.216 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -60.5 138.46 58.01 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.256 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.488 ' HG ' ' HB3' ' A' ' 139' ' ' ALA . 93.7 p -157.97 163.37 37.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.424 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.06 131.04 68.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.64 148.01 47.7 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.303 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -86.09 134.36 33.83 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.1 2.63 90.56 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.8 tp10 -91.1 129.82 37.06 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-O 120.913 0.387 . . . . 0.0 110.517 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.9 m -70.01 133.03 46.81 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.719 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.3 m -130.61 159.09 42.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.49 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.02 130.05 55.94 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -156.24 162.93 40.1 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 119.774 -0.77 . . . . 0.0 112.49 -177.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -97.09 142.33 29.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.225 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.1 t -101.18 125.27 55.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.031 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.8 p . . . . . 0 C--N 1.326 -0.416 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.651 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 . . . . . 0 C--O 1.227 -0.107 0 CA-C-O 120.885 0.374 . . . . 0.0 110.661 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -74.46 150.76 39.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.042 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.59 157.96 41.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.186 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 53.52 47.97 22.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.029 0.443 . . . . 0.0 110.131 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 97.5 t -73.36 123.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.084 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -140.18 164.04 31.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.841 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.06 164.45 54.48 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_exo -60.79 138.33 78.64 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.995 1.797 . . . . 0.0 112.096 -179.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.14 18.78 79.37 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.69 0.74 89.98 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.8 t -59.87 137.69 90.47 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.46 150.31 87.0 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 121.588 1.525 . . . . 0.0 111.296 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.1 t -69.03 129.67 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.616 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -60.63 -44.38 96.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.507 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 88.41 164.78 40.62 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.668 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 139' ' ' ALA . 83.5 p -80.62 165.35 22.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.822 0.344 . . . . 0.0 110.572 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -62.47 -39.05 92.18 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.488 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -66.26 -9.81 36.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.139 -179.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.488 ' HB3' ' HG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.275 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.43 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 N--CA 1.45 -0.434 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.96 -45.36 97.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.07 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -153.33 161.74 42.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.084 -179.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.433 HG22 ' N ' ' A' ' 58' ' ' LYS . 12.6 t -97.51 -146.29 0.31 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.587 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.433 ' N ' HG22 ' A' ' 57' ' ' THR . 38.4 mtmm -52.12 113.65 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.538 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 93.2 t -127.49 128.55 69.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.768 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 94.7 mt -65.36 130.05 41.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.042 0.448 . . . . 0.0 109.925 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.29 170.27 25.52 Favored Glycine 0 C--O 1.228 -0.259 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.9 m -130.66 137.07 49.4 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.886 0.374 . . . . 0.0 110.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.32 116.2 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.832 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.2 ptpt -74.53 -35.37 63.13 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 176.7 139.49 0.07 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.987 178.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -138.98 115.97 10.9 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -100.57 118.48 36.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.014 0.435 . . . . 0.0 110.905 -178.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.92 -45.17 97.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.421 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.2 ttp85 -59.71 -45.29 92.57 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -61.38 -38.2 86.17 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.869 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.45 3.86 62.75 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.324 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -149.64 160.73 43.27 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 117.528 0.664 . . . . 0.0 110.051 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.53 179.9 33.87 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.615 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -132.67 147.27 52.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.17 0.509 . . . . 0.0 112.101 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 80.4 mt -121.56 129.06 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.846 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -97.33 108.26 20.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.877 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . 0.468 ' HE ' ' HG1' ' A' ' 80' ' ' THR . 88.3 mtm-85 -62.89 131.26 48.14 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.073 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.68 -9.07 57.76 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.333 179.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -94.03 -29.85 15.0 Favored 'General case' 0 N--CA 1.458 -0.057 0 CA-C-O 120.911 0.386 . . . . 0.0 110.134 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.468 ' HG1' ' HE ' ' A' ' 77' ' ' ARG . 76.5 p -116.83 -13.17 10.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.679 -178.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.7 mttt 54.22 33.79 18.89 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.066 -179.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -117.94 131.58 56.49 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.28 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -71.94 130.62 41.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.055 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.8 p -124.03 147.75 28.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.907 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -75.47 142.41 42.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.354 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.2 p -144.81 146.49 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.099 0.476 . . . . 0.0 111.016 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -135.19 154.58 51.56 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.848 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -61.04 -24.88 66.52 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 111.971 0.36 . . . . 0.0 111.971 -178.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 72.1 p -76.89 -13.86 59.94 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.351 179.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.69 2.56 54.64 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.091 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.5 mt -96.23 107.31 19.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.022 0.439 . . . . 0.0 111.183 -178.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -67.99 -43.09 79.73 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.334 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.97 141.01 48.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.098 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -144.51 160.73 40.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.6 t-20 -56.29 119.91 31.26 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.28 -31.57 93.99 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.075 1.85 . . . . 0.0 112.527 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -62.59 -19.19 63.48 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.431 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -111.21 140.37 45.83 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.655 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -95.08 -13.99 24.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.889 0.376 . . . . 0.0 110.775 179.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.0 tp -106.03 125.49 51.06 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.195 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.7 mtt-85 -62.89 130.83 46.53 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.634 -0.427 . . . . 0.0 110.305 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 47.2 t -157.9 154.62 28.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.537 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.88 130.57 74.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.24 144.81 45.11 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.376 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -74.93 129.88 38.43 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.27 1.45 85.88 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -178.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -76.92 132.62 39.18 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 120.9 0.381 . . . . 0.0 110.538 -179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -74.55 129.45 37.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.711 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 14.2 m -133.57 162.46 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.417 -177.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -124.81 141.24 52.25 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.434 ' HB3' HG22 ' A' ' 125' ' ' VAL . 20.6 p90 -160.87 163.41 32.02 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 119.715 -0.794 . . . . 0.0 112.494 -177.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -90.01 124.98 35.22 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.277 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.4 t -92.62 127.04 45.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.457 -0.497 . . . . 0.0 109.974 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 C--N 1.327 -0.376 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.506 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 . . . . . 0 C--O 1.227 -0.104 0 CA-C-O 120.83 0.347 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.98 145.98 39.86 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.8 159.52 44.08 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.208 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 54.44 43.17 30.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.035 0.445 . . . . 0.0 110.185 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.434 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.1 t -72.77 121.08 22.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.098 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -138.58 171.36 14.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.795 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.47 177.28 46.78 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.95 137.67 35.45 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 121.935 1.757 . . . . 0.0 112.19 -178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 18.93 77.24 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.02 2.14 89.55 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 94.4 t -61.98 137.06 95.4 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.762 -0.257 . . . . 0.0 110.553 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.41 147.68 76.39 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.568 1.512 . . . . 0.0 111.311 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.7 t -67.64 127.32 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.591 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -61.52 -41.48 97.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.535 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.01 -175.04 49.99 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.616 -0.594 . . . . 0.0 111.616 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 75.5 m -111.4 160.29 17.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.885 0.374 . . . . 0.0 110.572 -179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -59.45 -39.28 83.09 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.439 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -60.59 -15.38 27.38 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.12 179.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.23 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.526 179.978 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.1 t . . . . . 0 N--CA 1.45 -0.455 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.74 -44.12 99.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.039 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.06 158.23 43.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -98.68 -153.43 0.43 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.699 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -53.97 118.28 3.88 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.407 -178.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.64 128.65 60.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.699 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 95.3 mt -68.28 135.88 52.62 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.097 0.475 . . . . 0.0 109.801 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.89 178.35 27.44 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.587 ' HG1' HD22 ' A' ' 78' ' ' ASN . 86.7 m -130.38 137.52 49.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.801 0.334 . . . . 0.0 110.535 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.4 t -75.75 116.19 18.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.741 -178.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -69.82 -41.75 74.56 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 60.6 p-90 178.24 138.37 0.08 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.944 177.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -132.54 115.3 15.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 178.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -94.84 117.41 30.09 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.0 t -63.9 -44.82 98.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.471 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 64.6 mtp85 -61.89 -41.41 97.84 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -63.21 -37.63 87.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.856 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.85 3.28 66.16 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.301 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -149.98 160.04 43.92 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 117.482 0.641 . . . . 0.0 110.107 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.26 179.81 36.45 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 120.499 -0.857 . . . . 0.0 111.515 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -130.7 150.59 51.81 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.192 0.52 . . . . 0.0 112.146 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.411 HD12 HG22 ' A' ' 75' ' ' ILE . 83.3 mt -120.05 127.06 75.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.858 178.48 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.81 110.26 21.7 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.938 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . 0.44 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -65.9 128.9 37.88 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.101 179.161 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.587 HD22 ' HG1' ' A' ' 62' ' ' THR . 99.4 m-20 -74.39 -25.81 59.71 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.309 179.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -71.81 -41.66 67.96 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.151 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.5 p -108.11 -7.24 16.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.66 -176.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . 0.44 ' N ' ' O ' ' A' ' 77' ' ' ARG . 75.1 mmtt 52.29 31.16 8.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.906 0.384 . . . . 0.0 109.967 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -118.37 133.96 55.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.315 0.578 . . . . 0.0 111.274 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -64.23 146.28 54.58 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.067 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.24 130.46 69.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.871 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -68.07 130.37 42.75 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.9 149.12 18.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.219 0.533 . . . . 0.0 110.921 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -127.12 161.1 29.26 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.888 179.21 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.9 pt20 -61.12 -24.5 66.3 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -81.06 -11.51 59.5 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.388 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.25 -3.8 58.44 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.193 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -90.62 102.15 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 111.082 -178.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -63.71 -43.09 97.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.293 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -120.62 140.9 50.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.076 -178.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -139.79 153.33 47.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.461 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.455 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.0 p-10 -57.65 132.9 82.45 Favored Pre-proline 0 CA--C 1.539 0.529 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.8 -13.27 31.93 Favored 'Trans proline' 0 N--CA 1.499 1.8 0 C-N-CA 121.947 1.765 . . . . 0.0 112.573 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -62.29 -29.16 70.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.284 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.501 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 97.3 mttt -123.13 147.38 46.85 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 120.646 0.26 . . . . 0.0 110.668 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -89.57 -15.6 32.49 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.908 0.385 . . . . 0.0 110.821 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.9 tp -97.63 123.92 41.73 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.229 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -65.66 131.73 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.947 0.403 . . . . 0.0 110.283 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.7 p -158.73 162.76 37.17 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.562 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 26.3 t -125.34 129.07 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.48 144.77 44.64 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.368 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . 0.41 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 39.7 p-10 -75.37 130.41 38.96 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.87 1.86 87.77 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -79.21 130.41 35.44 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.516 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 90.5 m -72.93 130.08 39.57 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.688 179.049 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.8 m -134.53 162.67 38.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.368 -177.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -123.19 137.69 54.83 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.41 ' HB3' HG22 ' A' ' 125' ' ' VAL . 33.1 p90 -160.81 165.42 30.29 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.607 -177.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -100.54 146.11 27.5 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.325 178.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.79 127.6 60.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.524 -0.47 . . . . 0.0 109.985 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.4 p . . . . . 0 C--N 1.326 -0.433 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.196 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 . . . . . 0 C--O 1.227 -0.107 0 CA-C-O 120.917 0.389 . . . . 0.0 110.548 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -78.6 151.17 32.5 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.02 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.18 156.44 41.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.243 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.4 t30 56.78 48.18 16.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.971 0.415 . . . . 0.0 110.14 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.41 HG22 ' HB3' ' A' ' 111' ' ' PHE . 90.3 t -76.06 124.53 34.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.044 -179.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 65.4 p -138.12 167.2 22.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.759 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.69 169.32 53.57 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 178.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_exo -60.64 136.53 67.53 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 122.031 1.821 . . . . 0.0 112.182 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.63 20.99 77.68 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.73 0.99 90.04 Favored Glycine 0 CA--C 1.532 1.127 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.4 t -61.18 141.55 93.88 Favored Pre-proline 0 CA--C 1.536 0.436 0 O-C-N 122.805 -0.232 . . . . 0.0 110.602 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -58.17 147.6 82.8 Favored 'Trans proline' 0 N--CA 1.497 1.732 0 C-N-CA 121.651 1.567 . . . . 0.0 111.285 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.455 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 41.2 t -68.5 125.06 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.628 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 tp60 -60.26 -39.92 88.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.483 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.17 -171.83 50.68 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 66.9 m -112.93 153.36 28.1 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.847 0.356 . . . . 0.0 110.55 -179.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -58.63 -36.92 74.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -59.56 -16.77 27.37 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.112 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.501 ' HB3' ' HD3' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.331 -0.22 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.482 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.451 -0.424 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.81 -43.02 94.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.117 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.93 160.59 42.65 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.177 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.2 p -99.2 -147.18 0.33 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.712 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -54.85 117.33 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.251 -0.58 . . . . 0.0 110.507 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.7 t -130.92 132.38 63.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.722 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.0 mt -65.69 130.08 42.01 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.082 0.468 . . . . 0.0 109.816 178.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.18 172.4 26.8 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.5 m -128.11 140.52 51.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.809 0.338 . . . . 0.0 110.513 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 88.1 t -76.32 106.88 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.77 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.477 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 39.1 ttpt -61.15 -45.19 95.66 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.477 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -176.88 139.39 0.29 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.926 178.026 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -137.35 115.57 11.74 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -101.27 121.39 41.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.015 0.436 . . . . 0.0 110.821 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.4 HG21 ' N ' ' A' ' 139' ' ' ALA . 74.4 t -62.98 -46.23 96.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.407 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -60.58 -44.85 95.74 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -62.23 -37.92 87.25 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.846 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.65 2.95 66.88 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.374 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -148.43 161.68 41.13 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 117.473 0.636 . . . . 0.0 110.029 178.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.01 -179.01 32.58 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.532 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -130.94 145.2 51.95 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.145 0.498 . . . . 0.0 112.19 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.412 HD12 HG23 ' A' ' 109' ' ' VAL . 82.2 mt -120.29 125.08 73.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.865 179.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -93.33 110.86 22.4 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -64.51 132.9 51.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.193 179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -88.72 -6.69 57.27 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.315 179.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -95.9 -31.43 13.13 Favored 'General case' 0 C--O 1.232 0.182 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.163 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.0 p -114.08 -11.67 12.67 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.772 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.9 mttp 55.83 35.38 25.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.919 0.39 . . . . 0.0 110.004 -178.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -119.04 146.49 45.01 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.386 0.613 . . . . 0.0 111.232 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -84.18 121.48 27.52 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.986 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 75.0 t -112.14 126.46 69.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.94 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -64.9 134.02 53.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.337 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.18 148.42 30.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.138 0.494 . . . . 0.0 110.916 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -133.63 162.28 32.36 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.905 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.34 -39.44 93.11 Favored 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -68.05 -15.82 63.76 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.453 179.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.21 -1.33 56.8 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.181 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -97.82 104.36 15.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-O 120.997 0.427 . . . . 0.0 111.164 -178.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -65.37 -43.18 91.6 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.267 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -123.03 144.63 49.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.925 0.393 . . . . 0.0 111.035 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 p-10 -151.39 177.26 10.46 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.296 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -65.52 119.46 60.11 Favored Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.62 -33.99 98.57 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.988 1.792 . . . . 0.0 112.61 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtt85 -63.47 -21.25 66.2 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.344 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -95.41 119.79 34.52 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.668 -179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -61.34 -48.27 82.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 110.814 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 86.9 mt -95.2 145.25 25.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.232 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.18 136.02 56.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.2 t -155.41 152.72 29.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.476 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.41 130.3 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.91 140.37 45.63 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.386 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -73.11 129.21 37.57 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.4 1.01 80.64 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -77.13 132.28 38.75 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.841 0.353 . . . . 0.0 110.56 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.0 m -71.13 130.37 41.33 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.693 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.412 HG23 HD12 ' A' ' 75' ' ' ILE . 19.9 m -134.27 160.25 41.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.442 -177.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -119.13 136.94 53.92 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.0 p90 -158.78 164.24 35.99 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.495 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -96.65 141.17 30.22 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.291 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.8 128.2 50.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.984 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 p . . . . . 0 C--N 1.327 -0.406 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.226 -0.133 0 CA-C-O 120.852 0.358 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -104.29 144.34 31.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.972 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.35 159.55 44.18 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.246 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 57.49 47.23 16.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.024 0.44 . . . . 0.0 110.185 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 93.7 t -77.18 122.68 32.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.152 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.6 p -137.46 169.36 17.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.779 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.59 172.91 47.76 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -67.63 137.02 41.11 Favored 'Trans proline' 0 C--N 1.302 -1.891 0 C-N-CA 122.01 1.807 . . . . 0.0 112.121 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.02 16.23 80.68 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.88 90.36 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 1.3 p -69.4 148.76 97.26 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 122.795 -0.238 . . . . 0.0 110.508 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.48 148.19 91.67 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.631 1.554 . . . . 0.0 111.36 179.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 78.0 t -70.79 132.26 33.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.592 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -60.71 -41.24 94.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.517 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.2 49.09 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.602 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.8 m -113.24 154.92 25.98 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.831 0.348 . . . . 0.0 110.544 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.3 -35.84 78.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -61.68 -19.44 62.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.117 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.4 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.256 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.476 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.97 -44.98 99.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.045 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -151.44 163.24 39.43 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 t -99.91 -148.93 0.36 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.749 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.448 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 25.1 pttm -52.11 117.92 3.12 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.451 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 80.8 t -133.27 130.11 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.699 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.6 mt -73.3 135.98 44.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.164 0.507 . . . . 0.0 109.835 178.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.87 179.59 24.63 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.6 m -128.91 136.31 50.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.901 0.382 . . . . 0.0 110.359 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.0 t -75.13 108.6 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.555 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.56 -48.32 81.49 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.555 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.3 p-90 -178.61 139.15 0.17 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.006 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -134.19 115.18 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -94.52 117.41 30.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.013 0.435 . . . . 0.0 110.897 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 139' ' ' ALA . 64.5 t -62.69 -44.78 99.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.46 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.09 -44.67 97.0 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -63.03 -38.62 91.93 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.31 2.18 64.05 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.322 179.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -148.28 160.14 43.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 117.371 0.585 . . . . 0.0 110.074 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.3 -177.6 34.53 Favored Glycine 0 CA--C 1.525 0.707 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.545 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -128.8 145.24 51.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.146 0.498 . . . . 0.0 112.147 -178.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 90.7 mt -116.35 125.16 73.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.881 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.99 109.84 20.85 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.977 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -62.89 133.64 54.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.106 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -86.14 -1.38 57.36 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.29 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -100.85 -32.64 10.57 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 120.914 0.388 . . . . 0.0 110.107 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.8 p -113.85 -10.49 12.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.692 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.3 mttt 56.26 31.51 18.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 120.993 0.425 . . . . 0.0 110.04 -179.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.63 141.58 49.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.252 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -67.23 145.55 55.09 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.053 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 91.4 t -128.48 131.77 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -69.83 138.6 52.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.297 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.9 p -147.09 148.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.18 0.514 . . . . 0.0 110.912 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -129.39 160.54 32.78 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.934 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -59.84 -40.51 88.76 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.9 p -67.85 -13.34 62.06 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.448 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.09 -7.68 59.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.103 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.401 HD13 HG22 ' A' ' 103' ' ' VAL . 83.2 mt -92.82 96.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.934 0.397 . . . . 0.0 111.143 -178.333 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -63.0 -42.35 99.82 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.27 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.546 ' HB2' HG22 ' A' ' 126' ' ' THR . 3.7 mptp? -119.25 132.09 55.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.059 -179.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -145.53 157.72 43.95 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.483 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -57.2 119.33 30.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -68.19 -20.06 43.9 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 121.946 1.764 . . . . 0.0 112.577 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -64.5 -20.05 65.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.39 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.43 ' HD3' ' HB1' ' A' ' 139' ' ' ALA . 99.0 mttt -100.92 140.47 35.17 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.719 0.295 . . . . 0.0 110.619 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -69.51 -41.58 75.86 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.721 -178.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.6 142.8 35.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.193 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -74.27 128.12 34.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 110.304 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 66.9 m -146.67 165.08 30.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.515 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.401 HG22 HD13 ' A' ' 91' ' ' ILE . 47.3 t -119.7 128.42 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.101 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -60.59 140.4 48.05 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.355 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -80.11 130.1 34.99 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.07 2.87 90.68 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -89.13 133.45 34.39 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 120.875 0.369 . . . . 0.0 110.496 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 86.5 m -69.38 131.31 44.6 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.682 178.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 28.1 m -129.24 159.39 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.419 -177.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -119.17 128.55 54.35 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -155.98 162.07 40.4 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.555 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -92.47 150.67 20.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.283 178.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.3 t -109.31 125.01 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.94 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.4 p . . . . . 0 C--N 1.326 -0.445 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.642 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 . . . . . 0 N--CA 1.461 0.093 0 CA-C-O 120.864 0.364 . . . . 0.0 110.653 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -76.17 150.17 37.19 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.993 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.79 157.2 41.63 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 56.18 48.68 16.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.947 0.403 . . . . 0.0 110.03 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.7 t -73.81 125.17 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.124 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.546 HG22 ' HB2' ' A' ' 93' ' ' LYS . 67.9 p -139.25 163.81 31.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.761 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.03 167.83 54.71 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 109.216 -1.553 . . . . 0.0 109.216 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_exo -60.14 138.43 81.59 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 121.946 1.764 . . . . 0.0 112.132 -178.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 69.88 20.79 76.36 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.48 90.54 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.8 t -62.11 139.68 96.01 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.84 -0.212 . . . . 0.0 110.504 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -58.3 148.05 81.42 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 C-N-CA 121.608 1.539 . . . . 0.0 111.286 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.0 t -67.64 129.72 32.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.619 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 26.7 mp0 -61.55 -42.37 98.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.489 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.19 -171.8 53.65 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 179.335 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 57.3 m -114.85 158.06 22.45 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 110.545 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -61.7 -37.38 83.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.518 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -64.26 -13.35 48.91 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.04 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.461 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.276 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.45 -0.435 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.8 mt -61.4 -44.33 98.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.08 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -142.94 162.11 36.34 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.055 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -100.61 -151.98 0.42 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.606 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -49.44 117.58 2.28 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.487 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.7 t -132.82 130.53 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.693 179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.2 mt -73.2 138.21 45.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.148 0.499 . . . . 0.0 109.811 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.15 178.81 27.38 Favored Glycine 0 N--CA 1.451 -0.363 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 88.2 m -127.56 137.17 52.52 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.502 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 90.4 t -76.28 108.57 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.749 -178.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.542 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -61.15 -48.86 79.65 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.542 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.1 p-90 -177.64 143.01 0.33 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.96 178.037 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -144.42 120.57 10.8 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 70' ' ' ASN . 79.8 m-20 -103.36 133.34 48.6 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.911 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.7 t -71.25 -38.39 69.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.436 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -58.41 -47.41 83.98 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -176.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.403 ' OD1' ' O ' ' A' ' 67' ' ' ASN . 53.1 p30 -80.62 -16.04 55.07 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.803 -178.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 70' ' ' ASN . . . 70.96 18.81 76.58 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.295 177.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -149.93 164.08 36.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 117.462 0.631 . . . . 0.0 110.181 179.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.13 -173.35 38.12 Favored Glycine 0 CA--C 1.524 0.604 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.505 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -128.75 146.74 50.81 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.108 0.48 . . . . 0.0 112.114 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.5 mt -120.38 126.7 75.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.955 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -94.95 111.09 22.91 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.956 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 84.6 mtp180 -63.09 131.6 49.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.165 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.4 p30 -89.81 2.33 55.06 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.414 -0.515 . . . . 0.0 111.323 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -107.27 -33.53 7.38 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.993 0.425 . . . . 0.0 110.198 179.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 74.4 p -116.2 -9.05 11.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.711 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.4 mttm 54.11 33.49 17.93 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 -178.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -112.85 132.96 55.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.233 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -73.91 125.4 28.12 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.052 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.85 131.89 70.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.883 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -63.35 142.78 58.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.351 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -139.91 145.9 25.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-O 121.218 0.532 . . . . 0.0 110.889 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -136.62 157.4 46.86 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.911 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -61.31 -39.25 89.8 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.0 p -66.79 -17.15 64.73 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -83.45 -4.27 58.35 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.154 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 81.7 mt -96.99 97.93 6.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.995 0.426 . . . . 0.0 111.217 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -64.51 -41.3 96.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.283 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.514 ' HB3' HG22 ' A' ' 126' ' ' THR . 40.3 ttmt -119.45 136.33 54.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -149.43 170.82 17.69 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.357 179.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.432 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 31.5 p-10 -65.95 125.54 90.17 Favored Pre-proline 0 CA--C 1.539 0.526 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.83 -19.62 58.8 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.035 1.823 . . . . 0.0 112.59 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -64.57 -22.97 67.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -104.69 128.25 52.71 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.648 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -69.31 -37.55 77.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.754 179.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.98 131.56 48.32 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.141 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -59.45 136.36 57.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.028 0.442 . . . . 0.0 110.279 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.465 ' HG ' ' H ' ' A' ' 136' ' ' SER . 46.3 t -158.17 155.33 28.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.572 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.64 129.36 75.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.88 151.12 51.21 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.316 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -86.67 136.1 33.15 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.71 2.86 90.25 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.9 tp10 -92.92 128.81 38.92 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.938 0.399 . . . . 0.0 110.5 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -67.12 133.31 49.59 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.751 179.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.9 m -129.53 159.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.456 -178.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -118.66 128.83 54.9 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -157.76 161.15 38.45 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.767 -0.773 . . . . 0.0 112.538 -178.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.404 ' OD1' ' C ' ' A' ' 112' ' ' ASP . 55.8 p30 -90.32 174.53 7.53 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.281 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -127.61 127.67 68.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 C-N-CA 120.509 -0.476 . . . . 0.0 109.978 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 91.8 t . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.687 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.6 pt-20 . . . . . 0 N--CA 1.461 0.092 0 CA-C-O 120.97 0.414 . . . . 0.0 110.666 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -97.77 148.46 23.34 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.96 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.09 41.76 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.236 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.1 t30 53.35 47.92 23.13 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.141 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.7 t -75.28 125.55 34.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.069 -178.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 93' ' ' LYS . 69.7 p -136.92 169.21 18.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.743 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -77.27 175.58 53.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.05 137.85 35.54 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 122.074 1.849 . . . . 0.0 112.061 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.7 19.64 79.31 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.87 1.48 90.61 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 -179.147 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 86.6 t -62.65 137.61 96.56 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-O 119.647 -0.216 . . . . 0.0 110.611 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -59.14 148.44 85.75 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 121.697 1.598 . . . . 0.0 111.259 179.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.432 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 43.7 t -67.59 128.17 30.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.669 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -63.58 -39.62 94.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.539 -179.146 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.91 -175.58 53.16 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 179.311 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.465 ' H ' ' HG ' ' A' ' 102' ' ' SER . 41.4 t -101.28 160.4 14.44 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.824 0.345 . . . . 0.0 110.554 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -61.09 -37.99 84.68 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.416 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -64.35 -14.04 53.96 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.092 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.477 -179.712 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 84.9 t . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.6 mt -63.41 -44.14 98.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.046 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.25 163.73 36.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.07 0.462 . . . . 0.0 111.067 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.429 HG22 ' N ' ' A' ' 58' ' ' LYS . 12.6 t -98.1 -146.57 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.679 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.429 ' N ' HG22 ' A' ' 57' ' ' THR . 63.5 mttp -50.82 116.4 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.407 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.1 t -131.78 130.03 61.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.697 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.7 mt -73.55 137.21 44.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.055 0.455 . . . . 0.0 109.808 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.32 177.9 27.2 Favored Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.414 ' HG1' HD22 ' A' ' 78' ' ' ASN . 96.4 m -128.22 135.76 50.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.856 0.36 . . . . 0.0 110.486 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.2 t -76.93 109.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.765 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.54 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.1 tttt -62.22 -48.39 80.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.54 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 62.2 p-90 -175.8 147.63 0.81 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 114.678 -1.146 . . . . 0.0 109.903 178.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -137.45 115.44 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 41.4 t-20 -93.49 110.27 21.85 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.978 0.418 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 53.4 t -61.21 -46.7 96.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.391 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.1 ttp180 -62.01 -43.76 98.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -178.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.16 -39.39 92.48 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.81 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.49 4.04 59.58 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.382 179.255 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -148.26 160.82 42.57 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.423 0.611 . . . . 0.0 110.04 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.53 -177.22 33.44 Favored Glycine 0 CA--C 1.525 0.71 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.573 -179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -131.5 147.9 52.58 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.134 0.492 . . . . 0.0 112.193 -179.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.2 mt -120.77 127.36 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.843 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -91.92 110.45 21.81 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.807 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 96.4 mtm-85 -62.18 135.2 57.39 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.126 179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.414 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.9 m-20 -82.54 -6.95 59.62 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.382 179.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -94.75 -33.07 13.04 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.959 0.409 . . . . 0.0 110.138 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 68.0 p -116.9 -10.6 10.96 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.642 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 54.44 34.51 21.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.976 0.417 . . . . 0.0 110.026 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -121.04 132.64 55.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.247 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -66.23 148.14 52.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.037 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -132.78 152.15 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.914 179.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -73.24 133.11 43.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.297 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.4 p -144.84 144.11 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.149 0.499 . . . . 0.0 110.911 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -136.19 157.79 45.96 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.841 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -58.46 -24.73 61.05 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -178.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.3 p -73.6 -20.49 60.59 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.421 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.24 -7.74 58.88 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.137 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.3 mt -90.0 94.9 5.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.872 0.367 . . . . 0.0 111.198 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -64.34 -38.15 90.03 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.437 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -122.94 142.86 50.35 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.101 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -153.28 177.13 11.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.35 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -63.63 118.62 46.43 Favored Pre-proline 0 CA--C 1.539 0.552 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.7 -34.66 99.07 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.056 1.838 . . . . 0.0 112.545 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.09 -19.9 66.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.467 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -97.65 114.53 26.5 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-O 120.74 0.305 . . . . 0.0 110.604 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -60.69 -47.89 84.23 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.893 0.378 . . . . 0.0 110.761 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 64.0 tp -91.18 130.67 37.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.182 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -59.76 136.73 58.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.055 0.455 . . . . 0.0 110.249 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.1 t -154.18 154.25 33.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.505 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.7 131.95 71.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.4 144.64 47.74 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.324 -178.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -83.14 118.59 23.69 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.65 -0.73 74.29 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -82.82 132.33 35.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.862 0.363 . . . . 0.0 110.532 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 85.8 m -69.04 132.48 46.7 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.648 178.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -130.01 159.77 41.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.47 -178.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -119.96 126.62 51.31 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -155.45 163.81 39.55 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.558 -177.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.31 153.33 20.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.224 178.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -110.29 125.09 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.403 -0.519 . . . . 0.0 109.983 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 75.8 t . . . . . 0 C--N 1.326 -0.423 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.941 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.227 -0.121 0 CA-C-O 120.966 0.412 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -94.14 146.59 23.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.01 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.35 157.06 40.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.135 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 58.19 47.33 14.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.977 0.418 . . . . 0.0 110.164 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.2 t -76.07 123.22 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.074 -179.025 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.2 p -134.96 159.96 39.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.813 179.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.55 162.21 53.94 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.105 -1.598 . . . . 0.0 109.105 178.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.83 136.99 77.34 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.039 1.826 . . . . 0.0 112.108 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.57 83.0 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.2 1.45 90.47 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.462 HG22 ' HD2' ' A' ' 132' ' ' PRO . 9.9 p -68.89 141.66 92.58 Favored Pre-proline 0 CA--C 1.535 0.4 0 CA-C-O 119.673 -0.203 . . . . 0.0 110.501 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.462 ' HD2' HG22 ' A' ' 131' ' ' VAL . 20.4 Cg_endo -59.09 150.24 74.72 Favored 'Trans proline' 0 N--CA 1.497 1.721 0 C-N-CA 121.634 1.556 . . . . 0.0 111.315 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -64.42 133.58 29.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.552 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -62.43 -42.41 99.43 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.496 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.41 162.59 36.16 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 85.1 p -80.59 166.3 21.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.894 0.378 . . . . 0.0 110.496 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -63.4 -36.87 85.17 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.511 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -72.1 -5.23 33.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.121 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.448 -179.802 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t . . . . . 0 N--CA 1.45 -0.454 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.0 -44.53 97.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.069 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -155.27 163.24 40.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.056 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.545 ' O ' HG21 ' A' ' 59' ' ' VAL . 11.4 t -96.19 -149.51 0.31 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.685 179.622 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -55.1 118.0 3.96 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.52 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.545 HG21 ' O ' ' A' ' 57' ' ' THR . 87.5 t -129.58 128.55 65.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.701 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.7 mt -68.98 135.31 50.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.122 0.486 . . . . 0.0 109.733 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.04 -177.82 27.0 Favored Glycine 0 CA--C 1.521 0.42 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.587 ' HG1' HD22 ' A' ' 78' ' ' ASN . 94.4 m -128.28 135.34 49.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.876 0.37 . . . . 0.0 110.391 -179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 97.1 t -71.28 110.87 4.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.765 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.526 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -61.52 -48.92 78.85 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.526 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.9 p-90 -177.77 140.08 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.957 178.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -137.1 119.17 15.43 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -101.22 120.88 40.9 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.892 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.407 HG21 ' C ' ' A' ' 138' ' ' TYR . 67.3 t -62.93 -45.73 98.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.525 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -61.82 -44.68 96.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -178.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -62.09 -38.78 90.13 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.902 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.61 2.1 65.53 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.397 179.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -147.54 161.96 40.05 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 117.467 0.633 . . . . 0.0 110.112 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.55 -179.05 36.9 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.561 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -126.99 146.27 50.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.153 0.501 . . . . 0.0 112.172 -178.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.409 HG22 ' CE2' ' A' ' 111' ' ' PHE . 87.2 mt -119.31 125.34 74.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.827 178.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.77 109.88 21.32 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.836 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -65.96 134.78 53.66 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.19 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.587 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.7 m-20 -85.06 -5.31 59.35 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.418 -0.513 . . . . 0.0 111.268 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -96.49 -33.19 11.95 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.176 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 66.5 p -115.15 -9.61 12.27 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.627 -178.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt 53.63 32.5 14.59 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 121.062 0.458 . . . . 0.0 110.147 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -119.73 131.83 55.48 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.233 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.02 142.43 58.38 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.986 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 79.0 t -126.89 132.42 70.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.899 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -66.19 138.19 57.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.312 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.79 147.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.225 0.536 . . . . 0.0 110.946 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -136.88 159.96 40.31 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.905 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -59.98 -20.4 57.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -178.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 64.1 p -82.52 -12.81 57.52 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.465 179.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.05 1.36 57.24 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.132 179.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.7 mt -95.97 101.68 12.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.929 0.395 . . . . 0.0 111.136 -178.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -63.11 -45.15 93.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.365 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -115.07 136.8 52.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.04 -178.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -143.26 137.85 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.31 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.433 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.4 p-10 -58.96 138.39 87.49 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.057 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.34 -9.12 24.76 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.004 1.802 . . . . 0.0 112.499 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.55 -35.95 77.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.412 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -105.04 137.91 42.07 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-O 120.687 0.279 . . . . 0.0 110.672 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . 0.43 ' HB2' HD23 ' A' ' 100' ' ' LEU . 98.2 m-85 -68.42 -41.95 79.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.756 -179.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.43 HD23 ' HB2' ' A' ' 99' ' ' TYR . 1.3 mm? -97.98 146.41 25.53 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.31 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -67.51 128.52 36.74 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.381 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.7 m -147.51 161.74 40.47 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.477 -179.271 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 t -125.97 131.11 72.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -61.64 143.48 48.65 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.266 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -81.58 123.29 28.54 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.0 3.83 88.87 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -84.74 136.67 33.61 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.939 0.399 . . . . 0.0 110.503 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 89.6 m -70.66 130.88 42.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.607 179.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -134.91 164.82 32.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.445 -178.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -124.87 137.7 54.28 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.415 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.3 p90 -160.12 162.52 34.01 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.813 -0.755 . . . . 0.0 112.481 -177.394 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -90.65 137.34 32.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.268 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.7 t -103.83 126.22 58.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.988 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.8 m . . . . . 0 C--N 1.327 -0.408 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 179.536 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 . . . . . 0 N--CA 1.461 0.091 0 CA-C-O 120.892 0.377 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.92 152.87 33.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.12 158.22 42.65 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.14 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 53.07 47.28 24.92 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.105 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.415 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.6 t -74.43 124.05 31.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.071 -179.048 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 50.3 p -139.78 170.06 16.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.825 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.31 164.68 54.72 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 178.378 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -59.44 137.18 76.51 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 C-N-CA 121.977 1.785 . . . . 0.0 112.177 -179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.31 20.81 77.06 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.25 2.48 90.5 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -179.577 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.6 t -60.98 141.3 93.61 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 122.777 -0.249 . . . . 0.0 110.553 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -56.28 148.06 63.09 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 121.549 1.499 . . . . 0.0 111.315 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.433 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 42.9 t -69.78 126.24 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.64 -179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 16.2 tm0? -60.9 -40.42 93.01 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.54 -178.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.41 -174.39 54.95 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -111.75 162.84 14.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.841 0.353 . . . . 0.0 110.502 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -60.84 -37.91 83.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.509 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.407 ' C ' HG21 ' A' ' 68' ' ' VAL . 96.4 m-85 -71.02 -5.77 33.84 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.067 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.214 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.521 -179.035 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.87 -44.26 99.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.102 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.94 162.91 37.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 -179.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.494 ' O ' HG21 ' A' ' 59' ' ' VAL . 7.9 t -108.84 -134.8 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.707 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.442 ' N ' HG22 ' A' ' 57' ' ' THR . 68.6 mttm -54.71 102.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.346 -0.541 . . . . 0.0 110.369 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.494 HG21 ' O ' ' A' ' 57' ' ' THR . 97.4 t -127.26 128.75 70.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.729 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 88.6 mt -79.66 135.99 36.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.104 0.478 . . . . 0.0 109.862 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.49 178.18 21.81 Favored Glycine 0 CA--C 1.519 0.298 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 134.76 50.67 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.852 0.358 . . . . 0.0 110.463 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.406 HG23 HG12 ' A' ' 103' ' ' VAL . 86.6 t -75.77 109.99 10.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.75 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.526 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.67 -49.19 77.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.526 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 61.4 p-90 -174.51 152.78 1.75 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.899 178.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -147.06 117.07 7.24 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.6 m-20 -97.45 120.87 38.6 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.908 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -63.18 -44.8 99.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.462 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.43 HH11 ' HD2' ' A' ' 69' ' ' ARG . 9.0 ptm85 -65.22 -34.84 79.32 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -69.3 -35.35 75.9 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.521 -0.471 . . . . 0.0 110.788 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 89.38 1.42 78.39 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.367 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -150.15 162.74 39.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.445 0.623 . . . . 0.0 110.085 179.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.73 179.85 34.09 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.493 -0.86 . . . . 0.0 111.535 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -123.49 143.52 50.11 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.133 0.492 . . . . 0.0 112.091 -178.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.1 mt -120.63 126.2 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.841 178.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.91 114.75 27.38 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.875 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -71.43 128.69 36.69 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.035 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.3 p30 -83.93 -1.59 54.85 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.337 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -101.21 -31.54 10.96 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-O 120.947 0.403 . . . . 0.0 110.176 179.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.72 -12.48 11.51 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.682 -179.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.86 32.45 19.68 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.995 -179.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.78 135.35 55.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.244 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -63.32 144.95 56.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.072 -179.421 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.35 133.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.901 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -80.98 125.19 29.84 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.325 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 32.6 m -131.17 159.86 42.72 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-O 121.133 0.492 . . . . 0.0 110.973 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -137.95 155.97 48.34 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.837 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -60.93 -22.98 64.92 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.9 p -80.96 -13.0 59.28 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.422 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.05 2.93 55.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.094 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.9 mt -98.03 106.68 19.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.876 0.37 . . . . 0.0 111.171 -178.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -63.84 -44.35 93.45 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.327 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.03 144.13 50.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.928 0.394 . . . . 0.0 111.051 -179.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 p-10 -150.26 174.32 12.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.418 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.0 t-20 -62.67 120.2 57.79 Favored Pre-proline 0 CA--C 1.541 0.604 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.49 -23.07 58.21 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.035 1.823 . . . . 0.0 112.595 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.4 mmm-85 -67.02 -21.63 65.92 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.413 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -91.48 136.93 32.76 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.62 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -69.18 -39.55 78.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.753 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 8.0 mp -113.5 151.52 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.173 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.66 139.25 58.74 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.319 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.8 p -156.0 161.36 40.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.603 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.406 HG12 HG23 ' A' ' 63' ' ' VAL . 52.7 t -123.12 125.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.8 146.86 48.94 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.363 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -84.55 133.78 34.44 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.88 4.8 89.61 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.565 -1.014 . . . . 0.0 110.565 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -92.61 129.77 38.44 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.96 0.41 . . . . 0.0 110.504 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.5 m -66.81 133.55 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.576 178.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.5 m -128.89 158.15 41.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.459 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -120.0 130.11 54.59 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -160.8 165.14 30.79 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.549 -177.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -95.28 144.98 25.41 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.306 178.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -105.06 126.3 60.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.022 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.8 p . . . . . 0 C--N 1.328 -0.36 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.58 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 . . . . . 0 C--O 1.227 -0.122 0 CA-C-O 120.926 0.393 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -116.67 149.81 39.17 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.23 156.99 42.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.191 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 54.81 43.89 29.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.051 0.453 . . . . 0.0 110.123 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.8 t -72.45 121.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.054 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.1 p -137.88 166.23 24.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.725 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.61 175.24 49.79 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.49 138.21 38.12 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.929 1.753 . . . . 0.0 112.097 -179.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 19.99 77.94 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.79 1.12 90.56 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.03 137.52 95.58 Favored Pre-proline 0 CA--C 1.535 0.39 0 O-C-N 122.822 -0.222 . . . . 0.0 110.556 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -59.45 146.26 95.51 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.656 1.57 . . . . 0.0 111.247 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -64.96 135.27 28.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.69 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -59.51 -42.78 92.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.469 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.28 176.71 51.16 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 179.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.404 ' O ' ' HB3' ' A' ' 139' ' ' ALA . 43.8 t -97.0 143.93 27.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.92 0.391 . . . . 0.0 110.54 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -60.14 -21.07 61.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.552 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -74.93 -12.59 60.39 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.113 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.404 ' HB3' ' O ' ' A' ' 136' ' ' SER . . . . . . . . 0 C--N 1.331 -0.215 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.515 -179.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.5 t . . . . . 0 N--CA 1.451 -0.404 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.5 mt -62.82 -45.3 99.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.029 -178.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.83 167.62 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.116 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.443 HG22 ' N ' ' A' ' 58' ' ' LYS . 7.5 t -105.66 -134.77 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.68 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.443 ' N ' HG22 ' A' ' 57' ' ' THR . 87.8 tttt -50.34 112.91 0.76 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.482 -179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.5 t -135.45 131.29 51.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.771 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 67.2 mt -75.01 133.75 41.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.121 0.486 . . . . 0.0 109.75 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.89 175.57 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 90.1 m -131.17 138.93 49.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.829 0.347 . . . . 0.0 110.432 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 97.2 t -72.62 109.18 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.78 -178.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.544 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -62.49 -48.04 81.35 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.544 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 59.0 p-90 -177.23 139.53 0.26 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.969 178.154 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -135.71 120.84 18.87 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -104.65 119.87 40.0 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.923 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.36 -45.47 98.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.482 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -60.57 -44.92 95.66 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -62.13 -38.15 87.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.813 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.1 1.47 64.97 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.34 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.5 p90 -147.5 160.16 42.91 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 117.473 0.636 . . . . 0.0 110.072 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.91 174.61 36.73 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.489 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -129.16 148.6 51.11 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.187 0.518 . . . . 0.0 112.141 -179.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.428 HD13 HG23 ' A' ' 109' ' ' VAL . 84.5 mt -116.55 127.18 74.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.844 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.12 109.05 19.96 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -60.38 134.99 57.6 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.159 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -84.37 -0.15 51.53 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.301 179.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -101.87 -33.04 9.94 Favored 'General case' 0 C--O 1.231 0.085 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.058 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.7 p -116.59 -9.09 11.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.693 -178.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mmtm 55.81 31.75 18.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.96 0.41 . . . . 0.0 110.037 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -117.69 133.99 55.37 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.303 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.15 144.57 56.8 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.098 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.2 t -124.14 126.94 73.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.913 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.76 129.03 38.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.318 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.93 149.76 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.186 0.517 . . . . 0.0 110.921 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.01 160.13 33.73 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.858 178.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -60.24 -29.79 68.99 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -73.53 -15.66 61.29 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.385 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.19 -0.07 53.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.17 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.4 mt -92.98 101.3 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.967 0.413 . . . . 0.0 111.226 -178.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -62.94 -43.86 97.65 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -121.79 143.02 49.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.148 -179.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -152.77 163.79 39.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.434 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -61.76 121.15 62.81 Favored Pre-proline 0 CA--C 1.539 0.539 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.46 -21.63 66.09 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 121.967 1.778 . . . . 0.0 112.553 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.82 -22.16 66.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.326 179.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -100.89 120.67 40.49 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-O 120.751 0.31 . . . . 0.0 110.686 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 88.8 t80 -61.03 -48.3 82.41 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.703 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.5 tp -93.09 129.53 39.03 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.141 -179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -61.82 139.23 58.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.297 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.2 p -158.31 163.95 36.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.452 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.8 t -125.16 129.53 73.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.25 144.66 48.01 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.319 -178.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 105' ' ' ASP . 41.0 p-10 -77.36 129.2 35.51 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.36 2.01 86.94 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 110.526 -1.029 . . . . 0.0 110.526 -178.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.7 tt0 -78.37 130.91 36.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 120.988 0.423 . . . . 0.0 110.469 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.4 m -71.09 130.76 42.35 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.713 178.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.428 HG23 HD13 ' A' ' 75' ' ' ILE . 21.6 m -133.71 158.43 42.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.524 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -115.78 132.42 56.64 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -161.33 167.11 26.42 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.473 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -88.57 149.53 23.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.252 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.8 t -108.43 123.9 64.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.481 -0.488 . . . . 0.0 109.957 -179.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.4 t . . . . . 0 C--N 1.326 -0.439 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.402 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 C--O 1.226 -0.158 0 CA-C-O 120.925 0.393 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -118.69 142.43 47.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.045 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.11 153.34 42.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.184 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 54.36 43.08 30.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.059 0.457 . . . . 0.0 110.174 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.05 125.39 28.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.106 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.9 p -135.67 169.43 17.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.824 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.09 177.24 45.69 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 178.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 136.38 32.93 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 121.911 1.74 . . . . 0.0 112.188 -178.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.68 21.53 77.87 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.07 1.79 90.41 Favored Glycine 0 CA--C 1.531 1.084 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 85.5 t -63.16 140.43 97.67 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 122.853 -0.204 . . . . 0.0 110.527 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -58.06 148.53 76.75 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 121.58 1.52 . . . . 0.0 111.292 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.2 t -69.15 128.99 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.605 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -61.47 -41.85 97.88 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.435 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.83 -175.9 48.94 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -109.5 159.96 16.62 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.845 0.355 . . . . 0.0 110.53 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt -61.49 -37.81 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -63.63 -15.37 58.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.078 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.281 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.451 -179.651 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.8 t . . . . . 0 N--CA 1.451 -0.401 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.64 -45.0 98.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.068 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.55 163.45 39.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.109 -178.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.544 ' O ' HG21 ' A' ' 59' ' ' VAL . 13.1 t -98.12 -149.09 0.33 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.7 179.725 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.0 mtmt -53.92 119.31 4.85 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.449 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.544 HG21 ' O ' ' A' ' 57' ' ' THR . 72.2 t -131.38 131.67 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.629 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.418 HD23 ' OE2' ' A' ' 110' ' ' GLU . 62.2 mt -65.7 131.07 45.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.102 0.477 . . . . 0.0 109.835 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.62 176.13 24.78 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 91.8 m -129.33 135.46 48.77 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.735 0.302 . . . . 0.0 110.508 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 95.2 t -70.88 108.02 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.826 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.554 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.7 tttt -61.66 -47.81 83.65 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.073 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.554 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 58.1 p-90 -177.1 138.94 0.26 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.602 -1.181 . . . . 0.0 109.942 178.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -136.07 117.57 14.8 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -100.59 119.68 38.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.004 0.43 . . . . 0.0 110.907 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.438 HG21 ' N ' ' A' ' 139' ' ' ALA . 65.3 t -62.18 -46.33 96.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.422 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.13 -46.16 90.6 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -61.41 -39.23 89.98 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.924 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.61 1.93 63.6 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.349 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -148.21 161.22 41.91 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.505 0.653 . . . . 0.0 110.062 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.48 -177.91 33.0 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.568 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -129.24 143.96 51.04 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 82.8 mt -116.93 123.42 71.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.814 178.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -91.11 109.12 20.37 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.933 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . 0.423 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -63.64 130.29 43.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.083 178.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -74.99 -26.86 59.88 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.358 179.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -70.77 -41.78 71.27 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.905 0.383 . . . . 0.0 110.224 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.2 p -104.49 -11.14 17.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.675 -178.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . 0.423 ' N ' ' O ' ' A' ' 77' ' ' ARG . 98.6 mttt 55.86 31.19 17.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.927 0.394 . . . . 0.0 110.043 -178.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -120.45 145.84 46.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.225 179.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -70.31 147.22 49.91 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.073 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 88.3 t -130.12 132.53 65.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.816 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -66.31 138.29 57.52 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.328 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -151.44 149.88 13.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.232 0.539 . . . . 0.0 110.879 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -133.48 155.38 49.65 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.83 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.2 pt20 -60.9 -25.52 66.79 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 63.2 p -79.56 -13.05 59.8 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.479 178.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.24 1.56 55.53 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.119 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.91 108.9 21.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.847 0.356 . . . . 0.0 111.202 -178.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -64.32 -43.11 95.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.318 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.85 138.98 54.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.147 -178.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -144.91 157.19 44.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.476 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -56.98 120.15 36.18 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.83 -32.23 94.4 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.015 1.81 . . . . 0.0 112.581 179.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -62.41 -21.79 65.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.418 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -85.62 127.59 34.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 120.693 0.282 . . . . 0.0 110.623 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -65.46 -39.47 92.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.795 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.3 150.32 39.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.254 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -63.15 136.8 57.97 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.7 p -159.38 163.05 35.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.495 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.72 128.39 72.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.525 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.66 138.62 38.1 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.274 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.01 135.76 38.68 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.57 3.19 90.15 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -92.36 128.45 38.21 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 121.002 0.429 . . . . 0.0 110.537 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.6 m -68.16 132.99 48.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.674 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.99 158.04 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.235 -0.586 . . . . 0.0 111.394 -178.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.418 ' OE2' HD23 ' A' ' 60' ' ' LEU . 99.1 mt-10 -117.37 134.4 54.87 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.153 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 39.8 p90 -158.75 162.2 37.08 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.819 -0.753 . . . . 0.0 112.586 -177.61 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -88.88 144.09 26.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.25 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.3 123.78 59.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.987 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.325 -0.467 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.67 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 C--O 1.226 -0.145 0 CA-C-O 120.925 0.393 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -105.96 143.49 34.03 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.034 -179.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.13 157.71 43.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.184 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 55.4 49.48 16.81 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.939 0.4 . . . . 0.0 110.07 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 86.7 t -75.8 125.17 35.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.14 -179.152 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -137.5 163.57 30.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.76 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.4 165.76 54.17 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.6 136.05 68.41 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.962 1.774 . . . . 0.0 112.154 -178.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.3 19.44 79.65 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 178.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.36 1.59 90.31 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.4 t -60.96 139.06 94.09 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-O 119.692 -0.194 . . . . 0.0 110.572 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -60.69 149.06 89.5 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.679 1.586 . . . . 0.0 111.323 179.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.6 t -70.28 128.81 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.55 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.2 tp60 -61.07 -39.99 91.98 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.534 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.14 -175.71 53.82 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 65.4 m -107.54 155.65 19.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.59 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -62.64 -35.52 79.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.493 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -62.11 -13.65 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.099 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.438 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.24 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.468 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -62.71 131.41 48.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -89.96 133.04 35.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.213 0.53 . . . . 0.0 111.02 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 79.9 t -101.13 104.44 16.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.489 178.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.46 ' HB ' HG11 ' A' ' 113' ' ' VAL . 96.0 mt -61.92 -44.21 98.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.037 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.85 159.34 43.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.117 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.8 p -107.81 -140.7 0.38 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.661 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt -50.93 102.52 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.262 -0.575 . . . . 0.0 110.505 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.3 t -128.49 130.19 69.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.712 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 87.1 mt -82.12 137.01 35.08 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.93 -179.88 22.47 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 89.8 m -127.29 136.18 51.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.792 0.329 . . . . 0.0 110.501 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 89.3 t -76.67 112.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.74 -178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.552 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.45 -48.15 80.93 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.552 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -178.76 143.66 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.961 177.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -138.73 118.73 13.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -98.77 120.89 39.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.987 0.422 . . . . 0.0 110.81 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.402 HG21 ' N ' ' A' ' 139' ' ' ALA . 69.9 t -64.16 -45.1 97.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.42 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.1 ttp85 -61.31 -44.46 97.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.41 -38.36 89.4 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.843 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.36 3.96 66.67 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 121.091 -0.575 . . . . 0.0 112.401 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -149.28 161.38 42.16 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.441 0.621 . . . . 0.0 110.137 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.75 -177.08 35.46 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 120.554 -0.831 . . . . 0.0 111.577 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.456 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.6 m-85 -131.56 147.7 52.55 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.107 0.48 . . . . 0.0 112.233 -179.242 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.2 mt -120.24 127.68 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.856 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -93.32 109.83 21.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.849 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.9 mtm180 -65.6 131.78 47.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.093 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.9 p30 -86.91 -0.21 56.13 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.278 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -100.32 -32.7 10.72 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.892 0.377 . . . . 0.0 110.098 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.75 -10.59 11.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.674 -179.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 56.9 mtmt 55.37 32.34 18.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 109.996 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -121.25 132.37 54.77 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.319 0.58 . . . . 0.0 111.222 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -67.04 146.47 54.3 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.049 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.0 p -134.03 148.03 30.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.931 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -73.45 138.46 45.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.354 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -143.01 145.56 22.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 121.112 0.482 . . . . 0.0 110.947 178.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -137.4 158.85 43.52 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.868 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -61.28 -39.19 89.49 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.5 p -67.27 -15.7 63.85 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.469 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.02 0.75 54.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.5 mt -98.65 104.97 16.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.038 0.447 . . . . 0.0 111.136 -178.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -62.67 -44.93 95.01 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.331 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.431 ' HB2' HG23 ' A' ' 126' ' ' THR . 75.9 mmtt -125.62 145.39 50.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.002 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -150.98 176.59 10.98 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.399 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -63.71 121.14 68.92 Favored Pre-proline 0 CA--C 1.54 0.589 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.38 -25.61 63.69 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.999 1.799 . . . . 0.0 112.535 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.0 mmm180 -69.96 -17.95 63.33 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.436 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -95.78 123.85 39.54 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.689 0.28 . . . . 0.0 110.632 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -66.02 -39.8 90.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.858 0.361 . . . . 0.0 110.752 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -103.66 136.68 42.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.219 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.1 mtm180 -65.1 137.18 57.51 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.316 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 86.1 p -160.05 164.0 33.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 59.4 t -123.43 128.37 74.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.21 145.73 44.95 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.309 -179.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -83.0 137.91 33.96 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.49 2.78 88.29 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -93.57 132.13 38.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.88 0.371 . . . . 0.0 110.465 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -69.59 133.19 47.32 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.611 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.68 159.67 40.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.522 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -120.95 131.07 54.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -160.75 167.31 27.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.507 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -100.55 138.05 38.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.284 178.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.46 HG11 ' HB ' ' A' ' 55' ' ' ILE . 55.4 t -95.87 124.79 48.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 120.523 -0.471 . . . . 0.0 109.863 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.1 t -119.77 129.82 74.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -61.45 126.62 28.01 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.854 -178.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -117.69 160.22 13.8 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.5 mp0 -62.1 -39.58 92.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.743 0.306 . . . . 0.0 110.979 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -87.56 -5.37 58.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.372 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 141.89 -169.83 25.12 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.69 139.28 58.32 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.405 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -122.94 134.95 54.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.589 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.7 145.83 24.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.033 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.8 155.7 39.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.159 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 54.28 50.45 16.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.999 0.428 . . . . 0.0 110.131 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -78.4 119.62 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.112 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.431 HG23 ' HB2' ' A' ' 93' ' ' LYS . 82.3 p -138.41 164.58 28.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.769 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.05 171.27 51.1 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.18 137.64 37.66 Favored 'Trans proline' 0 C--N 1.3 -1.994 0 C-N-CA 122.0 1.8 . . . . 0.0 112.122 -179.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.11 19.43 79.79 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.5 0.58 89.35 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 76.0 t -61.2 137.77 94.35 Favored Pre-proline 0 CA--C 1.535 0.391 0 O-C-N 122.802 -0.234 . . . . 0.0 110.51 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.15 150.3 87.86 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 121.61 1.54 . . . . 0.0 111.351 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.05 132.39 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.588 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -61.66 -40.27 94.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.616 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.01 -176.98 53.91 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 72.6 m -103.19 153.78 20.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.82 0.343 . . . . 0.0 110.56 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -59.89 -37.75 80.28 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.401 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -62.31 -15.56 48.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.12 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.402 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -58.32 139.98 54.25 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.569 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.659 -179.781 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.561 0 C3'-C2'-C1' 104.339 1.171 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.87 0 O4'-C4'-C3' 103.772 -1.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.537 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.429 -1.537 0 P-O3'-C3' 121.558 1.548 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -1.03 0 O4'-C4'-C3' 103.826 -1.774 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.793 0 O4'-C4'-C3' 103.859 -1.741 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.266 0 C1'-O4'-C4' 106.647 -2.181 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.849 0 O4'-C1'-C2' 107.278 1.071 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -71.0 145.54 49.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.276 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -106.98 128.59 54.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.152 0.501 . . . . 0.0 110.972 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.2 t -92.03 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.395 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.427 ' HB ' HG11 ' A' ' 113' ' ' VAL . 95.3 mt -62.29 -44.17 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.061 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.77 164.95 33.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.098 0.475 . . . . 0.0 111.061 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 10.9 t -98.05 -151.4 0.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.647 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 22.5 pttp -47.03 116.0 1.24 Allowed 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.453 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 93.9 t -129.79 128.08 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.688 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.6 mt -75.18 136.5 41.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.12 0.486 . . . . 0.0 109.827 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -152.86 -175.87 24.8 Favored Glycine 0 CA--C 1.52 0.363 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.5 m -130.54 136.76 49.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.81 0.338 . . . . 0.0 110.503 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.427 HG22 HG11 ' A' ' 103' ' ' VAL . 77.5 t -73.21 115.57 14.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.752 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.445 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.2 ttpt -63.73 -47.05 82.63 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.445 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 56.5 p-90 -176.43 148.18 0.73 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 114.673 -1.148 . . . . 0.0 109.901 177.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -143.4 115.62 8.44 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -101.0 123.29 44.96 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.88 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.3 t -63.33 -46.08 96.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.461 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -60.29 -45.49 93.15 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.53 88.33 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.894 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.93 2.61 66.53 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.01 161.87 41.49 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 117.456 0.628 . . . . 0.0 110.064 179.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.74 -177.92 31.3 Favored Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.601 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.444 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 95.5 m-85 -131.72 146.5 52.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.152 0.501 . . . . 0.0 112.157 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.492 HD11 HG23 ' A' ' 109' ' ' VAL . 86.8 mt -120.55 127.25 75.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.838 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -92.94 109.84 21.29 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.879 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.4 mtm180 -62.75 133.39 54.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.109 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 p30 -87.74 -0.15 56.52 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.279 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.9 -32.12 11.14 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 120.974 0.416 . . . . 0.0 110.113 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 75.2 p -113.44 -11.03 13.17 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.698 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt 57.69 31.44 20.41 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 0.0 110.007 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -120.1 142.66 48.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.356 0.598 . . . . 0.0 111.198 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.36 144.82 51.5 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.051 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 87.3 t -128.21 128.2 68.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.972 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -72.8 130.1 39.7 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.341 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.91 159.42 43.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.215 0.531 . . . . 0.0 110.917 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.34 155.93 47.36 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.936 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -60.86 -23.05 64.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.2 p -81.85 -11.94 58.71 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.421 178.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.22 0.9 56.98 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.156 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.4 mt -96.8 100.3 10.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.943 0.401 . . . . 0.0 111.168 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -63.36 -44.12 95.72 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.298 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -122.33 144.88 48.74 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.954 0.406 . . . . 0.0 111.031 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.5 p-10 -155.07 175.69 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.38 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -66.63 120.55 71.77 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -64.81 -25.66 60.42 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.039 1.826 . . . . 0.0 112.552 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -65.47 -20.73 66.48 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.395 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.82 128.68 40.19 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.696 0.284 . . . . 0.0 110.633 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -66.13 -38.67 88.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.754 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.9 mt -108.89 149.7 28.77 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.214 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -69.68 129.94 41.0 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.384 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.425 ' HG ' ' HB3' ' A' ' 139' ' ' ALA . 65.8 m -143.46 157.9 44.07 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.474 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.427 HG11 HG22 ' A' ' 63' ' ' VAL . 48.8 t -126.41 131.69 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.18 49.21 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.361 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.56 115.18 26.77 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 95.14 -8.42 69.85 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -72.21 156.11 39.5 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.921 0.391 . . . . 0.0 110.492 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.3 m -86.96 129.47 34.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.653 178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.492 HG23 HD11 ' A' ' 75' ' ' ILE . 33.0 m -129.86 158.98 42.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.431 -177.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -119.91 129.44 54.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -158.11 161.03 37.92 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.783 -0.767 . . . . 0.0 112.567 -177.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -85.36 152.98 22.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.336 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.427 HG11 ' HB ' ' A' ' 55' ' ' ILE . 59.8 t -107.18 124.67 63.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 120.473 -0.491 . . . . 0.0 109.985 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 83.3 t -121.28 129.41 75.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -67.3 125.81 27.25 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.954 -178.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -118.11 156.59 15.58 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -60.26 -45.4 93.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.729 0.3 . . . . 0.0 110.957 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.3 pttm -77.12 -18.86 57.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.368 . . . . 0.0 111.324 178.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.48 33.29 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.32 140.16 58.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.86 0.362 . . . . 0.0 110.509 179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -127.31 135.39 50.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.621 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.33 154.66 21.74 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.034 179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.36 151.9 32.38 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.297 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 53.35 46.52 26.18 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.161 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.9 t -70.75 124.09 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.126 -179.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -140.91 165.55 27.21 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.76 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.78 172.93 52.61 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.6 136.77 31.54 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.061 1.841 . . . . 0.0 112.102 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.25 20.25 79.67 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 3.04 90.67 Favored Glycine 0 CA--C 1.532 1.146 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 75.4 t -63.68 138.09 97.28 Favored Pre-proline 0 CA--C 1.536 0.416 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.66 152.42 81.95 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.579 1.519 . . . . 0.0 111.337 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 94.7 t -68.92 131.31 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.563 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -61.11 -45.4 94.87 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.518 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.92 159.1 26.42 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -74.9 162.49 28.58 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.82 0.343 . . . . 0.0 110.581 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -72.35 -24.91 61.35 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.528 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -69.83 -15.4 63.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.052 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.425 ' HB3' ' HG ' ' A' ' 102' ' ' SER . . . -58.5 140.58 53.8 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.433 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.597 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.514 -1.384 0 C4'-C3'-C2' 101.715 -1.485 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.428 -0.77 0 P-O3'-C3' 121.099 1.166 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.591 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.433 -1.162 0 O4'-C4'-C3' 103.95 -1.65 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.801 0 C3'-C2'-C1' 101.793 -0.648 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.847 0 O4'-C4'-C3' 104.28 -1.32 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.28 0 C1'-O4'-C4' 106.8 -2.072 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.433 -1.147 0 O4'-C1'-C2' 107.509 1.281 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -72.82 148.59 44.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.239 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -68.96 133.41 48.14 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.264 0.554 . . . . 0.0 110.969 179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 98.1 t -93.87 99.83 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.348 179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.1 mt -62.43 -43.32 98.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.036 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.84 160.8 42.89 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.08 0.467 . . . . 0.0 111.107 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 p -99.22 -146.21 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.646 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -50.06 108.01 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.451 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.72 129.83 71.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.721 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.3 mt -74.83 137.1 41.64 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.22 -179.42 24.17 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.562 ' HG1' HD21 ' A' ' 78' ' ' ASN . 93.8 m -128.15 135.87 50.36 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.856 0.36 . . . . 0.0 110.451 -179.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.7 t -75.99 109.25 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.708 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.538 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.04 -49.65 75.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.538 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 60.9 p-90 -174.72 146.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.979 178.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -142.58 121.16 12.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -103.47 123.12 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.592 -0.443 . . . . 0.0 110.868 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.0 t -63.79 -45.88 95.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.477 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.04 -44.77 96.89 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -62.2 -38.14 87.99 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 91.86 2.26 69.56 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.423 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -148.77 161.3 42.07 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-N 117.454 0.627 . . . . 0.0 110.057 179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.5 178.36 36.55 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.536 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -126.12 143.39 51.14 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.201 0.524 . . . . 0.0 112.118 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 86.2 mt -120.02 127.23 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.828 178.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -89.0 118.08 28.48 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.2 mtm180 -72.51 131.9 43.13 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.212 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.562 HD21 ' HG1' ' A' ' 62' ' ' THR . 98.7 m-20 -83.36 -6.35 59.44 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.267 179.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.87 -33.25 11.7 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.002 0.429 . . . . 0.0 110.086 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -114.06 -11.68 12.69 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.861 -0.608 . . . . 0.0 111.734 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.8 mttp 55.62 33.02 20.36 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.641 -0.424 . . . . 0.0 109.964 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -122.51 137.83 54.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.289 0.566 . . . . 0.0 111.248 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.24 142.27 57.8 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.046 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 80.0 t -127.79 131.16 70.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.876 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -69.08 138.8 54.62 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.328 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.21 149.31 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.163 0.506 . . . . 0.0 110.979 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -136.13 159.31 42.11 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.855 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -61.3 -39.49 90.65 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.2 p -66.6 -18.31 65.3 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.4 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.95 -0.79 55.48 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.095 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.0 mt -95.74 103.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.97 0.414 . . . . 0.0 111.091 -178.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -63.25 -43.96 96.53 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.292 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -127.27 147.38 50.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.088 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -154.44 177.55 11.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.336 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -65.6 120.8 71.32 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.09 -22.16 62.17 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.069 1.846 . . . . 0.0 112.515 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.3 mmm180 -67.46 -21.75 65.52 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -100.87 122.62 43.77 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-O 120.701 0.286 . . . . 0.0 110.534 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -61.0 -48.43 81.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.74 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 -60.95 132.48 54.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.999 0.428 . . . . 0.0 110.37 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 66.8 m -148.39 159.9 43.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.547 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 52.6 t -121.33 127.8 75.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -69.2 149.53 49.02 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.403 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -85.81 134.68 33.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.56 4.02 90.13 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -91.44 130.47 37.27 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.989 0.423 . . . . 0.0 110.465 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.4 m -69.15 132.71 46.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.651 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.4 m -129.99 157.53 42.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.471 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -117.59 126.74 53.07 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -156.57 163.6 39.17 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.718 -0.793 . . . . 0.0 112.537 -177.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -88.52 149.64 23.52 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.238 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.9 t -106.86 124.93 62.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.429 -0.508 . . . . 0.0 109.964 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 97.7 t -117.8 129.24 74.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -61.81 124.44 20.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.027 0.441 . . . . 0.0 110.935 -178.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.7 157.85 14.72 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 179.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -63.04 -39.55 95.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.663 0.268 . . . . 0.0 110.913 -179.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -91.22 -11.62 37.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.334 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 158.29 -171.29 35.14 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -66.04 147.85 52.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -119.39 157.46 28.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.645 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -119.89 143.22 48.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.076 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.1 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.261 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 53.5 45.84 27.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.977 0.418 . . . . 0.0 110.147 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.4 t -72.99 120.44 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.136 -179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.49 164.2 30.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.877 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.54 172.46 50.57 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.13 136.9 33.16 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 122.041 1.827 . . . . 0.0 112.162 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.33 19.68 79.78 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.03 1.26 89.73 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 71.0 t -62.0 138.06 95.66 Favored Pre-proline 0 CA--C 1.536 0.408 0 O-C-N 122.776 -0.25 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.91 150.3 88.31 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 121.687 1.591 . . . . 0.0 111.335 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.54 133.95 30.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.561 -179.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -60.48 -41.75 94.84 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.589 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.96 179.54 52.71 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.4 m -106.03 160.88 14.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.927 0.394 . . . . 0.0 110.552 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -61.09 -37.43 82.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.535 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -65.21 -14.6 61.03 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.118 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.85 142.02 51.65 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.479 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.54 -179.792 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.613 0 O4'-C4'-C3' 107.04 1.44 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.856 0 C3'-C2'-C1' 104.542 1.316 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.444 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.427 -0.813 0 P-O3'-C3' 121.473 1.477 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.858 0 C3'-C2'-C1' 101.773 -0.662 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.887 0 O4'-C4'-C3' 104.05 -1.55 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.268 0 C1'-O4'-C4' 107.07 -1.879 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.788 0 O4'-C1'-C2' 107.069 0.881 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -71.5 145.05 49.41 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.159 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -66.57 134.39 52.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.183 0.516 . . . . 0.0 110.94 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t -101.8 106.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.798 . . . . 0.0 109.408 178.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.45 ' HB ' HG11 ' A' ' 113' ' ' VAL . 96.1 mt -63.17 -44.78 99.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.039 -178.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.1 163.57 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.086 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.416 HG23 ' N ' ' A' ' 58' ' ' LYS . 13.7 t -102.68 -148.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.658 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.416 ' N ' HG23 ' A' ' 57' ' ' THR . 59.1 mtmt -52.67 115.43 1.8 Allowed 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.388 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -132.3 130.38 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.755 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.1 mt -75.3 131.23 40.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.12 0.486 . . . . 0.0 109.771 178.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.66 -177.03 20.95 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.4 m -128.38 137.41 51.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.868 0.366 . . . . 0.0 110.478 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.1 t -73.82 115.06 14.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.552 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.4 tttt -62.88 -48.95 76.79 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 179.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.552 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 53.6 p-90 -179.31 140.28 0.15 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.99 178.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -135.96 117.26 14.59 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -102.67 123.67 46.8 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.876 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.4 t -62.84 -45.64 98.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.487 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -61.08 -45.37 95.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -62.74 -38.61 91.2 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.493 -0.483 . . . . 0.0 110.836 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.13 2.24 68.88 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.37 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -148.44 161.44 41.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.394 0.597 . . . . 0.0 110.14 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.22 -179.5 32.19 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.571 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.417 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.6 m-85 -129.37 146.47 51.23 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 79.2 mt -125.7 128.22 72.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.79 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -94.26 126.22 39.38 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.857 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . 0.504 ' HE ' ' HG1' ' A' ' 80' ' ' THR . 95.1 mtm-85 -74.9 131.47 40.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.092 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -84.07 -0.16 50.69 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.305 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -100.79 -33.31 10.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.945 0.403 . . . . 0.0 110.112 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.504 ' HG1' ' HE ' ' A' ' 77' ' ' ARG . 81.4 p -116.5 -8.57 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.758 -0.656 . . . . 0.0 111.647 -179.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt 56.22 30.86 17.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.397 . . . . 0.0 110.006 -179.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -117.08 137.14 52.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.21 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.5 p-10 -74.25 158.05 34.76 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.113 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.23 148.51 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.947 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -77.94 136.68 38.04 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.375 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.2 p -143.96 148.1 19.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.159 0.504 . . . . 0.0 110.976 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -133.28 159.11 41.18 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.945 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.85 -25.56 65.13 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.8 p -74.86 -16.15 60.69 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.478 179.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.24 0.46 55.33 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.142 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -95.13 100.47 11.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.12 -178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -64.65 -41.8 95.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.298 179.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.15 138.4 52.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.123 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -148.54 153.73 38.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.342 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -58.62 120.83 48.67 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.31 -19.19 61.93 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 121.92 1.746 . . . . 0.0 112.557 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.0 mmm-85 -63.31 -23.96 67.64 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.408 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -101.39 133.24 46.31 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 120.686 0.279 . . . . 0.0 110.652 -179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -68.62 -38.46 80.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.745 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.9 mt -103.92 142.8 33.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.244 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.5 mtt85 -66.87 137.98 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.303 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.2 t -156.59 153.25 28.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.471 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 42.3 t -119.58 131.96 70.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -59.16 143.09 46.18 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.344 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -81.96 120.24 24.98 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.14 2.39 89.37 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.6 tp10 -81.71 137.42 35.39 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.903 0.383 . . . . 0.0 110.554 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 88.1 m -68.83 132.46 46.8 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.726 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.0 157.78 42.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.413 -178.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -117.43 126.99 53.58 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -154.82 162.09 41.24 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 119.807 -0.757 . . . . 0.0 112.565 -177.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -93.14 149.13 21.44 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.246 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.45 HG11 ' HB ' ' A' ' 55' ' ' ILE . 62.0 t -107.47 126.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.469 -0.492 . . . . 0.0 109.956 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.448 HG23 ' N ' ' A' ' 115' ' ' GLU . 12.5 p -133.56 142.08 42.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.448 ' N ' HG23 ' A' ' 114' ' ' VAL . 96.7 mt-10 -63.39 134.02 55.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.988 0.423 . . . . 0.0 110.877 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -118.51 164.91 12.88 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 51.5 mp0 -62.19 -40.6 96.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.712 0.292 . . . . 0.0 110.989 -179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.85 -0.03 57.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.343 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 136.54 -168.91 24.0 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -58.31 136.67 57.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -132.43 135.33 46.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.695 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.15 152.67 29.1 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.973 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.97 157.12 43.18 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.193 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 53.4 44.88 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.436 . . . . 0.0 110.215 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.1 t -72.05 124.07 27.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.073 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.4 p -136.67 168.48 19.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.789 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.65 171.07 54.45 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -66.61 138.97 51.5 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 C-N-CA 121.929 1.753 . . . . 0.0 112.175 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.27 16.8 79.66 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.89 2.45 90.55 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 1.3 p -68.4 147.95 98.18 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-O 119.704 -0.189 . . . . 0.0 110.55 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.48 150.73 73.79 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.582 1.521 . . . . 0.0 111.309 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t -66.36 131.34 32.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.622 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -61.74 -39.97 93.45 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.497 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.47 -173.64 54.85 Favored Glycine 0 CA--C 1.524 0.623 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.66 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 71.1 m -112.5 157.96 20.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.822 0.344 . . . . 0.0 110.59 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -60.55 -37.69 82.08 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.384 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -60.87 -19.5 60.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.111 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -60.05 137.81 58.01 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.449 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.627 -179.821 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.473 0 C3'-C2'-C1' 104.964 1.617 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.938 0 O4'-C4'-C3' 102.782 -2.818 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.58 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.433 -1.19 0 O4'-C4'-C3' 103.518 -2.082 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.886 0 C3'-C2'-C1' 101.076 -1.16 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.81 0 C4'-C3'-C2' 102.403 -0.797 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.33 0 C1'-O4'-C4' 107.268 -1.737 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.83 0 C3'-C2'-C1' 104.29 1.135 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 23.1 t0 . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -71.51 145.74 48.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.225 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -62.74 133.71 55.2 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.176 0.512 . . . . 0.0 110.974 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.74 101.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.46 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.45 -42.94 97.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.108 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.11 157.32 43.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.9 p -102.47 -149.99 0.4 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.609 179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -48.25 104.66 0.06 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.497 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 96.7 t -125.04 129.37 73.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.696 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.0 mt -75.37 138.59 41.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.132 0.492 . . . . 0.0 109.762 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.39 -178.15 25.0 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.564 ' HG1' HD22 ' A' ' 78' ' ' ASN . 93.9 m -129.05 137.76 51.48 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.878 0.37 . . . . 0.0 110.491 -179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.11 109.86 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.754 -179.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.529 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 61.9 tttm -61.16 -50.93 71.18 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.529 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.3 p-90 -176.65 139.55 0.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.016 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -137.92 116.57 12.17 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -99.34 121.72 41.49 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.964 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.26 -45.82 97.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.426 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -62.71 -42.1 99.48 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -62.2 -39.06 91.49 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.835 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.4 2.23 65.87 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.354 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -149.56 162.19 40.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 117.464 0.632 . . . . 0.0 109.984 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.33 -179.28 35.95 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.499 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.444 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.9 m-85 -130.33 144.9 51.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.213 0.53 . . . . 0.0 112.127 -178.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.4 mt -120.11 126.33 75.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.839 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -93.16 119.76 32.71 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -72.85 133.79 44.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.161 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.564 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.4 m-20 -83.23 -8.58 59.45 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.29 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -93.04 -33.18 14.2 Favored 'General case' 0 C--O 1.231 0.121 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.092 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 79.1 p -115.31 -9.13 12.23 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.75 -178.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.4 mttt 53.37 32.7 14.25 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.972 -179.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -120.39 134.74 55.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.332 0.587 . . . . 0.0 111.219 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -64.36 144.2 57.34 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.03 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 95.0 t -130.05 133.1 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.878 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -65.51 138.29 57.97 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.396 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.18 147.76 18.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.251 0.548 . . . . 0.0 110.855 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -137.73 160.2 39.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.926 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -61.73 -39.03 90.13 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -178.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.7 p -67.99 -16.07 63.88 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.453 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.84 2.41 51.48 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.0 mt -98.6 107.73 20.91 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.885 0.374 . . . . 0.0 111.245 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -65.63 -42.65 91.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.349 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.038 -178.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -144.11 168.78 19.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.388 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -55.12 121.14 34.54 Favored Pre-proline 0 CA--C 1.539 0.553 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.96 -41.69 72.5 Favored 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 121.933 1.756 . . . . 0.0 112.597 -178.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -63.86 -14.63 54.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.527 ' HD2' ' HB2' ' A' ' 139' ' ' ALA . 14.8 tppt? -104.39 118.03 35.61 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 120.688 0.28 . . . . 0.0 110.616 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -77.26 -22.83 51.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.915 0.388 . . . . 0.0 110.785 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.4 tp -100.72 125.61 47.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.173 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.64 133.8 56.46 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.584 -0.447 . . . . 0.0 110.31 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.3 t -160.79 151.92 18.93 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.495 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 56.6 t -118.59 127.13 75.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.68 145.85 46.02 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.334 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -83.56 135.42 34.64 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.3 4.06 89.86 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -92.43 131.87 37.24 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 120.958 0.409 . . . . 0.0 110.461 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.6 m -69.47 133.66 47.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.64 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.8 m -131.8 158.47 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.462 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.67 130.52 55.09 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -156.57 164.12 38.57 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 119.778 -0.769 . . . . 0.0 112.541 -177.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -97.3 140.28 32.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.368 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.3 t -100.86 125.65 54.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.066 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -121.24 132.03 71.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -63.38 126.86 28.85 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.942 -178.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.07 164.15 12.18 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -61.66 -42.63 99.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.765 0.317 . . . . 0.0 111.006 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -83.39 -21.56 33.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.408 179.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 160.73 -169.24 36.38 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.729 -0.949 . . . . 0.0 110.729 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.19 143.93 57.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.887 0.375 . . . . 0.0 110.39 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -131.55 150.46 52.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.591 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -105.19 145.16 30.99 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.14 162.93 39.49 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.195 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 54.06 45.23 27.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.985 0.421 . . . . 0.0 110.173 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.7 t -74.25 123.91 30.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.048 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.9 p -138.32 167.93 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.806 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.96 174.38 53.05 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.86 137.6 38.58 Favored 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.065 1.844 . . . . 0.0 112.121 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.02 20.19 78.81 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.92 2.11 90.65 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 94.5 t -63.37 137.21 97.01 Favored Pre-proline 0 CA--C 1.537 0.449 0 O-C-N 122.78 -0.247 . . . . 0.0 110.56 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.94 145.42 91.32 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.561 1.507 . . . . 0.0 111.314 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.58 132.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -60.84 -43.1 98.73 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.456 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.99 -179.93 52.83 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 37.9 t -106.19 141.07 38.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.849 0.357 . . . . 0.0 110.589 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.5 ptmt -59.26 -21.88 60.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.44 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 70.1 m-85 -66.07 -22.62 66.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.139 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.527 ' HB2' ' HD2' ' A' ' 98' ' ' LYS . . . -56.92 137.57 55.14 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.47 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.62 -179.627 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.526 0 C3'-C2'-C1' 105.019 1.656 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.856 0 O4'-C4'-C3' 103.675 -1.925 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.575 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.432 -1.278 0 O4'-C4'-C3' 103.326 -2.274 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.943 0 C3'-C2'-C1' 100.782 -1.37 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.819 0 O4'-C1'-C2' 107.379 1.163 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.243 0 C1'-O4'-C4' 105.9 -2.714 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.818 0 O4'-C1'-C2' 107.534 1.304 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.5 t0 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -142.89 157.3 44.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.211 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -102.02 129.11 48.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.175 0.512 . . . . 0.0 110.969 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.4 t -96.17 102.15 13.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.399 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.442 ' HB ' HG11 ' A' ' 113' ' ' VAL . 97.4 mt -63.14 -44.28 99.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.033 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.01 164.08 35.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.434 HG23 ' N ' ' A' ' 58' ' ' LYS . 15.0 t -101.99 -149.05 0.38 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.648 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 57' ' ' THR . 58.4 mtmt -52.3 117.01 2.52 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.431 -178.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.8 t -133.21 131.37 58.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.687 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.3 mt -76.01 136.07 39.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.084 0.469 . . . . 0.0 109.776 178.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.55 -179.36 24.42 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.602 ' HG1' HD22 ' A' ' 78' ' ' ASN . 94.5 m -127.06 140.67 52.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.937 0.398 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.0 t -82.21 111.24 18.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.739 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.467 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 64.9 tttp -62.77 -49.93 73.03 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 63.2 p-90 -169.81 154.41 5.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.645 -1.161 . . . . 0.0 109.927 177.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -142.5 118.68 10.75 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 -98.23 112.1 24.2 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.993 0.425 . . . . 0.0 110.892 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.423 HG21 ' N ' ' A' ' 139' ' ' ALA . 73.9 t -61.75 -45.05 99.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.381 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.2 ttt85 -61.09 -44.5 97.26 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.08 -38.71 92.27 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.444 -0.503 . . . . 0.0 110.821 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.15 4.49 59.87 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.387 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.466 ' HB3' ' HD1' ' A' ' 87' ' ' HIS . 47.7 p90 -152.37 162.0 41.8 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 117.43 0.615 . . . . 0.0 110.102 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.04 -176.05 27.73 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.56 -179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.448 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 90.9 m-85 -126.3 145.14 50.55 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.155 0.502 . . . . 0.0 112.138 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 83.3 mt -120.12 125.45 74.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.896 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -90.66 109.59 20.76 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.479 -0.488 . . . . 0.0 110.813 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -62.87 135.32 57.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.13 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.602 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.9 m-20 -86.37 -2.3 58.3 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.316 179.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -100.14 -34.05 10.2 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.973 0.416 . . . . 0.0 110.144 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.7 p -115.44 -9.25 12.13 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.679 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mmtm 55.43 29.96 14.15 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -115.18 133.62 55.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.375 0.607 . . . . 0.0 111.299 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.9 142.52 58.26 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.985 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.7 t -124.83 133.27 69.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -70.77 138.18 50.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.313 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.73 148.69 15.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.183 0.516 . . . . 0.0 110.954 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.466 ' HD1' ' HB3' ' A' ' 72' ' ' TYR . 94.8 m-70 -132.79 155.77 48.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.886 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -60.15 -23.67 64.1 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 80.5 p -83.33 -10.41 58.5 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.591 -0.443 . . . . 0.0 110.401 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.91 3.61 55.39 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.116 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.1 mt -99.13 106.1 18.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-O 120.994 0.426 . . . . 0.0 111.228 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -63.31 -44.78 94.02 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.327 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -122.3 141.21 51.76 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.125 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -150.23 176.34 10.95 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.349 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -64.95 120.42 66.56 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.69 -23.35 63.4 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.01 1.807 . . . . 0.0 112.578 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.9 mmm-85 -68.5 -19.62 64.54 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.412 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -98.93 129.33 45.25 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 120.678 0.275 . . . . 0.0 110.661 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -67.52 -37.86 83.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.966 0.412 . . . . 0.0 110.731 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.2 mt -105.6 141.34 37.22 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.258 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.28 138.76 57.87 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.319 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.8 p -156.96 162.75 39.61 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.532 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 45.6 t -125.88 130.97 72.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.38 143.8 37.94 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.294 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . 0.4 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 41.0 p-10 -75.92 132.75 40.46 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.65 4.83 89.45 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -86.93 129.48 34.86 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.007 0.432 . . . . 0.0 110.488 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 99.6 m -71.1 131.2 43.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.67 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.3 158.49 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.455 -177.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.91 129.0 54.95 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 178.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.412 ' HB3' HG22 ' A' ' 125' ' ' VAL . 45.9 p90 -155.68 162.82 40.5 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.582 -177.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -92.4 149.46 21.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.375 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.442 HG11 ' HB ' ' A' ' 55' ' ' ILE . 60.5 t -108.19 126.35 64.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.937 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p -127.16 133.13 68.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -69.63 126.84 30.93 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.865 -178.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.47 162.88 12.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -61.19 -39.58 90.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.713 0.292 . . . . 0.0 110.95 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -85.56 -11.73 53.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.38 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 146.79 -172.84 27.2 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -63.47 140.12 58.84 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.885 0.374 . . . . 0.0 110.417 179.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.94 152.55 49.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.672 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -109.96 147.75 32.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.989 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.43 161.08 41.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.145 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 54.51 44.37 28.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.984 0.421 . . . . 0.0 110.125 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 111' ' ' PHE . 91.8 t -72.81 122.77 26.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.092 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 62.7 p -136.91 163.79 29.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.783 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.43 168.57 54.8 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.099 -1.601 . . . . 0.0 109.099 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.52 138.09 81.69 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 121.903 1.736 . . . . 0.0 112.094 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.21 19.04 75.45 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.77 4.42 90.34 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.4 t -62.63 136.94 96.35 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 122.699 -0.295 . . . . 0.0 110.484 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -58.44 146.96 88.24 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.552 1.502 . . . . 0.0 111.335 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.4 132.37 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.645 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 11.8 tp-100 -61.34 -41.41 96.99 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.549 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.23 -176.59 50.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.2 m -105.49 157.85 17.08 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.75 0.31 . . . . 0.0 110.64 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -60.84 -37.39 81.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.51 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -63.88 -17.3 63.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.055 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -60.66 138.47 58.07 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.435 -179.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.41 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.63 -179.791 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.57 0 C3'-C2'-C1' 105.055 1.682 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.83 0 O4'-C4'-C3' 103.023 -2.577 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.501 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.426 -1.789 0 O4'-C4'-C3' 103.202 -2.398 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.436 -0.899 0 O4'-C4'-C3' 103.987 -1.613 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.528 0.979 0 O4'-C1'-C2' 107.033 0.848 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.353 0 C1'-O4'-C4' 106.905 -1.997 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.879 0 C4'-C3'-C2' 104.835 1.635 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -144.43 160.24 41.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.207 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -66.94 136.06 54.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.196 0.522 . . . . 0.0 110.9 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.6 t -99.04 101.91 12.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.482 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.25 -44.42 99.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.071 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.52 157.25 43.1 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.4 p -102.41 -147.42 0.37 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.668 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -51.93 107.44 0.2 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.441 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 76.1 t -125.11 131.24 72.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.745 -179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.434 HD22 ' OE2' ' A' ' 110' ' ' GLU . 68.8 mt -69.09 134.98 50.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.069 0.462 . . . . 0.0 109.838 178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.77 178.23 30.82 Favored Glycine 0 CA--C 1.519 0.341 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.681 ' HG1' HD22 ' A' ' 78' ' ' ASN . 97.6 m -130.77 137.77 49.62 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.866 0.365 . . . . 0.0 110.466 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 88.1 t -70.45 112.39 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.813 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.527 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.45 -48.59 80.44 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.527 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.8 p-90 -177.32 140.06 0.27 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 114.564 -1.198 . . . . 0.0 109.95 177.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -138.14 115.28 10.96 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -100.21 124.44 45.64 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.934 -178.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -63.3 -46.08 96.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.452 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -61.19 -44.44 97.29 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.91 -39.21 93.84 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.872 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.42 4.78 65.83 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.365 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -151.75 162.59 40.77 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 117.442 0.621 . . . . 0.0 110.078 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.65 -178.4 34.6 Favored Glycine 0 CA--C 1.525 0.689 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.557 -179.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.442 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.7 m-85 -129.64 148.67 51.56 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.124 0.488 . . . . 0.0 112.095 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 82.4 mt -118.67 126.79 75.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.428 -0.806 . . . . 0.0 109.863 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -91.54 110.24 21.55 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.876 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -65.72 130.36 43.0 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.085 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.681 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.7 m-20 -87.54 -3.58 58.99 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.331 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -97.74 -31.5 12.22 Favored 'General case' 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.393 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.0 p -113.28 -9.89 13.38 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.686 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp 57.77 32.14 21.48 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.024 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -126.23 148.88 49.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.34 0.59 . . . . 0.0 111.168 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -82.3 158.87 23.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -142.93 150.6 17.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -78.15 135.79 37.72 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.352 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.5 p -146.52 147.99 17.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.104 0.478 . . . . 0.0 110.864 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -136.21 159.1 42.76 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.9 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.6 pt20 -59.19 -25.02 63.6 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -74.44 -16.05 60.88 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.468 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.459 ' HB1' ' HA ' ' A' ' 123' ' ' ALA . . . -89.32 2.96 53.63 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.155 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.5 mt -95.87 103.12 14.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.905 0.383 . . . . 0.0 111.153 -178.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -65.19 -43.67 90.9 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.314 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -119.17 144.23 46.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.134 -178.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.0 t30 -144.1 171.18 14.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.439 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -61.07 122.87 72.6 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.64 -23.12 57.04 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 121.906 1.737 . . . . 0.0 112.522 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.4 mmm-85 -73.38 -14.06 61.21 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.399 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -114.2 142.22 46.54 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 120.746 0.308 . . . . 0.0 110.658 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -98.35 4.91 48.61 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.694 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.7 mt -119.42 142.4 48.25 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.156 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -81.15 125.98 30.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.416 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 87.9 p -156.38 162.44 40.05 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.507 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.7 t -131.53 134.63 60.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.38 147.98 50.36 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.338 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -84.91 120.82 26.91 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.25 -5.61 82.8 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.04 135.21 41.27 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-O 121.069 0.462 . . . . 0.0 110.44 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.2 m -70.88 131.46 43.79 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.636 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 19.9 m -135.93 159.38 39.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.39 -178.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.434 ' OE2' HD22 ' A' ' 60' ' ' LEU . 98.2 mt-10 -116.11 138.54 51.16 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 178.028 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.6 p90 -159.44 164.04 34.87 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.523 -177.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -98.59 138.49 35.71 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.218 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.0 t -107.02 127.21 62.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 120.463 -0.495 . . . . 0.0 110.033 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m -119.56 156.73 21.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -89.37 118.06 28.75 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.008 0.432 . . . . 0.0 110.91 -178.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -106.91 167.91 14.1 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -61.77 -44.71 96.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.715 0.293 . . . . 0.0 110.943 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -74.9 -22.89 58.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.37 179.081 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 153.83 -164.76 31.37 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -65.59 143.16 57.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.88 0.372 . . . . 0.0 110.38 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -127.43 159.32 34.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.636 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.16 143.41 43.25 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.966 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.459 ' HA ' ' HB1' ' A' ' 90' ' ' ALA . . . -153.22 161.07 42.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.231 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 56.84 47.17 18.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 110.125 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.7 t -77.61 121.08 29.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.114 -179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 59.2 p -137.88 169.04 18.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.797 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.26 167.73 54.84 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.63 138.12 77.84 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.99 1.793 . . . . 0.0 112.146 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.5 20.58 78.48 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 178.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.47 89.84 Favored Glycine 0 CA--C 1.532 1.108 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.02 138.21 94.15 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-O 119.667 -0.206 . . . . 0.0 110.556 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -61.56 148.37 93.15 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 121.662 1.575 . . . . 0.0 111.233 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.5 t -63.81 130.77 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.653 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -62.31 -40.11 95.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.615 -179.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.77 157.42 33.15 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 81.5 p -76.19 160.2 29.93 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 120.921 0.391 . . . . 0.0 110.539 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -70.32 -23.48 62.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.513 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -80.09 -2.96 46.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.144 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.31 138.73 56.21 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.465 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.62 -179.528 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.517 0 C3'-C2'-C1' 105.11 1.722 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.925 0 O4'-C4'-C3' 103.714 -1.886 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.574 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.429 -1.51 0 O4'-C4'-C3' 103.22 -2.38 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.899 0 C3'-C2'-C1' 101.774 -0.661 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.895 0 O4'-C1'-C2' 107.203 1.003 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.316 0 C1'-O4'-C4' 107.46 -1.6 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.832 0 O4'-C1'-C2' 106.875 0.704 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 23.4 pttp -146.92 159.44 43.54 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.165 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -110.86 131.61 54.9 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.21 0.529 . . . . 0.0 110.996 -179.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 97.0 t -94.68 102.95 14.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.389 178.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.4 mt -63.77 -45.9 95.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.002 -179.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -158.21 162.2 37.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.478 HG22 ' N ' ' A' ' 58' ' ' LYS . 11.7 t -96.38 -142.86 0.28 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.57 179.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.478 ' N ' HG22 ' A' ' 57' ' ' THR . 76.0 mmtt -50.34 103.28 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.291 -0.563 . . . . 0.0 110.416 -179.38 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.0 t -119.28 128.59 75.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 80.0 mt -64.33 130.75 45.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.082 0.468 . . . . 0.0 109.776 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.16 174.45 23.75 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -129.22 134.31 47.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.941 0.4 . . . . 0.0 110.488 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.6 t -75.43 108.48 7.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.723 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 22.0 ttmm -63.2 -48.22 79.23 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 62.4 p-90 -176.14 143.82 0.55 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.616 -1.174 . . . . 0.0 109.925 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -138.53 115.65 10.98 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.403 HD21 ' ND2' ' A' ' 70' ' ' ASN . 99.5 m-20 -100.0 119.21 37.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.978 0.418 . . . . 0.0 110.922 -179.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.58 -46.7 94.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.509 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -62.46 -41.49 98.8 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.406 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 96.2 m-20 -62.82 -38.61 91.39 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.494 -0.482 . . . . 0.0 110.809 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.37 4.54 64.2 Favored Glycine 0 CA--C 1.531 1.042 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.382 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.406 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 40.9 p90 -148.88 160.18 43.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 117.528 0.664 . . . . 0.0 110.107 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.66 173.22 37.16 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.515 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -128.12 146.88 50.56 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.096 0.474 . . . . 0.0 112.232 -179.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.3 mt -120.61 125.86 74.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.855 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -91.4 111.15 22.53 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.509 -0.477 . . . . 0.0 110.899 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.7 mtm180 -61.5 133.35 55.62 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.113 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -86.29 -12.16 50.26 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.311 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -89.49 -29.87 18.67 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-O 121.022 0.439 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.6 p -116.46 -11.42 11.15 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.694 -178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 58.0 mtpt 57.04 32.11 21.1 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -119.77 134.04 55.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.22 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -64.72 143.19 58.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.058 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.0 t -127.78 130.98 70.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -70.99 130.04 40.55 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.425 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.04 149.55 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.163 0.506 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -131.14 164.99 24.28 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.889 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.64 -39.75 94.82 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -69.69 -17.2 63.46 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.443 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.36 -2.63 53.49 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.169 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.7 mt -96.77 106.48 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.949 0.404 . . . . 0.0 111.112 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.75 -43.06 97.56 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.296 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -125.11 142.42 51.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.129 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -148.88 176.18 10.63 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.437 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.5 t-20 -66.23 117.33 42.21 Favored Pre-proline 0 CA--C 1.54 0.569 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.91 -31.34 95.3 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.979 1.786 . . . . 0.0 112.588 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.8 mmm-85 -64.23 -19.96 65.71 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.294 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -93.14 129.0 39.28 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 120.671 0.272 . . . . 0.0 110.613 -179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -67.68 -37.96 83.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.873 0.368 . . . . 0.0 110.785 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.1 mt -110.1 144.63 38.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.257 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -65.82 137.67 57.38 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.329 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.409 ' HG ' ' HB1' ' A' ' 139' ' ' ALA . 90.2 p -156.86 163.07 39.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.455 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 46.9 t -128.82 130.39 68.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.56 149.0 49.22 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.384 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -86.56 134.47 33.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.62 1.68 90.55 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -91.75 130.27 37.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-O 120.888 0.375 . . . . 0.0 110.526 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -70.16 134.36 48.05 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.69 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.93 161.2 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.433 -178.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -120.54 136.35 54.81 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 178.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.432 ' HB3' HG22 ' A' ' 125' ' ' VAL . 29.2 p90 -157.58 161.06 38.71 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.563 -178.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -83.35 122.07 27.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.21 179.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.3 t -88.83 122.26 39.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.491 -0.484 . . . . 0.0 109.998 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 59.4 t -122.01 129.24 75.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -67.61 127.08 31.43 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.899 -178.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -120.74 157.61 15.84 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -58.88 -47.84 83.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.026 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.5 pttm -71.58 -22.08 61.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.353 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 154.25 -168.31 32.52 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.67 140.13 58.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.942 0.401 . . . . 0.0 110.353 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -120.16 135.43 54.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.676 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -100.55 141.04 33.96 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.956 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.92 157.72 43.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.185 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 54.59 43.76 29.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.96 0.409 . . . . 0.0 110.076 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.432 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.7 t -70.18 125.43 28.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.09 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.0 p -138.92 164.76 28.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.775 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.91 164.35 54.24 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.02 136.73 71.3 Favored 'Trans proline' 0 C--N 1.301 -1.942 0 C-N-CA 122.001 1.801 . . . . 0.0 112.06 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 76.89 13.64 83.42 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.96 -0.56 89.1 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.488 HG23 ' HD2' ' A' ' 132' ' ' PRO . 9.4 p -64.82 141.38 98.32 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-O 119.679 -0.2 . . . . 0.0 110.586 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.488 ' HD2' HG23 ' A' ' 131' ' ' VAL . 18.4 Cg_endo -58.03 147.69 81.15 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.66 1.573 . . . . 0.0 111.349 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -69.9 134.46 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.585 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -60.94 -43.67 98.35 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.515 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.16 158.32 30.92 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -72.92 157.01 38.26 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.84 0.352 . . . . 0.0 110.619 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -69.3 -19.65 63.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.455 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -79.87 -7.7 58.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.128 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.409 ' HB1' ' HG ' ' A' ' 102' ' ' SER . . . -61.25 140.31 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.504 -179.39 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.563 -179.634 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.511 -1.664 0 N19-C1'-C2' 115.781 0.988 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.834 0 C4'-C3'-C2' 101.926 -1.274 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.466 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C4'-C3' 103.779 -1.821 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.92 0 C4'-C3'-C2' 102.199 -1.001 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.528 0.968 0 O4'-C1'-C2' 107.49 1.263 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.352 0 C1'-O4'-C4' 106.057 -2.602 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C1'-C2' 107.293 1.085 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 61.6 mtpt -123.63 146.8 47.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.189 -179.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -105.35 131.89 52.22 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.217 0.532 . . . . 0.0 110.867 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.421 ' CG1' ' O ' ' A' ' 54' ' ' VAL . 7.2 p -99.62 103.95 15.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.386 178.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.431 ' HB ' HG11 ' A' ' 113' ' ' VAL . 97.9 mt -62.06 -44.61 99.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.098 -179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -143.68 160.37 40.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 14.4 p -98.02 -150.97 0.36 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -51.32 116.87 2.25 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.466 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.7 t -132.59 131.2 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.681 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.8 mt -75.33 134.71 40.96 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.043 0.449 . . . . 0.0 109.849 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.29 -179.48 23.38 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.4 m -129.11 135.86 49.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 110.483 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.4 t -73.54 113.1 11.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.731 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.467 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.6 ttpt -62.34 -46.77 87.21 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.9 p-90 -176.14 146.19 0.66 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.001 177.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -140.5 115.51 9.75 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -103.02 121.44 42.57 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.936 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.3 t -63.07 -44.56 99.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.452 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.42 ' HG3' ' N ' ' A' ' 70' ' ' ASN . 17.7 ptm180 -63.08 -35.11 79.18 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.42 ' N ' ' HG3' ' A' ' 69' ' ' ARG . 97.2 m-20 -69.36 -35.15 75.58 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.822 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 90.14 0.87 76.64 Favored Glycine 0 CA--C 1.531 1.057 0 C-N-CA 121.06 -0.591 . . . . 0.0 112.361 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -150.26 161.51 42.3 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 117.544 0.672 . . . . 0.0 110.086 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -154.98 179.43 31.02 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.603 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.435 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 95.9 m-85 -129.16 145.64 51.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.144 0.497 . . . . 0.0 112.131 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 84.9 mt -119.74 123.58 71.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.849 178.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.64 109.16 20.57 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.817 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -63.14 130.93 46.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.115 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.3 p30 -85.43 -0.08 53.79 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.406 -0.518 . . . . 0.0 111.37 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -99.07 -34.48 10.38 Favored 'General case' 0 C--O 1.231 0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.127 178.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 77.9 p -114.4 -10.95 12.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.687 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 58.09 29.99 18.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.95 0.405 . . . . 0.0 110.025 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -116.2 132.96 56.52 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 121.362 0.601 . . . . 0.0 111.247 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -62.67 142.25 58.17 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.089 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 76.6 t -128.1 131.01 69.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -65.92 141.12 58.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.394 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.8 p -146.92 148.45 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.182 0.515 . . . . 0.0 110.935 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -137.63 159.04 43.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.784 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -60.33 -41.93 94.58 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.5 t -64.98 -16.63 63.61 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.478 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.16 -2.97 57.79 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.123 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -93.45 101.45 12.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.987 0.422 . . . . 0.0 111.152 -178.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -63.55 -43.31 97.44 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.305 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -120.63 140.65 51.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.151 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -149.73 156.36 41.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -60.48 121.45 60.46 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.49 -22.18 65.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 121.995 1.797 . . . . 0.0 112.478 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.52 -21.55 66.17 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.35 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -86.34 130.83 34.37 Favored 'General case' 0 N--CA 1.456 -0.127 0 CA-C-O 120.748 0.308 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 84.8 t80 -61.23 -48.5 81.2 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -116.43 139.98 49.85 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.206 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -55.71 138.01 48.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.075 0.464 . . . . 0.0 110.291 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.2 p -158.84 165.08 35.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.511 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 46.3 t -124.04 129.61 74.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.0 147.76 51.17 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -80.66 121.04 25.36 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.14 -0.86 88.93 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.16 135.11 41.11 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 120.941 0.401 . . . . 0.0 110.463 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 91.1 m -70.07 131.57 44.52 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.637 179.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.77 159.18 43.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.37 -0.532 . . . . 0.0 111.511 -178.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -120.74 129.87 53.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.42 ' HB3' HG23 ' A' ' 125' ' ' VAL . 44.7 p90 -157.64 163.86 37.81 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 112.549 -177.589 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -93.68 144.85 25.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.205 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.431 HG11 ' HB ' ' A' ' 55' ' ' ILE . 58.9 t -97.07 125.65 50.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.592 -0.443 . . . . 0.0 109.942 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 99.3 t -121.24 132.1 71.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -72.61 122.59 21.65 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.967 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -108.93 164.45 12.52 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 51.5 mp0 -62.69 -40.65 97.79 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.771 0.32 . . . . 0.0 110.982 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.9 mtmm -90.89 -6.45 54.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.29 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.13 -177.41 28.25 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -69.35 148.14 50.1 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.944 0.402 . . . . 0.0 110.341 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -133.79 158.91 42.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.636 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -105.45 146.73 29.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.973 -179.647 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.1 157.86 43.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.255 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 54.42 45.32 27.34 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.118 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.42 HG23 ' HB3' ' A' ' 111' ' ' PHE . 97.0 t -71.51 122.15 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.08 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.6 p -138.75 161.64 36.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.796 179.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 162.48 54.43 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.96 138.0 83.11 Favored 'Trans proline' 0 C--N 1.301 -1.926 0 C-N-CA 122.005 1.803 . . . . 0.0 112.149 -178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.23 19.24 78.55 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 178.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.89 3.01 89.54 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.0 t -60.72 137.63 93.12 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 122.811 -0.229 . . . . 0.0 110.472 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 153.06 79.84 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 121.64 1.56 . . . . 0.0 111.309 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -70.65 129.11 34.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.617 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.3 tp60 -60.72 -44.34 96.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.55 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.39 162.0 28.28 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 179.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.525 ' O ' ' HB3' ' A' ' 139' ' ' ALA . 84.0 p -81.4 163.06 23.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.933 0.397 . . . . 0.0 110.56 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.51 -37.13 86.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.502 179.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -66.67 -7.63 22.0 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.137 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 136' ' ' SER . . . -49.17 129.58 18.16 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.495 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.506 -178.984 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.511 0 C3'-C2'-C1' 104.824 1.517 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.806 0 O4'-C4'-C3' 102.817 -2.783 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.573 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.705 0 O4'-C4'-C3' 103.785 -1.815 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.857 0 C3'-C2'-C1' 101.798 -0.645 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.882 0 O4'-C1'-C2' 107.427 1.207 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.351 0 C4'-C3'-C2' 104.785 1.585 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.809 0 O4'-C1'-C2' 107.353 1.139 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 63.5 mtpt -69.87 146.47 51.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.317 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -63.75 135.17 56.46 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 121.212 0.529 . . . . 0.0 111.008 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.1 t -102.49 102.36 13.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.417 178.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.54 -44.13 99.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.087 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.08 43.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.45 ' HG1' ' HG2' ' A' ' 58' ' ' LYS . 4.2 p -104.41 -147.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.632 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.45 ' HG2' ' HG1' ' A' ' 57' ' ' THR . 21.4 pttm -48.11 106.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.452 -179.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.2 t -127.53 130.58 70.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.718 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 93.1 mt -74.88 135.82 41.52 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 109.824 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.36 178.33 25.05 Favored Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.713 ' HG1' HD22 ' A' ' 78' ' ' ASN . 98.1 m -128.32 137.94 52.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 120.853 0.359 . . . . 0.0 110.547 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 94.0 t -77.1 109.79 12.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.689 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.463 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.5 ttpt -62.79 -46.96 85.58 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.463 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 51.5 p-90 -176.67 146.87 0.6 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.954 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -141.35 125.0 16.81 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.4 m-20 -107.48 122.53 46.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.992 0.425 . . . . 0.0 110.941 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.9 t -63.22 -46.71 95.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.462 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -62.02 -43.29 99.16 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.45 88.04 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.807 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.48 0.99 69.25 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.374 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -148.3 163.52 36.81 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 117.503 0.652 . . . . 0.0 110.076 179.16 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.21 -179.67 32.32 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.538 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.466 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.8 m-85 -126.45 143.08 51.31 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.095 0.474 . . . . 0.0 112.111 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.1 mt -121.8 126.52 74.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.859 178.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -94.09 109.97 21.71 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.93 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -63.62 134.57 55.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.073 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.713 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.6 m-20 -88.62 -9.89 50.6 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.275 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.3 p-10 -96.71 -12.9 23.17 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.146 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 55.7 p -133.84 -10.51 2.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.709 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.5 mttp 51.61 35.51 14.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.952 0.406 . . . . 0.0 109.976 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -120.11 134.11 55.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.223 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -67.81 130.03 41.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.118 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 96.2 t -119.21 131.77 70.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.52 139.49 55.63 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.293 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.11 148.34 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 CA-C-O 121.133 0.492 . . . . 0.0 110.948 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -131.74 155.59 47.43 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.9 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -59.35 -28.46 66.87 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.8 p -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.431 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.99 0.25 55.48 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.198 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.2 mt -93.83 103.11 14.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.013 0.435 . . . . 0.0 111.128 -178.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -64.96 -42.22 94.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.281 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -125.69 136.1 52.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.074 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -146.76 176.47 9.84 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.375 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -62.2 121.2 64.64 Favored Pre-proline 0 CA--C 1.539 0.54 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.31 -26.12 64.0 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 121.965 1.777 . . . . 0.0 112.65 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.1 -14.45 61.85 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.426 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 4.0 mptp? -99.34 113.93 26.52 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 120.717 0.294 . . . . 0.0 110.647 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.21 -47.83 84.3 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.889 0.376 . . . . 0.0 110.758 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.3 tp -94.09 130.83 40.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.216 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -60.5 138.46 58.01 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.256 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.488 ' HG ' ' HB3' ' A' ' 139' ' ' ALA . 93.7 p -157.97 163.37 37.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.424 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.06 131.04 68.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.64 148.01 47.7 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.303 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -86.09 134.36 33.83 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.1 2.63 90.56 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.8 tp10 -91.1 129.82 37.06 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-O 120.913 0.387 . . . . 0.0 110.517 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.9 m -70.01 133.03 46.81 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.719 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.3 m -130.61 159.09 42.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.49 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.02 130.05 55.94 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -156.24 162.93 40.1 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 119.774 -0.77 . . . . 0.0 112.49 -177.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -97.09 142.33 29.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.225 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.1 t -101.18 125.27 55.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.031 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.8 p -118.32 138.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.3 tm-20 -63.6 128.05 34.09 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.924 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.85 162.86 12.42 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -60.69 -40.94 94.05 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.773 0.32 . . . . 0.0 111.042 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -89.56 -11.54 42.44 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.342 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.81 -173.9 30.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -63.39 137.53 58.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.877 0.37 . . . . 0.0 110.459 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -128.83 135.38 49.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.661 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -74.46 150.76 39.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.042 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.59 157.96 41.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.186 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 53.52 47.97 22.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.029 0.443 . . . . 0.0 110.131 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 97.5 t -73.36 123.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.084 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -140.18 164.04 31.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.841 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.06 164.45 54.48 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_exo -60.79 138.33 78.64 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.995 1.797 . . . . 0.0 112.096 -179.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.14 18.78 79.37 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.69 0.74 89.98 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.8 t -59.87 137.69 90.47 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.46 150.31 87.0 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 121.588 1.525 . . . . 0.0 111.296 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.1 t -69.03 129.67 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.616 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -60.63 -44.38 96.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.507 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 88.41 164.78 40.62 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.668 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 139' ' ' ALA . 83.5 p -80.62 165.35 22.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.822 0.344 . . . . 0.0 110.572 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -62.47 -39.05 92.18 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.488 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -66.26 -9.81 36.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.139 -179.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.488 ' HB3' ' HG ' ' A' ' 102' ' ' SER . . . -56.45 140.35 46.17 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.43 -179.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.552 -179.894 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.52 0 C3'-C2'-C1' 104.875 1.554 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.847 0 C4'-C3'-C2' 101.443 -1.757 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.514 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.74 0 O4'-C4'-C3' 103.47 -2.13 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.435 -0.971 0 O4'-C4'-C3' 103.579 -2.021 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.855 0 O4'-C1'-C2' 107.42 1.2 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.437 0 C1'-O4'-C4' 106.869 -2.022 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.818 0 O4'-C1'-C2' 106.787 0.624 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -144.36 155.95 44.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.254 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -80.2 134.38 36.12 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.197 0.522 . . . . 0.0 110.987 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 77.8 t -101.49 103.34 14.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.438 178.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.96 -45.36 97.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.07 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -153.33 161.74 42.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.084 -179.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.433 HG22 ' N ' ' A' ' 58' ' ' LYS . 12.6 t -97.51 -146.29 0.31 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.587 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.433 ' N ' HG22 ' A' ' 57' ' ' THR . 38.4 mtmm -52.12 113.65 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.538 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 93.2 t -127.49 128.55 69.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.768 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 94.7 mt -65.36 130.05 41.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.042 0.448 . . . . 0.0 109.925 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.29 170.27 25.52 Favored Glycine 0 C--O 1.228 -0.259 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.9 m -130.66 137.07 49.4 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.886 0.374 . . . . 0.0 110.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.32 116.2 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.832 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.2 ptpt -74.53 -35.37 63.13 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 176.7 139.49 0.07 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.987 178.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -138.98 115.97 10.9 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -100.57 118.48 36.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.014 0.435 . . . . 0.0 110.905 -178.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.92 -45.17 97.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.421 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.2 ttp85 -59.71 -45.29 92.57 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -61.38 -38.2 86.17 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.869 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.45 3.86 62.75 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.324 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -149.64 160.73 43.27 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 117.528 0.664 . . . . 0.0 110.051 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.53 179.9 33.87 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.615 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.468 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 93.6 m-85 -132.67 147.27 52.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.17 0.509 . . . . 0.0 112.101 -179.021 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 80.4 mt -121.56 129.06 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.846 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -97.33 108.26 20.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.877 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . 0.468 ' HE ' ' HG1' ' A' ' 80' ' ' THR . 88.3 mtm-85 -62.89 131.26 48.14 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.073 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.68 -9.07 57.76 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.333 179.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -94.03 -29.85 15.0 Favored 'General case' 0 N--CA 1.458 -0.057 0 CA-C-O 120.911 0.386 . . . . 0.0 110.134 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.468 ' HG1' ' HE ' ' A' ' 77' ' ' ARG . 76.5 p -116.83 -13.17 10.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.679 -178.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.7 mttt 54.22 33.79 18.89 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.066 -179.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -117.94 131.58 56.49 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.28 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -71.94 130.62 41.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.055 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.8 p -124.03 147.75 28.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.907 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -75.47 142.41 42.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.354 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.2 p -144.81 146.49 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.099 0.476 . . . . 0.0 111.016 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -135.19 154.58 51.56 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.848 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -61.04 -24.88 66.52 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 111.971 0.36 . . . . 0.0 111.971 -178.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 72.1 p -76.89 -13.86 59.94 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.351 179.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.69 2.56 54.64 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.091 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.5 mt -96.23 107.31 19.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.022 0.439 . . . . 0.0 111.183 -178.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -67.99 -43.09 79.73 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.334 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.97 141.01 48.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.098 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -144.51 160.73 40.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.6 t-20 -56.29 119.91 31.26 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.28 -31.57 93.99 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.075 1.85 . . . . 0.0 112.527 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -62.59 -19.19 63.48 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.431 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -111.21 140.37 45.83 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.655 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -95.08 -13.99 24.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.889 0.376 . . . . 0.0 110.775 179.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.0 tp -106.03 125.49 51.06 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.195 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.7 mtt-85 -62.89 130.83 46.53 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.634 -0.427 . . . . 0.0 110.305 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 47.2 t -157.9 154.62 28.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.537 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 45.0 t -120.88 130.57 74.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.24 144.81 45.11 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.376 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -74.93 129.88 38.43 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.27 1.45 85.88 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -178.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -76.92 132.62 39.18 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 120.9 0.381 . . . . 0.0 110.538 -179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -74.55 129.45 37.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.711 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 14.2 m -133.57 162.46 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.417 -177.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -124.81 141.24 52.25 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.434 ' HB3' HG22 ' A' ' 125' ' ' VAL . 20.6 p90 -160.87 163.41 32.02 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 119.715 -0.794 . . . . 0.0 112.494 -177.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -90.01 124.98 35.22 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.277 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.4 t -92.62 127.04 45.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.457 -0.497 . . . . 0.0 109.974 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 33.3 m -125.37 157.33 34.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -93.27 119.28 32.24 Favored 'General case' 0 C--N 1.324 -0.53 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.93 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.01 165.37 13.24 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -60.18 -46.53 89.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.726 0.298 . . . . 0.0 110.994 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -74.55 -24.61 58.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.379 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 157.31 -168.39 34.13 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.57 142.17 58.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.846 0.355 . . . . 0.0 110.462 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 -129.22 156.84 43.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.673 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.98 145.98 39.86 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.8 159.52 44.08 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.208 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 54.44 43.17 30.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.035 0.445 . . . . 0.0 110.185 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.434 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.1 t -72.77 121.08 22.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.098 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -138.58 171.36 14.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.795 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.47 177.28 46.78 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.95 137.67 35.45 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 121.935 1.757 . . . . 0.0 112.19 -178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 18.93 77.24 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.02 2.14 89.55 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 94.4 t -61.98 137.06 95.4 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.762 -0.257 . . . . 0.0 110.553 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.41 147.68 76.39 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.568 1.512 . . . . 0.0 111.311 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.7 t -67.64 127.32 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.591 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -61.52 -41.48 97.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.535 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.01 -175.04 49.99 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.616 -0.594 . . . . 0.0 111.616 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 75.5 m -111.4 160.29 17.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.885 0.374 . . . . 0.0 110.572 -179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -59.45 -39.28 83.09 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.439 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -60.59 -15.38 27.38 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.12 179.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.33 141.63 50.54 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.526 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.615 -179.762 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.471 0 C3'-C2'-C1' 104.966 1.618 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.456 0.908 0 C4'-C3'-C2' 101.321 -1.879 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.552 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.426 -1.839 0 O4'-C4'-C3' 102.968 -2.632 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.814 0 P-O3'-C3' 120.412 0.593 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.829 0 O4'-C1'-C2' 107.415 1.195 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.399 0 C1'-O4'-C4' 107.227 -1.766 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.835 0 O4'-C4'-C3' 104.384 -1.216 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 57.1 t0 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 17.9 ptpt -141.15 159.15 42.82 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.272 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -106.62 132.52 52.52 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.224 0.535 . . . . 0.0 110.987 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.1 t -97.76 100.13 10.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.426 -0.806 . . . . 0.0 109.469 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.74 -44.12 99.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.039 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.06 158.23 43.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -98.68 -153.43 0.43 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.699 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -53.97 118.28 3.88 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.407 -178.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.64 128.65 60.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.699 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 95.3 mt -68.28 135.88 52.62 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.097 0.475 . . . . 0.0 109.801 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.89 178.35 27.44 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.587 ' HG1' HD22 ' A' ' 78' ' ' ASN . 86.7 m -130.38 137.52 49.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.801 0.334 . . . . 0.0 110.535 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.4 t -75.75 116.19 18.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.741 -178.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -69.82 -41.75 74.56 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 60.6 p-90 178.24 138.37 0.08 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.944 177.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -132.54 115.3 15.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 178.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -94.84 117.41 30.09 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.0 t -63.9 -44.82 98.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.471 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 64.6 mtp85 -61.89 -41.41 97.84 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -63.21 -37.63 87.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.856 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.85 3.28 66.16 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.301 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -149.98 160.04 43.92 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 117.482 0.641 . . . . 0.0 110.107 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.26 179.81 36.45 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 120.499 -0.857 . . . . 0.0 111.515 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.408 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 68.8 m-85 -130.7 150.59 51.81 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.192 0.52 . . . . 0.0 112.146 -178.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.411 HD12 HG22 ' A' ' 75' ' ' ILE . 83.3 mt -120.05 127.06 75.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.858 178.48 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.81 110.26 21.7 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.938 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . 0.44 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -65.9 128.9 37.88 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.101 179.161 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.587 HD22 ' HG1' ' A' ' 62' ' ' THR . 99.4 m-20 -74.39 -25.81 59.71 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.309 179.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -71.81 -41.66 67.96 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.151 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.5 p -108.11 -7.24 16.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.66 -176.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . 0.44 ' N ' ' O ' ' A' ' 77' ' ' ARG . 75.1 mmtt 52.29 31.16 8.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.906 0.384 . . . . 0.0 109.967 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -118.37 133.96 55.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.315 0.578 . . . . 0.0 111.274 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -64.23 146.28 54.58 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.067 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.24 130.46 69.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.871 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -68.07 130.37 42.75 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.9 149.12 18.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.219 0.533 . . . . 0.0 110.921 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -127.12 161.1 29.26 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.888 179.21 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.9 pt20 -61.12 -24.5 66.3 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -81.06 -11.51 59.5 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.388 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.25 -3.8 58.44 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.193 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -90.62 102.15 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 111.082 -178.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -63.71 -43.09 97.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.293 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -120.62 140.9 50.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.076 -178.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -139.79 153.33 47.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.461 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.455 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.0 p-10 -57.65 132.9 82.45 Favored Pre-proline 0 CA--C 1.539 0.529 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.8 -13.27 31.93 Favored 'Trans proline' 0 N--CA 1.499 1.8 0 C-N-CA 121.947 1.765 . . . . 0.0 112.573 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -62.29 -29.16 70.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.284 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.501 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 97.3 mttt -123.13 147.38 46.85 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 120.646 0.26 . . . . 0.0 110.668 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -89.57 -15.6 32.49 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.908 0.385 . . . . 0.0 110.821 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.468 HD21 ' H ' ' A' ' 140' ' ' ALA . 65.9 tp -97.63 123.92 41.73 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.229 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -65.66 131.73 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.947 0.403 . . . . 0.0 110.283 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.7 p -158.73 162.76 37.17 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.562 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 26.3 t -125.34 129.07 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.48 144.77 44.64 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.368 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . 0.41 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 39.7 p-10 -75.37 130.41 38.96 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.87 1.86 87.77 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -79.21 130.41 35.44 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.516 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 90.5 m -72.93 130.08 39.57 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.688 179.049 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.8 m -134.53 162.67 38.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.368 -177.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -123.19 137.69 54.83 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.41 ' HB3' HG22 ' A' ' 125' ' ' VAL . 33.1 p90 -160.81 165.42 30.29 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.607 -177.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -100.54 146.11 27.5 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.325 178.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.79 127.6 60.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.524 -0.47 . . . . 0.0 109.985 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.4 p -122.08 134.07 66.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -65.89 126.89 29.94 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.546 -0.461 . . . . 0.0 110.947 -178.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.8 166.04 12.24 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -59.64 -48.16 82.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 111.062 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.4 pttm -73.83 -22.82 59.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.315 179.041 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 153.72 -169.4 32.37 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.29 139.16 58.52 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.836 0.351 . . . . 0.0 110.428 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -134.97 136.02 41.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.548 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -78.6 151.17 32.5 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.02 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.18 156.44 41.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.243 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.4 t30 56.78 48.18 16.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.971 0.415 . . . . 0.0 110.14 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.41 HG22 ' HB3' ' A' ' 111' ' ' PHE . 90.3 t -76.06 124.53 34.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.044 -179.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 65.4 p -138.12 167.2 22.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.759 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.69 169.32 53.57 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 178.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_exo -60.64 136.53 67.53 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 122.031 1.821 . . . . 0.0 112.182 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.63 20.99 77.68 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.73 0.99 90.04 Favored Glycine 0 CA--C 1.532 1.127 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.4 t -61.18 141.55 93.88 Favored Pre-proline 0 CA--C 1.536 0.436 0 O-C-N 122.805 -0.232 . . . . 0.0 110.602 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -58.17 147.6 82.8 Favored 'Trans proline' 0 N--CA 1.497 1.732 0 C-N-CA 121.651 1.567 . . . . 0.0 111.285 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.455 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 41.2 t -68.5 125.06 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.628 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 tp60 -60.26 -39.92 88.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.483 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.17 -171.83 50.68 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 66.9 m -112.93 153.36 28.1 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.847 0.356 . . . . 0.0 110.55 -179.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -58.63 -36.92 74.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -59.56 -16.77 27.37 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.112 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.501 ' HB3' ' HD3' ' A' ' 98' ' ' LYS . . . -58.95 142.09 51.92 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.482 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.468 ' H ' HD21 ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.605 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.43 -1.438 0 C3'-C2'-C1' 104.425 1.232 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.888 0 C4'-C3'-C2' 101.819 -1.381 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.408 ' C2 ' ' CZ ' ' A' ' 74' ' ' PHE . . . . . . . . 0 O5'--C5' 1.43 -0.624 0 C4'-C3'-C2' 101.65 -1.55 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.796 0 C4'-C3'-C2' 101.604 -1.596 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.816 0 O4'-C4'-C3' 104.365 -1.235 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.406 0 C1'-O4'-C4' 105.879 -2.729 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.803 0 O4'-C1'-C2' 107.126 0.932 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.6 p-10 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -70.34 143.74 51.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.201 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -63.76 135.85 56.98 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.17 0.509 . . . . 0.0 111.008 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.38 101.23 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.373 178.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.81 -43.02 94.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.117 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.93 160.59 42.65 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.177 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.2 p -99.2 -147.18 0.33 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.712 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -54.85 117.33 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.251 -0.58 . . . . 0.0 110.507 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.7 t -130.92 132.38 63.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.722 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.0 mt -65.69 130.08 42.01 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.082 0.468 . . . . 0.0 109.816 178.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.18 172.4 26.8 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.5 m -128.11 140.52 51.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.809 0.338 . . . . 0.0 110.513 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 88.1 t -76.32 106.88 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.77 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.477 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 39.1 ttpt -61.15 -45.19 95.66 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.477 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -176.88 139.39 0.29 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.926 178.026 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -137.35 115.57 11.74 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -101.27 121.39 41.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.015 0.436 . . . . 0.0 110.821 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.4 HG21 ' N ' ' A' ' 139' ' ' ALA . 74.4 t -62.98 -46.23 96.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.407 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -60.58 -44.85 95.74 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -62.23 -37.92 87.25 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.846 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.65 2.95 66.88 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.374 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -148.43 161.68 41.13 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 117.473 0.636 . . . . 0.0 110.029 178.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.01 -179.01 32.58 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.532 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.471 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.2 m-85 -130.94 145.2 51.95 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.145 0.498 . . . . 0.0 112.19 -179.055 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.412 HD12 HG23 ' A' ' 109' ' ' VAL . 82.2 mt -120.29 125.08 73.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.865 179.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -93.33 110.86 22.4 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -64.51 132.9 51.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.193 179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -88.72 -6.69 57.27 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.315 179.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -95.9 -31.43 13.13 Favored 'General case' 0 C--O 1.232 0.182 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.163 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.0 p -114.08 -11.67 12.67 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.772 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.9 mttp 55.83 35.38 25.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.919 0.39 . . . . 0.0 110.004 -178.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -119.04 146.49 45.01 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.386 0.613 . . . . 0.0 111.232 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -84.18 121.48 27.52 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.986 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 75.0 t -112.14 126.46 69.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.94 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -64.9 134.02 53.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.337 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.18 148.42 30.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.138 0.494 . . . . 0.0 110.916 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -133.63 162.28 32.36 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.905 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.34 -39.44 93.11 Favored 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -68.05 -15.82 63.76 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.453 179.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.21 -1.33 56.8 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.181 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -97.82 104.36 15.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-O 120.997 0.427 . . . . 0.0 111.164 -178.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -65.37 -43.18 91.6 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.267 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -123.03 144.63 49.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.925 0.393 . . . . 0.0 111.035 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 p-10 -151.39 177.26 10.46 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.296 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -65.52 119.46 60.11 Favored Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.62 -33.99 98.57 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.988 1.792 . . . . 0.0 112.61 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtt85 -63.47 -21.25 66.2 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.344 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -95.41 119.79 34.52 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.668 -179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -61.34 -48.27 82.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 110.814 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 86.9 mt -95.2 145.25 25.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.232 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.18 136.02 56.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.2 t -155.41 152.72 29.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.476 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.41 130.3 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.91 140.37 45.63 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.386 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -73.11 129.21 37.57 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.4 1.01 80.64 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -77.13 132.28 38.75 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.841 0.353 . . . . 0.0 110.56 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.0 m -71.13 130.37 41.33 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.693 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.412 HG23 HD12 ' A' ' 75' ' ' ILE . 19.9 m -134.27 160.25 41.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.442 -177.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -119.13 136.94 53.92 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.0 p90 -158.78 164.24 35.99 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.495 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -96.65 141.17 30.22 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.291 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.8 128.2 50.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.984 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 p -124.34 135.27 64.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.5 tm-20 -66.33 128.95 38.14 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.89 -178.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.33 158.04 15.16 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 52.5 mp0 -59.86 -45.44 92.46 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.657 0.265 . . . . 0.0 111.025 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -76.5 -16.89 59.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.249 178.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.17 -171.19 30.14 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.88 140.75 58.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.912 0.387 . . . . 0.0 110.4 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -128.14 154.45 45.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.608 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -104.29 144.34 31.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.972 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.35 159.55 44.18 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.246 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 57.49 47.23 16.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.024 0.44 . . . . 0.0 110.185 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 93.7 t -77.18 122.68 32.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.152 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.6 p -137.46 169.36 17.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.779 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.59 172.91 47.76 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -67.63 137.02 41.11 Favored 'Trans proline' 0 C--N 1.302 -1.891 0 C-N-CA 122.01 1.807 . . . . 0.0 112.121 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.02 16.23 80.68 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.88 90.36 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 1.3 p -69.4 148.76 97.26 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 122.795 -0.238 . . . . 0.0 110.508 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.48 148.19 91.67 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.631 1.554 . . . . 0.0 111.36 179.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 78.0 t -70.79 132.26 33.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.592 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -60.71 -41.24 94.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.517 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.2 49.09 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.602 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.8 m -113.24 154.92 25.98 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.831 0.348 . . . . 0.0 110.544 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.3 -35.84 78.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -61.68 -19.44 62.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.117 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.4 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -60.1 140.78 56.66 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.476 -179.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.513 -179.617 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.514 -1.356 0 O4'-C4'-C3' 104.289 -1.311 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.877 0 P-O3'-C3' 121.031 1.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.532 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.431 -1.393 0 O4'-C4'-C3' 103.636 -1.964 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.828 0 C5'-C4'-O4' 108.417 -0.614 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.848 0 O4'-C1'-C2' 107.341 1.128 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.353 0 C1'-O4'-C4' 107.546 -1.539 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.847 0 O4'-C4'-C3' 104.767 -0.833 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 33.1 t0 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -71.02 144.78 50.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.238 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.86 134.55 56.84 Favored 'General case' 0 CA--C 1.516 -0.346 0 CA-C-O 121.249 0.547 . . . . 0.0 110.915 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t -96.77 101.78 12.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.344 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.97 -44.98 99.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.045 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -151.44 163.24 39.43 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 t -99.91 -148.93 0.36 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.749 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.448 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 25.1 pttm -52.11 117.92 3.12 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.451 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 80.8 t -133.27 130.11 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.699 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.6 mt -73.3 135.98 44.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.164 0.507 . . . . 0.0 109.835 178.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.87 179.59 24.63 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.6 m -128.91 136.31 50.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.901 0.382 . . . . 0.0 110.359 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.0 t -75.13 108.6 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.555 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.56 -48.32 81.49 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.555 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.3 p-90 -178.61 139.15 0.17 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.006 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -134.19 115.18 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -94.52 117.41 30.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.013 0.435 . . . . 0.0 110.897 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 139' ' ' ALA . 64.5 t -62.69 -44.78 99.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.46 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.09 -44.67 97.0 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -63.03 -38.62 91.93 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.31 2.18 64.05 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.322 179.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -148.28 160.14 43.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 117.371 0.585 . . . . 0.0 110.074 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.3 -177.6 34.53 Favored Glycine 0 CA--C 1.525 0.707 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.545 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -128.8 145.24 51.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.146 0.498 . . . . 0.0 112.147 -178.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 90.7 mt -116.35 125.16 73.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.881 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.99 109.84 20.85 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.977 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -62.89 133.64 54.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.106 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -86.14 -1.38 57.36 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.29 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -100.85 -32.64 10.57 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 120.914 0.388 . . . . 0.0 110.107 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.8 p -113.85 -10.49 12.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.692 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.3 mttt 56.26 31.51 18.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 120.993 0.425 . . . . 0.0 110.04 -179.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.63 141.58 49.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.252 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -67.23 145.55 55.09 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.053 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 91.4 t -128.48 131.77 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -69.83 138.6 52.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.297 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 5.9 p -147.09 148.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.18 0.514 . . . . 0.0 110.912 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -129.39 160.54 32.78 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.934 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -59.84 -40.51 88.76 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.9 p -67.85 -13.34 62.06 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.448 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.09 -7.68 59.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.103 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.401 HD13 HG22 ' A' ' 103' ' ' VAL . 83.2 mt -92.82 96.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.934 0.397 . . . . 0.0 111.143 -178.333 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -63.0 -42.35 99.82 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.27 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.546 ' HB2' HG22 ' A' ' 126' ' ' THR . 3.7 mptp? -119.25 132.09 55.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.059 -179.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -145.53 157.72 43.95 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.483 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -57.2 119.33 30.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -68.19 -20.06 43.9 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 121.946 1.764 . . . . 0.0 112.577 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -64.5 -20.05 65.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.39 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.43 ' HD3' ' HB1' ' A' ' 139' ' ' ALA . 99.0 mttt -100.92 140.47 35.17 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.719 0.295 . . . . 0.0 110.619 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -69.51 -41.58 75.86 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.721 -178.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.6 142.8 35.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.193 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -74.27 128.12 34.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 110.304 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 66.9 m -146.67 165.08 30.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.515 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.401 HG22 HD13 ' A' ' 91' ' ' ILE . 47.3 t -119.7 128.42 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.101 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -60.59 140.4 48.05 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.355 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -80.11 130.1 34.99 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.07 2.87 90.68 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -89.13 133.45 34.39 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 120.875 0.369 . . . . 0.0 110.496 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 86.5 m -69.38 131.31 44.6 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.682 178.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 28.1 m -129.24 159.39 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.419 -177.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -119.17 128.55 54.35 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -155.98 162.07 40.4 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.555 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -92.47 150.67 20.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.283 178.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.3 t -109.31 125.01 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.94 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.4 p -123.41 140.06 48.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -83.73 111.73 19.42 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.925 -178.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -95.01 176.0 34.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -62.13 -44.56 96.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.701 0.286 . . . . 0.0 110.935 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -75.77 -23.67 55.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.364 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 152.91 -167.18 31.62 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -63.62 143.54 57.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 110.452 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -143.75 136.24 27.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.653 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -76.17 150.17 37.19 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.993 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.79 157.2 41.63 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 56.18 48.68 16.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.947 0.403 . . . . 0.0 110.03 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.7 t -73.81 125.17 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.124 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.546 HG22 ' HB2' ' A' ' 93' ' ' LYS . 67.9 p -139.25 163.81 31.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.761 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.03 167.83 54.71 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 109.216 -1.553 . . . . 0.0 109.216 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_exo -60.14 138.43 81.59 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 121.946 1.764 . . . . 0.0 112.132 -178.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 69.88 20.79 76.36 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.48 90.54 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 89.8 t -62.11 139.68 96.01 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.84 -0.212 . . . . 0.0 110.504 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -58.3 148.05 81.42 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 C-N-CA 121.608 1.539 . . . . 0.0 111.286 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.0 t -67.64 129.72 32.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.619 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 26.7 mp0 -61.55 -42.37 98.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.489 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.19 -171.8 53.65 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 179.335 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 57.3 m -114.85 158.06 22.45 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 110.545 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -61.7 -37.38 83.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.518 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -64.26 -13.35 48.91 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.04 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.461 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -59.54 -39.41 83.87 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.581 -179.99 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.486 0 C3'-C2'-C1' 104.689 1.421 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -1.003 0 O4'-C4'-C3' 103.491 -2.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.437 -0.85 0 O4'-C4'-C3' 103.697 -1.903 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.935 0 O4'-C4'-C3' 103.677 -1.923 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.843 0 O4'-C1'-C2' 107.501 1.274 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.533 1.465 0 C1'-O4'-C4' 106.619 -2.201 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.818 0 O4'-C4'-C3' 104.199 -1.401 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.3 t0 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 58.2 mtmt -70.39 144.5 51.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.142 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -106.04 131.25 53.55 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 121.162 0.506 . . . . 0.0 111.039 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -96.73 103.02 14.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.36 178.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.8 mt -61.4 -44.33 98.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.08 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -142.94 162.11 36.34 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.055 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -100.61 -151.98 0.42 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.606 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -49.44 117.58 2.28 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.487 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.7 t -132.82 130.53 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.693 179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.2 mt -73.2 138.21 45.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.148 0.499 . . . . 0.0 109.811 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.15 178.81 27.38 Favored Glycine 0 N--CA 1.451 -0.363 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 88.2 m -127.56 137.17 52.52 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.502 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 90.4 t -76.28 108.57 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.749 -178.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.542 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -61.15 -48.86 79.65 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.542 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.1 p-90 -177.64 143.01 0.33 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.96 178.037 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -144.42 120.57 10.8 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 70' ' ' ASN . 79.8 m-20 -103.36 133.34 48.6 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.911 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.7 t -71.25 -38.39 69.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.436 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -58.41 -47.41 83.98 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -176.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.403 ' OD1' ' O ' ' A' ' 67' ' ' ASN . 53.1 p30 -80.62 -16.04 55.07 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.803 -178.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 70' ' ' ASN . . . 70.96 18.81 76.58 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.295 177.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -149.93 164.08 36.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 117.462 0.631 . . . . 0.0 110.181 179.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.13 -173.35 38.12 Favored Glycine 0 CA--C 1.524 0.604 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.505 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.446 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 98.4 m-85 -128.75 146.74 50.81 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.108 0.48 . . . . 0.0 112.114 -178.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.5 mt -120.38 126.7 75.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.955 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -94.95 111.09 22.91 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.956 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 84.6 mtp180 -63.09 131.6 49.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.165 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.4 p30 -89.81 2.33 55.06 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.414 -0.515 . . . . 0.0 111.323 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -107.27 -33.53 7.38 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.993 0.425 . . . . 0.0 110.198 179.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 74.4 p -116.2 -9.05 11.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.711 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.4 mttm 54.11 33.49 17.93 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 -178.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -112.85 132.96 55.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.233 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -73.91 125.4 28.12 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.052 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.85 131.89 70.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.883 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -63.35 142.78 58.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.351 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -139.91 145.9 25.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-O 121.218 0.532 . . . . 0.0 110.889 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -136.62 157.4 46.86 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.911 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -61.31 -39.25 89.8 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.0 p -66.79 -17.15 64.73 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -83.45 -4.27 58.35 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.154 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 81.7 mt -96.99 97.93 6.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.995 0.426 . . . . 0.0 111.217 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -64.51 -41.3 96.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.283 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.514 ' HB3' HG22 ' A' ' 126' ' ' THR . 40.3 ttmt -119.45 136.33 54.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -149.43 170.82 17.69 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.357 179.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.432 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 31.5 p-10 -65.95 125.54 90.17 Favored Pre-proline 0 CA--C 1.539 0.526 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.83 -19.62 58.8 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.035 1.823 . . . . 0.0 112.59 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -64.57 -22.97 67.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -104.69 128.25 52.71 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.648 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -69.31 -37.55 77.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.754 179.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.98 131.56 48.32 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.141 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -59.45 136.36 57.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.028 0.442 . . . . 0.0 110.279 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.465 ' HG ' ' H ' ' A' ' 136' ' ' SER . 46.3 t -158.17 155.33 28.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.572 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.64 129.36 75.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.88 151.12 51.21 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.316 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -86.67 136.1 33.15 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.71 2.86 90.25 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.9 tp10 -92.92 128.81 38.92 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.938 0.399 . . . . 0.0 110.5 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -67.12 133.31 49.59 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.751 179.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.9 m -129.53 159.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.456 -178.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -118.66 128.83 54.9 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -157.76 161.15 38.45 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.767 -0.773 . . . . 0.0 112.538 -178.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.404 ' OD1' ' C ' ' A' ' 112' ' ' ASP . 55.8 p30 -90.32 174.53 7.53 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.281 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -127.61 127.67 68.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 C-N-CA 120.509 -0.476 . . . . 0.0 109.978 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 91.8 t -120.03 130.95 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -72.45 114.25 10.37 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.058 0.456 . . . . 0.0 110.896 -179.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -84.82 179.71 51.22 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -68.81 -29.28 67.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.702 0.287 . . . . 0.0 110.962 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.425 ' HZ3' " H1'" ' B' ' 302' ' ' ' DA' . 17.2 ptmt -116.79 -23.25 8.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.402 -179.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -170.9 173.4 44.61 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -70.24 155.38 40.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.788 0.328 . . . . 0.0 110.512 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.6 pt-20 -136.89 158.25 44.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.666 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -97.77 148.46 23.34 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.96 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.09 41.76 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.236 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.1 t30 53.35 47.92 23.13 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.141 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.7 t -75.28 125.55 34.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.069 -178.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 93' ' ' LYS . 69.7 p -136.92 169.21 18.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.743 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -77.27 175.58 53.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.05 137.85 35.54 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 122.074 1.849 . . . . 0.0 112.061 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.7 19.64 79.31 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.87 1.48 90.61 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 -179.147 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 86.6 t -62.65 137.61 96.56 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-O 119.647 -0.216 . . . . 0.0 110.611 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -59.14 148.44 85.75 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 121.697 1.598 . . . . 0.0 111.259 179.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.432 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 43.7 t -67.59 128.17 30.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.669 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -63.58 -39.62 94.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.539 -179.146 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.91 -175.58 53.16 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 179.311 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.465 ' H ' ' HG ' ' A' ' 102' ' ' SER . 41.4 t -101.28 160.4 14.44 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.824 0.345 . . . . 0.0 110.554 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -61.09 -37.99 84.68 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.416 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -64.35 -14.04 53.96 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.092 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.51 138.88 57.55 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.477 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.58 -179.807 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . 1.382 ' N6 ' ' H62' ' B' ' 301' ' ' ' DA' . . . . . . . . 0 C4'--C3' 1.513 -1.491 0 O4'-C4'-C3' 104.386 -1.214 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . 0.425 " H1'" ' HZ3' ' A' ' 118' ' ' LYS . . . . . . . . 0 O4'--C4' 1.455 0.853 0 C4'-C3'-C2' 102.025 -1.175 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.501 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.699 0 O4'-C4'-C3' 102.897 -2.703 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.435 -0.964 0 O4'-C4'-C3' 104.121 -1.479 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.874 0 O4'-C1'-C2' 107.362 1.148 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.25 0 C1'-O4'-C4' 106.677 -2.159 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.798 0 C3'-C2'-C1' 101.948 -0.537 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -71.49 150.5 44.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -128.11 130.07 47.58 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.196 0.522 . . . . 0.0 110.937 179.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 84.9 t -91.74 100.57 11.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.397 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.6 mt -63.41 -44.14 98.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.046 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.25 163.73 36.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.07 0.462 . . . . 0.0 111.067 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.429 HG22 ' N ' ' A' ' 58' ' ' LYS . 12.6 t -98.1 -146.57 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.679 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.429 ' N ' HG22 ' A' ' 57' ' ' THR . 63.5 mttp -50.82 116.4 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.407 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.1 t -131.78 130.03 61.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.697 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.7 mt -73.55 137.21 44.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.055 0.455 . . . . 0.0 109.808 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.32 177.9 27.2 Favored Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.414 ' HG1' HD22 ' A' ' 78' ' ' ASN . 96.4 m -128.22 135.76 50.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.856 0.36 . . . . 0.0 110.486 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.2 t -76.93 109.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.765 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.54 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.1 tttt -62.22 -48.39 80.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.54 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 62.2 p-90 -175.8 147.63 0.81 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 114.678 -1.146 . . . . 0.0 109.903 178.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -137.45 115.44 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 41.4 t-20 -93.49 110.27 21.85 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.978 0.418 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 53.4 t -61.21 -46.7 96.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.391 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.1 ttp180 -62.01 -43.76 98.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -178.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.16 -39.39 92.48 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.81 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.49 4.04 59.58 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.382 179.255 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -148.26 160.82 42.57 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.423 0.611 . . . . 0.0 110.04 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.53 -177.22 33.44 Favored Glycine 0 CA--C 1.525 0.71 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.573 -179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.455 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.5 m-85 -131.5 147.9 52.58 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.134 0.492 . . . . 0.0 112.193 -179.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.2 mt -120.77 127.36 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.843 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -91.92 110.45 21.81 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.807 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 96.4 mtm-85 -62.18 135.2 57.39 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.126 179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.414 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.9 m-20 -82.54 -6.95 59.62 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.382 179.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -94.75 -33.07 13.04 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.959 0.409 . . . . 0.0 110.138 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 68.0 p -116.9 -10.6 10.96 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.642 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 54.44 34.51 21.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.976 0.417 . . . . 0.0 110.026 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -121.04 132.64 55.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.247 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -66.23 148.14 52.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.037 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 120' ' ' ALA . 7.1 p -132.78 152.15 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.914 179.672 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -73.24 133.11 43.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.297 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.4 p -144.84 144.11 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.149 0.499 . . . . 0.0 110.911 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -136.19 157.79 45.96 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.841 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -58.46 -24.73 61.05 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -178.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.3 p -73.6 -20.49 60.59 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.421 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.24 -7.74 58.88 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.137 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.3 mt -90.0 94.9 5.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.872 0.367 . . . . 0.0 111.198 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -64.34 -38.15 90.03 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.437 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -122.94 142.86 50.35 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.101 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -153.28 177.13 11.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.35 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -63.63 118.62 46.43 Favored Pre-proline 0 CA--C 1.539 0.552 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.7 -34.66 99.07 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.056 1.838 . . . . 0.0 112.545 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.09 -19.9 66.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.467 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -97.65 114.53 26.5 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-O 120.74 0.305 . . . . 0.0 110.604 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -60.69 -47.89 84.23 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.893 0.378 . . . . 0.0 110.761 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 64.0 tp -91.18 130.67 37.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.182 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -59.76 136.73 58.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.055 0.455 . . . . 0.0 110.249 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.1 t -154.18 154.25 33.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.505 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.7 131.95 71.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.4 144.64 47.74 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.324 -178.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -83.14 118.59 23.69 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.65 -0.73 74.29 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -82.82 132.33 35.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.862 0.363 . . . . 0.0 110.532 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 85.8 m -69.04 132.48 46.7 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.648 178.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -130.01 159.77 41.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.47 -178.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -119.96 126.62 51.31 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -155.45 163.81 39.55 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.558 -177.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.31 153.33 20.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.224 178.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -110.29 125.09 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.403 -0.519 . . . . 0.0 109.983 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 75.8 t -123.41 129.75 74.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 51.5 tp10 -70.27 127.09 31.59 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.905 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.95 159.98 13.71 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.6 mp0 -61.55 -39.51 91.38 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.741 0.305 . . . . 0.0 110.957 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -85.23 -8.38 58.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.354 179.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 144.96 -169.77 26.61 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.4 ' O ' HG23 ' A' ' 84' ' ' VAL . . . -64.52 143.85 57.62 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.885 0.374 . . . . 0.0 110.52 179.697 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -129.08 136.4 50.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.668 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -94.14 146.59 23.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.01 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.35 157.06 40.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.135 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 58.19 47.33 14.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.977 0.418 . . . . 0.0 110.164 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.2 t -76.07 123.22 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.074 -179.025 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.2 p -134.96 159.96 39.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.813 179.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.55 162.21 53.94 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.105 -1.598 . . . . 0.0 109.105 178.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.83 136.99 77.34 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.039 1.826 . . . . 0.0 112.108 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.57 83.0 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.2 1.45 90.47 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.462 HG22 ' HD2' ' A' ' 132' ' ' PRO . 9.9 p -68.89 141.66 92.58 Favored Pre-proline 0 CA--C 1.535 0.4 0 CA-C-O 119.673 -0.203 . . . . 0.0 110.501 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.462 ' HD2' HG22 ' A' ' 131' ' ' VAL . 20.4 Cg_endo -59.09 150.24 74.72 Favored 'Trans proline' 0 N--CA 1.497 1.721 0 C-N-CA 121.634 1.556 . . . . 0.0 111.315 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -64.42 133.58 29.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.552 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -62.43 -42.41 99.43 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.496 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.41 162.59 36.16 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 85.1 p -80.59 166.3 21.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.894 0.378 . . . . 0.0 110.496 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -63.4 -36.87 85.17 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.511 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -72.1 -5.23 33.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.121 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.6 140.39 54.45 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.448 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.636 -179.818 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.555 0 C3'-C2'-C1' 104.658 1.399 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -0.992 0 C4'-C3'-C2' 101.247 -1.953 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.56 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.77 0 O4'-C4'-C3' 103.189 -2.411 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.821 0 O4'-C1'-C2' 107.405 1.186 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.429 -1.517 0 C3'-C2'-C1' 104.482 1.273 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.432 -1.256 0 C1'-O4'-C4' 107.597 -1.502 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.882 0 C5'-C4'-O4' 108.618 -0.489 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -140.89 152.07 44.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.281 -179.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -78.05 136.56 37.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.234 0.54 . . . . 0.0 110.907 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 101.88 12.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.375 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.0 -44.53 97.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.069 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -155.27 163.24 40.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.056 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.545 ' O ' HG21 ' A' ' 59' ' ' VAL . 11.4 t -96.19 -149.51 0.31 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.685 179.622 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -55.1 118.0 3.96 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.52 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.545 HG21 ' O ' ' A' ' 57' ' ' THR . 87.5 t -129.58 128.55 65.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.701 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.7 mt -68.98 135.31 50.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.122 0.486 . . . . 0.0 109.733 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.04 -177.82 27.0 Favored Glycine 0 CA--C 1.521 0.42 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.587 ' HG1' HD22 ' A' ' 78' ' ' ASN . 94.4 m -128.28 135.34 49.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.876 0.37 . . . . 0.0 110.391 -179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 97.1 t -71.28 110.87 4.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.765 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.526 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -61.52 -48.92 78.85 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.526 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.9 p-90 -177.77 140.08 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.957 178.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -137.1 119.17 15.43 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -101.22 120.88 40.9 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.892 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.407 HG21 ' C ' ' A' ' 138' ' ' TYR . 67.3 t -62.93 -45.73 98.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.525 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -61.82 -44.68 96.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -178.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -62.09 -38.78 90.13 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.902 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.61 2.1 65.53 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.397 179.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -147.54 161.96 40.05 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 117.467 0.633 . . . . 0.0 110.112 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.55 -179.05 36.9 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.561 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.459 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 92.3 m-85 -126.99 146.27 50.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.153 0.501 . . . . 0.0 112.172 -178.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.409 HG22 ' CE2' ' A' ' 111' ' ' PHE . 87.2 mt -119.31 125.34 74.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.827 178.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.77 109.88 21.32 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.836 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -65.96 134.78 53.66 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.19 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.587 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.7 m-20 -85.06 -5.31 59.35 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.418 -0.513 . . . . 0.0 111.268 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -96.49 -33.19 11.95 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.176 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 66.5 p -115.15 -9.61 12.27 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.627 -178.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt 53.63 32.5 14.59 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 121.062 0.458 . . . . 0.0 110.147 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -119.73 131.83 55.48 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.233 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.02 142.43 58.38 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.986 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 79.0 t -126.89 132.42 70.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.899 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -66.19 138.19 57.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.312 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.79 147.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.225 0.536 . . . . 0.0 110.946 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -136.88 159.96 40.31 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.905 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pm0 -59.98 -20.4 57.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -178.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 64.1 p -82.52 -12.81 57.52 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.465 179.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.05 1.36 57.24 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.132 179.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.7 mt -95.97 101.68 12.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.929 0.395 . . . . 0.0 111.136 -178.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -63.11 -45.15 93.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.365 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -115.07 136.8 52.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.04 -178.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -143.26 137.85 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.31 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.433 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.4 p-10 -58.96 138.39 87.49 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.057 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.34 -9.12 24.76 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.004 1.802 . . . . 0.0 112.499 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.55 -35.95 77.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.412 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -105.04 137.91 42.07 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-O 120.687 0.279 . . . . 0.0 110.672 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.43 ' HB2' HD23 ' A' ' 100' ' ' LEU . 98.2 m-85 -68.42 -41.95 79.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.756 -179.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.43 HD23 ' HB2' ' A' ' 99' ' ' TYR . 1.3 mm? -97.98 146.41 25.53 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.31 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -67.51 128.52 36.74 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.381 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.7 m -147.51 161.74 40.47 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.477 -179.271 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 t -125.97 131.11 72.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -61.64 143.48 48.65 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.266 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -81.58 123.29 28.54 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.0 3.83 88.87 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -84.74 136.67 33.61 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.939 0.399 . . . . 0.0 110.503 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 89.6 m -70.66 130.88 42.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.607 179.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -134.91 164.82 32.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.445 -178.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -124.87 137.7 54.28 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.415 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.3 p90 -160.12 162.52 34.01 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.813 -0.755 . . . . 0.0 112.481 -177.394 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -90.65 137.34 32.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.268 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.7 t -103.83 126.22 58.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.988 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.8 m -123.97 153.33 30.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -91.72 115.07 27.75 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.082 0.468 . . . . 0.0 111.023 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -97.31 172.13 27.46 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -63.89 -39.67 94.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.675 0.274 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -85.17 -18.9 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 154.94 -171.3 33.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -66.63 143.24 57.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.883 0.373 . . . . 0.0 110.412 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -138.08 136.06 36.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.628 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.92 152.87 33.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.12 158.22 42.65 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.14 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 53.07 47.28 24.92 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.105 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.415 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.6 t -74.43 124.05 31.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.071 -179.048 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 50.3 p -139.78 170.06 16.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.825 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.31 164.68 54.72 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 178.378 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -59.44 137.18 76.51 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 C-N-CA 121.977 1.785 . . . . 0.0 112.177 -179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.31 20.81 77.06 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.25 2.48 90.5 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -179.577 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.6 t -60.98 141.3 93.61 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 122.777 -0.249 . . . . 0.0 110.553 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -56.28 148.06 63.09 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 121.549 1.499 . . . . 0.0 111.315 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.433 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 42.9 t -69.78 126.24 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.64 -179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 16.2 tm0? -60.9 -40.42 93.01 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.54 -178.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.41 -174.39 54.95 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -111.75 162.84 14.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.841 0.353 . . . . 0.0 110.502 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -60.84 -37.91 83.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.509 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.417 ' CE2' ' C2 ' ' B' ' 307' ' ' ' DT' . 96.4 m-85 -71.02 -5.77 33.84 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.067 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.14 -38.92 80.82 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.521 -179.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.578 -179.476 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.43 -1.446 0 C3'-C2'-C1' 104.69 1.422 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.802 0 O4'-C4'-C3' 104.335 -1.265 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.52 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.434 -1.068 0 O4'-C4'-C3' 103.126 -2.474 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.457 0.982 0 C3'-C2'-C1' 101.34 -0.971 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.873 0 O4'-C1'-C2' 106.98 0.8 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.236 0 C1'-O4'-C4' 107.378 -1.659 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . 0.417 ' C2 ' ' CE2' ' A' ' 138' ' ' TYR . . . . . . . . 0 O5'--C5' 1.427 -0.833 0 O4'-C1'-C2' 104.899 -1.092 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 30.3 mmmt -78.82 152.34 31.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.185 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.2 tttm -105.31 130.9 53.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.183 0.516 . . . . 0.0 110.958 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.4 p -95.97 100.85 11.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.414 179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.87 -44.26 99.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.102 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.94 162.91 37.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 -179.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.494 ' O ' HG21 ' A' ' 59' ' ' VAL . 7.9 t -108.84 -134.8 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.707 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.442 ' N ' HG22 ' A' ' 57' ' ' THR . 68.6 mttm -54.71 102.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.346 -0.541 . . . . 0.0 110.369 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.494 HG21 ' O ' ' A' ' 57' ' ' THR . 97.4 t -127.26 128.75 70.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.729 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 88.6 mt -79.66 135.99 36.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.104 0.478 . . . . 0.0 109.862 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.49 178.18 21.81 Favored Glycine 0 CA--C 1.519 0.298 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 134.76 50.67 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.852 0.358 . . . . 0.0 110.463 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.406 HG23 HG12 ' A' ' 103' ' ' VAL . 86.6 t -75.77 109.99 10.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.75 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.526 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.67 -49.19 77.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.526 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 61.4 p-90 -174.51 152.78 1.75 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.899 178.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -147.06 117.07 7.24 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.6 m-20 -97.45 120.87 38.6 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.908 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -63.18 -44.8 99.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.462 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.43 HH11 ' HD2' ' A' ' 69' ' ' ARG . 9.0 ptm85 -65.22 -34.84 79.32 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -69.3 -35.35 75.9 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.521 -0.471 . . . . 0.0 110.788 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 89.38 1.42 78.39 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.367 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -150.15 162.74 39.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.445 0.623 . . . . 0.0 110.085 179.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.73 179.85 34.09 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.493 -0.86 . . . . 0.0 111.535 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.474 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 81.9 m-85 -123.49 143.52 50.11 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.133 0.492 . . . . 0.0 112.091 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.1 mt -120.63 126.2 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.841 178.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.91 114.75 27.38 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.875 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -71.43 128.69 36.69 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.035 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.3 p30 -83.93 -1.59 54.85 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.337 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -101.21 -31.54 10.96 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-O 120.947 0.403 . . . . 0.0 110.176 179.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.72 -12.48 11.51 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.682 -179.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.86 32.45 19.68 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.995 -179.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.78 135.35 55.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.244 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -63.32 144.95 56.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.072 -179.421 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.35 133.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.901 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -80.98 125.19 29.84 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.325 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 32.6 m -131.17 159.86 42.72 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-O 121.133 0.492 . . . . 0.0 110.973 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -137.95 155.97 48.34 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.837 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -60.93 -22.98 64.92 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.9 p -80.96 -13.0 59.28 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.422 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.05 2.93 55.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.094 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.9 mt -98.03 106.68 19.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.876 0.37 . . . . 0.0 111.171 -178.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -63.84 -44.35 93.45 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.327 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.03 144.13 50.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.928 0.394 . . . . 0.0 111.051 -179.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 p-10 -150.26 174.32 12.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.418 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.0 t-20 -62.67 120.2 57.79 Favored Pre-proline 0 CA--C 1.541 0.604 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.49 -23.07 58.21 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.035 1.823 . . . . 0.0 112.595 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.4 mmm-85 -67.02 -21.63 65.92 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.413 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -91.48 136.93 32.76 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.62 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -69.18 -39.55 78.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.753 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 8.0 mp -113.5 151.52 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.173 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.66 139.25 58.74 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.319 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.8 p -156.0 161.36 40.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.603 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.406 HG12 HG23 ' A' ' 63' ' ' VAL . 52.7 t -123.12 125.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.8 146.86 48.94 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.363 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -84.55 133.78 34.44 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.88 4.8 89.61 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.565 -1.014 . . . . 0.0 110.565 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -92.61 129.77 38.44 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.96 0.41 . . . . 0.0 110.504 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.5 m -66.81 133.55 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.576 178.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.5 m -128.89 158.15 41.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.459 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -120.0 130.11 54.59 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -160.8 165.14 30.79 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.549 -177.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -95.28 144.98 25.41 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.306 178.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -105.06 126.3 60.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.022 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.8 p -125.15 130.91 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.96 128.89 37.79 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.941 -178.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.84 160.72 13.05 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -60.47 -42.85 97.08 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.741 0.305 . . . . 0.0 110.97 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -86.46 -14.37 43.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.334 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 156.09 -175.2 33.9 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.05 142.24 58.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.381 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -125.98 159.13 33.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -116.67 149.81 39.17 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.23 156.99 42.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.191 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 54.81 43.89 29.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.051 0.453 . . . . 0.0 110.123 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.8 t -72.45 121.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.054 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.1 p -137.88 166.23 24.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.725 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.61 175.24 49.79 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.49 138.21 38.12 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.929 1.753 . . . . 0.0 112.097 -179.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 19.99 77.94 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.79 1.12 90.56 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.03 137.52 95.58 Favored Pre-proline 0 CA--C 1.535 0.39 0 O-C-N 122.822 -0.222 . . . . 0.0 110.556 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -59.45 146.26 95.51 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.656 1.57 . . . . 0.0 111.247 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -64.96 135.27 28.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.69 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -59.51 -42.78 92.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.469 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.28 176.71 51.16 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 179.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.404 ' O ' ' HB3' ' A' ' 139' ' ' ALA . 43.8 t -97.0 143.93 27.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.92 0.391 . . . . 0.0 110.54 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -60.14 -21.07 61.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.552 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -74.93 -12.59 60.39 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.113 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.404 ' HB3' ' O ' ' A' ' 136' ' ' SER . . . -58.37 141.03 52.53 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.515 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.61 -179.498 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.522 0 C3'-C2'-C1' 104.461 1.258 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.831 0 O4'-C4'-C3' 103.812 -1.788 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.521 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.425 -1.886 0 O4'-C4'-C3' 102.856 -2.744 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.81 0 P-O3'-C3' 120.438 0.615 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.776 0 C4'-C3'-C2' 102.477 -0.723 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.214 0 C1'-O4'-C4' 106.43 -2.336 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.794 0 O4'-C1'-C2' 107.356 1.142 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 60.1 mtmt -70.62 143.9 51.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.261 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -104.9 129.37 53.28 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-O 121.218 0.533 . . . . 0.0 110.921 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.5 t -94.09 103.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.41 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.5 mt -62.82 -45.3 99.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.029 -178.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.83 167.62 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.116 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.443 HG22 ' N ' ' A' ' 58' ' ' LYS . 7.5 t -105.66 -134.77 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.68 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.443 ' N ' HG22 ' A' ' 57' ' ' THR . 87.8 tttt -50.34 112.91 0.76 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.482 -179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 72.5 t -135.45 131.29 51.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.771 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 67.2 mt -75.01 133.75 41.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.121 0.486 . . . . 0.0 109.75 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.89 175.57 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 90.1 m -131.17 138.93 49.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.829 0.347 . . . . 0.0 110.432 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 97.2 t -72.62 109.18 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.78 -178.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.544 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -62.49 -48.04 81.35 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.544 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 59.0 p-90 -177.23 139.53 0.26 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.969 178.154 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -135.71 120.84 18.87 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -104.65 119.87 40.0 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.923 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.36 -45.47 98.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.482 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -60.57 -44.92 95.66 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -62.13 -38.15 87.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.813 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.1 1.47 64.97 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.34 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.5 p90 -147.5 160.16 42.91 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 117.473 0.636 . . . . 0.0 110.072 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.91 174.61 36.73 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.489 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -129.16 148.6 51.11 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.187 0.518 . . . . 0.0 112.141 -179.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.428 HD13 HG23 ' A' ' 109' ' ' VAL . 84.5 mt -116.55 127.18 74.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.844 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.12 109.05 19.96 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -60.38 134.99 57.6 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.159 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -84.37 -0.15 51.53 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.301 179.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -101.87 -33.04 9.94 Favored 'General case' 0 C--O 1.231 0.085 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.058 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.7 p -116.59 -9.09 11.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.693 -178.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mmtm 55.81 31.75 18.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.96 0.41 . . . . 0.0 110.037 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -117.69 133.99 55.37 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.303 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.15 144.57 56.8 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.098 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.2 t -124.14 126.94 73.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.913 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.76 129.03 38.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.318 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.93 149.76 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.186 0.517 . . . . 0.0 110.921 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.01 160.13 33.73 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.858 178.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -60.24 -29.79 68.99 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -73.53 -15.66 61.29 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.385 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.19 -0.07 53.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.17 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.4 mt -92.98 101.3 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.967 0.413 . . . . 0.0 111.226 -178.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -62.94 -43.86 97.65 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -121.79 143.02 49.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.148 -179.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -152.77 163.79 39.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.434 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -61.76 121.15 62.81 Favored Pre-proline 0 CA--C 1.539 0.539 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.46 -21.63 66.09 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 121.967 1.778 . . . . 0.0 112.553 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.82 -22.16 66.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.326 179.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -100.89 120.67 40.49 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-O 120.751 0.31 . . . . 0.0 110.686 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 88.8 t80 -61.03 -48.3 82.41 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.703 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.5 tp -93.09 129.53 39.03 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.141 -179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -61.82 139.23 58.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.297 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.2 p -158.31 163.95 36.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.452 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.8 t -125.16 129.53 73.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.25 144.66 48.01 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.319 -178.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 105' ' ' ASP . 41.0 p-10 -77.36 129.2 35.51 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.36 2.01 86.94 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 110.526 -1.029 . . . . 0.0 110.526 -178.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.7 tt0 -78.37 130.91 36.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 120.988 0.423 . . . . 0.0 110.469 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.4 m -71.09 130.76 42.35 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.713 178.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.428 HG23 HD13 ' A' ' 75' ' ' ILE . 21.6 m -133.71 158.43 42.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.524 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -115.78 132.42 56.64 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -161.33 167.11 26.42 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.473 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -88.57 149.53 23.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.252 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.8 t -108.43 123.9 64.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.481 -0.488 . . . . 0.0 109.957 -179.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.4 t -122.99 128.13 75.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 50.1 tp10 -64.99 124.87 23.18 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.946 -178.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -120.76 159.59 15.39 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -61.98 -40.06 94.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.709 0.29 . . . . 0.0 110.937 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -81.95 -9.3 59.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.391 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 142.7 -167.54 26.21 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.504 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.29 141.94 58.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.5 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.56 151.93 35.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.655 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -118.69 142.43 47.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.045 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.11 153.34 42.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.184 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 54.36 43.08 30.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.059 0.457 . . . . 0.0 110.174 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.05 125.39 28.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.106 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.9 p -135.67 169.43 17.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.824 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.09 177.24 45.69 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 178.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 136.38 32.93 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 121.911 1.74 . . . . 0.0 112.188 -178.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.68 21.53 77.87 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.07 1.79 90.41 Favored Glycine 0 CA--C 1.531 1.084 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 85.5 t -63.16 140.43 97.67 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 122.853 -0.204 . . . . 0.0 110.527 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -58.06 148.53 76.75 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 121.58 1.52 . . . . 0.0 111.292 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.2 t -69.15 128.99 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.605 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -61.47 -41.85 97.88 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.435 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.83 -175.9 48.94 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -109.5 159.96 16.62 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.845 0.355 . . . . 0.0 110.53 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt -61.49 -37.81 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -63.63 -15.37 58.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.078 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.78 142.52 53.14 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.451 -179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.626 -179.846 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.642 0 O4'-C1'-C2' 107.132 0.938 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.433 -1.146 0 O4'-C4'-C3' 103.948 -1.652 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.537 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.428 -0.721 0 O4'-C4'-C3' 103.752 -1.848 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.781 0 O4'-C1'-C2' 107.584 1.349 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.902 0 O4'-C4'-C3' 104.298 -1.302 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.189 0 C1'-O4'-C4' 106.784 -2.083 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.828 0 O4'-C1'-C2' 107.427 1.207 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 52.8 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.7 mtpp -72.04 146.97 47.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.185 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.8 tttp -63.44 134.49 55.74 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 110.926 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.8 t -97.46 101.7 12.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.334 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.64 -45.0 98.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.068 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.55 163.45 39.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.109 -178.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.544 ' O ' HG21 ' A' ' 59' ' ' VAL . 13.1 t -98.12 -149.09 0.33 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.7 179.725 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.0 mtmt -53.92 119.31 4.85 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.449 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.544 HG21 ' O ' ' A' ' 57' ' ' THR . 72.2 t -131.38 131.67 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.629 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.418 HD23 ' OE2' ' A' ' 110' ' ' GLU . 62.2 mt -65.7 131.07 45.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.102 0.477 . . . . 0.0 109.835 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.62 176.13 24.78 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 91.8 m -129.33 135.46 48.77 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.735 0.302 . . . . 0.0 110.508 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 95.2 t -70.88 108.02 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.826 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.554 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.7 tttt -61.66 -47.81 83.65 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.073 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.554 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 58.1 p-90 -177.1 138.94 0.26 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.602 -1.181 . . . . 0.0 109.942 178.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -136.07 117.57 14.8 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -100.59 119.68 38.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.004 0.43 . . . . 0.0 110.907 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.438 HG21 ' N ' ' A' ' 139' ' ' ALA . 65.3 t -62.18 -46.33 96.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.422 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.13 -46.16 90.6 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -61.41 -39.23 89.98 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.924 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.61 1.93 63.6 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.349 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -148.21 161.22 41.91 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.505 0.653 . . . . 0.0 110.062 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.48 -177.91 33.0 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.568 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . 0.461 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 81.5 m-85 -129.24 143.96 51.04 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 82.8 mt -116.93 123.42 71.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.814 178.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -91.11 109.12 20.37 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.933 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . 0.423 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -63.64 130.29 43.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.083 178.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -74.99 -26.86 59.88 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.358 179.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -70.77 -41.78 71.27 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.905 0.383 . . . . 0.0 110.224 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.2 p -104.49 -11.14 17.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.675 -178.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . 0.423 ' N ' ' O ' ' A' ' 77' ' ' ARG . 98.6 mttt 55.86 31.19 17.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.927 0.394 . . . . 0.0 110.043 -178.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -120.45 145.84 46.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.225 179.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -70.31 147.22 49.91 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.073 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 88.3 t -130.12 132.53 65.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.816 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -66.31 138.29 57.52 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.328 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -151.44 149.88 13.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.232 0.539 . . . . 0.0 110.879 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -133.48 155.38 49.65 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.83 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.2 pt20 -60.9 -25.52 66.79 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 63.2 p -79.56 -13.05 59.8 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.479 178.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.24 1.56 55.53 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.119 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.91 108.9 21.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.847 0.356 . . . . 0.0 111.202 -178.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -64.32 -43.11 95.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.318 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.85 138.98 54.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.147 -178.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -144.91 157.19 44.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.476 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -56.98 120.15 36.18 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.83 -32.23 94.4 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.015 1.81 . . . . 0.0 112.581 179.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -62.41 -21.79 65.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.418 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -85.62 127.59 34.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 120.693 0.282 . . . . 0.0 110.623 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -65.46 -39.47 92.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.795 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.3 150.32 39.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.254 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -63.15 136.8 57.97 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.7 p -159.38 163.05 35.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.495 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.72 128.39 72.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.525 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.66 138.62 38.1 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.274 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.01 135.76 38.68 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.57 3.19 90.15 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -92.36 128.45 38.21 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 121.002 0.429 . . . . 0.0 110.537 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.6 m -68.16 132.99 48.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.674 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.99 158.04 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.235 -0.586 . . . . 0.0 111.394 -178.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.418 ' OE2' HD23 ' A' ' 60' ' ' LEU . 99.1 mt-10 -117.37 134.4 54.87 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.153 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 39.8 p90 -158.75 162.2 37.08 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.819 -0.753 . . . . 0.0 112.586 -177.61 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -88.88 144.09 26.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.25 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.3 123.78 59.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.987 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p -121.11 134.52 64.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.67 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -61.69 126.85 28.8 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.554 -0.459 . . . . 0.0 110.968 -178.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -109.42 167.42 12.87 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 52.6 tp10 -60.97 -43.91 98.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.719 0.295 . . . . 0.0 110.945 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -90.72 -18.19 25.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.403 -178.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 164.34 -171.54 39.88 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.96 143.65 56.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 110.437 -179.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -126.63 154.54 43.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.726 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -105.96 143.49 34.03 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.034 -179.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.13 157.71 43.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.184 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 55.4 49.48 16.81 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.939 0.4 . . . . 0.0 110.07 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 86.7 t -75.8 125.17 35.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.14 -179.152 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -137.5 163.57 30.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.76 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.4 165.76 54.17 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.6 136.05 68.41 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.962 1.774 . . . . 0.0 112.154 -178.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.3 19.44 79.65 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 178.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.36 1.59 90.31 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.4 t -60.96 139.06 94.09 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-O 119.692 -0.194 . . . . 0.0 110.572 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -60.69 149.06 89.5 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.679 1.586 . . . . 0.0 111.323 179.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.6 t -70.28 128.81 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.55 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.2 tp60 -61.07 -39.99 91.98 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.534 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.14 -175.71 53.82 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 65.4 m -107.54 155.65 19.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.59 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -62.64 -35.52 79.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.493 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -62.11 -13.65 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.099 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.438 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -56.79 137.97 53.9 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.468 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.641 -179.58 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.471 0 O4'-C4'-C3' 107.037 1.437 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.822 0 O4'-C1'-C2' 107.582 1.348 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 303' ' ' ' DC' . . . . . 0.606 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.43 -1.433 0 O4'-C4'-C3' 103.428 -2.172 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.893 0 P-O3'-C3' 120.357 0.547 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.425 -0.907 0 O4'-C1'-C2' 107.218 1.017 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.31 0 C4'-C3'-C2' 104.885 1.685 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C4'-C3' 104.73 -0.87 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 79.9 t . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.457 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.0 mt -61.92 -44.21 98.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.037 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.524 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.85 159.34 43.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.117 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.557 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.8 p -107.81 -140.7 0.38 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.661 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt -50.93 102.52 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.262 -0.575 . . . . 0.0 110.505 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 57' ' ' THR . 84.3 t -128.49 130.19 69.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.712 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 87.1 mt -82.12 137.01 35.08 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.93 -179.88 22.47 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 89.8 m -127.29 136.18 51.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.792 0.329 . . . . 0.0 110.501 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 89.3 t -76.67 112.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.74 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.534 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.45 -48.15 80.93 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.072 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.534 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -178.76 143.66 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.961 177.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -138.73 118.73 13.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -98.77 120.89 39.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.987 0.422 . . . . 0.0 110.81 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.402 HG21 ' N ' ' A' ' 139' ' ' ALA . 69.9 t -64.16 -45.1 97.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.42 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.1 ttp85 -61.31 -44.46 97.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.41 -38.36 89.4 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.843 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.36 3.96 66.67 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 121.091 -0.575 . . . . 0.0 112.401 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -149.28 161.38 42.16 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.441 0.621 . . . . 0.0 110.137 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.429 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -162.75 -177.08 35.46 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 120.554 -0.831 . . . . 0.0 111.577 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -131.56 147.7 52.55 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.107 0.48 . . . . 0.0 112.233 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.2 mt -120.24 127.68 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.856 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -93.32 109.83 21.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.849 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.9 mtm180 -65.6 131.78 47.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.093 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.9 p30 -86.91 -0.21 56.13 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.278 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -100.32 -32.7 10.72 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.892 0.377 . . . . 0.0 110.098 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.75 -10.59 11.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.674 -179.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 56.9 mtmt 55.37 32.34 18.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 109.996 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -121.25 132.37 54.77 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.319 0.58 . . . . 0.0 111.222 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -67.04 146.47 54.3 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.049 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.0 p -134.03 148.03 30.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.931 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -73.45 138.46 45.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.354 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 73' ' ' GLY . 4.8 p -143.01 145.56 22.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 121.112 0.482 . . . . 0.0 110.947 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -137.4 158.85 43.52 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.868 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -61.28 -39.19 89.49 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.65 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.5 p -67.27 -15.7 63.85 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.469 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.02 0.75 54.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.496 HD11 HG23 ' A' ' 103' ' ' VAL . 83.5 mt -98.65 104.97 16.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.038 0.447 . . . . 0.0 111.136 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -62.67 -44.93 95.01 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.331 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.412 ' HB2' HG22 ' A' ' 126' ' ' THR . 75.9 mmtt -125.62 145.39 50.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.002 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -150.98 176.59 10.98 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.399 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -63.71 121.14 68.92 Favored Pre-proline 0 CA--C 1.54 0.589 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.38 -25.61 63.69 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.999 1.799 . . . . 0.0 112.535 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.0 mmm180 -69.96 -17.95 63.33 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.436 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -95.78 123.85 39.54 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.689 0.28 . . . . 0.0 110.632 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -66.02 -39.8 90.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.858 0.361 . . . . 0.0 110.752 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -103.66 136.68 42.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.219 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.1 mtm180 -65.1 137.18 57.51 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.316 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 86.1 p -160.05 164.0 33.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 59.4 t -123.43 128.37 74.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.21 145.73 44.95 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.309 -179.117 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -83.0 137.91 33.96 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.49 2.78 88.29 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -93.57 132.13 38.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.88 0.371 . . . . 0.0 110.465 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -69.59 133.19 47.32 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.611 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.68 159.67 40.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.522 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -120.95 131.07 54.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -160.75 167.31 27.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.507 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -100.55 138.05 38.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.284 178.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.524 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 55.4 t -95.87 124.79 48.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 120.523 -0.471 . . . . 0.0 109.863 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.1 t . . . . . 0 C--N 1.326 -0.418 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.461 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 120.918 0.39 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.7 145.83 24.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.033 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.8 155.7 39.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.159 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 54.28 50.45 16.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.999 0.428 . . . . 0.0 110.131 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -78.4 119.62 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.112 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.412 HG22 ' HB2' ' A' ' 93' ' ' LYS . 82.3 p -138.41 164.58 28.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.769 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.05 171.27 51.1 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -69.18 137.64 37.66 Favored 'Trans proline' 0 C--N 1.3 -1.994 0 C-N-CA 122.0 1.8 . . . . 0.0 112.122 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.11 19.43 79.79 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.5 0.58 89.35 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 128' ' ' PRO . 76.0 t -61.2 137.77 94.35 Favored Pre-proline 0 CA--C 1.535 0.391 0 O-C-N 122.802 -0.234 . . . . 0.0 110.51 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.15 150.3 87.86 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 121.61 1.54 . . . . 0.0 111.351 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.05 132.39 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.588 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -61.66 -40.27 94.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.616 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.01 -176.98 53.91 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 72.6 m -103.19 153.78 20.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.82 0.343 . . . . 0.0 110.56 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -59.89 -37.75 80.28 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.401 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -62.31 -15.56 48.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.12 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.402 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.331 -0.233 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.569 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.2 t . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.426 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.3 mt -62.29 -44.17 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.061 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.77 164.95 33.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.098 0.475 . . . . 0.0 111.061 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.81 ' O ' HG23 ' A' ' 59' ' ' VAL . 10.9 t -98.05 -151.4 0.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.647 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.458 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 22.5 pttp -47.03 116.0 1.24 Allowed 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.453 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.81 HG23 ' O ' ' A' ' 57' ' ' THR . 93.9 t -129.79 128.08 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.688 179.391 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.6 mt -75.18 136.5 41.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.12 0.486 . . . . 0.0 109.827 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -152.86 -175.87 24.8 Favored Glycine 0 CA--C 1.52 0.363 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.5 m -130.54 136.76 49.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.81 0.338 . . . . 0.0 110.503 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.731 HG21 HG12 ' A' ' 103' ' ' VAL . 77.5 t -73.21 115.57 14.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.752 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.43 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.2 ttpt -63.73 -47.05 82.63 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.43 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 56.5 p-90 -176.43 148.18 0.73 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 114.673 -1.148 . . . . 0.0 109.901 177.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -143.4 115.62 8.44 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -101.0 123.29 44.96 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.88 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.3 t -63.33 -46.08 96.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.461 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -60.29 -45.49 93.15 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.53 88.33 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.894 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.93 2.61 66.53 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.01 161.87 41.49 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 117.456 0.628 . . . . 0.0 110.064 179.387 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.443 ' O ' HG22 ' A' ' 86' ' ' VAL . . . -157.74 -177.92 31.3 Favored Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.601 -179.577 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -131.72 146.5 52.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.152 0.501 . . . . 0.0 112.157 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.856 HD12 HG11 ' A' ' 86' ' ' VAL . 86.8 mt -120.55 127.25 75.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.838 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -92.94 109.84 21.29 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.879 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.4 mtm180 -62.75 133.39 54.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.109 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 p30 -87.74 -0.15 56.52 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.279 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.9 -32.12 11.14 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 120.974 0.416 . . . . 0.0 110.113 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 75.2 p -113.44 -11.03 13.17 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.698 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt 57.69 31.44 20.41 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 0.0 110.007 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -120.1 142.66 48.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.356 0.598 . . . . 0.0 111.198 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.36 144.82 51.5 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.051 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 87.3 t -128.21 128.2 68.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.972 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -72.8 130.1 39.7 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.341 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.057 HG12 ' HB3' ' A' ' 122' ' ' ALA . 33.3 m -132.91 159.42 43.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.215 0.531 . . . . 0.0 110.917 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.34 155.93 47.36 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.936 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -60.86 -23.05 64.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.2 p -81.85 -11.94 58.71 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.421 178.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.22 0.9 56.98 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.156 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.4 mt -96.8 100.3 10.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.943 0.401 . . . . 0.0 111.168 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -63.36 -44.12 95.72 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.298 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -122.33 144.88 48.74 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.954 0.406 . . . . 0.0 111.031 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.5 p-10 -155.07 175.69 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.38 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -66.63 120.55 71.77 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -64.81 -25.66 60.42 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.039 1.826 . . . . 0.0 112.552 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -65.47 -20.73 66.48 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.395 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.82 128.68 40.19 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.696 0.284 . . . . 0.0 110.633 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -66.13 -38.67 88.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.754 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.9 mt -108.89 149.7 28.77 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.214 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -69.68 129.94 41.0 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.384 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 65.8 m -143.46 157.9 44.07 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.474 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.731 HG12 HG21 ' A' ' 63' ' ' VAL . 48.8 t -126.41 131.69 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.18 49.21 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.361 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.56 115.18 26.77 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 95.14 -8.42 69.85 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -72.21 156.11 39.5 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.921 0.391 . . . . 0.0 110.492 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.3 m -86.96 129.47 34.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.653 178.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.0 m -129.86 158.98 42.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.431 -177.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -119.91 129.44 54.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 50.3 p90 -158.11 161.03 37.92 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.783 -0.767 . . . . 0.0 112.567 -177.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -85.36 152.98 22.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.336 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.426 HG12 ' HB ' ' A' ' 55' ' ' ILE . 59.8 t -107.18 124.67 63.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 120.473 -0.491 . . . . 0.0 109.985 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 83.3 t . . . . . 0 C--N 1.327 -0.409 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.776 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 . . . . . 0 C--O 1.228 -0.03 0 CA-C-O 120.89 0.376 . . . . 0.0 110.621 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 1.057 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -85.33 154.66 21.74 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.034 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.36 151.9 32.38 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.297 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 53.35 46.52 26.18 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.161 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 98.9 t -70.75 124.09 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.126 -179.125 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -140.91 165.55 27.21 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.76 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.78 172.93 52.61 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 53.5 Cg_endo -70.6 136.77 31.54 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.061 1.841 . . . . 0.0 112.102 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.25 20.25 79.67 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 3.04 90.67 Favored Glycine 0 CA--C 1.532 1.146 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 75.4 t -63.68 138.09 97.28 Favored Pre-proline 0 CA--C 1.536 0.416 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.66 152.42 81.95 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.579 1.519 . . . . 0.0 111.337 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 94.7 t -68.92 131.31 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.563 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -61.11 -45.4 94.87 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.518 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.92 159.1 26.42 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -74.9 162.49 28.58 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.82 0.343 . . . . 0.0 110.581 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -72.35 -24.91 61.35 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.528 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -69.83 -15.4 63.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.052 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.481 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.268 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.433 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 98.1 t . . . . . 0 N--CA 1.452 -0.374 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.1 mt -62.43 -43.32 98.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.036 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.84 160.8 42.89 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.08 0.467 . . . . 0.0 111.107 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.651 ' O ' HG23 ' A' ' 59' ' ' VAL . 3.2 p -99.22 -146.21 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.646 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -50.06 108.01 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.451 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 57' ' ' THR . 70.1 t -126.72 129.83 71.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.721 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.3 mt -74.83 137.1 41.64 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.22 -179.42 24.17 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.8 m -128.15 135.87 50.36 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.856 0.36 . . . . 0.0 110.451 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 84.7 t -75.99 109.25 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.708 -179.385 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.04 -49.65 75.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 60.9 p-90 -174.72 146.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.979 178.141 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -142.58 121.16 12.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -103.47 123.12 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.592 -0.443 . . . . 0.0 110.868 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.0 t -63.79 -45.88 95.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.477 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.04 -44.77 96.89 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -62.2 -38.14 87.99 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 91.86 2.26 69.56 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.423 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -148.77 161.3 42.07 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-N 117.454 0.627 . . . . 0.0 110.057 179.017 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.5 178.36 36.55 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.536 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -126.12 143.39 51.14 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.201 0.524 . . . . 0.0 112.118 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 86.2 mt -120.02 127.23 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.828 178.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -89.0 118.08 28.48 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.2 mtm180 -72.51 131.9 43.13 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.212 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -83.36 -6.35 59.44 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.267 179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.87 -33.25 11.7 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.002 0.429 . . . . 0.0 110.086 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -114.06 -11.68 12.69 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.861 -0.608 . . . . 0.0 111.734 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.8 mttp 55.62 33.02 20.36 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.641 -0.424 . . . . 0.0 109.964 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -122.51 137.83 54.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.289 0.566 . . . . 0.0 111.248 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.24 142.27 57.8 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.046 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.478 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 80.0 t -127.79 131.16 70.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.876 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -69.08 138.8 54.62 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.328 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.21 149.31 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.163 0.506 . . . . 0.0 110.979 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -136.13 159.31 42.11 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.855 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.457 HE22 HD21 ' A' ' 100' ' ' LEU . 97.5 mt-30 -61.3 -39.49 90.65 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.2 p -66.6 -18.31 65.3 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.4 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.95 -0.79 55.48 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.095 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.463 HD11 HG23 ' A' ' 103' ' ' VAL . 84.0 mt -95.74 103.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.97 0.414 . . . . 0.0 111.091 -178.453 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -63.25 -43.96 96.53 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.292 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -127.27 147.38 50.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.088 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -154.44 177.55 11.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.336 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -65.6 120.8 71.32 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.09 -22.16 62.17 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.069 1.846 . . . . 0.0 112.515 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.3 mmm180 -67.46 -21.75 65.52 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -100.87 122.62 43.77 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-O 120.701 0.286 . . . . 0.0 110.534 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -61.0 -48.43 81.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.74 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.457 HD21 HE22 ' A' ' 88' ' ' GLN . 66.3 tp -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 -60.95 132.48 54.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.999 0.428 . . . . 0.0 110.37 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.8 m -148.39 159.9 43.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.547 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 52.6 t -121.33 127.8 75.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.421 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -69.2 149.53 49.02 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.403 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -85.81 134.68 33.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.56 4.02 90.13 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -91.44 130.47 37.27 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.989 0.423 . . . . 0.0 110.465 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.4 m -69.15 132.71 46.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.651 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.4 m -129.99 157.53 42.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.471 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -117.59 126.74 53.07 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 51.0 p90 -156.57 163.6 39.17 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.718 -0.793 . . . . 0.0 112.537 -177.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -88.52 149.64 23.52 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.238 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.9 t -106.86 124.93 62.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.429 -0.508 . . . . 0.0 109.964 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 97.7 t . . . . . 0 C--N 1.327 -0.402 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.346 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 C--O 1.227 -0.117 0 CA-C-O 120.928 0.394 . . . . 0.0 110.645 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.478 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -119.89 143.22 48.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.076 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.1 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.261 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 53.5 45.84 27.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.977 0.418 . . . . 0.0 110.147 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 85.4 t -72.99 120.44 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.136 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.49 164.2 30.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.877 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.54 172.46 50.57 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 52.5 Cg_endo -70.13 136.9 33.16 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 122.041 1.827 . . . . 0.0 112.162 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.33 19.68 79.78 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.03 1.26 89.73 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 71.0 t -62.0 138.06 95.66 Favored Pre-proline 0 CA--C 1.536 0.408 0 O-C-N 122.776 -0.25 . . . . 0.0 110.556 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.91 150.3 88.31 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 121.687 1.591 . . . . 0.0 111.335 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.54 133.95 30.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.561 -179.464 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -60.48 -41.75 94.84 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.589 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.96 179.54 52.71 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.4 m -106.03 160.88 14.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.927 0.394 . . . . 0.0 110.552 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -61.09 -37.43 82.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.535 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -65.21 -14.6 61.03 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.118 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.539 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.331 -0.233 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.479 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t . . . . . 0 N--CA 1.45 -0.432 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.447 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.1 mt -63.17 -44.78 99.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.039 -178.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.1 163.57 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.086 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.588 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.7 t -102.68 -148.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.658 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.416 ' N ' HG23 ' A' ' 57' ' ' THR . 59.1 mtmt -52.67 115.43 1.8 Allowed 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.388 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 57' ' ' THR . 75.7 t -132.3 130.38 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.755 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.1 mt -75.3 131.23 40.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.12 0.486 . . . . 0.0 109.771 178.521 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.66 -177.03 20.95 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.4 m -128.38 137.41 51.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.868 0.366 . . . . 0.0 110.478 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.704 HG21 HG12 ' A' ' 103' ' ' VAL . 96.1 t -73.82 115.06 14.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.247 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.536 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.4 tttt -62.88 -48.95 76.79 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 179.486 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.536 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 53.6 p-90 -179.31 140.28 0.15 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.99 178.551 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -135.96 117.26 14.59 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -102.67 123.67 46.8 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.876 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.4 t -62.84 -45.64 98.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.487 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -61.08 -45.37 95.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -62.74 -38.61 91.2 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.493 -0.483 . . . . 0.0 110.836 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.13 2.24 68.88 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.37 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -148.44 161.44 41.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.394 0.597 . . . . 0.0 110.14 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -157.22 -179.5 32.19 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.571 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -129.37 146.47 51.23 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.359 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 79.2 mt -125.7 128.22 72.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.79 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -94.26 126.22 39.38 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.857 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 95.1 mtm-85 -74.9 131.47 40.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.092 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -84.07 -0.16 50.69 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.305 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -100.79 -33.31 10.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.945 0.403 . . . . 0.0 110.112 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 81.4 p -116.5 -8.57 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.758 -0.656 . . . . 0.0 111.647 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt 56.22 30.86 17.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.397 . . . . 0.0 110.006 -179.135 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -117.08 137.14 52.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.21 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.5 p-10 -74.25 158.05 34.76 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.113 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.23 148.51 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.947 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -77.94 136.68 38.04 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.375 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -143.96 148.1 19.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.159 0.504 . . . . 0.0 110.976 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -133.28 159.11 41.18 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.945 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.85 -25.56 65.13 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.8 p -74.86 -16.15 60.69 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.478 179.224 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.24 0.46 55.33 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.142 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.436 HD11 HG23 ' A' ' 103' ' ' VAL . 80.5 mt -95.13 100.47 11.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.12 -178.168 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -64.65 -41.8 95.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.298 179.022 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.15 138.4 52.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.123 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -148.54 153.73 38.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.342 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -58.62 120.83 48.67 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.31 -19.19 61.93 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 121.92 1.746 . . . . 0.0 112.557 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.0 mmm-85 -63.31 -23.96 67.64 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.408 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -101.39 133.24 46.31 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 120.686 0.279 . . . . 0.0 110.652 -179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -68.62 -38.46 80.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.745 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.9 mt -103.92 142.8 33.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.244 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.5 mtt85 -66.87 137.98 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.303 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -156.59 153.25 28.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.471 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 63' ' ' VAL . 42.3 t -119.58 131.96 70.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -59.16 143.09 46.18 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.344 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -81.96 120.24 24.98 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.14 2.39 89.37 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.6 tp10 -81.71 137.42 35.39 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.903 0.383 . . . . 0.0 110.554 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 88.1 m -68.83 132.46 46.8 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.726 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.0 157.78 42.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.413 -178.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -117.43 126.99 53.58 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.407 ' HB3' HG22 ' A' ' 125' ' ' VAL . 48.4 p90 -154.82 162.09 41.24 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 119.807 -0.757 . . . . 0.0 112.565 -177.496 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -93.14 149.13 21.44 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.246 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.447 HG12 ' HB ' ' A' ' 55' ' ' ILE . 62.0 t -107.47 126.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.469 -0.492 . . . . 0.0 109.956 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 C--N 1.327 -0.407 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.945 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.226 -0.139 0 CA-C-O 120.827 0.346 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.15 152.67 29.1 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.973 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.97 157.12 43.18 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.193 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 53.4 44.88 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.436 . . . . 0.0 110.215 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.407 HG22 ' HB3' ' A' ' 111' ' ' PHE . 95.1 t -72.05 124.07 27.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.073 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.4 p -136.67 168.48 19.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.789 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.65 171.07 54.45 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -66.61 138.97 51.5 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 C-N-CA 121.929 1.753 . . . . 0.0 112.175 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.27 16.8 79.66 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.89 2.45 90.55 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.706 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -68.4 147.95 98.18 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-O 119.704 -0.189 . . . . 0.0 110.55 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PRO . . . . . 0.706 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.6 Cg_exo -59.48 150.73 73.79 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.582 1.521 . . . . 0.0 111.309 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t -66.36 131.34 32.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.622 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -61.74 -39.97 93.45 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.497 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.47 -173.64 54.85 Favored Glycine 0 CA--C 1.524 0.623 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.66 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 71.1 m -112.5 157.96 20.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.822 0.344 . . . . 0.0 110.59 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -60.55 -37.69 82.08 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.384 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -60.87 -19.5 60.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.111 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.449 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.45 -42.94 97.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.108 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.417 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -147.11 157.32 43.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.799 ' O ' HG23 ' A' ' 59' ' ' VAL . 9.9 p -102.47 -149.99 0.4 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.609 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -48.25 104.66 0.06 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.497 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 57' ' ' THR . 96.7 t -125.04 129.37 73.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.696 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.0 mt -75.37 138.59 41.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.132 0.492 . . . . 0.0 109.762 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.39 -178.15 25.0 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -129.05 137.76 51.48 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.878 0.37 . . . . 0.0 110.491 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 92.1 t -73.11 109.86 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.754 -179.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.511 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 61.9 tttm -61.16 -50.93 71.18 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.511 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.3 p-90 -176.65 139.55 0.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.016 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -137.92 116.57 12.17 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -99.34 121.72 41.49 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.964 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.26 -45.82 97.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.426 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -62.71 -42.1 99.48 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -62.2 -39.06 91.49 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.835 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.4 2.23 65.87 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.354 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -149.56 162.19 40.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 117.464 0.632 . . . . 0.0 109.984 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.33 -179.28 35.95 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.499 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -130.33 144.9 51.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.213 0.53 . . . . 0.0 112.127 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.4 mt -120.11 126.33 75.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.839 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -93.16 119.76 32.71 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -72.85 133.79 44.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.161 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -83.23 -8.58 59.45 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.29 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -93.04 -33.18 14.2 Favored 'General case' 0 C--O 1.231 0.121 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.092 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 79.1 p -115.31 -9.13 12.23 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.75 -178.537 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.4 mttt 53.37 32.7 14.25 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.972 -179.15 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -120.39 134.74 55.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.332 0.587 . . . . 0.0 111.219 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -64.36 144.2 57.34 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.03 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 95.0 t -130.05 133.1 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.878 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -65.51 138.29 57.97 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.396 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.18 147.76 18.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.251 0.548 . . . . 0.0 110.855 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -137.73 160.2 39.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.926 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.406 ' HA ' HD12 ' A' ' 91' ' ' ILE . 97.2 mt-30 -61.73 -39.03 90.13 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -178.512 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.7 p -67.99 -16.07 63.88 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.453 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.84 2.41 51.48 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.406 HD12 ' HA ' ' A' ' 88' ' ' GLN . 85.0 mt -98.6 107.73 20.91 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.885 0.374 . . . . 0.0 111.245 -178.698 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -65.63 -42.65 91.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.349 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.038 -178.128 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -144.11 168.78 19.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.388 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -55.12 121.14 34.54 Favored Pre-proline 0 CA--C 1.539 0.553 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.96 -41.69 72.5 Favored 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 121.933 1.756 . . . . 0.0 112.597 -178.011 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -63.86 -14.63 54.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? -104.39 118.03 35.61 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 120.688 0.28 . . . . 0.0 110.616 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -77.26 -22.83 51.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.915 0.388 . . . . 0.0 110.785 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.4 tp -100.72 125.61 47.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.173 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.64 133.8 56.46 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.584 -0.447 . . . . 0.0 110.31 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.3 t -160.79 151.92 18.93 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.495 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 56.6 t -118.59 127.13 75.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.68 145.85 46.02 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.334 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -83.56 135.42 34.64 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.3 4.06 89.86 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -92.43 131.87 37.24 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 120.958 0.409 . . . . 0.0 110.461 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.6 m -69.47 133.66 47.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.64 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.8 m -131.8 158.47 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.462 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.67 130.52 55.09 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -156.57 164.12 38.57 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 119.778 -0.769 . . . . 0.0 112.541 -177.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -97.3 140.28 32.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.368 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.3 t -100.86 125.65 54.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.066 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.326 -0.44 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.673 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 . . . . . 0 C--O 1.226 -0.147 0 CA-C-O 121.008 0.432 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.531 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -105.19 145.16 30.99 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.975 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.14 162.93 39.49 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.195 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 54.06 45.23 27.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.985 0.421 . . . . 0.0 110.173 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.7 t -74.25 123.91 30.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.048 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.9 p -138.32 167.93 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.806 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.96 174.38 53.05 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.433 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -68.86 137.6 38.58 Favored 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.065 1.844 . . . . 0.0 112.121 -178.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.02 20.19 78.81 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.92 2.11 90.65 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.5 t -63.37 137.21 97.01 Favored Pre-proline 0 CA--C 1.537 0.449 0 O-C-N 122.78 -0.247 . . . . 0.0 110.56 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.94 145.42 91.32 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.561 1.507 . . . . 0.0 111.314 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.58 132.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -60.84 -43.1 98.73 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.456 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.99 -179.93 52.83 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 37.9 t -106.19 141.07 38.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.849 0.357 . . . . 0.0 110.589 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.5 ptmt -59.26 -21.88 60.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.44 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 70.1 m-85 -66.07 -22.62 66.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.139 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.199 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.47 -179.516 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.4 t . . . . . 0 N--CA 1.45 -0.473 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.438 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.4 mt -63.14 -44.28 99.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.033 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -149.01 164.08 35.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 15.0 t -101.99 -149.05 0.38 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.648 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 57' ' ' THR . 58.4 mtmt -52.3 117.01 2.52 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.431 -178.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 84.8 t -133.21 131.37 58.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.687 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.3 mt -76.01 136.07 39.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.084 0.469 . . . . 0.0 109.776 178.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.55 -179.36 24.42 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.5 m -127.06 140.67 52.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.937 0.398 . . . . 0.0 110.455 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.691 HG21 HG12 ' A' ' 103' ' ' VAL . 93.0 t -82.21 111.24 18.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.739 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 64.9 tttp -62.77 -49.93 73.03 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.552 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 63.2 p-90 -169.81 154.41 5.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.645 -1.161 . . . . 0.0 109.927 177.66 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -142.5 118.68 10.75 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 -98.23 112.1 24.2 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.993 0.425 . . . . 0.0 110.892 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.423 HG21 ' N ' ' A' ' 139' ' ' ALA . 73.9 t -61.75 -45.05 99.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.381 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.2 ttt85 -61.09 -44.5 97.26 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.08 -38.71 92.27 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.444 -0.503 . . . . 0.0 110.821 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.15 4.49 59.87 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.387 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -152.37 162.0 41.8 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 117.43 0.615 . . . . 0.0 110.102 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.521 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -156.04 -176.05 27.73 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.56 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -126.3 145.14 50.55 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.155 0.502 . . . . 0.0 112.138 -179.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 83.3 mt -120.12 125.45 74.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.896 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -90.66 109.59 20.76 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.479 -0.488 . . . . 0.0 110.813 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -62.87 135.32 57.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.13 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -86.37 -2.3 58.3 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.316 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -100.14 -34.05 10.2 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.973 0.416 . . . . 0.0 110.144 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.7 p -115.44 -9.25 12.13 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.679 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mmtm 55.43 29.96 14.15 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -115.18 133.62 55.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.375 0.607 . . . . 0.0 111.299 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.9 142.52 58.26 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.985 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.7 t -124.83 133.27 69.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -70.77 138.18 50.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.313 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -148.73 148.69 15.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.183 0.516 . . . . 0.0 110.954 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -132.79 155.77 48.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.886 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -60.15 -23.67 64.1 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 80.5 p -83.33 -10.41 58.5 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.591 -0.443 . . . . 0.0 110.401 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.91 3.61 55.39 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.116 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.428 HD11 HG23 ' A' ' 103' ' ' VAL . 86.1 mt -99.13 106.1 18.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-O 120.994 0.426 . . . . 0.0 111.228 -178.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -63.31 -44.78 94.02 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.327 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -122.3 141.21 51.76 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.125 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -150.23 176.34 10.95 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.349 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -64.95 120.42 66.56 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.69 -23.35 63.4 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.01 1.807 . . . . 0.0 112.578 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.9 mmm-85 -68.5 -19.62 64.54 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.412 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -98.93 129.33 45.25 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 120.678 0.275 . . . . 0.0 110.661 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -67.52 -37.86 83.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.966 0.412 . . . . 0.0 110.731 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.2 mt -105.6 141.34 37.22 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.258 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.28 138.76 57.87 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.319 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.409 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 93.8 p -156.96 162.75 39.61 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.532 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.691 HG12 HG21 ' A' ' 63' ' ' VAL . 45.6 t -125.88 130.97 72.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.38 143.8 37.94 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.294 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ASP . . . . . 0.4 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 41.0 p-10 -75.92 132.75 40.46 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.65 4.83 89.45 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 63' ' ' VAL . 85.3 tt0 -86.93 129.48 34.86 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.007 0.432 . . . . 0.0 110.488 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 99.6 m -71.1 131.2 43.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.67 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.3 158.49 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.455 -177.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.91 129.0 54.95 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 178.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 45.9 p90 -155.68 162.82 40.5 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.582 -177.289 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -92.4 149.46 21.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.375 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HB ' ' A' ' 55' ' ' ILE . 60.5 t -108.19 126.35 64.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.937 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.624 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 C--O 1.226 -0.154 0 CA-C-O 120.973 0.416 . . . . 0.0 110.672 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -109.96 147.75 32.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.989 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.43 161.08 41.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.145 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 54.51 44.37 28.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.984 0.421 . . . . 0.0 110.125 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 91.8 t -72.81 122.77 26.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.092 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 62.7 p -136.91 163.79 29.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.783 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.43 168.57 54.8 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.099 -1.601 . . . . 0.0 109.099 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.426 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.5 Cg_exo -59.52 138.09 81.69 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 121.903 1.736 . . . . 0.0 112.094 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.21 19.04 75.45 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.308 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.77 4.42 90.34 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -62.63 136.94 96.35 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 122.699 -0.295 . . . . 0.0 110.484 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -58.44 146.96 88.24 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.552 1.502 . . . . 0.0 111.335 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.4 132.37 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.645 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 11.8 tp-100 -61.34 -41.41 96.99 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.549 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.23 -176.59 50.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.2 m -105.49 157.85 17.08 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.75 0.31 . . . . 0.0 110.64 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -60.84 -37.39 81.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.51 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -63.88 -17.3 63.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.055 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--O 1.233 0.202 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.435 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.6 t . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.25 -44.42 99.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.071 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.52 157.25 43.1 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.632 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.4 p -102.41 -147.42 0.37 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.668 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -51.93 107.44 0.2 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.441 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 57' ' ' THR . 76.1 t -125.11 131.24 72.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.745 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 68.8 mt -69.09 134.98 50.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.069 0.462 . . . . 0.0 109.838 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.77 178.23 30.82 Favored Glycine 0 CA--C 1.519 0.341 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m -130.77 137.77 49.62 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.866 0.365 . . . . 0.0 110.466 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -70.45 112.39 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.813 -179.397 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.51 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.45 -48.59 80.44 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.51 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.8 p-90 -177.32 140.06 0.27 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 114.564 -1.198 . . . . 0.0 109.95 177.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -138.14 115.28 10.96 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -100.21 124.44 45.64 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.934 -178.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -63.3 -46.08 96.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.452 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -61.19 -44.44 97.29 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.91 -39.21 93.84 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.872 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.42 4.78 65.83 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.365 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -151.75 162.59 40.77 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 117.442 0.621 . . . . 0.0 110.078 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.65 -178.4 34.6 Favored Glycine 0 CA--C 1.525 0.689 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.557 -179.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -129.64 148.67 51.56 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.124 0.488 . . . . 0.0 112.095 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.421 HG13 HG11 ' A' ' 86' ' ' VAL . 82.4 mt -118.67 126.79 75.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.428 -0.806 . . . . 0.0 109.863 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -91.54 110.24 21.55 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.876 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -65.72 130.36 43.0 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.085 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -87.54 -3.58 58.99 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.331 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -97.74 -31.5 12.22 Favored 'General case' 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.393 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.0 p -113.28 -9.89 13.38 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.686 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp 57.77 32.14 21.48 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.024 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -126.23 148.88 49.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.34 0.59 . . . . 0.0 111.168 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -82.3 158.87 23.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -142.93 150.6 17.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -78.15 135.79 37.72 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.352 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.421 HG11 HG13 ' A' ' 75' ' ' ILE . 5.5 p -146.52 147.99 17.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.104 0.478 . . . . 0.0 110.864 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -136.21 159.1 42.76 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.9 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.465 ' HA ' HD12 ' A' ' 91' ' ' ILE . 27.6 pt20 -59.19 -25.02 63.6 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -178.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -74.44 -16.05 60.88 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.468 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.461 ' HB1' ' HA ' ' A' ' 123' ' ' ALA . . . -89.32 2.96 53.63 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.155 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.465 HD12 ' HA ' ' A' ' 88' ' ' GLN . 84.5 mt -95.87 103.12 14.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.905 0.383 . . . . 0.0 111.153 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -65.19 -43.67 90.9 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.314 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -119.17 144.23 46.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.134 -178.589 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.0 t30 -144.1 171.18 14.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.439 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -61.07 122.87 72.6 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.64 -23.12 57.04 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 121.906 1.737 . . . . 0.0 112.522 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.4 mmm-85 -73.38 -14.06 61.21 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.399 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -114.2 142.22 46.54 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 120.746 0.308 . . . . 0.0 110.658 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.488 ' CE1' HD21 ' A' ' 100' ' ' LEU . 43.9 p90 -98.35 4.91 48.61 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.694 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.488 HD21 ' CE1' ' A' ' 99' ' ' TYR . 88.7 mt -119.42 142.4 48.25 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.156 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -81.15 125.98 30.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.416 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 87.9 p -156.38 162.44 40.05 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.507 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 39.7 t -131.53 134.63 60.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.38 147.98 50.36 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.338 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -84.91 120.82 26.91 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.25 -5.61 82.8 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.04 135.21 41.27 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-O 121.069 0.462 . . . . 0.0 110.44 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.2 m -70.88 131.46 43.79 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.636 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 19.9 m -135.93 159.38 39.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.39 -178.403 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -116.11 138.54 51.16 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.6 p90 -159.44 164.04 34.87 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.523 -177.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -98.59 138.49 35.71 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.218 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.0 t -107.02 127.21 62.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 120.463 -0.495 . . . . 0.0 110.033 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.326 -0.422 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.15 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 . . . . . 0 C--O 1.227 -0.128 0 CA-C-O 120.952 0.406 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.16 143.41 43.25 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.966 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.461 ' HA ' ' HB1' ' A' ' 90' ' ' ALA . . . -153.22 161.07 42.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.231 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 56.84 47.17 18.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 110.125 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.7 t -77.61 121.08 29.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.114 -179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 59.2 p -137.88 169.04 18.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.797 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.26 167.73 54.84 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 131' ' ' VAL . 34.8 Cg_exo -60.63 138.12 77.84 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.99 1.793 . . . . 0.0 112.146 -178.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.5 20.58 78.48 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 178.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.47 89.84 Favored Glycine 0 CA--C 1.532 1.108 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 128' ' ' PRO . 78.3 t -61.02 138.21 94.15 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-O 119.667 -0.206 . . . . 0.0 110.556 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -61.56 148.37 93.15 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 121.662 1.575 . . . . 0.0 111.233 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.5 t -63.81 130.77 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.653 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -62.31 -40.11 95.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.615 -179.373 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.77 157.42 33.15 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 81.5 p -76.19 160.2 29.93 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 120.921 0.391 . . . . 0.0 110.539 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -70.32 -23.48 62.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.513 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -80.09 -2.96 46.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.144 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.242 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.465 -179.967 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 97.0 t . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.454 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.4 mt -63.77 -45.9 95.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.002 -179.056 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -158.21 162.2 37.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.762 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.7 t -96.38 -142.86 0.28 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.57 179.55 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.478 ' N ' HG23 ' A' ' 57' ' ' THR . 76.0 mmtt -50.34 103.28 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.291 -0.563 . . . . 0.0 110.416 -179.38 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 57' ' ' THR . 95.0 t -119.28 128.59 75.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 80.0 mt -64.33 130.75 45.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.082 0.468 . . . . 0.0 109.776 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.16 174.45 23.75 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -129.22 134.31 47.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.941 0.4 . . . . 0.0 110.488 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.674 HG21 HG12 ' A' ' 103' ' ' VAL . 98.6 t -75.43 108.48 7.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.723 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 22.0 ttmm -63.2 -48.22 79.23 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 62.4 p-90 -176.14 143.82 0.55 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.616 -1.174 . . . . 0.0 109.925 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -138.53 115.65 10.98 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.404 ' HA ' HD21 ' A' ' 67' ' ' ASN . 8.8 m120 -100.0 119.21 37.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.978 0.418 . . . . 0.0 110.922 -179.058 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.58 -46.7 94.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.509 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -62.46 -41.49 98.8 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.404 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 96.2 m-20 -62.82 -38.61 91.39 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.494 -0.482 . . . . 0.0 110.809 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.37 4.54 64.2 Favored Glycine 0 CA--C 1.531 1.042 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.382 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.404 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 40.9 p90 -148.88 160.18 43.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 117.528 0.664 . . . . 0.0 110.107 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.66 173.22 37.16 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.515 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -128.12 146.88 50.56 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.096 0.474 . . . . 0.0 112.232 -179.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.3 mt -120.61 125.86 74.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.855 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -91.4 111.15 22.53 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.509 -0.477 . . . . 0.0 110.899 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.459 ' NH1' HG11 ' A' ' 113' ' ' VAL . 88.7 mtm180 -61.5 133.35 55.62 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.113 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -86.29 -12.16 50.26 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.311 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -89.49 -29.87 18.67 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-O 121.022 0.439 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.6 p -116.46 -11.42 11.15 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.694 -178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 58.0 mtpt 57.04 32.11 21.1 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -119.77 134.04 55.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.22 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -64.72 143.19 58.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.058 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.593 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 58.0 t -127.78 130.98 70.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.829 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -70.99 130.04 40.55 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.425 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.04 149.55 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.163 0.506 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -131.14 164.99 24.28 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.889 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.64 -39.75 94.82 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -69.69 -17.2 63.46 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.443 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.36 -2.63 53.49 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.169 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.7 mt -96.77 106.48 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.949 0.404 . . . . 0.0 111.112 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.75 -43.06 97.56 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.296 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -125.11 142.42 51.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.129 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -148.88 176.18 10.63 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.437 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.5 t-20 -66.23 117.33 42.21 Favored Pre-proline 0 CA--C 1.54 0.569 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.91 -31.34 95.3 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.979 1.786 . . . . 0.0 112.588 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.8 mmm-85 -64.23 -19.96 65.71 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.294 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.482 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 76.0 mmtt -93.14 129.0 39.28 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 120.671 0.272 . . . . 0.0 110.613 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -67.68 -37.96 83.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.873 0.368 . . . . 0.0 110.785 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.1 mt -110.1 144.63 38.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.257 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -65.82 137.67 57.38 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.329 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.2 p -156.86 163.07 39.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.455 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.674 HG12 HG21 ' A' ' 63' ' ' VAL . 46.9 t -128.82 130.39 68.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.56 149.0 49.22 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.384 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -86.56 134.47 33.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.62 1.68 90.55 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -91.75 130.27 37.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-O 120.888 0.375 . . . . 0.0 110.526 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -70.16 134.36 48.05 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.69 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.93 161.2 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.433 -178.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -120.54 136.35 54.81 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 178.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.452 ' HB3' HG22 ' A' ' 125' ' ' VAL . 29.2 p90 -157.58 161.06 38.71 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.563 -178.168 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -83.35 122.07 27.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.21 179.051 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.459 HG11 ' NH1' ' A' ' 77' ' ' ARG . 61.3 t -88.83 122.26 39.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.491 -0.484 . . . . 0.0 109.998 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 59.4 t . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.546 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 . . . . . 0 C--O 1.227 -0.08 0 CA-C-O 120.822 0.344 . . . . 0.0 110.676 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.593 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -100.55 141.04 33.96 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.956 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.92 157.72 43.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.185 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 54.59 43.76 29.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.96 0.409 . . . . 0.0 110.076 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.7 t -70.18 125.43 28.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.09 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.0 p -138.92 164.76 28.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.775 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.91 164.35 54.24 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.526 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.4 Cg_exo -60.02 136.73 71.3 Favored 'Trans proline' 0 C--N 1.301 -1.942 0 C-N-CA 122.001 1.801 . . . . 0.0 112.06 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 76.89 13.64 83.42 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.96 -0.56 89.1 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.526 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.4 p -64.82 141.38 98.32 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-O 119.679 -0.2 . . . . 0.0 110.586 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PRO . . . . . 0.409 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 18.4 Cg_endo -58.03 147.69 81.15 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.66 1.573 . . . . 0.0 111.349 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -69.9 134.46 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.585 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -60.94 -43.67 98.35 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.515 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.16 158.32 30.92 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -72.92 157.01 38.26 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.84 0.352 . . . . 0.0 110.619 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -69.3 -19.65 63.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.455 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -79.87 -7.7 58.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.128 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.482 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.33 -0.259 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.504 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 54' ' ' VAL . 7.2 p . . . . . 0 N--CA 1.45 -0.426 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.429 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.9 mt -62.06 -44.61 99.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.098 -179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.465 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.68 160.37 40.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.64 ' O ' HG23 ' A' ' 59' ' ' VAL . 14.4 p -98.02 -150.97 0.36 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.612 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -51.32 116.87 2.25 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.466 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 57' ' ' THR . 86.7 t -132.59 131.2 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.681 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.8 mt -75.33 134.71 40.96 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.043 0.449 . . . . 0.0 109.849 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.29 -179.48 23.38 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.4 m -129.11 135.86 49.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 110.483 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.709 HG21 HG12 ' A' ' 103' ' ' VAL . 85.4 t -73.54 113.1 11.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.731 -179.319 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.45 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.6 ttpt -62.34 -46.77 87.21 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.9 p-90 -176.14 146.19 0.66 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.001 177.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -140.5 115.51 9.75 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -103.02 121.44 42.57 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.936 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.3 t -63.07 -44.56 99.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.452 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.426 ' HG3' ' N ' ' A' ' 70' ' ' ASN . 17.7 ptm180 -63.08 -35.11 79.18 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.426 ' N ' ' HG3' ' A' ' 69' ' ' ARG . 97.2 m-20 -69.36 -35.15 75.58 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.822 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 90.14 0.87 76.64 Favored Glycine 0 CA--C 1.531 1.057 0 C-N-CA 121.06 -0.591 . . . . 0.0 112.361 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -150.26 161.51 42.3 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 117.544 0.672 . . . . 0.0 110.086 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -154.98 179.43 31.02 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.603 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.16 145.64 51.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.144 0.497 . . . . 0.0 112.131 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 84.9 mt -119.74 123.58 71.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.849 178.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.64 109.16 20.57 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.817 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -63.14 130.93 46.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.115 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.3 p30 -85.43 -0.08 53.79 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.406 -0.518 . . . . 0.0 111.37 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -99.07 -34.48 10.38 Favored 'General case' 0 C--O 1.231 0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.127 178.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 77.9 p -114.4 -10.95 12.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.687 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 58.09 29.99 18.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.95 0.405 . . . . 0.0 110.025 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -116.2 132.96 56.52 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 121.362 0.601 . . . . 0.0 111.247 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -62.67 142.25 58.17 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.089 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.504 HG11 ' HB2' ' A' ' 122' ' ' ALA . 76.6 t -128.1 131.01 69.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -65.92 141.12 58.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.394 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.8 p -146.92 148.45 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.182 0.515 . . . . 0.0 110.935 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.407 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 80.8 m80 -137.63 159.04 43.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.784 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -60.33 -41.93 94.58 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.5 t -64.98 -16.63 63.61 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.478 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -84.16 -2.97 57.79 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.123 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.534 HD11 HG23 ' A' ' 103' ' ' VAL . 79.9 mt -93.45 101.45 12.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.987 0.422 . . . . 0.0 111.152 -178.303 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -63.55 -43.31 97.44 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.305 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -120.63 140.65 51.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.151 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -149.73 156.36 41.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -60.48 121.45 60.46 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.49 -22.18 65.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 121.995 1.797 . . . . 0.0 112.478 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.52 -21.55 66.17 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.35 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -86.34 130.83 34.37 Favored 'General case' 0 N--CA 1.456 -0.127 0 CA-C-O 120.748 0.308 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 84.8 t80 -61.23 -48.5 81.2 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -116.43 139.98 49.85 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.206 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -55.71 138.01 48.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.075 0.464 . . . . 0.0 110.291 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 94.2 p -158.84 165.08 35.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.511 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.709 HG12 HG21 ' A' ' 63' ' ' VAL . 46.3 t -124.04 129.61 74.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.0 147.76 51.17 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -80.66 121.04 25.36 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.087 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.14 -0.86 88.93 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.16 135.11 41.11 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 120.941 0.401 . . . . 0.0 110.463 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 91.1 m -70.07 131.57 44.52 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.637 179.046 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.77 159.18 43.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.37 -0.532 . . . . 0.0 111.511 -178.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -120.74 129.87 53.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.439 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.7 p90 -157.64 163.86 37.81 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 112.549 -177.589 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -93.68 144.85 25.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.205 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.9 t -97.07 125.65 50.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.592 -0.443 . . . . 0.0 109.942 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 99.3 t . . . . . 0 C--N 1.326 -0.445 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 -179.53 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 120.985 0.421 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.504 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.45 146.73 29.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.973 -179.647 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.1 157.86 43.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.255 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 54.42 45.32 27.34 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.118 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.439 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.0 t -71.51 122.15 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.08 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.6 p -138.75 161.64 36.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.796 179.384 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 162.48 54.43 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.501 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.1 Cg_exo -58.96 138.0 83.11 Favored 'Trans proline' 0 C--N 1.301 -1.926 0 C-N-CA 122.005 1.803 . . . . 0.0 112.149 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.23 19.24 78.55 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 178.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.89 3.01 89.54 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 128' ' ' PRO . 95.0 t -60.72 137.63 93.12 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 122.811 -0.229 . . . . 0.0 110.472 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 153.06 79.84 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 121.64 1.56 . . . . 0.0 111.309 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -70.65 129.11 34.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.617 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 12.6 tp-100 -60.72 -44.34 96.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.55 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.39 162.0 28.28 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 179.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -81.4 163.06 23.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.933 0.397 . . . . 0.0 110.56 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.51 -37.13 86.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.502 179.473 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -66.67 -7.63 22.0 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.137 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.462 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.278 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.495 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.1 t . . . . . 0 N--CA 1.45 -0.45 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.54 -44.13 99.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.087 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.08 43.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.736 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -104.41 -147.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.632 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.415 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 21.4 pttm -48.11 106.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.452 -179.429 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 57' ' ' THR . 85.2 t -127.53 130.58 70.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.718 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 93.1 mt -74.88 135.82 41.52 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 109.824 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.36 178.33 25.05 Favored Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.1 m -128.32 137.94 52.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 120.853 0.359 . . . . 0.0 110.547 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 94.0 t -77.1 109.79 12.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.689 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.5 ttpt -62.79 -46.96 85.58 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 51.5 p-90 -176.67 146.87 0.6 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.954 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -141.35 125.0 16.81 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.4 m-20 -107.48 122.53 46.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.992 0.425 . . . . 0.0 110.941 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.9 t -63.22 -46.71 95.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.462 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -62.02 -43.29 99.16 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.45 88.04 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.807 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.48 0.99 69.25 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.374 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -148.3 163.52 36.81 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 117.503 0.652 . . . . 0.0 110.076 179.16 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.21 -179.67 32.32 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.538 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -126.45 143.08 51.31 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.095 0.474 . . . . 0.0 112.111 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.431 HG13 HG11 ' A' ' 86' ' ' VAL . 87.1 mt -121.8 126.52 74.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.859 178.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -94.09 109.97 21.71 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.93 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -63.62 134.57 55.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.073 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -88.62 -9.89 50.6 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.275 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.3 p-10 -96.71 -12.9 23.17 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.146 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 55.7 p -133.84 -10.51 2.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.709 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.5 mttp 51.61 35.51 14.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.952 0.406 . . . . 0.0 109.976 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -120.11 134.11 55.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.223 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -67.81 130.03 41.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.118 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 96.2 t -119.21 131.77 70.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.52 139.49 55.63 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.293 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 HG13 ' A' ' 75' ' ' ILE . 7.5 p -148.11 148.34 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 CA-C-O 121.133 0.492 . . . . 0.0 110.948 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -131.74 155.59 47.43 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.9 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.469 ' OE1' HD11 ' A' ' 100' ' ' LEU . 26.8 pt20 -59.35 -28.46 66.87 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.8 p -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.431 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.99 0.25 55.48 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.198 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.448 HD11 HG23 ' A' ' 103' ' ' VAL . 82.2 mt -93.83 103.11 14.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.013 0.435 . . . . 0.0 111.128 -178.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -64.96 -42.22 94.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.281 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.452 ' HB3' HG22 ' A' ' 126' ' ' THR . 22.8 ttmm -125.69 136.1 52.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.074 -178.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -146.76 176.47 9.84 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.375 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -62.2 121.2 64.64 Favored Pre-proline 0 CA--C 1.539 0.54 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.31 -26.12 64.0 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 121.965 1.777 . . . . 0.0 112.65 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.1 -14.45 61.85 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.426 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 4.0 mptp? -99.34 113.93 26.52 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 120.717 0.294 . . . . 0.0 110.647 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.21 -47.83 84.3 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.889 0.376 . . . . 0.0 110.758 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.469 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.3 tp -94.09 130.83 40.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.216 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -60.5 138.46 58.01 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.256 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.532 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 93.7 p -157.97 163.37 37.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.424 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 51.9 t -129.06 131.04 68.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.64 148.01 47.7 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.303 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -86.09 134.36 33.83 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.1 2.63 90.56 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.8 tp10 -91.1 129.82 37.06 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-O 120.913 0.387 . . . . 0.0 110.517 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.9 m -70.01 133.03 46.81 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.719 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.3 m -130.61 159.09 42.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.49 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.02 130.05 55.94 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.6 p90 -156.24 162.93 40.1 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 119.774 -0.77 . . . . 0.0 112.49 -177.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -97.09 142.33 29.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.225 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.1 t -101.18 125.27 55.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.031 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.8 p . . . . . 0 C--N 1.326 -0.416 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.44 ' O ' HG12 ' A' ' 114' ' ' VAL . 89.0 tt0 . . . . . 0 C--O 1.227 -0.107 0 CA-C-O 120.885 0.374 . . . . 0.0 110.661 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -74.46 150.76 39.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.042 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.59 157.96 41.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.186 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 53.52 47.97 22.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.029 0.443 . . . . 0.0 110.131 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.5 t -73.36 123.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.084 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 93' ' ' LYS . 81.6 p -140.18 164.04 31.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.841 179.308 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.06 164.45 54.48 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG23 ' A' ' 131' ' ' VAL . 37.3 Cg_exo -60.79 138.33 78.64 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.995 1.797 . . . . 0.0 112.096 -179.32 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.14 18.78 79.37 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.69 0.74 89.98 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -59.87 137.69 90.47 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.431 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.46 150.31 87.0 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 121.588 1.525 . . . . 0.0 111.296 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.1 t -69.03 129.67 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.616 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -60.63 -44.38 96.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.507 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 88.41 164.78 40.62 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.668 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -80.62 165.35 22.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.822 0.344 . . . . 0.0 110.572 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -62.47 -39.05 92.18 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.488 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -66.26 -9.81 36.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.139 -179.208 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.275 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.43 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 N--CA 1.45 -0.434 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.96 -45.36 97.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.07 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -153.33 161.74 42.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.084 -179.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.694 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -97.51 -146.29 0.31 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.587 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.433 ' N ' HG23 ' A' ' 57' ' ' THR . 38.4 mtmm -52.12 113.65 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.538 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 57' ' ' THR . 93.2 t -127.49 128.55 69.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.768 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 94.7 mt -65.36 130.05 41.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.042 0.448 . . . . 0.0 109.925 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.29 170.27 25.52 Favored Glycine 0 C--O 1.228 -0.259 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.9 m -130.66 137.07 49.4 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.886 0.374 . . . . 0.0 110.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 103' ' ' VAL . 91.5 t -75.32 116.2 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.832 -179.364 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.2 ptpt -74.53 -35.37 63.13 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 176.7 139.49 0.07 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.987 178.121 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -138.98 115.97 10.9 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -100.57 118.48 36.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.014 0.435 . . . . 0.0 110.905 -178.358 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.92 -45.17 97.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.421 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.2 ttp85 -59.71 -45.29 92.57 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -61.38 -38.2 86.17 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.869 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.45 3.86 62.75 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.324 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -149.64 160.73 43.27 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 117.528 0.664 . . . . 0.0 110.051 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.53 179.9 33.87 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.615 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -132.67 147.27 52.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.17 0.509 . . . . 0.0 112.101 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.407 HG13 HG11 ' A' ' 86' ' ' VAL . 80.4 mt -121.56 129.06 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.846 178.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -97.33 108.26 20.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.877 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.3 mtm-85 -62.89 131.26 48.14 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.073 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.68 -9.07 57.76 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.333 179.151 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -94.03 -29.85 15.0 Favored 'General case' 0 N--CA 1.458 -0.057 0 CA-C-O 120.911 0.386 . . . . 0.0 110.134 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.5 p -116.83 -13.17 10.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.679 -178.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.7 mttt 54.22 33.79 18.89 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.066 -179.128 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -117.94 131.58 56.49 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.28 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -71.94 130.62 41.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.055 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.8 p -124.03 147.75 28.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.907 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -75.47 142.41 42.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.354 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.427 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -144.81 146.49 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.099 0.476 . . . . 0.0 111.016 179.159 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -135.19 154.58 51.56 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.848 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -61.04 -24.88 66.52 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 111.971 0.36 . . . . 0.0 111.971 -178.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 72.1 p -76.89 -13.86 59.94 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.351 179.142 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.69 2.56 54.64 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.091 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 103' ' ' VAL . 82.5 mt -96.23 107.31 19.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.022 0.439 . . . . 0.0 111.183 -178.5 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -67.99 -43.09 79.73 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.334 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.97 141.01 48.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.098 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 t30 -144.51 160.73 40.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.6 t-20 -56.29 119.91 31.26 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.28 -31.57 93.99 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.075 1.85 . . . . 0.0 112.527 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -62.59 -19.19 63.48 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.431 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -111.21 140.37 45.83 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.655 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -95.08 -13.99 24.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.889 0.376 . . . . 0.0 110.775 179.731 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.0 tp -106.03 125.49 51.06 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.195 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.7 mtt-85 -62.89 130.83 46.53 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.634 -0.427 . . . . 0.0 110.305 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 47.2 t -157.9 154.62 28.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.537 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 63' ' ' VAL . 45.0 t -120.88 130.57 74.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.593 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.24 144.81 45.11 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.376 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -74.93 129.88 38.43 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.27 1.45 85.88 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -178.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.468 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -76.92 132.62 39.18 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 120.9 0.381 . . . . 0.0 110.538 -179.507 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -74.55 129.45 37.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.711 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 14.2 m -133.57 162.46 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.417 -177.704 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -124.81 141.24 52.25 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.451 ' HB3' HG22 ' A' ' 125' ' ' VAL . 20.6 p90 -160.87 163.41 32.02 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 119.715 -0.794 . . . . 0.0 112.494 -177.474 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -90.01 124.98 35.22 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.277 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.4 t -92.62 127.04 45.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.457 -0.497 . . . . 0.0 109.974 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 C--N 1.327 -0.376 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.506 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 . . . . . 0 C--O 1.227 -0.104 0 CA-C-O 120.83 0.347 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.98 145.98 39.86 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.8 159.52 44.08 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.208 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 54.44 43.17 30.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.035 0.445 . . . . 0.0 110.185 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.451 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.1 t -72.77 121.08 22.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.098 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -138.58 171.36 14.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.795 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.47 177.28 46.78 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 131' ' ' VAL . 55.7 Cg_endo -69.95 137.67 35.45 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 121.935 1.757 . . . . 0.0 112.19 -178.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 18.93 77.24 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.02 2.14 89.55 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.4 t -61.98 137.06 95.4 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.762 -0.257 . . . . 0.0 110.553 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.41 147.68 76.39 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.568 1.512 . . . . 0.0 111.311 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.7 t -67.64 127.32 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.591 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -61.52 -41.48 97.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.535 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.01 -175.04 49.99 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.616 -0.594 . . . . 0.0 111.616 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 75.5 m -111.4 160.29 17.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.885 0.374 . . . . 0.0 110.572 -179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -59.45 -39.28 83.09 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.439 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -60.59 -15.38 27.38 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.12 179.726 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.23 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.526 179.978 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.1 t . . . . . 0 N--CA 1.45 -0.455 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.74 -44.12 99.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.039 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.06 158.23 43.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.593 ' O ' HG23 ' A' ' 59' ' ' VAL . 1.7 p -98.68 -153.43 0.43 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.699 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -53.97 118.28 3.88 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.407 -178.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 57' ' ' THR . 94.6 t -131.64 128.65 60.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.699 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 95.3 mt -68.28 135.88 52.62 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.097 0.475 . . . . 0.0 109.801 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.89 178.35 27.44 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.327 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 86.7 m -130.38 137.52 49.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.801 0.334 . . . . 0.0 110.535 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.698 HG21 HG12 ' A' ' 103' ' ' VAL . 77.4 t -75.75 116.19 18.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.741 -178.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 64' ' ' LYS . 9.4 ptmt -69.82 -41.75 74.56 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 60.6 p-90 178.24 138.37 0.08 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.944 177.517 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -132.54 115.3 15.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 178.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -94.84 117.41 30.09 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.0 t -63.9 -44.82 98.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.471 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 64.6 mtp85 -61.89 -41.41 97.84 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.47 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -63.21 -37.63 87.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.856 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.85 3.28 66.16 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.301 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -149.98 160.04 43.92 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 117.482 0.641 . . . . 0.0 110.107 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.26 179.81 36.45 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 120.499 -0.857 . . . . 0.0 111.515 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -130.7 150.59 51.81 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.192 0.52 . . . . 0.0 112.146 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.403 HG21 ' CE2' ' A' ' 111' ' ' PHE . 83.3 mt -120.05 127.06 75.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.858 178.48 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.81 110.26 21.7 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.938 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.44 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -65.9 128.9 37.88 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.101 179.161 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -74.39 -25.81 59.71 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.309 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -71.81 -41.66 67.96 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.151 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.5 p -108.11 -7.24 16.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.66 -176.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LYS . . . . . 0.44 ' N ' ' O ' ' A' ' 77' ' ' ARG . 75.1 mmtt 52.29 31.16 8.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.906 0.384 . . . . 0.0 109.967 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -118.37 133.96 55.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.315 0.578 . . . . 0.0 111.274 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -64.23 146.28 54.58 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.067 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.603 HG11 ' HB2' ' A' ' 122' ' ' ALA . 86.5 t -128.24 130.46 69.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.871 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -68.07 130.37 42.75 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.9 149.12 18.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.219 0.533 . . . . 0.0 110.921 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -127.12 161.1 29.26 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.888 179.21 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.9 pt20 -61.12 -24.5 66.3 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -81.06 -11.51 59.5 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.388 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.25 -3.8 58.44 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.193 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.607 HD11 HG23 ' A' ' 103' ' ' VAL . 85.6 mt -90.62 102.15 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 111.082 -178.405 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -63.71 -43.09 97.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.293 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -120.62 140.9 50.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.076 -178.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -139.79 153.33 47.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.461 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.438 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.0 p-10 -57.65 132.9 82.45 Favored Pre-proline 0 CA--C 1.539 0.529 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.464 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.8 -13.27 31.93 Favored 'Trans proline' 0 N--CA 1.499 1.8 0 C-N-CA 121.947 1.765 . . . . 0.0 112.573 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -62.29 -29.16 70.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.284 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.425 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 97.3 mttt -123.13 147.38 46.85 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 120.646 0.26 . . . . 0.0 110.668 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -89.57 -15.6 32.49 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.908 0.385 . . . . 0.0 110.821 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.9 tp -97.63 123.92 41.73 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.229 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -65.66 131.73 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.947 0.403 . . . . 0.0 110.283 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.7 p -158.73 162.76 37.17 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.562 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.698 HG12 HG21 ' A' ' 63' ' ' VAL . 26.3 t -125.34 129.07 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.408 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.48 144.77 44.64 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.368 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ASP . . . . . 0.41 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 39.7 p-10 -75.37 130.41 38.96 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.87 1.86 87.77 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -79.21 130.41 35.44 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.516 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 90.5 m -72.93 130.08 39.57 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.688 179.049 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.8 m -134.53 162.67 38.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.368 -177.219 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -123.19 137.69 54.83 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.831 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.43 ' HB3' HG22 ' A' ' 125' ' ' VAL . 33.1 p90 -160.81 165.42 30.29 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.607 -177.504 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -100.54 146.11 27.5 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.325 178.445 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.79 127.6 60.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.524 -0.47 . . . . 0.0 109.985 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.4 p . . . . . 0 C--N 1.326 -0.433 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.196 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 . . . . . 0 C--O 1.227 -0.107 0 CA-C-O 120.917 0.389 . . . . 0.0 110.548 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.603 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -78.6 151.17 32.5 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.02 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.18 156.44 41.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.243 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.4 t30 56.78 48.18 16.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.971 0.415 . . . . 0.0 110.14 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.43 HG22 ' HB3' ' A' ' 111' ' ' PHE . 90.3 t -76.06 124.53 34.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.044 -179.145 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 65.4 p -138.12 167.2 22.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.759 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.69 169.32 53.57 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 178.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.425 ' O ' HG23 ' A' ' 131' ' ' VAL . 38.9 Cg_exo -60.64 136.53 67.53 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 122.031 1.821 . . . . 0.0 112.182 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.63 20.99 77.68 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.104 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.73 0.99 90.04 Favored Glycine 0 CA--C 1.532 1.127 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -61.18 141.55 93.88 Favored Pre-proline 0 CA--C 1.536 0.436 0 O-C-N 122.805 -0.232 . . . . 0.0 110.602 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -58.17 147.6 82.8 Favored 'Trans proline' 0 N--CA 1.497 1.732 0 C-N-CA 121.651 1.567 . . . . 0.0 111.285 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 41.2 t -68.5 125.06 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.628 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 tp60 -60.26 -39.92 88.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.483 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.17 -171.83 50.68 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 66.9 m -112.93 153.36 28.1 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.847 0.356 . . . . 0.0 110.55 -179.325 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -58.63 -36.92 74.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -59.56 -16.77 27.37 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.112 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.425 ' HB3' ' HD3' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.331 -0.22 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.482 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.451 -0.424 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.81 -43.02 94.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.117 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.93 160.59 42.65 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.177 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.582 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -99.2 -147.18 0.33 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -54.85 117.33 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.251 -0.58 . . . . 0.0 110.507 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 57' ' ' THR . 95.7 t -130.92 132.38 63.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.0 mt -65.69 130.08 42.01 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.082 0.468 . . . . 0.0 109.816 178.207 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.18 172.4 26.8 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.5 m -128.11 140.52 51.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.809 0.338 . . . . 0.0 110.513 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.718 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -76.32 106.88 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.77 -179.111 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.459 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 39.1 ttpt -61.15 -45.19 95.66 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.459 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -176.88 139.39 0.29 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.926 178.026 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -137.35 115.57 11.74 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.059 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -101.27 121.39 41.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.015 0.436 . . . . 0.0 110.821 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.4 HG21 ' N ' ' A' ' 139' ' ' ALA . 74.4 t -62.98 -46.23 96.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.407 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -60.58 -44.85 95.74 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -62.23 -37.92 87.25 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.846 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.65 2.95 66.88 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.374 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -148.43 161.68 41.13 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 117.473 0.636 . . . . 0.0 110.029 178.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.424 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.01 -179.01 32.58 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.532 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -130.94 145.2 51.95 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.145 0.498 . . . . 0.0 112.19 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.412 HD13 HG21 ' A' ' 109' ' ' VAL . 82.2 mt -120.29 125.08 73.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.865 179.438 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -93.33 110.86 22.4 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -64.51 132.9 51.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.193 179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -88.72 -6.69 57.27 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.315 179.3 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -95.9 -31.43 13.13 Favored 'General case' 0 C--O 1.232 0.182 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.163 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.0 p -114.08 -11.67 12.67 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.772 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.9 mttp 55.83 35.38 25.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.919 0.39 . . . . 0.0 110.004 -178.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -119.04 146.49 45.01 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.386 0.613 . . . . 0.0 111.232 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -84.18 121.48 27.52 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.986 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.576 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 75.0 t -112.14 126.46 69.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.94 179.319 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -64.9 134.02 53.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.337 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -134.18 148.42 30.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.138 0.494 . . . . 0.0 110.916 179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -133.63 162.28 32.36 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.905 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.34 -39.44 93.11 Favored 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -68.05 -15.82 63.76 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.453 179.219 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.21 -1.33 56.8 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.181 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -97.82 104.36 15.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-O 120.997 0.427 . . . . 0.0 111.164 -178.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -65.37 -43.18 91.6 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.267 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -123.03 144.63 49.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.925 0.393 . . . . 0.0 111.035 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 p-10 -151.39 177.26 10.46 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.296 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -65.52 119.46 60.11 Favored Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.62 -33.99 98.57 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.988 1.792 . . . . 0.0 112.61 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtt85 -63.47 -21.25 66.2 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.344 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -95.41 119.79 34.52 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.668 -179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -61.34 -48.27 82.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 110.814 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 86.9 mt -95.2 145.25 25.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.232 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.18 136.02 56.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.596 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -155.41 152.72 29.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.476 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.718 HG12 HG21 ' A' ' 63' ' ' VAL . 58.4 t -124.41 130.3 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.91 140.37 45.63 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.386 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -73.11 129.21 37.57 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.4 1.01 80.64 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.578 ' O ' HG23 ' A' ' 63' ' ' VAL . 88.1 tt0 -77.13 132.28 38.75 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.841 0.353 . . . . 0.0 110.56 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.0 m -71.13 130.37 41.33 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.693 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.412 HG21 HD13 ' A' ' 75' ' ' ILE . 19.9 m -134.27 160.25 41.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.442 -177.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -119.13 136.94 53.92 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.0 p90 -158.78 164.24 35.99 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.495 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -96.65 141.17 30.22 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.291 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.8 128.2 50.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.984 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 p . . . . . 0 C--N 1.327 -0.406 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.226 -0.133 0 CA-C-O 120.852 0.358 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.576 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -104.29 144.34 31.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.972 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.35 159.55 44.18 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.246 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 57.49 47.23 16.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.024 0.44 . . . . 0.0 110.185 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 93.7 t -77.18 122.68 32.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.152 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.6 p -137.46 169.36 17.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.779 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.59 172.91 47.76 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.032 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -67.63 137.02 41.11 Favored 'Trans proline' 0 C--N 1.302 -1.891 0 C-N-CA 122.01 1.807 . . . . 0.0 112.121 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.02 16.23 80.68 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.88 90.36 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.715 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -69.4 148.76 97.26 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 122.795 -0.238 . . . . 0.0 110.508 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PRO . . . . . 0.715 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.0 Cg_exo -60.48 148.19 91.67 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.631 1.554 . . . . 0.0 111.36 179.029 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 78.0 t -70.79 132.26 33.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.592 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -60.71 -41.24 94.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.517 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.2 49.09 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.602 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.8 m -113.24 154.92 25.98 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.831 0.348 . . . . 0.0 110.544 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.3 -35.84 78.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -61.68 -19.44 62.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.117 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.596 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.256 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.476 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.97 -44.98 99.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.045 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -151.44 163.24 39.43 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.3 t -99.91 -148.93 0.36 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.749 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.455 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 25.1 pttm -52.11 117.92 3.12 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.451 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 80.8 t -133.27 130.11 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.699 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.6 mt -73.3 135.98 44.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.164 0.507 . . . . 0.0 109.835 178.608 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.87 179.59 24.63 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.6 m -128.91 136.31 50.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.901 0.382 . . . . 0.0 110.359 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 103' ' ' VAL . 66.0 t -75.13 108.6 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.535 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.56 -48.32 81.49 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.535 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.3 p-90 -178.61 139.15 0.17 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.006 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -134.19 115.18 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -94.52 117.41 30.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.013 0.435 . . . . 0.0 110.897 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 139' ' ' ALA . 64.5 t -62.69 -44.78 99.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.46 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.09 -44.67 97.0 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -63.03 -38.62 91.93 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.31 2.18 64.05 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.322 179.046 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -148.28 160.14 43.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 117.371 0.585 . . . . 0.0 110.074 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.458 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -161.3 -177.6 34.53 Favored Glycine 0 CA--C 1.525 0.707 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.545 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -128.8 145.24 51.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.146 0.498 . . . . 0.0 112.147 -178.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 90.7 mt -116.35 125.16 73.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.881 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.99 109.84 20.85 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.977 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -62.89 133.64 54.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.106 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -86.14 -1.38 57.36 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.29 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -100.85 -32.64 10.57 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 120.914 0.388 . . . . 0.0 110.107 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.8 p -113.85 -10.49 12.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.692 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.3 mttt 56.26 31.51 18.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 120.993 0.425 . . . . 0.0 110.04 -179.294 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.63 141.58 49.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.252 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -67.23 145.55 55.09 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.053 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.572 HG11 ' HB2' ' A' ' 122' ' ' ALA . 91.4 t -128.48 131.77 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -69.83 138.6 52.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.297 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.9 p -147.09 148.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.18 0.514 . . . . 0.0 110.912 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.47 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 76.1 m80 -129.39 160.54 32.78 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.934 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -59.84 -40.51 88.76 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.9 p -67.85 -13.34 62.06 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.448 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -80.09 -7.68 59.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.103 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.573 HD11 HG23 ' A' ' 103' ' ' VAL . 83.2 mt -92.82 96.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.934 0.397 . . . . 0.0 111.143 -178.333 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -63.0 -42.35 99.82 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.27 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.541 ' HB2' HG22 ' A' ' 126' ' ' THR . 3.7 mptp? -119.25 132.09 55.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.059 -179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 18.3 t30 -145.53 157.72 43.95 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.483 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -57.2 119.33 30.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -68.19 -20.06 43.9 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 121.946 1.764 . . . . 0.0 112.577 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -64.5 -20.05 65.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.39 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.431 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 99.0 mttt -100.92 140.47 35.17 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.719 0.295 . . . . 0.0 110.619 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -69.51 -41.58 75.86 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.721 -178.562 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.6 142.8 35.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.193 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -74.27 128.12 34.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 110.304 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.514 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.9 m -146.67 165.08 30.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.515 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 47.3 t -119.7 128.42 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.101 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -60.59 140.4 48.05 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.355 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -80.11 130.1 34.99 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.07 2.87 90.68 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.9 tp10 -89.13 133.45 34.39 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 120.875 0.369 . . . . 0.0 110.496 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 86.5 m -69.38 131.31 44.6 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.682 178.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 28.1 m -129.24 159.39 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.419 -177.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -119.17 128.55 54.35 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -155.98 162.07 40.4 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.555 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -92.47 150.67 20.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.283 178.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.3 t -109.31 125.01 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.94 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.457 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.4 p . . . . . 0 C--N 1.326 -0.445 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG12 ' A' ' 114' ' ' VAL . 88.7 tt0 . . . . . 0 N--CA 1.461 0.093 0 CA-C-O 120.864 0.364 . . . . 0.0 110.653 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.572 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -76.17 150.17 37.19 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.993 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.79 157.2 41.63 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 56.18 48.68 16.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.947 0.403 . . . . 0.0 110.03 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.7 t -73.81 125.17 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.124 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.541 HG22 ' HB2' ' A' ' 93' ' ' LYS . 67.9 p -139.25 163.81 31.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.761 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.03 167.83 54.71 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 109.216 -1.553 . . . . 0.0 109.216 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.445 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.9 Cg_exo -60.14 138.43 81.59 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 121.946 1.764 . . . . 0.0 112.132 -178.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 69.88 20.79 76.36 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.48 90.54 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -62.11 139.68 96.01 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.84 -0.212 . . . . 0.0 110.504 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -58.3 148.05 81.42 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 C-N-CA 121.608 1.539 . . . . 0.0 111.286 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.0 t -67.64 129.72 32.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.619 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 26.7 mp0 -61.55 -42.37 98.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.489 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.19 -171.8 53.65 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 179.335 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 57.3 m -114.85 158.06 22.45 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 110.545 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -61.7 -37.38 83.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.518 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -64.26 -13.35 48.91 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.04 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.514 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.276 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.45 -0.435 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.8 mt -61.4 -44.33 98.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.08 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -142.94 162.11 36.34 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.055 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.699 ' O ' HG23 ' A' ' 59' ' ' VAL . 5.3 p -100.61 -151.98 0.42 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.606 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -49.44 117.58 2.28 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.487 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 57' ' ' THR . 92.7 t -132.82 130.53 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.693 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.2 mt -73.2 138.21 45.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.148 0.499 . . . . 0.0 109.811 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.15 178.81 27.38 Favored Glycine 0 N--CA 1.451 -0.363 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 88.2 m -127.56 137.17 52.52 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.502 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.685 HG21 HG12 ' A' ' 103' ' ' VAL . 90.4 t -76.28 108.57 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.749 -178.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.524 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -61.15 -48.86 79.65 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.15 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.524 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.1 p-90 -177.64 143.01 0.33 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.96 178.037 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -144.42 120.57 10.8 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 70' ' ' ASN . 79.8 m-20 -103.36 133.34 48.6 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.911 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.7 t -71.25 -38.39 69.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.436 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -58.41 -47.41 83.98 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -176.427 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.403 ' OD1' ' O ' ' A' ' 67' ' ' ASN . 53.1 p30 -80.62 -16.04 55.07 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.803 -178.411 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 70' ' ' ASN . . . 70.96 18.81 76.58 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.295 177.093 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -149.93 164.08 36.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 117.462 0.631 . . . . 0.0 110.181 179.221 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.13 -173.35 38.12 Favored Glycine 0 CA--C 1.524 0.604 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.505 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -128.75 146.74 50.81 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.108 0.48 . . . . 0.0 112.114 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.5 mt -120.38 126.7 75.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.955 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -94.95 111.09 22.91 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.956 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.421 ' NH2' HG21 ' A' ' 80' ' ' THR . 84.6 mtp180 -63.09 131.6 49.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.165 179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.4 p30 -89.81 2.33 55.06 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.414 -0.515 . . . . 0.0 111.323 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -107.27 -33.53 7.38 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.993 0.425 . . . . 0.0 110.198 179.097 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.421 HG21 ' NH2' ' A' ' 77' ' ' ARG . 74.4 p -116.2 -9.05 11.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.711 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.4 mttm 54.11 33.49 17.93 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 -178.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -112.85 132.96 55.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.233 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -73.91 125.4 28.12 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.052 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.85 131.89 70.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.883 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -63.35 142.78 58.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.351 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -139.91 145.9 25.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-O 121.218 0.532 . . . . 0.0 110.889 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -136.62 157.4 46.86 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.911 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -61.31 -39.25 89.8 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.0 p -66.79 -17.15 64.73 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -83.45 -4.27 58.35 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.154 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.425 HD11 HG23 ' A' ' 103' ' ' VAL . 81.7 mt -96.99 97.93 6.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.995 0.426 . . . . 0.0 111.217 -179.041 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -64.51 -41.3 96.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.283 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.531 ' HB3' HG22 ' A' ' 126' ' ' THR . 40.3 ttmt -119.45 136.33 54.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.009 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -149.43 170.82 17.69 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.357 179.25 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.415 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 31.5 p-10 -65.95 125.54 90.17 Favored Pre-proline 0 CA--C 1.539 0.526 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.83 -19.62 58.8 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.035 1.823 . . . . 0.0 112.59 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -64.57 -22.97 67.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -104.69 128.25 52.71 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.648 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -69.31 -37.55 77.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.754 179.427 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.98 131.56 48.32 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.141 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -59.45 136.36 57.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.028 0.442 . . . . 0.0 110.279 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.3 t -158.17 155.33 28.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.572 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.685 HG12 HG21 ' A' ' 63' ' ' VAL . 53.3 t -119.64 129.36 75.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.88 151.12 51.21 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.316 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -86.67 136.1 33.15 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.71 2.86 90.25 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.9 tp10 -92.92 128.81 38.92 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.938 0.399 . . . . 0.0 110.5 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -67.12 133.31 49.59 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.751 179.032 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.9 m -129.53 159.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.456 -178.576 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -118.66 128.83 54.9 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -157.76 161.15 38.45 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.767 -0.773 . . . . 0.0 112.538 -178.088 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.404 ' OD1' ' C ' ' A' ' 112' ' ' ASP . 55.8 p30 -90.32 174.53 7.53 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.281 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -127.61 127.67 68.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 C-N-CA 120.509 -0.476 . . . . 0.0 109.978 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 91.8 t . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.687 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.6 pt-20 . . . . . 0 N--CA 1.461 0.092 0 CA-C-O 120.97 0.414 . . . . 0.0 110.666 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -97.77 148.46 23.34 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.96 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.09 41.76 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.236 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.1 t30 53.35 47.92 23.13 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.141 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.7 t -75.28 125.55 34.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.069 -178.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.531 HG22 ' HB3' ' A' ' 93' ' ' LYS . 69.7 p -136.92 169.21 18.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.743 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -77.27 175.58 53.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.05 137.85 35.54 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 122.074 1.849 . . . . 0.0 112.061 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.7 19.64 79.31 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.87 1.48 90.61 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 -179.147 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 86.6 t -62.65 137.61 96.56 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-O 119.647 -0.216 . . . . 0.0 110.611 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -59.14 148.44 85.75 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 121.697 1.598 . . . . 0.0 111.259 179.184 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.415 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 43.7 t -67.59 128.17 30.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.669 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -63.58 -39.62 94.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.539 -179.146 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.91 -175.58 53.16 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 179.311 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 41.4 t -101.28 160.4 14.44 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.824 0.345 . . . . 0.0 110.554 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -61.09 -37.99 84.68 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.416 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -64.35 -14.04 53.96 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.092 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.477 -179.712 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 84.9 t . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.6 mt -63.41 -44.14 98.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.046 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.25 163.73 36.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.07 0.462 . . . . 0.0 111.067 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.643 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -98.1 -146.57 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.679 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 57' ' ' THR . 63.5 mttp -50.82 116.4 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.407 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 57' ' ' THR . 74.1 t -131.78 130.03 61.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.697 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.7 mt -73.55 137.21 44.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.055 0.455 . . . . 0.0 109.808 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.32 177.9 27.2 Favored Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.4 m -128.22 135.76 50.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.856 0.36 . . . . 0.0 110.486 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.71 HG21 HG12 ' A' ' 103' ' ' VAL . 77.2 t -76.93 109.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.765 -179.209 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.1 tttt -62.22 -48.39 80.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 62.2 p-90 -175.8 147.63 0.81 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 114.678 -1.146 . . . . 0.0 109.903 178.004 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -137.45 115.44 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 41.4 t-20 -93.49 110.27 21.85 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.978 0.418 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 53.4 t -61.21 -46.7 96.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.391 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.1 ttp180 -62.01 -43.76 98.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -178.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.16 -39.39 92.48 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.81 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.49 4.04 59.58 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.382 179.255 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -148.26 160.82 42.57 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.423 0.611 . . . . 0.0 110.04 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.454 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -160.53 -177.22 33.44 Favored Glycine 0 CA--C 1.525 0.71 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.573 -179.629 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -131.5 147.9 52.58 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.134 0.492 . . . . 0.0 112.193 -179.338 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.2 mt -120.77 127.36 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.843 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -91.92 110.45 21.81 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.807 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 96.4 mtm-85 -62.18 135.2 57.39 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.126 179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -82.54 -6.95 59.62 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.382 179.548 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -94.75 -33.07 13.04 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.959 0.409 . . . . 0.0 110.138 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 68.0 p -116.9 -10.6 10.96 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.642 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 54.44 34.51 21.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.976 0.417 . . . . 0.0 110.026 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -121.04 132.64 55.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.247 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -66.23 148.14 52.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.037 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -132.78 152.15 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.914 179.672 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -73.24 133.11 43.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.297 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.4 p -144.84 144.11 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.149 0.499 . . . . 0.0 110.911 178.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -136.19 157.79 45.96 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.841 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -58.46 -24.73 61.05 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -178.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.3 p -73.6 -20.49 60.59 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.421 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.24 -7.74 58.88 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.137 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.3 mt -90.0 94.9 5.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.872 0.367 . . . . 0.0 111.198 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -64.34 -38.15 90.03 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.437 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -122.94 142.86 50.35 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.101 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -153.28 177.13 11.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.35 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -63.63 118.62 46.43 Favored Pre-proline 0 CA--C 1.539 0.552 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.7 -34.66 99.07 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.056 1.838 . . . . 0.0 112.545 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.09 -19.9 66.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.467 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -97.65 114.53 26.5 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-O 120.74 0.305 . . . . 0.0 110.604 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -60.69 -47.89 84.23 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.893 0.378 . . . . 0.0 110.761 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 64.0 tp -91.18 130.67 37.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.182 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -59.76 136.73 58.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.055 0.455 . . . . 0.0 110.249 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.463 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.1 t -154.18 154.25 33.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.505 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.71 HG12 HG21 ' A' ' 63' ' ' VAL . 53.1 t -121.7 131.95 71.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.4 144.64 47.74 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.324 -178.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -83.14 118.59 23.69 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.65 -0.73 74.29 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -82.82 132.33 35.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.862 0.363 . . . . 0.0 110.532 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 85.8 m -69.04 132.48 46.7 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.648 178.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -130.01 159.77 41.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.47 -178.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -119.96 126.62 51.31 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -155.45 163.81 39.55 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.558 -177.187 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.31 153.33 20.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.224 178.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -110.29 125.09 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.403 -0.519 . . . . 0.0 109.983 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 75.8 t . . . . . 0 C--N 1.326 -0.423 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.941 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.227 -0.121 0 CA-C-O 120.966 0.412 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -94.14 146.59 23.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.01 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.35 157.06 40.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.135 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 58.19 47.33 14.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.977 0.418 . . . . 0.0 110.164 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.2 t -76.07 123.22 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.074 -179.025 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.2 p -134.96 159.96 39.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.813 179.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.55 162.21 53.94 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.105 -1.598 . . . . 0.0 109.105 178.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.51 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.8 Cg_exo -58.83 136.99 77.34 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.039 1.826 . . . . 0.0 112.108 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.57 83.0 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.2 1.45 90.47 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.9 p -68.89 141.66 92.58 Favored Pre-proline 0 CA--C 1.535 0.4 0 CA-C-O 119.673 -0.203 . . . . 0.0 110.501 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 20.4 Cg_endo -59.09 150.24 74.72 Favored 'Trans proline' 0 N--CA 1.497 1.721 0 C-N-CA 121.634 1.556 . . . . 0.0 111.315 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -64.42 133.58 29.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.552 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -62.43 -42.41 99.43 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.496 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.41 162.59 36.16 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 85.1 p -80.59 166.3 21.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.894 0.378 . . . . 0.0 110.496 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -63.4 -36.87 85.17 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.511 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -72.1 -5.23 33.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.121 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.463 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.329 -0.295 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.448 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t . . . . . 0 N--CA 1.45 -0.454 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.0 -44.53 97.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.069 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -155.27 163.24 40.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.056 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.547 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.4 t -96.19 -149.51 0.31 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.685 179.622 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -55.1 118.0 3.96 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.52 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 57' ' ' THR . 87.5 t -129.58 128.55 65.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.701 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.7 mt -68.98 135.31 50.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.122 0.486 . . . . 0.0 109.733 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.04 -177.82 27.0 Favored Glycine 0 CA--C 1.521 0.42 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.4 m -128.28 135.34 49.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.876 0.37 . . . . 0.0 110.391 -179.564 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.711 HG21 HG12 ' A' ' 103' ' ' VAL . 97.1 t -71.28 110.87 4.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.765 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -61.52 -48.92 78.85 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.9 p-90 -177.77 140.08 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.957 178.123 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -137.1 119.17 15.43 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -101.22 120.88 40.9 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.892 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.407 HG21 ' C ' ' A' ' 138' ' ' TYR . 67.3 t -62.93 -45.73 98.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.525 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -61.82 -44.68 96.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -178.677 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -62.09 -38.78 90.13 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.902 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.61 2.1 65.53 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.397 179.471 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -147.54 161.96 40.05 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 117.467 0.633 . . . . 0.0 110.112 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.55 -179.05 36.9 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.561 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -126.99 146.27 50.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.153 0.501 . . . . 0.0 112.172 -178.856 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.407 HG21 ' CE2' ' A' ' 111' ' ' PHE . 87.2 mt -119.31 125.34 74.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.827 178.463 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.77 109.88 21.32 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.836 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -65.96 134.78 53.66 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.19 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -85.06 -5.31 59.35 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.418 -0.513 . . . . 0.0 111.268 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -96.49 -33.19 11.95 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.176 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 66.5 p -115.15 -9.61 12.27 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.627 -178.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt 53.63 32.5 14.59 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 121.062 0.458 . . . . 0.0 110.147 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -119.73 131.83 55.48 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.233 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.02 142.43 58.38 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.986 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.411 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 79.0 t -126.89 132.42 70.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.899 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -66.19 138.19 57.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.312 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.79 147.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.225 0.536 . . . . 0.0 110.946 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -136.88 159.96 40.31 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.905 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.418 ' HA ' HD12 ' A' ' 91' ' ' ILE . 16.6 pm0 -59.98 -20.4 57.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 64.1 p -82.52 -12.81 57.52 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.465 179.064 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.05 1.36 57.24 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.132 179.397 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.459 HD11 HG23 ' A' ' 103' ' ' VAL . 80.7 mt -95.97 101.68 12.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.929 0.395 . . . . 0.0 111.136 -178.153 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -63.11 -45.15 93.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.365 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -115.07 136.8 52.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.04 -178.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -143.26 137.85 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.31 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.4 p-10 -58.96 138.39 87.49 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.057 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.34 -9.12 24.76 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.004 1.802 . . . . 0.0 112.499 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.55 -35.95 77.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.412 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -105.04 137.91 42.07 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-O 120.687 0.279 . . . . 0.0 110.672 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.445 ' HB2' HD22 ' A' ' 100' ' ' LEU . 98.2 m-85 -68.42 -41.95 79.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.756 -179.37 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.59 HD22 ' N ' ' A' ' 100' ' ' LEU . 1.3 mm? -97.98 146.41 25.53 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.31 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -67.51 128.52 36.74 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.381 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.406 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.7 m -147.51 161.74 40.47 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.477 -179.271 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.711 HG12 HG21 ' A' ' 63' ' ' VAL . 32.8 t -125.97 131.11 72.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -61.64 143.48 48.65 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.266 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -81.58 123.29 28.54 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.327 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.0 3.83 88.87 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -84.74 136.67 33.61 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.939 0.399 . . . . 0.0 110.503 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 89.6 m -70.66 130.88 42.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.607 179.137 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -134.91 164.82 32.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.445 -178.477 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -124.87 137.7 54.28 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.3 p90 -160.12 162.52 34.01 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.813 -0.755 . . . . 0.0 112.481 -177.394 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -90.65 137.34 32.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.268 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.7 t -103.83 126.22 58.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.988 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 121' ' ' GLU . 35.8 m . . . . . 0 C--N 1.327 -0.408 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG22 ' A' ' 114' ' ' VAL . 88.9 tt0 . . . . . 0 N--CA 1.461 0.091 0 CA-C-O 120.892 0.377 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.411 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -77.92 152.87 33.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.12 158.22 42.65 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.14 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 53.07 47.28 24.92 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.105 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.6 t -74.43 124.05 31.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.071 -179.048 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 50.3 p -139.78 170.06 16.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.825 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.31 164.68 54.72 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 178.378 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.444 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.3 Cg_exo -59.44 137.18 76.51 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 C-N-CA 121.977 1.785 . . . . 0.0 112.177 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.31 20.81 77.06 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.25 2.48 90.5 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -179.577 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 128' ' ' PRO . 96.6 t -60.98 141.3 93.61 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 122.777 -0.249 . . . . 0.0 110.553 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -56.28 148.06 63.09 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 121.549 1.499 . . . . 0.0 111.315 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.416 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 42.9 t -69.78 126.24 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.64 -179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 16.2 tm0? -60.9 -40.42 93.01 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.54 -178.554 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.41 -174.39 54.95 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -111.75 162.84 14.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.841 0.353 . . . . 0.0 110.502 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -60.84 -37.91 83.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.509 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.407 ' C ' HG21 ' A' ' 68' ' ' VAL . 96.4 m-85 -71.02 -5.77 33.84 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.067 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.406 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.331 -0.214 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.521 -179.035 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.87 -44.26 99.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.102 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.436 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.94 162.91 37.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 -179.248 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.495 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.9 t -108.84 -134.8 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.707 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.441 ' N ' HG23 ' A' ' 57' ' ' THR . 68.6 mttm -54.71 102.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.346 -0.541 . . . . 0.0 110.369 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 57' ' ' THR . 97.4 t -127.26 128.75 70.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.729 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 88.6 mt -79.66 135.99 36.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.104 0.478 . . . . 0.0 109.862 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.49 178.18 21.81 Favored Glycine 0 CA--C 1.519 0.298 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.518 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 134.76 50.67 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.852 0.358 . . . . 0.0 110.463 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.661 HG21 HG12 ' A' ' 103' ' ' VAL . 86.6 t -75.77 109.99 10.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.75 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.67 -49.19 77.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 61.4 p-90 -174.51 152.78 1.75 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.899 178.05 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -147.06 117.07 7.24 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.6 m-20 -97.45 120.87 38.6 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.908 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -63.18 -44.8 99.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.462 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.42 HH11 ' HD2' ' A' ' 69' ' ' ARG . 9.0 ptm85 -65.22 -34.84 79.32 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -69.3 -35.35 75.9 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.521 -0.471 . . . . 0.0 110.788 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 89.38 1.42 78.39 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.367 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -150.15 162.74 39.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.445 0.623 . . . . 0.0 110.085 179.279 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.73 179.85 34.09 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.493 -0.86 . . . . 0.0 111.535 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -123.49 143.52 50.11 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.133 0.492 . . . . 0.0 112.091 -178.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.992 HD12 HG11 ' A' ' 86' ' ' VAL . 88.1 mt -120.63 126.2 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.841 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.91 114.75 27.38 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.875 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -71.43 128.69 36.69 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.035 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.3 p30 -83.93 -1.59 54.85 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.337 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -101.21 -31.54 10.96 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-O 120.947 0.403 . . . . 0.0 110.176 179.282 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.72 -12.48 11.51 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.682 -179.201 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.86 32.45 19.68 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.995 -179.153 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.78 135.35 55.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.244 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -63.32 144.95 56.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.072 -179.421 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.35 133.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.901 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -80.98 125.19 29.84 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.325 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.079 HG12 ' HB3' ' A' ' 122' ' ' ALA . 32.6 m -131.17 159.86 42.72 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-O 121.133 0.492 . . . . 0.0 110.973 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -137.95 155.97 48.34 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.837 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -60.93 -22.98 64.92 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.531 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.9 p -80.96 -13.0 59.28 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.422 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.05 2.93 55.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.094 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 103' ' ' VAL . 78.9 mt -98.03 106.68 19.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.876 0.37 . . . . 0.0 111.171 -178.331 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -63.84 -44.35 93.45 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.327 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.03 144.13 50.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.928 0.394 . . . . 0.0 111.051 -179.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 p-10 -150.26 174.32 12.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.418 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.0 t-20 -62.67 120.2 57.79 Favored Pre-proline 0 CA--C 1.541 0.604 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.49 -23.07 58.21 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.035 1.823 . . . . 0.0 112.595 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.4 mmm-85 -67.02 -21.63 65.92 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.413 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.61 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 75.5 mmtt -91.48 136.93 32.76 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.62 -179.403 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.404 ' C ' HD12 ' A' ' 100' ' ' LEU . 94.4 m-85 -69.18 -39.55 78.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.753 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 99' ' ' TYR . 8.0 mp -113.5 151.52 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.173 -179.465 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.66 139.25 58.74 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.319 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.8 p -156.0 161.36 40.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.603 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.661 HG12 HG21 ' A' ' 63' ' ' VAL . 52.7 t -123.12 125.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.8 146.86 48.94 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.363 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -84.55 133.78 34.44 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.88 4.8 89.61 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.565 -1.014 . . . . 0.0 110.565 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -92.61 129.77 38.44 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.96 0.41 . . . . 0.0 110.504 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.5 m -66.81 133.55 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.576 178.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.5 m -128.89 158.15 41.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.459 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -120.0 130.11 54.59 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -160.8 165.14 30.79 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.549 -177.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -95.28 144.98 25.41 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.306 178.288 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.436 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -105.06 126.3 60.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.022 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.8 p . . . . . 0 C--N 1.328 -0.36 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.58 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 . . . . . 0 C--O 1.227 -0.122 0 CA-C-O 120.926 0.393 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 1.079 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -116.67 149.81 39.17 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.23 156.99 42.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.191 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 54.81 43.89 29.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.051 0.453 . . . . 0.0 110.123 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.8 t -72.45 121.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.054 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.1 p -137.88 166.23 24.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.725 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.61 175.24 49.79 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.49 138.21 38.12 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.929 1.753 . . . . 0.0 112.097 -179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 19.99 77.94 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.79 1.12 90.56 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.03 137.52 95.58 Favored Pre-proline 0 CA--C 1.535 0.39 0 O-C-N 122.822 -0.222 . . . . 0.0 110.556 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -59.45 146.26 95.51 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.656 1.57 . . . . 0.0 111.247 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -64.96 135.27 28.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.69 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -59.51 -42.78 92.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.469 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.28 176.71 51.16 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 179.245 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 43.8 t -97.0 143.93 27.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.92 0.391 . . . . 0.0 110.54 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -60.14 -21.07 61.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.552 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -74.93 -12.59 60.39 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.113 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.61 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.331 -0.215 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.515 -179.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.5 t . . . . . 0 N--CA 1.451 -0.404 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.5 mt -62.82 -45.3 99.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.029 -178.723 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.83 167.62 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.116 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.5 t -105.66 -134.77 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.68 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.443 ' N ' HG23 ' A' ' 57' ' ' THR . 87.8 tttt -50.34 112.91 0.76 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.482 -179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 57' ' ' THR . 72.5 t -135.45 131.29 51.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.771 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.472 HD23 ' HG2' ' A' ' 110' ' ' GLU . 67.2 mt -75.01 133.75 41.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.121 0.486 . . . . 0.0 109.75 177.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.89 175.57 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 90.1 m -131.17 138.93 49.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.829 0.347 . . . . 0.0 110.432 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.721 HG21 HG12 ' A' ' 103' ' ' VAL . 97.2 t -72.62 109.18 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.78 -178.772 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -62.49 -48.04 81.35 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.006 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.528 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 59.0 p-90 -177.23 139.53 0.26 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.969 178.154 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -135.71 120.84 18.87 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -104.65 119.87 40.0 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.923 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.36 -45.47 98.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.482 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -60.57 -44.92 95.66 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -62.13 -38.15 87.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.813 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.1 1.47 64.97 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.34 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.5 p90 -147.5 160.16 42.91 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 117.473 0.636 . . . . 0.0 110.072 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.91 174.61 36.73 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.489 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -129.16 148.6 51.11 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.187 0.518 . . . . 0.0 112.141 -179.053 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.429 HD13 HG21 ' A' ' 109' ' ' VAL . 84.5 mt -116.55 127.18 74.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.844 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.12 109.05 19.96 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -60.38 134.99 57.6 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.159 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -84.37 -0.15 51.53 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.301 179.496 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -101.87 -33.04 9.94 Favored 'General case' 0 C--O 1.231 0.085 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.058 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.7 p -116.59 -9.09 11.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.693 -178.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mmtm 55.81 31.75 18.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.96 0.41 . . . . 0.0 110.037 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -117.69 133.99 55.37 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.303 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.15 144.57 56.8 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.098 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.449 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.2 t -124.14 126.94 73.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.913 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.76 129.03 38.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.318 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.93 149.76 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.186 0.517 . . . . 0.0 110.921 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.01 160.13 33.73 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.858 178.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.414 ' OE1' HD11 ' A' ' 100' ' ' LEU . 25.9 pt20 -60.24 -29.79 68.99 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -73.53 -15.66 61.29 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.385 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.19 -0.07 53.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.17 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.523 HD11 HG23 ' A' ' 103' ' ' VAL . 80.4 mt -92.98 101.3 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.967 0.413 . . . . 0.0 111.226 -178.545 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -62.94 -43.86 97.65 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -121.79 143.02 49.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.148 -179.347 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -152.77 163.79 39.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.434 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -61.76 121.15 62.81 Favored Pre-proline 0 CA--C 1.539 0.539 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.46 -21.63 66.09 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 121.967 1.778 . . . . 0.0 112.553 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.82 -22.16 66.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.326 179.637 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -100.89 120.67 40.49 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-O 120.751 0.31 . . . . 0.0 110.686 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 88.8 t80 -61.03 -48.3 82.41 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.703 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.414 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.5 tp -93.09 129.53 39.03 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.141 -179.25 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -61.82 139.23 58.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.297 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 90.2 p -158.31 163.95 36.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.452 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.721 HG12 HG21 ' A' ' 63' ' ' VAL . 43.8 t -125.16 129.53 73.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.25 144.66 48.01 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.319 -178.725 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 105' ' ' ASP . 41.0 p-10 -77.36 129.2 35.51 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.36 2.01 86.94 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 110.526 -1.029 . . . . 0.0 110.526 -178.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.7 tt0 -78.37 130.91 36.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 120.988 0.423 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.4 m -71.09 130.76 42.35 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.713 178.522 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.429 HG21 HD13 ' A' ' 75' ' ' ILE . 21.6 m -133.71 158.43 42.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.524 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.472 ' HG2' HD23 ' A' ' 60' ' ' LEU . 94.6 mt-10 -115.78 132.42 56.64 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.287 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -161.33 167.11 26.42 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.473 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -88.57 149.53 23.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.252 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.8 t -108.43 123.9 64.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.481 -0.488 . . . . 0.0 109.957 -179.789 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.4 t . . . . . 0 C--N 1.326 -0.439 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.402 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 C--O 1.226 -0.158 0 CA-C-O 120.925 0.393 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.449 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -118.69 142.43 47.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.045 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.11 153.34 42.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.184 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 54.36 43.08 30.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.059 0.457 . . . . 0.0 110.174 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.05 125.39 28.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.106 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.9 p -135.67 169.43 17.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.824 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.09 177.24 45.69 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 178.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.431 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.7 Cg_endo -69.73 136.38 32.93 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 121.911 1.74 . . . . 0.0 112.188 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.68 21.53 77.87 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.07 1.79 90.41 Favored Glycine 0 CA--C 1.531 1.084 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 128' ' ' PRO . 85.5 t -63.16 140.43 97.67 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 122.853 -0.204 . . . . 0.0 110.527 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -58.06 148.53 76.75 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 121.58 1.52 . . . . 0.0 111.292 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.2 t -69.15 128.99 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.605 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -61.47 -41.85 97.88 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.435 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.83 -175.9 48.94 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -109.5 159.96 16.62 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.845 0.355 . . . . 0.0 110.53 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt -61.49 -37.81 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -63.63 -15.37 58.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.078 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.48 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.281 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.451 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.8 t . . . . . 0 N--CA 1.451 -0.401 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.64 -45.0 98.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.068 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.55 163.45 39.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.109 -178.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.545 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.1 t -98.12 -149.09 0.33 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.7 179.725 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.0 mtmt -53.92 119.31 4.85 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.449 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 57' ' ' THR . 72.2 t -131.38 131.67 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.629 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 62.2 mt -65.7 131.07 45.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.102 0.477 . . . . 0.0 109.835 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.62 176.13 24.78 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 91.8 m -129.33 135.46 48.77 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.735 0.302 . . . . 0.0 110.508 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 95.2 t -70.88 108.02 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.826 -179.228 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.54 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.7 tttt -61.66 -47.81 83.65 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.073 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.54 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 58.1 p-90 -177.1 138.94 0.26 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.602 -1.181 . . . . 0.0 109.942 178.052 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -136.07 117.57 14.8 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -100.59 119.68 38.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.004 0.43 . . . . 0.0 110.907 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.437 HG21 ' N ' ' A' ' 139' ' ' ALA . 65.3 t -62.18 -46.33 96.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.422 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.13 -46.16 90.6 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -61.41 -39.23 89.98 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.924 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.61 1.93 63.6 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.349 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -148.21 161.22 41.91 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.505 0.653 . . . . 0.0 110.062 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -159.48 -177.91 33.0 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.568 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -129.24 143.96 51.04 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.425 HG13 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -116.93 123.42 71.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.814 178.797 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -91.11 109.12 20.37 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.933 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.423 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -63.64 130.29 43.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.083 178.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -74.99 -26.86 59.88 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.358 179.041 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -70.77 -41.78 71.27 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.905 0.383 . . . . 0.0 110.224 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.2 p -104.49 -11.14 17.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.675 -178.173 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' LYS . . . . . 0.423 ' N ' ' O ' ' A' ' 77' ' ' ARG . 98.6 mttt 55.86 31.19 17.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.927 0.394 . . . . 0.0 110.043 -178.486 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -120.45 145.84 46.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.225 179.72 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -70.31 147.22 49.91 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.073 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 122' ' ' ALA . 88.3 t -130.12 132.53 65.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.816 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -66.31 138.29 57.52 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.328 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.425 HG11 HG13 ' A' ' 75' ' ' ILE . 7.7 p -151.44 149.88 13.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.232 0.539 . . . . 0.0 110.879 179.012 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -133.48 155.38 49.65 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.83 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.2 pt20 -60.9 -25.52 66.79 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 63.2 p -79.56 -13.05 59.8 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.479 178.595 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.24 1.56 55.53 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.119 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.46 HD11 HG23 ' A' ' 103' ' ' VAL . 78.8 mt -93.91 108.9 21.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.847 0.356 . . . . 0.0 111.202 -178.239 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -64.32 -43.11 95.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.318 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.85 138.98 54.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.147 -178.455 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -144.91 157.19 44.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.476 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -56.98 120.15 36.18 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.83 -32.23 94.4 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.015 1.81 . . . . 0.0 112.581 179.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -62.41 -21.79 65.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.418 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -85.62 127.59 34.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 120.693 0.282 . . . . 0.0 110.623 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -65.46 -39.47 92.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.795 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.3 150.32 39.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.254 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -63.15 136.8 57.97 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.7 p -159.38 163.05 35.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.495 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 54.9 t -125.72 128.39 72.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.525 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.66 138.62 38.1 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.274 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.01 135.76 38.68 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.57 3.19 90.15 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.425 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.6 tp10 -92.36 128.45 38.21 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 121.002 0.429 . . . . 0.0 110.537 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.6 m -68.16 132.99 48.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.674 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.99 158.04 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.235 -0.586 . . . . 0.0 111.394 -178.562 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -117.37 134.4 54.87 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.153 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 39.8 p90 -158.75 162.2 37.08 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.819 -0.753 . . . . 0.0 112.586 -177.61 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -88.88 144.09 26.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.25 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.3 123.78 59.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.987 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.325 -0.467 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.67 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 C--O 1.226 -0.145 0 CA-C-O 120.925 0.393 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.96 143.49 34.03 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.034 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.13 157.71 43.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.184 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 55.4 49.48 16.81 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.939 0.4 . . . . 0.0 110.07 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 86.7 t -75.8 125.17 35.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.14 -179.152 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -137.5 163.57 30.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.76 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.4 165.76 54.17 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.082 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.8 Cg_exo -59.6 136.05 68.41 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.962 1.774 . . . . 0.0 112.154 -178.597 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.3 19.44 79.65 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 178.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.36 1.59 90.31 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 128' ' ' PRO . 90.4 t -60.96 139.06 94.09 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-O 119.692 -0.194 . . . . 0.0 110.572 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' HG13 ' A' ' 131' ' ' VAL . 24.0 Cg_endo -60.69 149.06 89.5 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.679 1.586 . . . . 0.0 111.323 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.6 t -70.28 128.81 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.55 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 12.7 tp-100 -61.07 -39.99 91.98 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.534 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.14 -175.71 53.82 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 65.4 m -107.54 155.65 19.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.59 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -62.64 -35.52 79.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.493 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -62.11 -13.65 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.099 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.437 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.24 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.468 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -62.71 131.41 48.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -89.96 133.04 35.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.213 0.53 . . . . 0.0 111.02 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 79.9 t -101.13 104.44 16.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.489 178.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.457 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.0 mt -61.92 -44.21 98.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.037 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.524 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.85 159.34 43.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.117 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.557 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.8 p -107.81 -140.7 0.38 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.661 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt -50.93 102.52 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.262 -0.575 . . . . 0.0 110.505 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 57' ' ' THR . 84.3 t -128.49 130.19 69.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.712 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 87.1 mt -82.12 137.01 35.08 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.93 -179.88 22.47 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 89.8 m -127.29 136.18 51.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.792 0.329 . . . . 0.0 110.501 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 89.3 t -76.67 112.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.74 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.534 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.45 -48.15 80.93 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.072 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.534 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -178.76 143.66 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.961 177.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -138.73 118.73 13.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -98.77 120.89 39.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.987 0.422 . . . . 0.0 110.81 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.402 HG21 ' N ' ' A' ' 139' ' ' ALA . 69.9 t -64.16 -45.1 97.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.42 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.1 ttp85 -61.31 -44.46 97.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.41 -38.36 89.4 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.843 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.36 3.96 66.67 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 121.091 -0.575 . . . . 0.0 112.401 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -149.28 161.38 42.16 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.441 0.621 . . . . 0.0 110.137 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.429 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -162.75 -177.08 35.46 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 120.554 -0.831 . . . . 0.0 111.577 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.456 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.6 m-85 -131.56 147.7 52.55 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.107 0.48 . . . . 0.0 112.233 -179.242 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.2 mt -120.24 127.68 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.856 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -93.32 109.83 21.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.849 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.9 mtm180 -65.6 131.78 47.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.093 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.9 p30 -86.91 -0.21 56.13 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.278 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -100.32 -32.7 10.72 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.892 0.377 . . . . 0.0 110.098 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.75 -10.59 11.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.674 -179.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 56.9 mtmt 55.37 32.34 18.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 109.996 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -121.25 132.37 54.77 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.319 0.58 . . . . 0.0 111.222 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -67.04 146.47 54.3 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.049 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.0 p -134.03 148.03 30.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.931 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -73.45 138.46 45.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.354 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 73' ' ' GLY . 4.8 p -143.01 145.56 22.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 121.112 0.482 . . . . 0.0 110.947 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -137.4 158.85 43.52 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.868 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -61.28 -39.19 89.49 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.5 p -67.27 -15.7 63.85 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.469 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.02 0.75 54.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.496 HD11 HG23 ' A' ' 103' ' ' VAL . 83.5 mt -98.65 104.97 16.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.038 0.447 . . . . 0.0 111.136 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -62.67 -44.93 95.01 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.331 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.412 ' HB2' HG22 ' A' ' 126' ' ' THR . 75.9 mmtt -125.62 145.39 50.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.002 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -150.98 176.59 10.98 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.399 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -63.71 121.14 68.92 Favored Pre-proline 0 CA--C 1.54 0.589 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.38 -25.61 63.69 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.999 1.799 . . . . 0.0 112.535 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.0 mmm180 -69.96 -17.95 63.33 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.436 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -95.78 123.85 39.54 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.689 0.28 . . . . 0.0 110.632 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -66.02 -39.8 90.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.858 0.361 . . . . 0.0 110.752 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -103.66 136.68 42.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.219 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.1 mtm180 -65.1 137.18 57.51 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.316 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 86.1 p -160.05 164.0 33.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 59.4 t -123.43 128.37 74.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.21 145.73 44.95 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.309 -179.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -83.0 137.91 33.96 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.49 2.78 88.29 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -93.57 132.13 38.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.88 0.371 . . . . 0.0 110.465 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -69.59 133.19 47.32 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.611 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.68 159.67 40.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.522 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -120.95 131.07 54.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -160.75 167.31 27.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.507 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -100.55 138.05 38.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.284 178.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.524 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 55.4 t -95.87 124.79 48.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 120.523 -0.471 . . . . 0.0 109.863 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.1 t -119.77 129.82 74.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -61.45 126.62 28.01 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.854 -178.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -117.69 160.22 13.8 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.5 mp0 -62.1 -39.58 92.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.743 0.306 . . . . 0.0 110.979 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -87.56 -5.37 58.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.372 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 141.89 -169.83 25.12 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.69 139.28 58.32 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.405 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -122.94 134.95 54.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.589 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.7 145.83 24.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.033 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.8 155.7 39.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.159 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 54.28 50.45 16.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.999 0.428 . . . . 0.0 110.131 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -78.4 119.62 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.112 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.412 HG22 ' HB2' ' A' ' 93' ' ' LYS . 82.3 p -138.41 164.58 28.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.769 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.05 171.27 51.1 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -69.18 137.64 37.66 Favored 'Trans proline' 0 C--N 1.3 -1.994 0 C-N-CA 122.0 1.8 . . . . 0.0 112.122 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.11 19.43 79.79 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.5 0.58 89.35 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 128' ' ' PRO . 76.0 t -61.2 137.77 94.35 Favored Pre-proline 0 CA--C 1.535 0.391 0 O-C-N 122.802 -0.234 . . . . 0.0 110.51 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.15 150.3 87.86 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 121.61 1.54 . . . . 0.0 111.351 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.05 132.39 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.588 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -61.66 -40.27 94.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.616 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.01 -176.98 53.91 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 72.6 m -103.19 153.78 20.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.82 0.343 . . . . 0.0 110.56 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -59.89 -37.75 80.28 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.401 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -62.31 -15.56 48.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.12 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.402 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -58.32 139.98 54.25 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.569 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.659 -179.781 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.561 0 C3'-C2'-C1' 104.339 1.171 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.87 0 O4'-C4'-C3' 103.772 -1.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.537 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.429 -1.537 0 P-O3'-C3' 121.558 1.548 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -1.03 0 O4'-C4'-C3' 103.826 -1.774 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.793 0 O4'-C4'-C3' 103.859 -1.741 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.266 0 C1'-O4'-C4' 106.647 -2.181 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.849 0 O4'-C1'-C2' 107.278 1.071 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -71.0 145.54 49.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.276 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -106.98 128.59 54.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.152 0.501 . . . . 0.0 110.972 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.2 t -92.03 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.395 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.426 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.3 mt -62.29 -44.17 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.061 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.77 164.95 33.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.098 0.475 . . . . 0.0 111.061 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.81 ' O ' HG23 ' A' ' 59' ' ' VAL . 10.9 t -98.05 -151.4 0.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.647 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.458 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 22.5 pttp -47.03 116.0 1.24 Allowed 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.453 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.81 HG23 ' O ' ' A' ' 57' ' ' THR . 93.9 t -129.79 128.08 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.688 179.391 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.6 mt -75.18 136.5 41.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.12 0.486 . . . . 0.0 109.827 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -152.86 -175.87 24.8 Favored Glycine 0 CA--C 1.52 0.363 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.5 m -130.54 136.76 49.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.81 0.338 . . . . 0.0 110.503 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.731 HG21 HG12 ' A' ' 103' ' ' VAL . 77.5 t -73.21 115.57 14.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.752 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.43 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.2 ttpt -63.73 -47.05 82.63 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.43 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 56.5 p-90 -176.43 148.18 0.73 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 114.673 -1.148 . . . . 0.0 109.901 177.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -143.4 115.62 8.44 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.452 ' ND2' ' C6 ' ' B' ' 305' ' ' ' DC' . 5.9 m120 -101.0 123.29 44.96 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.88 -178.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.3 t -63.33 -46.08 96.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.461 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -60.29 -45.49 93.15 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.53 88.33 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.894 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.93 2.61 66.53 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.01 161.87 41.49 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 117.456 0.628 . . . . 0.0 110.064 179.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.443 ' O ' HG22 ' A' ' 86' ' ' VAL . . . -157.74 -177.92 31.3 Favored Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.601 -179.577 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.444 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 95.5 m-85 -131.72 146.5 52.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.152 0.501 . . . . 0.0 112.157 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.856 HD12 HG11 ' A' ' 86' ' ' VAL . 86.8 mt -120.55 127.25 75.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.838 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -92.94 109.84 21.29 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.879 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.4 mtm180 -62.75 133.39 54.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.109 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 p30 -87.74 -0.15 56.52 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.279 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.9 -32.12 11.14 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 120.974 0.416 . . . . 0.0 110.113 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 75.2 p -113.44 -11.03 13.17 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.698 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt 57.69 31.44 20.41 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 0.0 110.007 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -120.1 142.66 48.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.356 0.598 . . . . 0.0 111.198 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.36 144.82 51.5 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.051 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 87.3 t -128.21 128.2 68.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.972 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -72.8 130.1 39.7 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.341 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.057 HG12 ' HB3' ' A' ' 122' ' ' ALA . 33.3 m -132.91 159.42 43.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.215 0.531 . . . . 0.0 110.917 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.34 155.93 47.36 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.936 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -60.86 -23.05 64.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.2 p -81.85 -11.94 58.71 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.421 178.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.22 0.9 56.98 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.156 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.4 mt -96.8 100.3 10.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.943 0.401 . . . . 0.0 111.168 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -63.36 -44.12 95.72 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.298 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -122.33 144.88 48.74 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.954 0.406 . . . . 0.0 111.031 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.5 p-10 -155.07 175.69 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.38 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -66.63 120.55 71.77 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -64.81 -25.66 60.42 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.039 1.826 . . . . 0.0 112.552 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -65.47 -20.73 66.48 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.395 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.82 128.68 40.19 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.696 0.284 . . . . 0.0 110.633 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -66.13 -38.67 88.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.754 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.9 mt -108.89 149.7 28.77 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.214 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -69.68 129.94 41.0 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.384 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 65.8 m -143.46 157.9 44.07 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.474 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.731 HG12 HG21 ' A' ' 63' ' ' VAL . 48.8 t -126.41 131.69 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.18 49.21 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.361 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.56 115.18 26.77 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 95.14 -8.42 69.85 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -72.21 156.11 39.5 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.921 0.391 . . . . 0.0 110.492 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.3 m -86.96 129.47 34.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.653 178.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.0 m -129.86 158.98 42.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.431 -177.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -119.91 129.44 54.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 50.3 p90 -158.11 161.03 37.92 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.783 -0.767 . . . . 0.0 112.567 -177.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -85.36 152.98 22.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.336 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.426 HG12 ' HB ' ' A' ' 55' ' ' ILE . 59.8 t -107.18 124.67 63.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 120.473 -0.491 . . . . 0.0 109.985 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 83.3 t -121.28 129.41 75.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -67.3 125.81 27.25 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.954 -178.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -118.11 156.59 15.58 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -60.26 -45.4 93.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.729 0.3 . . . . 0.0 110.957 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.3 pttm -77.12 -18.86 57.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.368 . . . . 0.0 111.324 178.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.48 33.29 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.32 140.16 58.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.86 0.362 . . . . 0.0 110.509 179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -127.31 135.39 50.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.621 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 1.057 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -85.33 154.66 21.74 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.034 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.36 151.9 32.38 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.297 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 53.35 46.52 26.18 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.161 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 98.9 t -70.75 124.09 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.126 -179.125 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -140.91 165.55 27.21 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.76 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.78 172.93 52.61 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 53.5 Cg_endo -70.6 136.77 31.54 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.061 1.841 . . . . 0.0 112.102 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.25 20.25 79.67 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 3.04 90.67 Favored Glycine 0 CA--C 1.532 1.146 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 75.4 t -63.68 138.09 97.28 Favored Pre-proline 0 CA--C 1.536 0.416 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.66 152.42 81.95 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.579 1.519 . . . . 0.0 111.337 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 94.7 t -68.92 131.31 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.563 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -61.11 -45.4 94.87 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.518 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.92 159.1 26.42 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -74.9 162.49 28.58 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.82 0.343 . . . . 0.0 110.581 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -72.35 -24.91 61.35 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.528 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -69.83 -15.4 63.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.052 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.481 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . -58.5 140.58 53.8 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.433 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.597 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.514 -1.384 0 C4'-C3'-C2' 101.715 -1.485 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.428 -0.77 0 P-O3'-C3' 121.099 1.166 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.591 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.433 -1.162 0 O4'-C4'-C3' 103.95 -1.65 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.801 0 C3'-C2'-C1' 101.793 -0.648 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . 0.452 ' C6 ' ' ND2' ' A' ' 67' ' ' ASN . . . . . . . . 0 C3'--C2' 1.526 0.847 0 O4'-C4'-C3' 104.28 -1.32 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.28 0 C1'-O4'-C4' 106.8 -2.072 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.433 -1.147 0 O4'-C1'-C2' 107.509 1.281 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -72.82 148.59 44.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.239 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -68.96 133.41 48.14 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.264 0.554 . . . . 0.0 110.969 179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 98.1 t -93.87 99.83 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.348 179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.1 mt -62.43 -43.32 98.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.036 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.84 160.8 42.89 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.08 0.467 . . . . 0.0 111.107 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.651 ' O ' HG23 ' A' ' 59' ' ' VAL . 3.2 p -99.22 -146.21 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.646 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -50.06 108.01 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.451 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 57' ' ' THR . 70.1 t -126.72 129.83 71.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.721 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.3 mt -74.83 137.1 41.64 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.22 -179.42 24.17 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.8 m -128.15 135.87 50.36 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.856 0.36 . . . . 0.0 110.451 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 84.7 t -75.99 109.25 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.708 -179.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.04 -49.65 75.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 60.9 p-90 -174.72 146.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.979 178.141 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -142.58 121.16 12.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -103.47 123.12 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.592 -0.443 . . . . 0.0 110.868 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.0 t -63.79 -45.88 95.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.477 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.04 -44.77 96.89 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -62.2 -38.14 87.99 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 91.86 2.26 69.56 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.423 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -148.77 161.3 42.07 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-N 117.454 0.627 . . . . 0.0 110.057 179.017 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.5 178.36 36.55 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.536 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -126.12 143.39 51.14 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.201 0.524 . . . . 0.0 112.118 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 86.2 mt -120.02 127.23 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.828 178.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -89.0 118.08 28.48 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.2 mtm180 -72.51 131.9 43.13 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.212 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -83.36 -6.35 59.44 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.267 179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.87 -33.25 11.7 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.002 0.429 . . . . 0.0 110.086 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -114.06 -11.68 12.69 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.861 -0.608 . . . . 0.0 111.734 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.8 mttp 55.62 33.02 20.36 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.641 -0.424 . . . . 0.0 109.964 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -122.51 137.83 54.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.289 0.566 . . . . 0.0 111.248 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.24 142.27 57.8 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.046 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.478 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 80.0 t -127.79 131.16 70.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.876 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -69.08 138.8 54.62 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.328 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.21 149.31 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.163 0.506 . . . . 0.0 110.979 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -136.13 159.31 42.11 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.855 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.457 HE22 HD21 ' A' ' 100' ' ' LEU . 97.5 mt-30 -61.3 -39.49 90.65 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.2 p -66.6 -18.31 65.3 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.4 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.95 -0.79 55.48 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.095 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.463 HD11 HG23 ' A' ' 103' ' ' VAL . 84.0 mt -95.74 103.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.97 0.414 . . . . 0.0 111.091 -178.453 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -63.25 -43.96 96.53 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.292 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -127.27 147.38 50.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.088 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -154.44 177.55 11.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.336 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -65.6 120.8 71.32 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.09 -22.16 62.17 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.069 1.846 . . . . 0.0 112.515 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.3 mmm180 -67.46 -21.75 65.52 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -100.87 122.62 43.77 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-O 120.701 0.286 . . . . 0.0 110.534 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -61.0 -48.43 81.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.74 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.457 HD21 HE22 ' A' ' 88' ' ' GLN . 66.3 tp -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 -60.95 132.48 54.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.999 0.428 . . . . 0.0 110.37 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.8 m -148.39 159.9 43.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.547 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 52.6 t -121.33 127.8 75.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.421 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -69.2 149.53 49.02 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.403 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -85.81 134.68 33.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.56 4.02 90.13 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -91.44 130.47 37.27 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.989 0.423 . . . . 0.0 110.465 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.4 m -69.15 132.71 46.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.651 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.4 m -129.99 157.53 42.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.471 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -117.59 126.74 53.07 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 51.0 p90 -156.57 163.6 39.17 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.718 -0.793 . . . . 0.0 112.537 -177.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -88.52 149.64 23.52 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.238 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.9 t -106.86 124.93 62.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.429 -0.508 . . . . 0.0 109.964 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 97.7 t -117.8 129.24 74.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -61.81 124.44 20.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.027 0.441 . . . . 0.0 110.935 -178.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.7 157.85 14.72 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 179.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -63.04 -39.55 95.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.663 0.268 . . . . 0.0 110.913 -179.306 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -91.22 -11.62 37.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.334 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 158.29 -171.29 35.14 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -66.04 147.85 52.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -119.39 157.46 28.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.645 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.478 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -119.89 143.22 48.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.076 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.1 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.261 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 53.5 45.84 27.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.977 0.418 . . . . 0.0 110.147 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 85.4 t -72.99 120.44 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.136 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.49 164.2 30.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.877 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.54 172.46 50.57 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 52.5 Cg_endo -70.13 136.9 33.16 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 122.041 1.827 . . . . 0.0 112.162 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.33 19.68 79.78 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.03 1.26 89.73 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 71.0 t -62.0 138.06 95.66 Favored Pre-proline 0 CA--C 1.536 0.408 0 O-C-N 122.776 -0.25 . . . . 0.0 110.556 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.91 150.3 88.31 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 121.687 1.591 . . . . 0.0 111.335 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.54 133.95 30.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.561 -179.464 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -60.48 -41.75 94.84 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.589 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.96 179.54 52.71 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.4 m -106.03 160.88 14.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.927 0.394 . . . . 0.0 110.552 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -61.09 -37.43 82.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.535 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -65.21 -14.6 61.03 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.118 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.539 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -58.85 142.02 51.65 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.479 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.54 -179.792 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.613 0 O4'-C4'-C3' 107.04 1.44 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.856 0 C3'-C2'-C1' 104.542 1.316 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.444 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.427 -0.813 0 P-O3'-C3' 121.473 1.477 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.858 0 C3'-C2'-C1' 101.773 -0.662 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.887 0 O4'-C4'-C3' 104.05 -1.55 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.268 0 C1'-O4'-C4' 107.07 -1.879 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.788 0 O4'-C1'-C2' 107.069 0.881 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -71.5 145.05 49.41 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.159 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.47 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.1 tttm -66.57 134.39 52.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.183 0.516 . . . . 0.0 110.94 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t -101.8 106.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.798 . . . . 0.0 109.408 178.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.447 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.1 mt -63.17 -44.78 99.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.039 -178.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.1 163.57 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.086 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.588 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.7 t -102.68 -148.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.658 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.416 ' N ' HG23 ' A' ' 57' ' ' THR . 59.1 mtmt -52.67 115.43 1.8 Allowed 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.388 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 57' ' ' THR . 75.7 t -132.3 130.38 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.755 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.1 mt -75.3 131.23 40.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.12 0.486 . . . . 0.0 109.771 178.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.66 -177.03 20.95 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.4 m -128.38 137.41 51.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.868 0.366 . . . . 0.0 110.478 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.704 HG21 HG12 ' A' ' 103' ' ' VAL . 96.1 t -73.82 115.06 14.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.247 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.536 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.4 tttt -62.88 -48.95 76.79 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 179.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.536 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 53.6 p-90 -179.31 140.28 0.15 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.99 178.551 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -135.96 117.26 14.59 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.438 ' ND2' ' O2 ' ' B' ' 305' ' ' ' DC' . 6.3 m120 -102.67 123.67 46.8 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.876 -179.345 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.4 t -62.84 -45.64 98.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.487 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -61.08 -45.37 95.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -62.74 -38.61 91.2 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.493 -0.483 . . . . 0.0 110.836 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.13 2.24 68.88 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.37 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -148.44 161.44 41.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.394 0.597 . . . . 0.0 110.14 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -157.22 -179.5 32.19 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.571 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.417 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.6 m-85 -129.37 146.47 51.23 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 79.2 mt -125.7 128.22 72.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.79 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -94.26 126.22 39.38 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.857 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 95.1 mtm-85 -74.9 131.47 40.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.092 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -84.07 -0.16 50.69 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.305 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -100.79 -33.31 10.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.945 0.403 . . . . 0.0 110.112 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 81.4 p -116.5 -8.57 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.758 -0.656 . . . . 0.0 111.647 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt 56.22 30.86 17.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.397 . . . . 0.0 110.006 -179.135 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -117.08 137.14 52.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.21 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.5 p-10 -74.25 158.05 34.76 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.113 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.23 148.51 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.947 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -77.94 136.68 38.04 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.375 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -143.96 148.1 19.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.159 0.504 . . . . 0.0 110.976 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -133.28 159.11 41.18 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.945 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.85 -25.56 65.13 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.8 p -74.86 -16.15 60.69 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.478 179.224 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.24 0.46 55.33 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.142 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.436 HD11 HG23 ' A' ' 103' ' ' VAL . 80.5 mt -95.13 100.47 11.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.12 -178.168 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -64.65 -41.8 95.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.298 179.022 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.15 138.4 52.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.123 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -148.54 153.73 38.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.342 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -58.62 120.83 48.67 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.31 -19.19 61.93 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 121.92 1.746 . . . . 0.0 112.557 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.0 mmm-85 -63.31 -23.96 67.64 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.408 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -101.39 133.24 46.31 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 120.686 0.279 . . . . 0.0 110.652 -179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -68.62 -38.46 80.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.745 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.9 mt -103.92 142.8 33.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.244 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.5 mtt85 -66.87 137.98 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.303 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -156.59 153.25 28.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.471 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 63' ' ' VAL . 42.3 t -119.58 131.96 70.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -59.16 143.09 46.18 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.344 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -81.96 120.24 24.98 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.14 2.39 89.37 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.6 tp10 -81.71 137.42 35.39 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.903 0.383 . . . . 0.0 110.554 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 88.1 m -68.83 132.46 46.8 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.726 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.0 157.78 42.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.413 -178.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -117.43 126.99 53.58 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.407 ' HB3' HG22 ' A' ' 125' ' ' VAL . 48.4 p90 -154.82 162.09 41.24 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 119.807 -0.757 . . . . 0.0 112.565 -177.496 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -93.14 149.13 21.44 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.246 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.447 HG12 ' HB ' ' A' ' 55' ' ' ILE . 62.0 t -107.47 126.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.469 -0.492 . . . . 0.0 109.956 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 53' ' ' LYS . 12.5 p -133.56 142.08 42.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.421 ' HG3' HG13 ' A' ' 55' ' ' ILE . 96.7 mt-10 -63.39 134.02 55.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.988 0.423 . . . . 0.0 110.877 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -118.51 164.91 12.88 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 51.5 mp0 -62.19 -40.6 96.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.712 0.292 . . . . 0.0 110.989 -179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.85 -0.03 57.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.343 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 136.54 -168.91 24.0 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.083 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -58.31 136.67 57.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -132.43 135.33 46.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.695 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.15 152.67 29.1 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.973 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.97 157.12 43.18 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.193 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 53.4 44.88 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.436 . . . . 0.0 110.215 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.407 HG22 ' HB3' ' A' ' 111' ' ' PHE . 95.1 t -72.05 124.07 27.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.073 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.4 p -136.67 168.48 19.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.789 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.65 171.07 54.45 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -66.61 138.97 51.5 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 C-N-CA 121.929 1.753 . . . . 0.0 112.175 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.27 16.8 79.66 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.89 2.45 90.55 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.706 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -68.4 147.95 98.18 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-O 119.704 -0.189 . . . . 0.0 110.55 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PRO . . . . . 0.706 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.6 Cg_exo -59.48 150.73 73.79 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.582 1.521 . . . . 0.0 111.309 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t -66.36 131.34 32.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.622 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -61.74 -39.97 93.45 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.497 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.47 -173.64 54.85 Favored Glycine 0 CA--C 1.524 0.623 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.66 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 71.1 m -112.5 157.96 20.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.822 0.344 . . . . 0.0 110.59 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -60.55 -37.69 82.08 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.384 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -60.87 -19.5 60.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.111 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -60.05 137.81 58.01 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.449 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.627 -179.821 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.473 0 C3'-C2'-C1' 104.964 1.617 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.938 0 O4'-C4'-C3' 102.782 -2.818 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.58 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.433 -1.19 0 O4'-C4'-C3' 103.518 -2.082 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.886 0 C3'-C2'-C1' 101.076 -1.16 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . 0.438 ' O2 ' ' ND2' ' A' ' 67' ' ' ASN . . . . . . . . 0 C3'--C2' 1.526 0.81 0 C4'-C3'-C2' 102.403 -0.797 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.33 0 C1'-O4'-C4' 107.268 -1.737 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.83 0 C3'-C2'-C1' 104.29 1.135 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 23.1 t0 . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -71.51 145.74 48.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.225 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -62.74 133.71 55.2 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.176 0.512 . . . . 0.0 110.974 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.74 101.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.46 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.45 -42.94 97.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.108 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.417 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -147.11 157.32 43.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.799 ' O ' HG23 ' A' ' 59' ' ' VAL . 9.9 p -102.47 -149.99 0.4 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.609 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -48.25 104.66 0.06 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.497 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 57' ' ' THR . 96.7 t -125.04 129.37 73.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.696 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.0 mt -75.37 138.59 41.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.132 0.492 . . . . 0.0 109.762 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.39 -178.15 25.0 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -129.05 137.76 51.48 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.878 0.37 . . . . 0.0 110.491 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 92.1 t -73.11 109.86 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.754 -179.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.511 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 61.9 tttm -61.16 -50.93 71.18 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.511 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.3 p-90 -176.65 139.55 0.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.016 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -137.92 116.57 12.17 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.401 ' ND2' ' O2 ' ' B' ' 305' ' ' ' DC' . 6.9 m120 -99.34 121.72 41.49 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.964 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.26 -45.82 97.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.426 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -62.71 -42.1 99.48 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -62.2 -39.06 91.49 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.835 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.4 2.23 65.87 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.354 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -149.56 162.19 40.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 117.464 0.632 . . . . 0.0 109.984 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.33 -179.28 35.95 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.499 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.444 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.9 m-85 -130.33 144.9 51.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.213 0.53 . . . . 0.0 112.127 -178.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.4 mt -120.11 126.33 75.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.839 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -93.16 119.76 32.71 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -72.85 133.79 44.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.161 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -83.23 -8.58 59.45 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.29 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -93.04 -33.18 14.2 Favored 'General case' 0 C--O 1.231 0.121 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.092 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 79.1 p -115.31 -9.13 12.23 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.75 -178.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.4 mttt 53.37 32.7 14.25 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.972 -179.15 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -120.39 134.74 55.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.332 0.587 . . . . 0.0 111.219 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -64.36 144.2 57.34 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.03 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 95.0 t -130.05 133.1 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.878 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -65.51 138.29 57.97 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.396 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.18 147.76 18.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.251 0.548 . . . . 0.0 110.855 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -137.73 160.2 39.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.926 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.406 ' HA ' HD12 ' A' ' 91' ' ' ILE . 97.2 mt-30 -61.73 -39.03 90.13 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -178.512 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.7 p -67.99 -16.07 63.88 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.453 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.84 2.41 51.48 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.406 HD12 ' HA ' ' A' ' 88' ' ' GLN . 85.0 mt -98.6 107.73 20.91 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.885 0.374 . . . . 0.0 111.245 -178.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -65.63 -42.65 91.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.349 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.038 -178.128 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -144.11 168.78 19.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.388 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -55.12 121.14 34.54 Favored Pre-proline 0 CA--C 1.539 0.553 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.96 -41.69 72.5 Favored 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 121.933 1.756 . . . . 0.0 112.597 -178.011 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -63.86 -14.63 54.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? -104.39 118.03 35.61 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 120.688 0.28 . . . . 0.0 110.616 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -77.26 -22.83 51.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.915 0.388 . . . . 0.0 110.785 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.4 tp -100.72 125.61 47.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.173 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.64 133.8 56.46 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.584 -0.447 . . . . 0.0 110.31 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.3 t -160.79 151.92 18.93 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.495 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 56.6 t -118.59 127.13 75.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.68 145.85 46.02 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.334 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -83.56 135.42 34.64 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.3 4.06 89.86 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -92.43 131.87 37.24 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 120.958 0.409 . . . . 0.0 110.461 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.6 m -69.47 133.66 47.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.64 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.8 m -131.8 158.47 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.462 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.67 130.52 55.09 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -156.57 164.12 38.57 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 119.778 -0.769 . . . . 0.0 112.541 -177.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -97.3 140.28 32.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.368 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.3 t -100.86 125.65 54.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.066 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -121.24 132.03 71.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -63.38 126.86 28.85 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.942 -178.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.07 164.15 12.18 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -61.66 -42.63 99.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.765 0.317 . . . . 0.0 111.006 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -83.39 -21.56 33.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.408 179.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 160.73 -169.24 36.38 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.729 -0.949 . . . . 0.0 110.729 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.19 143.93 57.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.887 0.375 . . . . 0.0 110.39 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -131.55 150.46 52.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.591 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.531 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -105.19 145.16 30.99 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.975 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.14 162.93 39.49 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.195 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 54.06 45.23 27.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.985 0.421 . . . . 0.0 110.173 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.7 t -74.25 123.91 30.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.048 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.9 p -138.32 167.93 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.806 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.96 174.38 53.05 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.433 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -68.86 137.6 38.58 Favored 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.065 1.844 . . . . 0.0 112.121 -178.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.02 20.19 78.81 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.92 2.11 90.65 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.5 t -63.37 137.21 97.01 Favored Pre-proline 0 CA--C 1.537 0.449 0 O-C-N 122.78 -0.247 . . . . 0.0 110.56 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.94 145.42 91.32 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.561 1.507 . . . . 0.0 111.314 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.58 132.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -60.84 -43.1 98.73 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.456 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.99 -179.93 52.83 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 37.9 t -106.19 141.07 38.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.849 0.357 . . . . 0.0 110.589 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.5 ptmt -59.26 -21.88 60.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.44 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 70.1 m-85 -66.07 -22.62 66.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.139 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -56.92 137.57 55.14 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.47 -179.516 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.62 -179.627 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.526 0 C3'-C2'-C1' 105.019 1.656 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.856 0 O4'-C4'-C3' 103.675 -1.925 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.575 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.432 -1.278 0 O4'-C4'-C3' 103.326 -2.274 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.943 0 C3'-C2'-C1' 100.782 -1.37 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . 0.401 ' O2 ' ' ND2' ' A' ' 67' ' ' ASN . . . . . . . . 0 O5'--C5' 1.427 -0.819 0 O4'-C1'-C2' 107.379 1.163 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.243 0 C1'-O4'-C4' 105.9 -2.714 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.818 0 O4'-C1'-C2' 107.534 1.304 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.5 t0 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -142.89 157.3 44.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.211 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.484 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.1 tttm -102.02 129.11 48.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.175 0.512 . . . . 0.0 110.969 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.4 t -96.17 102.15 13.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.399 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.438 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.4 mt -63.14 -44.28 99.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.033 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -149.01 164.08 35.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 15.0 t -101.99 -149.05 0.38 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.648 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 57' ' ' THR . 58.4 mtmt -52.3 117.01 2.52 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.431 -178.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 84.8 t -133.21 131.37 58.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.687 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.3 mt -76.01 136.07 39.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.084 0.469 . . . . 0.0 109.776 178.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.55 -179.36 24.42 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.5 m -127.06 140.67 52.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.937 0.398 . . . . 0.0 110.455 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.691 HG21 HG12 ' A' ' 103' ' ' VAL . 93.0 t -82.21 111.24 18.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.739 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 64.9 tttp -62.77 -49.93 73.03 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.552 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 63.2 p-90 -169.81 154.41 5.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.645 -1.161 . . . . 0.0 109.927 177.66 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -142.5 118.68 10.75 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 -98.23 112.1 24.2 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.993 0.425 . . . . 0.0 110.892 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.423 HG21 ' N ' ' A' ' 139' ' ' ALA . 73.9 t -61.75 -45.05 99.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.381 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.2 ttt85 -61.09 -44.5 97.26 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.08 -38.71 92.27 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.444 -0.503 . . . . 0.0 110.821 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.15 4.49 59.87 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.387 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -152.37 162.0 41.8 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 117.43 0.615 . . . . 0.0 110.102 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.521 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -156.04 -176.05 27.73 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.56 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.448 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 90.9 m-85 -126.3 145.14 50.55 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.155 0.502 . . . . 0.0 112.138 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 83.3 mt -120.12 125.45 74.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.896 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -90.66 109.59 20.76 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.479 -0.488 . . . . 0.0 110.813 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -62.87 135.32 57.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.13 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -86.37 -2.3 58.3 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.316 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -100.14 -34.05 10.2 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.973 0.416 . . . . 0.0 110.144 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.7 p -115.44 -9.25 12.13 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.679 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mmtm 55.43 29.96 14.15 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -115.18 133.62 55.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.375 0.607 . . . . 0.0 111.299 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.9 142.52 58.26 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.985 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.7 t -124.83 133.27 69.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -70.77 138.18 50.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.313 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -148.73 148.69 15.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.183 0.516 . . . . 0.0 110.954 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -132.79 155.77 48.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.886 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -60.15 -23.67 64.1 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 80.5 p -83.33 -10.41 58.5 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.591 -0.443 . . . . 0.0 110.401 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.91 3.61 55.39 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.116 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.428 HD11 HG23 ' A' ' 103' ' ' VAL . 86.1 mt -99.13 106.1 18.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-O 120.994 0.426 . . . . 0.0 111.228 -178.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -63.31 -44.78 94.02 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.327 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -122.3 141.21 51.76 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.125 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -150.23 176.34 10.95 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.349 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -64.95 120.42 66.56 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.69 -23.35 63.4 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.01 1.807 . . . . 0.0 112.578 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.9 mmm-85 -68.5 -19.62 64.54 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.412 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -98.93 129.33 45.25 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 120.678 0.275 . . . . 0.0 110.661 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -67.52 -37.86 83.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.966 0.412 . . . . 0.0 110.731 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.2 mt -105.6 141.34 37.22 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.258 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.28 138.76 57.87 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.319 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.409 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 93.8 p -156.96 162.75 39.61 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.532 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.691 HG12 HG21 ' A' ' 63' ' ' VAL . 45.6 t -125.88 130.97 72.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.38 143.8 37.94 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.294 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.4 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 41.0 p-10 -75.92 132.75 40.46 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.65 4.83 89.45 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 63' ' ' VAL . 85.3 tt0 -86.93 129.48 34.86 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.007 0.432 . . . . 0.0 110.488 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 99.6 m -71.1 131.2 43.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.67 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.3 158.49 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.455 -177.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.91 129.0 54.95 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 178.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 45.9 p90 -155.68 162.82 40.5 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.582 -177.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -92.4 149.46 21.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.375 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HB ' ' A' ' 55' ' ' ILE . 60.5 t -108.19 126.35 64.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.937 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 53' ' ' LYS . 14.6 p -127.16 133.13 68.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -69.63 126.84 30.93 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.865 -178.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.47 162.88 12.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -61.19 -39.58 90.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.713 0.292 . . . . 0.0 110.95 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -85.56 -11.73 53.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.38 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 146.79 -172.84 27.2 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -63.47 140.12 58.84 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.885 0.374 . . . . 0.0 110.417 179.599 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.94 152.55 49.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.672 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -109.96 147.75 32.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.989 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.43 161.08 41.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.145 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 54.51 44.37 28.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.984 0.421 . . . . 0.0 110.125 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 91.8 t -72.81 122.77 26.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.092 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 62.7 p -136.91 163.79 29.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.783 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.43 168.57 54.8 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.099 -1.601 . . . . 0.0 109.099 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.426 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.5 Cg_exo -59.52 138.09 81.69 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 121.903 1.736 . . . . 0.0 112.094 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.21 19.04 75.45 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.308 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.77 4.42 90.34 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -62.63 136.94 96.35 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 122.699 -0.295 . . . . 0.0 110.484 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -58.44 146.96 88.24 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.552 1.502 . . . . 0.0 111.335 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.4 132.37 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.645 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 11.8 tp-100 -61.34 -41.41 96.99 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.549 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.23 -176.59 50.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.2 m -105.49 157.85 17.08 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.75 0.31 . . . . 0.0 110.64 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -60.84 -37.39 81.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.51 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -63.88 -17.3 63.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.055 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -60.66 138.47 58.07 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.435 -179.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.41 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.63 -179.791 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.57 0 C3'-C2'-C1' 105.055 1.682 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.83 0 O4'-C4'-C3' 103.023 -2.577 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.501 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.426 -1.789 0 O4'-C4'-C3' 103.202 -2.398 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.436 -0.899 0 O4'-C4'-C3' 103.987 -1.613 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . 0.415 " H1'" ' C2 ' ' B' ' 306' ' ' ' DC' . . . . . . . . 0 C3'--C2' 1.528 0.979 0 O4'-C1'-C2' 107.033 0.848 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . 0.415 ' C2 ' " H1'" ' B' ' 305' ' ' ' DC' . . . . . . . . 0 C3'--C2' 1.532 1.353 0 C1'-O4'-C4' 106.905 -1.997 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.879 0 C4'-C3'-C2' 104.835 1.635 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -144.43 160.24 41.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.207 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -66.94 136.06 54.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.196 0.522 . . . . 0.0 110.9 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.6 t -99.04 101.91 12.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.482 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.25 -44.42 99.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.071 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.52 157.25 43.1 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.632 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.4 p -102.41 -147.42 0.37 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.668 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -51.93 107.44 0.2 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.441 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 57' ' ' THR . 76.1 t -125.11 131.24 72.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.745 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 68.8 mt -69.09 134.98 50.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.069 0.462 . . . . 0.0 109.838 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.77 178.23 30.82 Favored Glycine 0 CA--C 1.519 0.341 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m -130.77 137.77 49.62 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.866 0.365 . . . . 0.0 110.466 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -70.45 112.39 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.813 -179.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.51 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.45 -48.59 80.44 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.51 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.8 p-90 -177.32 140.06 0.27 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 114.564 -1.198 . . . . 0.0 109.95 177.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -138.14 115.28 10.96 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.401 ' HA ' HD21 ' A' ' 67' ' ' ASN . 6.2 m120 -100.21 124.44 45.64 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.934 -178.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -63.3 -46.08 96.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.452 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -61.19 -44.44 97.29 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.91 -39.21 93.84 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.872 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.42 4.78 65.83 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.365 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -151.75 162.59 40.77 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 117.442 0.621 . . . . 0.0 110.078 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.65 -178.4 34.6 Favored Glycine 0 CA--C 1.525 0.689 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.557 -179.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.442 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.7 m-85 -129.64 148.67 51.56 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.124 0.488 . . . . 0.0 112.095 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.421 HG13 HG11 ' A' ' 86' ' ' VAL . 82.4 mt -118.67 126.79 75.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.428 -0.806 . . . . 0.0 109.863 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -91.54 110.24 21.55 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.876 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -65.72 130.36 43.0 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.085 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -87.54 -3.58 58.99 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.331 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -97.74 -31.5 12.22 Favored 'General case' 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.393 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.0 p -113.28 -9.89 13.38 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.686 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp 57.77 32.14 21.48 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.024 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -126.23 148.88 49.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.34 0.59 . . . . 0.0 111.168 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -82.3 158.87 23.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -142.93 150.6 17.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -78.15 135.79 37.72 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.352 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.421 HG11 HG13 ' A' ' 75' ' ' ILE . 5.5 p -146.52 147.99 17.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.104 0.478 . . . . 0.0 110.864 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -136.21 159.1 42.76 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.9 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.465 ' HA ' HD12 ' A' ' 91' ' ' ILE . 27.6 pt20 -59.19 -25.02 63.6 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -178.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -74.44 -16.05 60.88 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.468 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.461 ' HB1' ' HA ' ' A' ' 123' ' ' ALA . . . -89.32 2.96 53.63 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.155 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.465 HD12 ' HA ' ' A' ' 88' ' ' GLN . 84.5 mt -95.87 103.12 14.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.905 0.383 . . . . 0.0 111.153 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -65.19 -43.67 90.9 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.314 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -119.17 144.23 46.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.134 -178.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.0 t30 -144.1 171.18 14.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.439 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -61.07 122.87 72.6 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.64 -23.12 57.04 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 121.906 1.737 . . . . 0.0 112.522 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.4 mmm-85 -73.38 -14.06 61.21 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.399 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -114.2 142.22 46.54 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 120.746 0.308 . . . . 0.0 110.658 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.488 ' CE1' HD21 ' A' ' 100' ' ' LEU . 43.9 p90 -98.35 4.91 48.61 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.694 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.699 ' CD1' ' HB3' ' A' ' 140' ' ' ALA . 88.7 mt -119.42 142.4 48.25 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.156 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -81.15 125.98 30.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.416 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 87.9 p -156.38 162.44 40.05 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.507 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 39.7 t -131.53 134.63 60.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.38 147.98 50.36 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.338 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -84.91 120.82 26.91 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.25 -5.61 82.8 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.04 135.21 41.27 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-O 121.069 0.462 . . . . 0.0 110.44 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.2 m -70.88 131.46 43.79 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.636 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 19.9 m -135.93 159.38 39.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.39 -178.403 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -116.11 138.54 51.16 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.6 p90 -159.44 164.04 34.87 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.523 -177.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -98.59 138.49 35.71 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.218 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.0 t -107.02 127.21 62.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 120.463 -0.495 . . . . 0.0 110.033 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m -119.56 156.73 21.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -89.37 118.06 28.75 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.008 0.432 . . . . 0.0 110.91 -178.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -106.91 167.91 14.1 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -61.77 -44.71 96.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.715 0.293 . . . . 0.0 110.943 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -74.9 -22.89 58.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.37 179.081 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 153.83 -164.76 31.37 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.041 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -65.59 143.16 57.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.88 0.372 . . . . 0.0 110.38 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -127.43 159.32 34.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.636 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.16 143.41 43.25 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.966 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.461 ' HA ' ' HB1' ' A' ' 90' ' ' ALA . . . -153.22 161.07 42.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.231 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 56.84 47.17 18.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 110.125 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.7 t -77.61 121.08 29.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.114 -179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 59.2 p -137.88 169.04 18.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.797 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.26 167.73 54.84 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 131' ' ' VAL . 34.8 Cg_exo -60.63 138.12 77.84 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.99 1.793 . . . . 0.0 112.146 -178.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.5 20.58 78.48 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 178.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.47 89.84 Favored Glycine 0 CA--C 1.532 1.108 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 128' ' ' PRO . 78.3 t -61.02 138.21 94.15 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-O 119.667 -0.206 . . . . 0.0 110.556 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -61.56 148.37 93.15 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 121.662 1.575 . . . . 0.0 111.233 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.5 t -63.81 130.77 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.653 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -62.31 -40.11 95.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.615 -179.373 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.77 157.42 33.15 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 81.5 p -76.19 160.2 29.93 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 120.921 0.391 . . . . 0.0 110.539 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -70.32 -23.48 62.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.513 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -80.09 -2.96 46.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.144 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.31 138.73 56.21 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.465 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.699 ' HB3' ' CD1' ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.62 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.517 0 C3'-C2'-C1' 105.11 1.722 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.925 0 O4'-C4'-C3' 103.714 -1.886 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.574 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.429 -1.51 0 O4'-C4'-C3' 103.22 -2.38 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.899 0 C3'-C2'-C1' 101.774 -0.661 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.895 0 O4'-C1'-C2' 107.203 1.003 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.316 0 C1'-O4'-C4' 107.46 -1.6 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.832 0 O4'-C1'-C2' 106.875 0.704 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 23.4 pttp -146.92 159.44 43.54 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.165 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.42 ' O ' HG13 ' A' ' 114' ' ' VAL . 64.1 tttp -110.86 131.61 54.9 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.21 0.529 . . . . 0.0 110.996 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 97.0 t -94.68 102.95 14.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.389 178.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.454 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.4 mt -63.77 -45.9 95.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.002 -179.056 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -158.21 162.2 37.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.762 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.7 t -96.38 -142.86 0.28 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.57 179.55 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.478 ' N ' HG23 ' A' ' 57' ' ' THR . 76.0 mmtt -50.34 103.28 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.291 -0.563 . . . . 0.0 110.416 -179.38 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 57' ' ' THR . 95.0 t -119.28 128.59 75.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 80.0 mt -64.33 130.75 45.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.082 0.468 . . . . 0.0 109.776 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.16 174.45 23.75 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -129.22 134.31 47.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.941 0.4 . . . . 0.0 110.488 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.674 HG21 HG12 ' A' ' 103' ' ' VAL . 98.6 t -75.43 108.48 7.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.723 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 22.0 ttmm -63.2 -48.22 79.23 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 62.4 p-90 -176.14 143.82 0.55 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.616 -1.174 . . . . 0.0 109.925 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -138.53 115.65 10.98 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.427 ' ND2' ' O2 ' ' B' ' 305' ' ' ' DC' . 8.8 m120 -100.0 119.21 37.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.978 0.418 . . . . 0.0 110.922 -179.058 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.58 -46.7 94.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.509 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -62.46 -41.49 98.8 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.404 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 96.2 m-20 -62.82 -38.61 91.39 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.494 -0.482 . . . . 0.0 110.809 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.37 4.54 64.2 Favored Glycine 0 CA--C 1.531 1.042 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.382 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.404 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 40.9 p90 -148.88 160.18 43.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 117.528 0.664 . . . . 0.0 110.107 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.66 173.22 37.16 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.515 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -128.12 146.88 50.56 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.096 0.474 . . . . 0.0 112.232 -179.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.3 mt -120.61 125.86 74.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.855 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -91.4 111.15 22.53 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.509 -0.477 . . . . 0.0 110.899 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.459 ' NH1' HG11 ' A' ' 113' ' ' VAL . 88.7 mtm180 -61.5 133.35 55.62 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.113 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -86.29 -12.16 50.26 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.311 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -89.49 -29.87 18.67 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-O 121.022 0.439 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.6 p -116.46 -11.42 11.15 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.694 -178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 58.0 mtpt 57.04 32.11 21.1 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -119.77 134.04 55.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.22 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -64.72 143.19 58.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.058 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.593 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 58.0 t -127.78 130.98 70.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.829 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -70.99 130.04 40.55 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.425 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.04 149.55 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.163 0.506 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -131.14 164.99 24.28 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.889 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.64 -39.75 94.82 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -69.69 -17.2 63.46 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.443 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.36 -2.63 53.49 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.169 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.7 mt -96.77 106.48 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.949 0.404 . . . . 0.0 111.112 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.75 -43.06 97.56 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.296 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -125.11 142.42 51.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.129 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -148.88 176.18 10.63 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.437 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.5 t-20 -66.23 117.33 42.21 Favored Pre-proline 0 CA--C 1.54 0.569 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.91 -31.34 95.3 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.979 1.786 . . . . 0.0 112.588 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.8 mmm-85 -64.23 -19.96 65.71 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.294 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.482 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 76.0 mmtt -93.14 129.0 39.28 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 120.671 0.272 . . . . 0.0 110.613 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -67.68 -37.96 83.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.873 0.368 . . . . 0.0 110.785 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.1 mt -110.1 144.63 38.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.257 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -65.82 137.67 57.38 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.329 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.2 p -156.86 163.07 39.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.455 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.674 HG12 HG21 ' A' ' 63' ' ' VAL . 46.9 t -128.82 130.39 68.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.56 149.0 49.22 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.384 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -86.56 134.47 33.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.62 1.68 90.55 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -91.75 130.27 37.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-O 120.888 0.375 . . . . 0.0 110.526 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -70.16 134.36 48.05 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.69 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.93 161.2 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.433 -178.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -120.54 136.35 54.81 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 178.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.452 ' HB3' HG22 ' A' ' 125' ' ' VAL . 29.2 p90 -157.58 161.06 38.71 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.563 -178.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -83.35 122.07 27.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.21 179.051 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.459 HG11 ' NH1' ' A' ' 77' ' ' ARG . 61.3 t -88.83 122.26 39.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.491 -0.484 . . . . 0.0 109.998 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.42 HG13 ' O ' ' A' ' 53' ' ' LYS . 59.4 t -122.01 129.24 75.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -67.61 127.08 31.43 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.899 -178.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -120.74 157.61 15.84 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -58.88 -47.84 83.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.026 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.5 pttm -71.58 -22.08 61.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.353 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 154.25 -168.31 32.52 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.67 140.13 58.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.942 0.401 . . . . 0.0 110.353 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -120.16 135.43 54.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.676 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.593 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -100.55 141.04 33.96 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.956 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.92 157.72 43.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.185 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 54.59 43.76 29.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.96 0.409 . . . . 0.0 110.076 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.7 t -70.18 125.43 28.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.09 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.0 p -138.92 164.76 28.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.775 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.91 164.35 54.24 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.526 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.4 Cg_exo -60.02 136.73 71.3 Favored 'Trans proline' 0 C--N 1.301 -1.942 0 C-N-CA 122.001 1.801 . . . . 0.0 112.06 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 76.89 13.64 83.42 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.96 -0.56 89.1 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.526 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.4 p -64.82 141.38 98.32 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-O 119.679 -0.2 . . . . 0.0 110.586 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PRO . . . . . 0.409 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 18.4 Cg_endo -58.03 147.69 81.15 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.66 1.573 . . . . 0.0 111.349 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -69.9 134.46 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.585 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -60.94 -43.67 98.35 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.515 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.16 158.32 30.92 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -72.92 157.01 38.26 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.84 0.352 . . . . 0.0 110.619 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -69.3 -19.65 63.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.455 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -79.87 -7.7 58.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.128 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.482 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . -61.25 140.31 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.504 -179.39 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.563 -179.634 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.511 -1.664 0 N19-C1'-C2' 115.781 0.988 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.834 0 C4'-C3'-C2' 101.926 -1.274 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.466 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C4'-C3' 103.779 -1.821 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.92 0 C4'-C3'-C2' 102.199 -1.001 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . 0.427 ' O2 ' ' ND2' ' A' ' 67' ' ' ASN . . . . . . . . 0 C3'--C2' 1.528 0.968 0 O4'-C1'-C2' 107.49 1.263 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.352 0 C1'-O4'-C4' 106.057 -2.602 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C1'-C2' 107.293 1.085 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 61.6 mtpt -123.63 146.8 47.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.189 -179.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -105.35 131.89 52.22 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.217 0.532 . . . . 0.0 110.867 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 54' ' ' VAL . 7.2 p -99.62 103.95 15.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.386 178.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.429 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.9 mt -62.06 -44.61 99.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.098 -179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.465 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.68 160.37 40.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.64 ' O ' HG23 ' A' ' 59' ' ' VAL . 14.4 p -98.02 -150.97 0.36 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.612 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -51.32 116.87 2.25 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.466 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 57' ' ' THR . 86.7 t -132.59 131.2 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.681 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.8 mt -75.33 134.71 40.96 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.043 0.449 . . . . 0.0 109.849 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.29 -179.48 23.38 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.4 m -129.11 135.86 49.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 110.483 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.709 HG21 HG12 ' A' ' 103' ' ' VAL . 85.4 t -73.54 113.1 11.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.731 -179.319 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.45 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.6 ttpt -62.34 -46.77 87.21 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.9 p-90 -176.14 146.19 0.66 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.001 177.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -140.5 115.51 9.75 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.438 ' ND2' ' O2 ' ' B' ' 305' ' ' ' DC' . 5.0 m120 -103.02 121.44 42.57 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.936 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.3 t -63.07 -44.56 99.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.452 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.426 ' HG3' ' N ' ' A' ' 70' ' ' ASN . 17.7 ptm180 -63.08 -35.11 79.18 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.426 ' N ' ' HG3' ' A' ' 69' ' ' ARG . 97.2 m-20 -69.36 -35.15 75.58 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.822 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 90.14 0.87 76.64 Favored Glycine 0 CA--C 1.531 1.057 0 C-N-CA 121.06 -0.591 . . . . 0.0 112.361 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -150.26 161.51 42.3 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 117.544 0.672 . . . . 0.0 110.086 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -154.98 179.43 31.02 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.603 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.435 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 95.9 m-85 -129.16 145.64 51.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.144 0.497 . . . . 0.0 112.131 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 84.9 mt -119.74 123.58 71.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.849 178.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.64 109.16 20.57 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.817 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -63.14 130.93 46.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.115 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.3 p30 -85.43 -0.08 53.79 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.406 -0.518 . . . . 0.0 111.37 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -99.07 -34.48 10.38 Favored 'General case' 0 C--O 1.231 0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.127 178.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 77.9 p -114.4 -10.95 12.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.687 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 58.09 29.99 18.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.95 0.405 . . . . 0.0 110.025 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -116.2 132.96 56.52 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 121.362 0.601 . . . . 0.0 111.247 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -62.67 142.25 58.17 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.089 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.504 HG11 ' HB2' ' A' ' 122' ' ' ALA . 76.6 t -128.1 131.01 69.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -65.92 141.12 58.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.394 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.8 p -146.92 148.45 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.182 0.515 . . . . 0.0 110.935 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.407 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 80.8 m80 -137.63 159.04 43.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.784 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -60.33 -41.93 94.58 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.5 t -64.98 -16.63 63.61 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.478 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -84.16 -2.97 57.79 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.123 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.534 HD11 HG23 ' A' ' 103' ' ' VAL . 79.9 mt -93.45 101.45 12.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.987 0.422 . . . . 0.0 111.152 -178.303 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -63.55 -43.31 97.44 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.305 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -120.63 140.65 51.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.151 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -149.73 156.36 41.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -60.48 121.45 60.46 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.49 -22.18 65.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 121.995 1.797 . . . . 0.0 112.478 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.52 -21.55 66.17 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.35 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -86.34 130.83 34.37 Favored 'General case' 0 N--CA 1.456 -0.127 0 CA-C-O 120.748 0.308 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 84.8 t80 -61.23 -48.5 81.2 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -116.43 139.98 49.85 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.206 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -55.71 138.01 48.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.075 0.464 . . . . 0.0 110.291 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 94.2 p -158.84 165.08 35.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.511 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.709 HG12 HG21 ' A' ' 63' ' ' VAL . 46.3 t -124.04 129.61 74.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.0 147.76 51.17 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -80.66 121.04 25.36 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.087 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.14 -0.86 88.93 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.16 135.11 41.11 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 120.941 0.401 . . . . 0.0 110.463 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 91.1 m -70.07 131.57 44.52 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.637 179.046 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.77 159.18 43.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.37 -0.532 . . . . 0.0 111.511 -178.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -120.74 129.87 53.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.439 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.7 p90 -157.64 163.86 37.81 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 112.549 -177.589 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -93.68 144.85 25.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.205 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.9 t -97.07 125.65 50.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.592 -0.443 . . . . 0.0 109.942 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 99.3 t -121.24 132.1 71.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -72.61 122.59 21.65 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.967 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -108.93 164.45 12.52 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 51.5 mp0 -62.69 -40.65 97.79 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.771 0.32 . . . . 0.0 110.982 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.9 mtmm -90.89 -6.45 54.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.29 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.13 -177.41 28.25 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -69.35 148.14 50.1 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.944 0.402 . . . . 0.0 110.341 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -133.79 158.91 42.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.636 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.504 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.45 146.73 29.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.973 -179.647 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.1 157.86 43.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.255 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 54.42 45.32 27.34 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.118 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.439 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.0 t -71.51 122.15 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.08 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.6 p -138.75 161.64 36.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.796 179.384 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 162.48 54.43 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.501 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.1 Cg_exo -58.96 138.0 83.11 Favored 'Trans proline' 0 C--N 1.301 -1.926 0 C-N-CA 122.005 1.803 . . . . 0.0 112.149 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.23 19.24 78.55 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 178.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.89 3.01 89.54 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 128' ' ' PRO . 95.0 t -60.72 137.63 93.12 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 122.811 -0.229 . . . . 0.0 110.472 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 153.06 79.84 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 121.64 1.56 . . . . 0.0 111.309 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -70.65 129.11 34.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.617 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 12.6 tp-100 -60.72 -44.34 96.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.55 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.39 162.0 28.28 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 179.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -81.4 163.06 23.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.933 0.397 . . . . 0.0 110.56 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.51 -37.13 86.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.502 179.473 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -66.67 -7.63 22.0 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.137 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.505 ' O ' ' HB2' ' A' ' 140' ' ' ALA . . . -49.17 129.58 18.16 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.495 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.505 ' HB2' ' O ' ' A' ' 139' ' ' ALA . . . . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.506 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.511 0 C3'-C2'-C1' 104.824 1.517 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.806 0 O4'-C4'-C3' 102.817 -2.783 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.573 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.705 0 O4'-C4'-C3' 103.785 -1.815 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.857 0 C3'-C2'-C1' 101.798 -0.645 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . 0.438 ' O2 ' ' ND2' ' A' ' 67' ' ' ASN . . . . . . . . 0 C3'--C2' 1.527 0.882 0 O4'-C1'-C2' 107.427 1.207 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.351 0 C4'-C3'-C2' 104.785 1.585 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.809 0 O4'-C1'-C2' 107.353 1.139 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 63.5 mtpt -69.87 146.47 51.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.317 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -63.75 135.17 56.46 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 121.212 0.529 . . . . 0.0 111.008 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.1 t -102.49 102.36 13.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.417 178.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.54 -44.13 99.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.087 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.08 43.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.736 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -104.41 -147.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.632 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.415 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 21.4 pttm -48.11 106.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.452 -179.429 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 57' ' ' THR . 85.2 t -127.53 130.58 70.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.718 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 93.1 mt -74.88 135.82 41.52 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 109.824 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.36 178.33 25.05 Favored Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.1 m -128.32 137.94 52.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 120.853 0.359 . . . . 0.0 110.547 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 94.0 t -77.1 109.79 12.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.689 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.5 ttpt -62.79 -46.96 85.58 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 51.5 p-90 -176.67 146.87 0.6 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.954 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -141.35 125.0 16.81 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.4 m-20 -107.48 122.53 46.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.992 0.425 . . . . 0.0 110.941 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.9 t -63.22 -46.71 95.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.462 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -62.02 -43.29 99.16 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.45 88.04 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.807 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.48 0.99 69.25 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.374 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -148.3 163.52 36.81 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 117.503 0.652 . . . . 0.0 110.076 179.16 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.21 -179.67 32.32 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.538 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.466 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.8 m-85 -126.45 143.08 51.31 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.095 0.474 . . . . 0.0 112.111 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.431 HG13 HG11 ' A' ' 86' ' ' VAL . 87.1 mt -121.8 126.52 74.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.859 178.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -94.09 109.97 21.71 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.93 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -63.62 134.57 55.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.073 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -88.62 -9.89 50.6 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.275 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.3 p-10 -96.71 -12.9 23.17 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.146 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 55.7 p -133.84 -10.51 2.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.709 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.5 mttp 51.61 35.51 14.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.952 0.406 . . . . 0.0 109.976 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -120.11 134.11 55.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.223 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -67.81 130.03 41.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.118 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 96.2 t -119.21 131.77 70.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.52 139.49 55.63 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.293 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 HG13 ' A' ' 75' ' ' ILE . 7.5 p -148.11 148.34 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 CA-C-O 121.133 0.492 . . . . 0.0 110.948 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -131.74 155.59 47.43 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.9 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.469 ' OE1' HD11 ' A' ' 100' ' ' LEU . 26.8 pt20 -59.35 -28.46 66.87 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.8 p -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.431 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.99 0.25 55.48 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.198 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.448 HD11 HG23 ' A' ' 103' ' ' VAL . 82.2 mt -93.83 103.11 14.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.013 0.435 . . . . 0.0 111.128 -178.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -64.96 -42.22 94.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.281 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.452 ' HB3' HG22 ' A' ' 126' ' ' THR . 22.8 ttmm -125.69 136.1 52.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.074 -178.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -146.76 176.47 9.84 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.375 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -62.2 121.2 64.64 Favored Pre-proline 0 CA--C 1.539 0.54 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.31 -26.12 64.0 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 121.965 1.777 . . . . 0.0 112.65 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.1 -14.45 61.85 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.426 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 4.0 mptp? -99.34 113.93 26.52 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 120.717 0.294 . . . . 0.0 110.647 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.21 -47.83 84.3 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.889 0.376 . . . . 0.0 110.758 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.469 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.3 tp -94.09 130.83 40.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.216 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -60.5 138.46 58.01 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.256 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.532 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 93.7 p -157.97 163.37 37.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.424 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 51.9 t -129.06 131.04 68.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.64 148.01 47.7 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.303 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -86.09 134.36 33.83 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.1 2.63 90.56 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.8 tp10 -91.1 129.82 37.06 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-O 120.913 0.387 . . . . 0.0 110.517 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.9 m -70.01 133.03 46.81 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.719 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.3 m -130.61 159.09 42.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.49 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.02 130.05 55.94 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.6 p90 -156.24 162.93 40.1 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 119.774 -0.77 . . . . 0.0 112.49 -177.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -97.09 142.33 29.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.225 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG1' ' HB1' ' A' ' 120' ' ' ALA . 65.1 t -101.18 125.27 55.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.031 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.8 p -118.32 138.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.3 tm-20 -63.6 128.05 34.09 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.924 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.85 162.86 12.42 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -60.69 -40.94 94.05 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.773 0.32 . . . . 0.0 111.042 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -89.56 -11.54 42.44 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.342 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.81 -173.9 30.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.465 ' HB1' ' CG1' ' A' ' 113' ' ' VAL . . . -63.39 137.53 58.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.877 0.37 . . . . 0.0 110.459 179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.44 ' O ' HG12 ' A' ' 114' ' ' VAL . 89.0 tt0 -128.83 135.38 49.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.661 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -74.46 150.76 39.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.042 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.59 157.96 41.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.186 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 53.52 47.97 22.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.029 0.443 . . . . 0.0 110.131 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.5 t -73.36 123.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.084 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 93' ' ' LYS . 81.6 p -140.18 164.04 31.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.841 179.308 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.06 164.45 54.48 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG23 ' A' ' 131' ' ' VAL . 37.3 Cg_exo -60.79 138.33 78.64 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.995 1.797 . . . . 0.0 112.096 -179.32 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.14 18.78 79.37 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.69 0.74 89.98 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -59.87 137.69 90.47 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.431 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.46 150.31 87.0 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 121.588 1.525 . . . . 0.0 111.296 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.1 t -69.03 129.67 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.616 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -60.63 -44.38 96.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.507 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 88.41 164.78 40.62 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.668 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -80.62 165.35 22.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.822 0.344 . . . . 0.0 110.572 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -62.47 -39.05 92.18 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.488 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -66.26 -9.81 36.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.139 -179.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . -56.45 140.35 46.17 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.43 -179.617 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.552 -179.894 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.52 0 C3'-C2'-C1' 104.875 1.554 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.847 0 C4'-C3'-C2' 101.443 -1.757 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.514 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.74 0 O4'-C4'-C3' 103.47 -2.13 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.435 -0.971 0 O4'-C4'-C3' 103.579 -2.021 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.855 0 O4'-C1'-C2' 107.42 1.2 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.437 0 C1'-O4'-C4' 106.869 -2.022 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.818 0 O4'-C1'-C2' 106.787 0.624 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.401 ' HE2' HG11 ' A' ' 114' ' ' VAL . 25.6 pttm -144.36 155.95 44.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.254 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -80.2 134.38 36.12 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.197 0.522 . . . . 0.0 110.987 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 77.8 t -101.49 103.34 14.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.438 178.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.96 -45.36 97.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.07 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -153.33 161.74 42.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.084 -179.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.694 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -97.51 -146.29 0.31 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.587 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.433 ' N ' HG23 ' A' ' 57' ' ' THR . 38.4 mtmm -52.12 113.65 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.538 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 57' ' ' THR . 93.2 t -127.49 128.55 69.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.768 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 94.7 mt -65.36 130.05 41.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.042 0.448 . . . . 0.0 109.925 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.29 170.27 25.52 Favored Glycine 0 C--O 1.228 -0.259 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.9 m -130.66 137.07 49.4 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.886 0.374 . . . . 0.0 110.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 103' ' ' VAL . 91.5 t -75.32 116.2 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.832 -179.364 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.2 ptpt -74.53 -35.37 63.13 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 176.7 139.49 0.07 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.987 178.121 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -138.98 115.97 10.9 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -100.57 118.48 36.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.014 0.435 . . . . 0.0 110.905 -178.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.92 -45.17 97.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.421 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.2 ttp85 -59.71 -45.29 92.57 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -61.38 -38.2 86.17 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.869 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.45 3.86 62.75 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.324 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -149.64 160.73 43.27 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 117.528 0.664 . . . . 0.0 110.051 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.53 179.9 33.87 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.615 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.468 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 93.6 m-85 -132.67 147.27 52.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.17 0.509 . . . . 0.0 112.101 -179.021 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.407 HG13 HG11 ' A' ' 86' ' ' VAL . 80.4 mt -121.56 129.06 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.846 178.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -97.33 108.26 20.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.877 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.3 mtm-85 -62.89 131.26 48.14 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.073 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.68 -9.07 57.76 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.333 179.151 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -94.03 -29.85 15.0 Favored 'General case' 0 N--CA 1.458 -0.057 0 CA-C-O 120.911 0.386 . . . . 0.0 110.134 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.5 p -116.83 -13.17 10.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.679 -178.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.7 mttt 54.22 33.79 18.89 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.066 -179.128 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -117.94 131.58 56.49 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.28 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -71.94 130.62 41.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.055 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.8 p -124.03 147.75 28.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.907 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -75.47 142.41 42.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.354 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.427 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -144.81 146.49 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.099 0.476 . . . . 0.0 111.016 179.159 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -135.19 154.58 51.56 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.848 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -61.04 -24.88 66.52 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 111.971 0.36 . . . . 0.0 111.971 -178.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 72.1 p -76.89 -13.86 59.94 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.351 179.142 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.69 2.56 54.64 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.091 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 103' ' ' VAL . 82.5 mt -96.23 107.31 19.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.022 0.439 . . . . 0.0 111.183 -178.5 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -67.99 -43.09 79.73 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.334 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.97 141.01 48.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.098 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 t30 -144.51 160.73 40.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.6 t-20 -56.29 119.91 31.26 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.28 -31.57 93.99 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.075 1.85 . . . . 0.0 112.527 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -62.59 -19.19 63.48 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.431 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -111.21 140.37 45.83 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.655 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.652 ' OH ' ' HB1' ' A' ' 140' ' ' ALA . 50.0 p90 -95.08 -13.99 24.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.889 0.376 . . . . 0.0 110.775 179.731 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.0 tp -106.03 125.49 51.06 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.195 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.7 mtt-85 -62.89 130.83 46.53 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.634 -0.427 . . . . 0.0 110.305 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 47.2 t -157.9 154.62 28.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.537 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 63' ' ' VAL . 45.0 t -120.88 130.57 74.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.593 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.24 144.81 45.11 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.376 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -74.93 129.88 38.43 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.27 1.45 85.88 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -178.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.468 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -76.92 132.62 39.18 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 120.9 0.381 . . . . 0.0 110.538 -179.507 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -74.55 129.45 37.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.711 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 14.2 m -133.57 162.46 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.417 -177.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -124.81 141.24 52.25 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.074 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.451 ' HB3' HG22 ' A' ' 125' ' ' VAL . 20.6 p90 -160.87 163.41 32.02 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 119.715 -0.794 . . . . 0.0 112.494 -177.474 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -90.01 124.98 35.22 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.277 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.4 t -92.62 127.04 45.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.457 -0.497 . . . . 0.0 109.974 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.401 HG11 ' HE2' ' A' ' 52' ' ' LYS . 33.3 m -125.37 157.33 34.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -93.27 119.28 32.24 Favored 'General case' 0 C--N 1.324 -0.53 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.93 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.01 165.37 13.24 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -60.18 -46.53 89.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.726 0.298 . . . . 0.0 110.994 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -74.55 -24.61 58.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.379 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 157.31 -168.39 34.13 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.57 142.17 58.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.846 0.355 . . . . 0.0 110.462 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 -129.22 156.84 43.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.673 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.98 145.98 39.86 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.8 159.52 44.08 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.208 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 54.44 43.17 30.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.035 0.445 . . . . 0.0 110.185 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.451 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.1 t -72.77 121.08 22.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.098 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -138.58 171.36 14.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.795 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.47 177.28 46.78 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 131' ' ' VAL . 55.7 Cg_endo -69.95 137.67 35.45 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 121.935 1.757 . . . . 0.0 112.19 -178.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 18.93 77.24 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.02 2.14 89.55 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.4 t -61.98 137.06 95.4 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.762 -0.257 . . . . 0.0 110.553 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.41 147.68 76.39 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.568 1.512 . . . . 0.0 111.311 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.7 t -67.64 127.32 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.591 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -61.52 -41.48 97.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.535 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.01 -175.04 49.99 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.616 -0.594 . . . . 0.0 111.616 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 75.5 m -111.4 160.29 17.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.885 0.374 . . . . 0.0 110.572 -179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -59.45 -39.28 83.09 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.439 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -60.59 -15.38 27.38 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.12 179.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.33 141.63 50.54 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.526 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.652 ' HB1' ' OH ' ' A' ' 99' ' ' TYR . . . . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.615 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.471 0 C3'-C2'-C1' 104.966 1.618 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.456 0.908 0 C4'-C3'-C2' 101.321 -1.879 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.552 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.426 -1.839 0 O4'-C4'-C3' 102.968 -2.632 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.814 0 P-O3'-C3' 120.412 0.593 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.829 0 O4'-C1'-C2' 107.415 1.195 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.399 0 C1'-O4'-C4' 107.227 -1.766 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.835 0 O4'-C4'-C3' 104.384 -1.216 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 57.1 t0 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.42 ' HD3' HG21 ' A' ' 114' ' ' VAL . 17.9 ptpt -141.15 159.15 42.82 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.272 -179.777 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.496 ' O ' HG23 ' A' ' 114' ' ' VAL . 87.8 tttt -106.62 132.52 52.52 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.224 0.535 . . . . 0.0 110.987 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.1 t -97.76 100.13 10.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.426 -0.806 . . . . 0.0 109.469 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.74 -44.12 99.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.039 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.06 158.23 43.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.593 ' O ' HG23 ' A' ' 59' ' ' VAL . 1.7 p -98.68 -153.43 0.43 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.699 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -53.97 118.28 3.88 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.407 -178.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 57' ' ' THR . 94.6 t -131.64 128.65 60.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.699 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 95.3 mt -68.28 135.88 52.62 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.097 0.475 . . . . 0.0 109.801 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.89 178.35 27.44 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.327 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 86.7 m -130.38 137.52 49.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.801 0.334 . . . . 0.0 110.535 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.698 HG21 HG12 ' A' ' 103' ' ' VAL . 77.4 t -75.75 116.19 18.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.741 -178.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 64' ' ' LYS . 9.4 ptmt -69.82 -41.75 74.56 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 60.6 p-90 178.24 138.37 0.08 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.944 177.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -132.54 115.3 15.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 178.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -94.84 117.41 30.09 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.41 ' H ' ' H5 ' ' B' ' 306' ' ' ' DC' . 62.0 t -63.9 -44.82 98.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.471 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 64.6 mtp85 -61.89 -41.41 97.84 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -63.21 -37.63 87.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.856 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.85 3.28 66.16 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.301 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -149.98 160.04 43.92 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 117.482 0.641 . . . . 0.0 110.107 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.26 179.81 36.45 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 120.499 -0.857 . . . . 0.0 111.515 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.408 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 68.8 m-85 -130.7 150.59 51.81 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.192 0.52 . . . . 0.0 112.146 -178.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.403 HG21 ' CE2' ' A' ' 111' ' ' PHE . 83.3 mt -120.05 127.06 75.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.858 178.48 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.81 110.26 21.7 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.938 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.44 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -65.9 128.9 37.88 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.101 179.161 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -74.39 -25.81 59.71 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.309 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -71.81 -41.66 67.96 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.151 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.5 p -108.11 -7.24 16.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.66 -176.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LYS . . . . . 0.44 ' N ' ' O ' ' A' ' 77' ' ' ARG . 75.1 mmtt 52.29 31.16 8.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.906 0.384 . . . . 0.0 109.967 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -118.37 133.96 55.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.315 0.578 . . . . 0.0 111.274 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -64.23 146.28 54.58 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.067 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.603 HG11 ' HB2' ' A' ' 122' ' ' ALA . 86.5 t -128.24 130.46 69.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.871 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -68.07 130.37 42.75 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.9 149.12 18.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.219 0.533 . . . . 0.0 110.921 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -127.12 161.1 29.26 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.888 179.21 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.9 pt20 -61.12 -24.5 66.3 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -81.06 -11.51 59.5 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.388 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.25 -3.8 58.44 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.193 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.607 HD11 HG23 ' A' ' 103' ' ' VAL . 85.6 mt -90.62 102.15 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 111.082 -178.405 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -63.71 -43.09 97.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.293 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -120.62 140.9 50.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.076 -178.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -139.79 153.33 47.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.461 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.438 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.0 p-10 -57.65 132.9 82.45 Favored Pre-proline 0 CA--C 1.539 0.529 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.464 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.8 -13.27 31.93 Favored 'Trans proline' 0 N--CA 1.499 1.8 0 C-N-CA 121.947 1.765 . . . . 0.0 112.573 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -62.29 -29.16 70.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.284 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.425 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 97.3 mttt -123.13 147.38 46.85 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 120.646 0.26 . . . . 0.0 110.668 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -89.57 -15.6 32.49 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.908 0.385 . . . . 0.0 110.821 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.461 HD23 ' H ' ' A' ' 140' ' ' ALA . 65.9 tp -97.63 123.92 41.73 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.229 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -65.66 131.73 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.947 0.403 . . . . 0.0 110.283 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.7 p -158.73 162.76 37.17 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.562 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.698 HG12 HG21 ' A' ' 63' ' ' VAL . 26.3 t -125.34 129.07 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.408 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.48 144.77 44.64 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.368 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.41 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 39.7 p-10 -75.37 130.41 38.96 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.87 1.86 87.77 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -79.21 130.41 35.44 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.516 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 90.5 m -72.93 130.08 39.57 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.688 179.049 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.8 m -134.53 162.67 38.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.368 -177.219 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -123.19 137.69 54.83 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.43 ' HB3' HG22 ' A' ' 125' ' ' VAL . 33.1 p90 -160.81 165.42 30.29 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.607 -177.504 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -100.54 146.11 27.5 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.325 178.445 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.79 127.6 60.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.524 -0.47 . . . . 0.0 109.985 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.496 HG23 ' O ' ' A' ' 53' ' ' LYS . 14.4 p -122.08 134.07 66.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -65.89 126.89 29.94 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.546 -0.461 . . . . 0.0 110.947 -178.32 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.8 166.04 12.24 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -59.64 -48.16 82.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 111.062 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.4 pttm -73.83 -22.82 59.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.315 179.041 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 153.72 -169.4 32.37 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.29 139.16 58.52 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.836 0.351 . . . . 0.0 110.428 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -134.97 136.02 41.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.548 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.603 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -78.6 151.17 32.5 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.02 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.18 156.44 41.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.243 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.4 t30 56.78 48.18 16.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.971 0.415 . . . . 0.0 110.14 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.43 HG22 ' HB3' ' A' ' 111' ' ' PHE . 90.3 t -76.06 124.53 34.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.044 -179.145 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 65.4 p -138.12 167.2 22.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.759 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.69 169.32 53.57 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 178.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.425 ' O ' HG23 ' A' ' 131' ' ' VAL . 38.9 Cg_exo -60.64 136.53 67.53 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 122.031 1.821 . . . . 0.0 112.182 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.63 20.99 77.68 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.104 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.73 0.99 90.04 Favored Glycine 0 CA--C 1.532 1.127 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -61.18 141.55 93.88 Favored Pre-proline 0 CA--C 1.536 0.436 0 O-C-N 122.805 -0.232 . . . . 0.0 110.602 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -58.17 147.6 82.8 Favored 'Trans proline' 0 N--CA 1.497 1.732 0 C-N-CA 121.651 1.567 . . . . 0.0 111.285 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 41.2 t -68.5 125.06 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.628 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 tp60 -60.26 -39.92 88.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.483 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.17 -171.83 50.68 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 66.9 m -112.93 153.36 28.1 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.847 0.356 . . . . 0.0 110.55 -179.325 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -58.63 -36.92 74.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -59.56 -16.77 27.37 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.112 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.425 ' HB3' ' HD3' ' A' ' 98' ' ' LYS . . . -58.95 142.09 51.92 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.482 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.461 ' H ' HD23 ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.605 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.43 -1.438 0 C3'-C2'-C1' 104.425 1.232 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.888 0 C4'-C3'-C2' 101.819 -1.381 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.408 ' C2 ' ' CZ ' ' A' ' 74' ' ' PHE . . . . . . . . 0 O5'--C5' 1.43 -0.624 0 C4'-C3'-C2' 101.65 -1.55 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.796 0 C4'-C3'-C2' 101.604 -1.596 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.816 0 O4'-C4'-C3' 104.365 -1.235 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . 0.41 ' H5 ' ' H ' ' A' ' 68' ' ' VAL . . . . . . . . 0 C3'--C2' 1.532 1.406 0 C1'-O4'-C4' 105.879 -2.729 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.803 0 O4'-C1'-C2' 107.126 0.932 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.6 p-10 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -70.34 143.74 51.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.201 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -63.76 135.85 56.98 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.17 0.509 . . . . 0.0 111.008 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.38 101.23 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.373 178.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.81 -43.02 94.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.117 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.93 160.59 42.65 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.177 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.582 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -99.2 -147.18 0.33 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -54.85 117.33 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.251 -0.58 . . . . 0.0 110.507 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 57' ' ' THR . 95.7 t -130.92 132.38 63.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.0 mt -65.69 130.08 42.01 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.082 0.468 . . . . 0.0 109.816 178.207 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.18 172.4 26.8 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.5 m -128.11 140.52 51.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.809 0.338 . . . . 0.0 110.513 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.718 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -76.32 106.88 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.77 -179.111 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.459 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 39.1 ttpt -61.15 -45.19 95.66 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.459 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -176.88 139.39 0.29 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.926 178.026 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -137.35 115.57 11.74 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.059 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.413 HD21 ' HA ' ' A' ' 67' ' ' ASN . 7.2 m120 -101.27 121.39 41.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.015 0.436 . . . . 0.0 110.821 -178.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.4 HG21 ' N ' ' A' ' 139' ' ' ALA . 74.4 t -62.98 -46.23 96.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.407 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -60.58 -44.85 95.74 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -62.23 -37.92 87.25 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.846 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.65 2.95 66.88 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.374 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -148.43 161.68 41.13 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 117.473 0.636 . . . . 0.0 110.029 178.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.424 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.01 -179.01 32.58 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.532 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.471 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.2 m-85 -130.94 145.2 51.95 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.145 0.498 . . . . 0.0 112.19 -179.055 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.412 HD13 HG21 ' A' ' 109' ' ' VAL . 82.2 mt -120.29 125.08 73.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.865 179.438 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -93.33 110.86 22.4 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -64.51 132.9 51.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.193 179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -88.72 -6.69 57.27 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.315 179.3 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -95.9 -31.43 13.13 Favored 'General case' 0 C--O 1.232 0.182 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.163 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.0 p -114.08 -11.67 12.67 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.772 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.9 mttp 55.83 35.38 25.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.919 0.39 . . . . 0.0 110.004 -178.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -119.04 146.49 45.01 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.386 0.613 . . . . 0.0 111.232 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -84.18 121.48 27.52 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.986 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.576 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 75.0 t -112.14 126.46 69.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.94 179.319 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' PHE . . . . . 0.518 ' CB ' ' HZ3' ' A' ' 118' ' ' LYS . 92.6 t80 -64.9 134.02 53.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.337 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -134.18 148.42 30.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.138 0.494 . . . . 0.0 110.916 179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -133.63 162.28 32.36 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.905 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.34 -39.44 93.11 Favored 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -68.05 -15.82 63.76 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.453 179.219 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.21 -1.33 56.8 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.181 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -97.82 104.36 15.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-O 120.997 0.427 . . . . 0.0 111.164 -178.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -65.37 -43.18 91.6 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.267 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -123.03 144.63 49.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.925 0.393 . . . . 0.0 111.035 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 p-10 -151.39 177.26 10.46 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.296 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -65.52 119.46 60.11 Favored Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.62 -33.99 98.57 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.988 1.792 . . . . 0.0 112.61 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtt85 -63.47 -21.25 66.2 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.344 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -95.41 119.79 34.52 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.668 -179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -61.34 -48.27 82.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 110.814 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 86.9 mt -95.2 145.25 25.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.232 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.18 136.02 56.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.596 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -155.41 152.72 29.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.476 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.718 HG12 HG21 ' A' ' 63' ' ' VAL . 58.4 t -124.41 130.3 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.91 140.37 45.63 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.386 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -73.11 129.21 37.57 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.4 1.01 80.64 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.578 ' O ' HG23 ' A' ' 63' ' ' VAL . 88.1 tt0 -77.13 132.28 38.75 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.841 0.353 . . . . 0.0 110.56 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.0 m -71.13 130.37 41.33 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.693 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.412 HG21 HD13 ' A' ' 75' ' ' ILE . 19.9 m -134.27 160.25 41.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.442 -177.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -119.13 136.94 53.92 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.0 p90 -158.78 164.24 35.99 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.495 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -96.65 141.17 30.22 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.291 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.8 128.2 50.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.984 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 p -124.34 135.27 64.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.5 tm-20 -66.33 128.95 38.14 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.89 -178.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.33 158.04 15.16 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 52.5 mp0 -59.86 -45.44 92.46 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.657 0.265 . . . . 0.0 111.025 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.518 ' HZ3' ' CB ' ' A' ' 85' ' ' PHE . 23.1 pttp -76.5 -16.89 59.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.249 178.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.17 -171.19 30.14 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.88 140.75 58.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.912 0.387 . . . . 0.0 110.4 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -128.14 154.45 45.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.608 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.576 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -104.29 144.34 31.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.972 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.35 159.55 44.18 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.246 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 57.49 47.23 16.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.024 0.44 . . . . 0.0 110.185 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 93.7 t -77.18 122.68 32.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.152 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.6 p -137.46 169.36 17.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.779 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.59 172.91 47.76 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.032 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -67.63 137.02 41.11 Favored 'Trans proline' 0 C--N 1.302 -1.891 0 C-N-CA 122.01 1.807 . . . . 0.0 112.121 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.02 16.23 80.68 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.88 90.36 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.715 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -69.4 148.76 97.26 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 122.795 -0.238 . . . . 0.0 110.508 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PRO . . . . . 0.715 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.0 Cg_exo -60.48 148.19 91.67 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.631 1.554 . . . . 0.0 111.36 179.029 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 78.0 t -70.79 132.26 33.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.592 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -60.71 -41.24 94.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.517 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.2 49.09 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.602 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.8 m -113.24 154.92 25.98 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.831 0.348 . . . . 0.0 110.544 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.3 -35.84 78.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -61.68 -19.44 62.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.117 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.596 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -60.1 140.78 56.66 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.476 -179.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.513 -179.617 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.514 -1.356 0 O4'-C4'-C3' 104.289 -1.311 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.877 0 P-O3'-C3' 121.031 1.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.532 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.431 -1.393 0 O4'-C4'-C3' 103.636 -1.964 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.828 0 C5'-C4'-O4' 108.417 -0.614 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.848 0 O4'-C1'-C2' 107.341 1.128 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.353 0 C1'-O4'-C4' 107.546 -1.539 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.847 0 O4'-C4'-C3' 104.767 -0.833 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 33.1 t0 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -71.02 144.78 50.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.238 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.86 134.55 56.84 Favored 'General case' 0 CA--C 1.516 -0.346 0 CA-C-O 121.249 0.547 . . . . 0.0 110.915 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t -96.77 101.78 12.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.344 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.97 -44.98 99.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.045 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -151.44 163.24 39.43 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.3 t -99.91 -148.93 0.36 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.749 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.455 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 25.1 pttm -52.11 117.92 3.12 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.451 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 80.8 t -133.27 130.11 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.699 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.6 mt -73.3 135.98 44.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.164 0.507 . . . . 0.0 109.835 178.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.87 179.59 24.63 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.6 m -128.91 136.31 50.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.901 0.382 . . . . 0.0 110.359 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 103' ' ' VAL . 66.0 t -75.13 108.6 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.535 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.56 -48.32 81.49 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.535 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.3 p-90 -178.61 139.15 0.17 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.006 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -134.19 115.18 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -94.52 117.41 30.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.013 0.435 . . . . 0.0 110.897 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 139' ' ' ALA . 64.5 t -62.69 -44.78 99.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.46 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.09 -44.67 97.0 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -63.03 -38.62 91.93 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.31 2.18 64.05 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.322 179.046 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -148.28 160.14 43.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 117.371 0.585 . . . . 0.0 110.074 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.458 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -161.3 -177.6 34.53 Favored Glycine 0 CA--C 1.525 0.707 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.545 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -128.8 145.24 51.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.146 0.498 . . . . 0.0 112.147 -178.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 90.7 mt -116.35 125.16 73.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.881 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.99 109.84 20.85 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.977 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -62.89 133.64 54.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.106 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -86.14 -1.38 57.36 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.29 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -100.85 -32.64 10.57 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 120.914 0.388 . . . . 0.0 110.107 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.8 p -113.85 -10.49 12.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.692 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.3 mttt 56.26 31.51 18.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 120.993 0.425 . . . . 0.0 110.04 -179.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.63 141.58 49.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.252 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -67.23 145.55 55.09 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.053 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.572 HG11 ' HB2' ' A' ' 122' ' ' ALA . 91.4 t -128.48 131.77 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -69.83 138.6 52.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.297 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.9 p -147.09 148.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.18 0.514 . . . . 0.0 110.912 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.47 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 76.1 m80 -129.39 160.54 32.78 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.934 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -59.84 -40.51 88.76 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.9 p -67.85 -13.34 62.06 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.448 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -80.09 -7.68 59.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.103 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.573 HD11 HG23 ' A' ' 103' ' ' VAL . 83.2 mt -92.82 96.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.934 0.397 . . . . 0.0 111.143 -178.333 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -63.0 -42.35 99.82 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.27 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.541 ' HB2' HG22 ' A' ' 126' ' ' THR . 3.7 mptp? -119.25 132.09 55.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.059 -179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 18.3 t30 -145.53 157.72 43.95 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.483 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -57.2 119.33 30.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -68.19 -20.06 43.9 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 121.946 1.764 . . . . 0.0 112.577 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -64.5 -20.05 65.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.39 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.431 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 99.0 mttt -100.92 140.47 35.17 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.719 0.295 . . . . 0.0 110.619 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -69.51 -41.58 75.86 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.721 -178.562 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.6 142.8 35.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.193 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -74.27 128.12 34.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 110.304 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.514 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.9 m -146.67 165.08 30.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.515 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 47.3 t -119.7 128.42 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.101 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -60.59 140.4 48.05 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.355 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -80.11 130.1 34.99 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.07 2.87 90.68 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.9 tp10 -89.13 133.45 34.39 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 120.875 0.369 . . . . 0.0 110.496 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 86.5 m -69.38 131.31 44.6 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.682 178.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 28.1 m -129.24 159.39 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.419 -177.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -119.17 128.55 54.35 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -155.98 162.07 40.4 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.555 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -92.47 150.67 20.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.283 178.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.3 t -109.31 125.01 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.94 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.457 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.4 p -123.41 140.06 48.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -83.73 111.73 19.42 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.925 -178.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -95.01 176.0 34.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -62.13 -44.56 96.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.701 0.286 . . . . 0.0 110.935 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -75.77 -23.67 55.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.364 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 152.91 -167.18 31.62 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -63.62 143.54 57.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 110.452 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG12 ' A' ' 114' ' ' VAL . 88.7 tt0 -143.75 136.24 27.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.653 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.572 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -76.17 150.17 37.19 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.993 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.79 157.2 41.63 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 56.18 48.68 16.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.947 0.403 . . . . 0.0 110.03 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.7 t -73.81 125.17 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.124 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.541 HG22 ' HB2' ' A' ' 93' ' ' LYS . 67.9 p -139.25 163.81 31.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.761 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.03 167.83 54.71 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 109.216 -1.553 . . . . 0.0 109.216 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.445 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.9 Cg_exo -60.14 138.43 81.59 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 121.946 1.764 . . . . 0.0 112.132 -178.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 69.88 20.79 76.36 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.48 90.54 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -62.11 139.68 96.01 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.84 -0.212 . . . . 0.0 110.504 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -58.3 148.05 81.42 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 C-N-CA 121.608 1.539 . . . . 0.0 111.286 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.0 t -67.64 129.72 32.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.619 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 26.7 mp0 -61.55 -42.37 98.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.489 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.19 -171.8 53.65 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 179.335 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 57.3 m -114.85 158.06 22.45 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 110.545 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -61.7 -37.38 83.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.518 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -64.26 -13.35 48.91 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.04 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.514 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -59.54 -39.41 83.87 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 139' ' ' ALA . . . . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.581 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.486 0 C3'-C2'-C1' 104.689 1.421 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -1.003 0 O4'-C4'-C3' 103.491 -2.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.437 -0.85 0 O4'-C4'-C3' 103.697 -1.903 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.935 0 O4'-C4'-C3' 103.677 -1.923 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.843 0 O4'-C1'-C2' 107.501 1.274 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.533 1.465 0 C1'-O4'-C4' 106.619 -2.201 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.818 0 O4'-C4'-C3' 104.199 -1.401 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.3 t0 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 58.2 mtmt -70.39 144.5 51.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.142 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -106.04 131.25 53.55 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 121.162 0.506 . . . . 0.0 111.039 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -96.73 103.02 14.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.36 178.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.8 mt -61.4 -44.33 98.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.08 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -142.94 162.11 36.34 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.055 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.699 ' O ' HG23 ' A' ' 59' ' ' VAL . 5.3 p -100.61 -151.98 0.42 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.606 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -49.44 117.58 2.28 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.487 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 57' ' ' THR . 92.7 t -132.82 130.53 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.693 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.2 mt -73.2 138.21 45.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.148 0.499 . . . . 0.0 109.811 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.15 178.81 27.38 Favored Glycine 0 N--CA 1.451 -0.363 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 88.2 m -127.56 137.17 52.52 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.502 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.685 HG21 HG12 ' A' ' 103' ' ' VAL . 90.4 t -76.28 108.57 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.749 -178.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.524 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -61.15 -48.86 79.65 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.15 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.524 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.1 p-90 -177.64 143.01 0.33 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.96 178.037 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -144.42 120.57 10.8 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 70' ' ' ASN . 79.8 m-20 -103.36 133.34 48.6 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.911 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.7 t -71.25 -38.39 69.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.436 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -58.41 -47.41 83.98 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -176.427 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.403 ' OD1' ' O ' ' A' ' 67' ' ' ASN . 53.1 p30 -80.62 -16.04 55.07 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.803 -178.411 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 70' ' ' ASN . . . 70.96 18.81 76.58 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.295 177.093 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -149.93 164.08 36.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 117.462 0.631 . . . . 0.0 110.181 179.221 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.13 -173.35 38.12 Favored Glycine 0 CA--C 1.524 0.604 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.505 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.446 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 98.4 m-85 -128.75 146.74 50.81 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.108 0.48 . . . . 0.0 112.114 -178.738 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.5 mt -120.38 126.7 75.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.955 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -94.95 111.09 22.91 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.956 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.421 ' NH2' HG21 ' A' ' 80' ' ' THR . 84.6 mtp180 -63.09 131.6 49.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.165 179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.4 p30 -89.81 2.33 55.06 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.414 -0.515 . . . . 0.0 111.323 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -107.27 -33.53 7.38 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.993 0.425 . . . . 0.0 110.198 179.097 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.421 HG21 ' NH2' ' A' ' 77' ' ' ARG . 74.4 p -116.2 -9.05 11.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.711 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.4 mttm 54.11 33.49 17.93 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 -178.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -112.85 132.96 55.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.233 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -73.91 125.4 28.12 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.052 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.85 131.89 70.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.883 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -63.35 142.78 58.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.351 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -139.91 145.9 25.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-O 121.218 0.532 . . . . 0.0 110.889 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -136.62 157.4 46.86 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.911 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -61.31 -39.25 89.8 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.0 p -66.79 -17.15 64.73 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -83.45 -4.27 58.35 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.154 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.425 HD11 HG23 ' A' ' 103' ' ' VAL . 81.7 mt -96.99 97.93 6.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.995 0.426 . . . . 0.0 111.217 -179.041 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -64.51 -41.3 96.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.283 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.531 ' HB3' HG22 ' A' ' 126' ' ' THR . 40.3 ttmt -119.45 136.33 54.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.009 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -149.43 170.82 17.69 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.357 179.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.415 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 31.5 p-10 -65.95 125.54 90.17 Favored Pre-proline 0 CA--C 1.539 0.526 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.83 -19.62 58.8 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.035 1.823 . . . . 0.0 112.59 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -64.57 -22.97 67.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -104.69 128.25 52.71 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.648 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -69.31 -37.55 77.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.754 179.427 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.98 131.56 48.32 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.141 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -59.45 136.36 57.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.028 0.442 . . . . 0.0 110.279 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.3 t -158.17 155.33 28.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.572 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.685 HG12 HG21 ' A' ' 63' ' ' VAL . 53.3 t -119.64 129.36 75.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.88 151.12 51.21 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.316 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -86.67 136.1 33.15 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.71 2.86 90.25 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.9 tp10 -92.92 128.81 38.92 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.938 0.399 . . . . 0.0 110.5 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -67.12 133.31 49.59 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.751 179.032 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.9 m -129.53 159.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.456 -178.576 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -118.66 128.83 54.9 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -157.76 161.15 38.45 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.767 -0.773 . . . . 0.0 112.538 -178.088 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.404 ' OD1' ' C ' ' A' ' 112' ' ' ASP . 55.8 p30 -90.32 174.53 7.53 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.281 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -127.61 127.67 68.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 C-N-CA 120.509 -0.476 . . . . 0.0 109.978 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 91.8 t -120.03 130.95 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -72.45 114.25 10.37 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.058 0.456 . . . . 0.0 110.896 -179.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -84.82 179.71 51.22 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -68.81 -29.28 67.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.702 0.287 . . . . 0.0 110.962 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -116.79 -23.25 8.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.402 -179.314 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -170.9 173.4 44.61 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.178 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -70.24 155.38 40.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.788 0.328 . . . . 0.0 110.512 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.6 pt-20 -136.89 158.25 44.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.666 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -97.77 148.46 23.34 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.96 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.09 41.76 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.236 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.1 t30 53.35 47.92 23.13 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.141 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.7 t -75.28 125.55 34.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.069 -178.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.531 HG22 ' HB3' ' A' ' 93' ' ' LYS . 69.7 p -136.92 169.21 18.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.743 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -77.27 175.58 53.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.05 137.85 35.54 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 122.074 1.849 . . . . 0.0 112.061 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.7 19.64 79.31 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.87 1.48 90.61 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 -179.147 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 86.6 t -62.65 137.61 96.56 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-O 119.647 -0.216 . . . . 0.0 110.611 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -59.14 148.44 85.75 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 121.697 1.598 . . . . 0.0 111.259 179.184 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.415 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 43.7 t -67.59 128.17 30.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.669 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -63.58 -39.62 94.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.539 -179.146 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.91 -175.58 53.16 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 179.311 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 41.4 t -101.28 160.4 14.44 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.824 0.345 . . . . 0.0 110.554 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -61.09 -37.99 84.68 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.416 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -64.35 -14.04 53.96 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.092 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.51 138.88 57.55 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.477 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.58 -179.807 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.491 0 O4'-C4'-C3' 104.386 -1.214 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.455 0.853 0 C4'-C3'-C2' 102.025 -1.175 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.501 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.699 0 O4'-C4'-C3' 102.897 -2.703 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.435 -0.964 0 O4'-C4'-C3' 104.121 -1.479 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.874 0 O4'-C1'-C2' 107.362 1.148 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.25 0 C1'-O4'-C4' 106.677 -2.159 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.798 0 C3'-C2'-C1' 101.948 -0.537 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -71.49 150.5 44.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -128.11 130.07 47.58 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.196 0.522 . . . . 0.0 110.937 179.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 84.9 t -91.74 100.57 11.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.397 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.741 HD11 ' OE1' ' A' ' 115' ' ' GLU . 96.6 mt -63.41 -44.14 98.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.046 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.25 163.73 36.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.07 0.462 . . . . 0.0 111.067 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.643 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -98.1 -146.57 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.679 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 57' ' ' THR . 63.5 mttp -50.82 116.4 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.407 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 57' ' ' THR . 74.1 t -131.78 130.03 61.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.697 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.7 mt -73.55 137.21 44.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.055 0.455 . . . . 0.0 109.808 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.32 177.9 27.2 Favored Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.4 m -128.22 135.76 50.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.856 0.36 . . . . 0.0 110.486 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.71 HG21 HG12 ' A' ' 103' ' ' VAL . 77.2 t -76.93 109.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.765 -179.209 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.1 tttt -62.22 -48.39 80.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 62.2 p-90 -175.8 147.63 0.81 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 114.678 -1.146 . . . . 0.0 109.903 178.004 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -137.45 115.44 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 41.4 t-20 -93.49 110.27 21.85 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.978 0.418 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 53.4 t -61.21 -46.7 96.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.391 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.1 ttp180 -62.01 -43.76 98.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -178.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.16 -39.39 92.48 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.81 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.49 4.04 59.58 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.382 179.255 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -148.26 160.82 42.57 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.423 0.611 . . . . 0.0 110.04 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.454 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -160.53 -177.22 33.44 Favored Glycine 0 CA--C 1.525 0.71 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.573 -179.629 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.455 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.5 m-85 -131.5 147.9 52.58 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.134 0.492 . . . . 0.0 112.193 -179.338 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.2 mt -120.77 127.36 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.843 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -91.92 110.45 21.81 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.807 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 96.4 mtm-85 -62.18 135.2 57.39 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.126 179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -82.54 -6.95 59.62 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.382 179.548 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -94.75 -33.07 13.04 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.959 0.409 . . . . 0.0 110.138 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 68.0 p -116.9 -10.6 10.96 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.642 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 54.44 34.51 21.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.976 0.417 . . . . 0.0 110.026 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -121.04 132.64 55.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.247 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -66.23 148.14 52.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.037 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -132.78 152.15 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.914 179.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -73.24 133.11 43.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.297 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.4 p -144.84 144.11 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.149 0.499 . . . . 0.0 110.911 178.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -136.19 157.79 45.96 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.841 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -58.46 -24.73 61.05 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -178.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.3 p -73.6 -20.49 60.59 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.421 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.24 -7.74 58.88 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.137 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.3 mt -90.0 94.9 5.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.872 0.367 . . . . 0.0 111.198 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -64.34 -38.15 90.03 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.437 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -122.94 142.86 50.35 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.101 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -153.28 177.13 11.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.35 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -63.63 118.62 46.43 Favored Pre-proline 0 CA--C 1.539 0.552 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.7 -34.66 99.07 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.056 1.838 . . . . 0.0 112.545 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.09 -19.9 66.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.467 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -97.65 114.53 26.5 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-O 120.74 0.305 . . . . 0.0 110.604 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -60.69 -47.89 84.23 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.893 0.378 . . . . 0.0 110.761 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.625 ' HB3' ' HB3' ' A' ' 140' ' ' ALA . 64.0 tp -91.18 130.67 37.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.182 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -59.76 136.73 58.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.055 0.455 . . . . 0.0 110.249 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.463 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.1 t -154.18 154.25 33.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.505 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.71 HG12 HG21 ' A' ' 63' ' ' VAL . 53.1 t -121.7 131.95 71.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.4 144.64 47.74 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.324 -178.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -83.14 118.59 23.69 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.65 -0.73 74.29 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -82.82 132.33 35.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.862 0.363 . . . . 0.0 110.532 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 85.8 m -69.04 132.48 46.7 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.648 178.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -130.01 159.77 41.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.47 -178.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -119.96 126.62 51.31 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -155.45 163.81 39.55 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.558 -177.187 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.31 153.33 20.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.224 178.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -110.29 125.09 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.403 -0.519 . . . . 0.0 109.983 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 75.8 t -123.41 129.75 74.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.741 ' OE1' HD11 ' A' ' 55' ' ' ILE . 51.5 tp10 -70.27 127.09 31.59 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.905 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.95 159.98 13.71 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.6 mp0 -61.55 -39.51 91.38 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.741 0.305 . . . . 0.0 110.957 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -85.23 -8.38 58.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.354 179.662 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 144.96 -169.77 26.61 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.52 143.85 57.62 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.885 0.374 . . . . 0.0 110.52 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -129.08 136.4 50.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.668 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -94.14 146.59 23.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.01 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.35 157.06 40.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.135 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 58.19 47.33 14.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.977 0.418 . . . . 0.0 110.164 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.2 t -76.07 123.22 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.074 -179.025 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.2 p -134.96 159.96 39.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.813 179.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.55 162.21 53.94 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.105 -1.598 . . . . 0.0 109.105 178.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.51 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.8 Cg_exo -58.83 136.99 77.34 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.039 1.826 . . . . 0.0 112.108 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.57 83.0 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.2 1.45 90.47 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.9 p -68.89 141.66 92.58 Favored Pre-proline 0 CA--C 1.535 0.4 0 CA-C-O 119.673 -0.203 . . . . 0.0 110.501 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 20.4 Cg_endo -59.09 150.24 74.72 Favored 'Trans proline' 0 N--CA 1.497 1.721 0 C-N-CA 121.634 1.556 . . . . 0.0 111.315 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -64.42 133.58 29.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.552 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -62.43 -42.41 99.43 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.496 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.41 162.59 36.16 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 85.1 p -80.59 166.3 21.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.894 0.378 . . . . 0.0 110.496 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -63.4 -36.87 85.17 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.511 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -72.1 -5.23 33.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.121 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.463 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -58.6 140.39 54.45 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.448 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.625 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.636 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.555 0 C3'-C2'-C1' 104.658 1.399 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -0.992 0 C4'-C3'-C2' 101.247 -1.953 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.56 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.77 0 O4'-C4'-C3' 103.189 -2.411 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.821 0 O4'-C1'-C2' 107.405 1.186 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.429 -1.517 0 C3'-C2'-C1' 104.482 1.273 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.432 -1.256 0 C1'-O4'-C4' 107.597 -1.502 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.882 0 C5'-C4'-O4' 108.618 -0.489 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.48 ' NZ ' HG11 ' A' ' 114' ' ' VAL . 22.6 pttp -140.89 152.07 44.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.281 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -78.05 136.56 37.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.234 0.54 . . . . 0.0 110.907 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 101.88 12.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.375 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.0 -44.53 97.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.069 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -155.27 163.24 40.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.056 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.547 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.4 t -96.19 -149.51 0.31 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.685 179.622 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -55.1 118.0 3.96 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.52 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 57' ' ' THR . 87.5 t -129.58 128.55 65.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.701 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.7 mt -68.98 135.31 50.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.122 0.486 . . . . 0.0 109.733 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.04 -177.82 27.0 Favored Glycine 0 CA--C 1.521 0.42 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.4 m -128.28 135.34 49.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.876 0.37 . . . . 0.0 110.391 -179.564 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.711 HG21 HG12 ' A' ' 103' ' ' VAL . 97.1 t -71.28 110.87 4.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.765 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -61.52 -48.92 78.85 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.9 p-90 -177.77 140.08 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.957 178.123 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -137.1 119.17 15.43 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.428 ' ND2' ' O2 ' ' B' ' 305' ' ' ' DC' . 7.0 m120 -101.22 120.88 40.9 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.892 179.741 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.407 HG21 ' C ' ' A' ' 138' ' ' TYR . 67.3 t -62.93 -45.73 98.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.525 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -61.82 -44.68 96.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -178.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -62.09 -38.78 90.13 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.902 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.61 2.1 65.53 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.397 179.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -147.54 161.96 40.05 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 117.467 0.633 . . . . 0.0 110.112 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.55 -179.05 36.9 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.561 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.459 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 92.3 m-85 -126.99 146.27 50.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.153 0.501 . . . . 0.0 112.172 -178.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.407 HG21 ' CE2' ' A' ' 111' ' ' PHE . 87.2 mt -119.31 125.34 74.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.827 178.463 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.77 109.88 21.32 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.836 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -65.96 134.78 53.66 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.19 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -85.06 -5.31 59.35 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.418 -0.513 . . . . 0.0 111.268 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -96.49 -33.19 11.95 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.176 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 66.5 p -115.15 -9.61 12.27 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.627 -178.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt 53.63 32.5 14.59 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 121.062 0.458 . . . . 0.0 110.147 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -119.73 131.83 55.48 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.233 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.02 142.43 58.38 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.986 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.411 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 79.0 t -126.89 132.42 70.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.899 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -66.19 138.19 57.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.312 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.79 147.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.225 0.536 . . . . 0.0 110.946 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -136.88 159.96 40.31 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.905 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.418 ' HA ' HD12 ' A' ' 91' ' ' ILE . 16.6 pm0 -59.98 -20.4 57.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 64.1 p -82.52 -12.81 57.52 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.465 179.064 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.05 1.36 57.24 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.132 179.397 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.459 HD11 HG23 ' A' ' 103' ' ' VAL . 80.7 mt -95.97 101.68 12.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.929 0.395 . . . . 0.0 111.136 -178.153 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -63.11 -45.15 93.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.365 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -115.07 136.8 52.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.04 -178.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -143.26 137.85 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.31 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.4 p-10 -58.96 138.39 87.49 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.057 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.34 -9.12 24.76 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.004 1.802 . . . . 0.0 112.499 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.55 -35.95 77.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.412 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -105.04 137.91 42.07 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-O 120.687 0.279 . . . . 0.0 110.672 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.445 ' HB2' HD22 ' A' ' 100' ' ' LEU . 98.2 m-85 -68.42 -41.95 79.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.756 -179.37 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.59 HD22 ' N ' ' A' ' 100' ' ' LEU . 1.3 mm? -97.98 146.41 25.53 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.31 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -67.51 128.52 36.74 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.381 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.406 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.7 m -147.51 161.74 40.47 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.477 -179.271 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.711 HG12 HG21 ' A' ' 63' ' ' VAL . 32.8 t -125.97 131.11 72.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -61.64 143.48 48.65 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.266 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -81.58 123.29 28.54 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.327 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.0 3.83 88.87 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -84.74 136.67 33.61 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.939 0.399 . . . . 0.0 110.503 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 89.6 m -70.66 130.88 42.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.607 179.137 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -134.91 164.82 32.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.445 -178.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -124.87 137.7 54.28 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.3 p90 -160.12 162.52 34.01 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.813 -0.755 . . . . 0.0 112.481 -177.394 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -90.65 137.34 32.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.268 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.7 t -103.83 126.22 58.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.988 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.48 HG11 ' NZ ' ' A' ' 52' ' ' LYS . 35.8 m -123.97 153.33 30.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -91.72 115.07 27.75 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.082 0.468 . . . . 0.0 111.023 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -97.31 172.13 27.46 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.548 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -63.89 -39.67 94.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.675 0.274 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -85.17 -18.9 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 154.94 -171.3 33.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -66.63 143.24 57.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.883 0.373 . . . . 0.0 110.412 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG22 ' A' ' 114' ' ' VAL . 88.9 tt0 -138.08 136.06 36.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.628 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.411 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -77.92 152.87 33.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.12 158.22 42.65 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.14 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 53.07 47.28 24.92 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.105 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.6 t -74.43 124.05 31.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.071 -179.048 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 50.3 p -139.78 170.06 16.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.825 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.31 164.68 54.72 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 178.378 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.444 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.3 Cg_exo -59.44 137.18 76.51 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 C-N-CA 121.977 1.785 . . . . 0.0 112.177 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.31 20.81 77.06 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.25 2.48 90.5 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -179.577 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 128' ' ' PRO . 96.6 t -60.98 141.3 93.61 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 122.777 -0.249 . . . . 0.0 110.553 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -56.28 148.06 63.09 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 121.549 1.499 . . . . 0.0 111.315 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.416 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 42.9 t -69.78 126.24 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.64 -179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 16.2 tm0? -60.9 -40.42 93.01 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.54 -178.554 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.41 -174.39 54.95 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -111.75 162.84 14.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.841 0.353 . . . . 0.0 110.502 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -60.84 -37.91 83.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.509 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.417 ' CE2' ' C2 ' ' B' ' 307' ' ' ' DT' . 96.4 m-85 -71.02 -5.77 33.84 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.067 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.501 ' O ' ' HB3' ' A' ' 140' ' ' ALA . . . -59.14 -38.92 80.82 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.521 -179.035 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 139' ' ' ALA . . . . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.578 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.43 -1.446 0 C3'-C2'-C1' 104.69 1.422 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.802 0 O4'-C4'-C3' 104.335 -1.265 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.52 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.434 -1.068 0 O4'-C4'-C3' 103.126 -2.474 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.457 0.982 0 C3'-C2'-C1' 101.34 -0.971 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . 0.428 ' O2 ' ' ND2' ' A' ' 67' ' ' ASN . . . . . . . . 0 O5'--C5' 1.426 -0.873 0 O4'-C1'-C2' 106.98 0.8 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.236 0 C1'-O4'-C4' 107.378 -1.659 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . 0.417 ' C2 ' ' CE2' ' A' ' 138' ' ' TYR . . . . . . . . 0 O5'--C5' 1.427 -0.833 0 O4'-C1'-C2' 104.899 -1.092 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 30.3 mmmt -78.82 152.34 31.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.185 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.475 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.2 tttm -105.31 130.9 53.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.183 0.516 . . . . 0.0 110.958 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 54' ' ' VAL . 1.4 p -95.97 100.85 11.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.414 179.178 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.87 -44.26 99.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.102 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.436 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.94 162.91 37.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 -179.248 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.495 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.9 t -108.84 -134.8 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.707 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.441 ' N ' HG23 ' A' ' 57' ' ' THR . 68.6 mttm -54.71 102.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.346 -0.541 . . . . 0.0 110.369 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 57' ' ' THR . 97.4 t -127.26 128.75 70.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.729 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 88.6 mt -79.66 135.99 36.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.104 0.478 . . . . 0.0 109.862 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.49 178.18 21.81 Favored Glycine 0 CA--C 1.519 0.298 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.518 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 134.76 50.67 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.852 0.358 . . . . 0.0 110.463 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.661 HG21 HG12 ' A' ' 103' ' ' VAL . 86.6 t -75.77 109.99 10.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.75 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.67 -49.19 77.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 61.4 p-90 -174.51 152.78 1.75 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.899 178.05 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -147.06 117.07 7.24 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -97.45 120.87 38.6 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.908 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -63.18 -44.8 99.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.462 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.42 HH11 ' HD2' ' A' ' 69' ' ' ARG . 9.0 ptm85 -65.22 -34.84 79.32 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -69.3 -35.35 75.9 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.521 -0.471 . . . . 0.0 110.788 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 89.38 1.42 78.39 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.367 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -150.15 162.74 39.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.445 0.623 . . . . 0.0 110.085 179.279 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.73 179.85 34.09 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.493 -0.86 . . . . 0.0 111.535 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.474 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 81.9 m-85 -123.49 143.52 50.11 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.133 0.492 . . . . 0.0 112.091 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.992 HD12 HG11 ' A' ' 86' ' ' VAL . 88.1 mt -120.63 126.2 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.841 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.91 114.75 27.38 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.875 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -71.43 128.69 36.69 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.035 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.3 p30 -83.93 -1.59 54.85 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.337 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -101.21 -31.54 10.96 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-O 120.947 0.403 . . . . 0.0 110.176 179.282 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.72 -12.48 11.51 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.682 -179.201 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.86 32.45 19.68 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.995 -179.153 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.78 135.35 55.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.244 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -63.32 144.95 56.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.072 -179.421 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.35 133.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.901 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -80.98 125.19 29.84 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.325 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.079 HG12 ' HB3' ' A' ' 122' ' ' ALA . 32.6 m -131.17 159.86 42.72 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-O 121.133 0.492 . . . . 0.0 110.973 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -137.95 155.97 48.34 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.837 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -60.93 -22.98 64.92 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.531 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.9 p -80.96 -13.0 59.28 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.422 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.05 2.93 55.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.094 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 103' ' ' VAL . 78.9 mt -98.03 106.68 19.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.876 0.37 . . . . 0.0 111.171 -178.331 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -63.84 -44.35 93.45 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.327 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.03 144.13 50.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.928 0.394 . . . . 0.0 111.051 -179.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 p-10 -150.26 174.32 12.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.418 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.0 t-20 -62.67 120.2 57.79 Favored Pre-proline 0 CA--C 1.541 0.604 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.49 -23.07 58.21 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.035 1.823 . . . . 0.0 112.595 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.4 mmm-85 -67.02 -21.63 65.92 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.413 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.61 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 75.5 mmtt -91.48 136.93 32.76 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.62 -179.403 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.404 ' C ' HD12 ' A' ' 100' ' ' LEU . 94.4 m-85 -69.18 -39.55 78.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.753 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 99' ' ' TYR . 8.0 mp -113.5 151.52 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.173 -179.465 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.66 139.25 58.74 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.319 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.8 p -156.0 161.36 40.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.603 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.661 HG12 HG21 ' A' ' 63' ' ' VAL . 52.7 t -123.12 125.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.8 146.86 48.94 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.363 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -84.55 133.78 34.44 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.88 4.8 89.61 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.565 -1.014 . . . . 0.0 110.565 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -92.61 129.77 38.44 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.96 0.41 . . . . 0.0 110.504 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.5 m -66.81 133.55 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.576 178.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.5 m -128.89 158.15 41.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.459 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -120.0 130.11 54.59 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -160.8 165.14 30.79 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.549 -177.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -95.28 144.98 25.41 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.306 178.288 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.436 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -105.06 126.3 60.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.022 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 53' ' ' LYS . 13.8 p -125.15 130.91 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.96 128.89 37.79 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.941 -178.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.84 160.72 13.05 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -60.47 -42.85 97.08 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.741 0.305 . . . . 0.0 110.97 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -86.46 -14.37 43.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.334 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 156.09 -175.2 33.9 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.05 142.24 58.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.381 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -125.98 159.13 33.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 1.079 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -116.67 149.81 39.17 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.23 156.99 42.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.191 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 54.81 43.89 29.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.051 0.453 . . . . 0.0 110.123 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.8 t -72.45 121.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.054 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.1 p -137.88 166.23 24.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.725 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.61 175.24 49.79 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.49 138.21 38.12 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.929 1.753 . . . . 0.0 112.097 -179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 19.99 77.94 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.79 1.12 90.56 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.03 137.52 95.58 Favored Pre-proline 0 CA--C 1.535 0.39 0 O-C-N 122.822 -0.222 . . . . 0.0 110.556 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -59.45 146.26 95.51 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.656 1.57 . . . . 0.0 111.247 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -64.96 135.27 28.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.69 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -59.51 -42.78 92.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.469 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.28 176.71 51.16 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 179.245 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 43.8 t -97.0 143.93 27.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.92 0.391 . . . . 0.0 110.54 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -60.14 -21.07 61.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.552 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -74.93 -12.59 60.39 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.113 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.61 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . -58.37 141.03 52.53 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.515 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.61 -179.498 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.522 0 C3'-C2'-C1' 104.461 1.258 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.831 0 O4'-C4'-C3' 103.812 -1.788 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.521 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.425 -1.886 0 O4'-C4'-C3' 102.856 -2.744 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.81 0 P-O3'-C3' 120.438 0.615 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.776 0 C4'-C3'-C2' 102.477 -0.723 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.214 0 C1'-O4'-C4' 106.43 -2.336 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.794 0 O4'-C1'-C2' 107.356 1.142 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 60.1 mtmt -70.62 143.9 51.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.261 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.44 ' O ' HG13 ' A' ' 114' ' ' VAL . 87.5 tttt -104.9 129.37 53.28 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-O 121.218 0.533 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.5 t -94.09 103.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.41 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.7 HD11 ' OE1' ' A' ' 115' ' ' GLU . 96.5 mt -62.82 -45.3 99.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.029 -178.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.83 167.62 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.116 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.5 t -105.66 -134.77 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.68 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.443 ' N ' HG23 ' A' ' 57' ' ' THR . 87.8 tttt -50.34 112.91 0.76 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.482 -179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 57' ' ' THR . 72.5 t -135.45 131.29 51.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.771 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.472 HD23 ' HG2' ' A' ' 110' ' ' GLU . 67.2 mt -75.01 133.75 41.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.121 0.486 . . . . 0.0 109.75 177.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.89 175.57 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 90.1 m -131.17 138.93 49.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.829 0.347 . . . . 0.0 110.432 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.721 HG21 HG12 ' A' ' 103' ' ' VAL . 97.2 t -72.62 109.18 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.78 -178.772 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -62.49 -48.04 81.35 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.006 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.528 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 59.0 p-90 -177.23 139.53 0.26 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.969 178.154 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -135.71 120.84 18.87 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -104.65 119.87 40.0 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.923 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.36 -45.47 98.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.482 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -60.57 -44.92 95.66 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -62.13 -38.15 87.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.813 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.1 1.47 64.97 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.34 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.5 p90 -147.5 160.16 42.91 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 117.473 0.636 . . . . 0.0 110.072 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.91 174.61 36.73 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.489 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -129.16 148.6 51.11 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.187 0.518 . . . . 0.0 112.141 -179.053 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.429 HD13 HG21 ' A' ' 109' ' ' VAL . 84.5 mt -116.55 127.18 74.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.844 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.12 109.05 19.96 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -60.38 134.99 57.6 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.159 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -84.37 -0.15 51.53 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.301 179.496 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -101.87 -33.04 9.94 Favored 'General case' 0 C--O 1.231 0.085 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.058 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.7 p -116.59 -9.09 11.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.693 -178.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mmtm 55.81 31.75 18.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.96 0.41 . . . . 0.0 110.037 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -117.69 133.99 55.37 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.303 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.15 144.57 56.8 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.098 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.449 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.2 t -124.14 126.94 73.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.913 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.76 129.03 38.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.318 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.93 149.76 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.186 0.517 . . . . 0.0 110.921 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.01 160.13 33.73 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.858 178.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.414 ' OE1' HD11 ' A' ' 100' ' ' LEU . 25.9 pt20 -60.24 -29.79 68.99 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -73.53 -15.66 61.29 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.385 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.19 -0.07 53.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.17 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.523 HD11 HG23 ' A' ' 103' ' ' VAL . 80.4 mt -92.98 101.3 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.967 0.413 . . . . 0.0 111.226 -178.545 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -62.94 -43.86 97.65 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -121.79 143.02 49.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.148 -179.347 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -152.77 163.79 39.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.434 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -61.76 121.15 62.81 Favored Pre-proline 0 CA--C 1.539 0.539 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.46 -21.63 66.09 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 121.967 1.778 . . . . 0.0 112.553 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.82 -22.16 66.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.326 179.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -100.89 120.67 40.49 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-O 120.751 0.31 . . . . 0.0 110.686 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 88.8 t80 -61.03 -48.3 82.41 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.703 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.414 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.5 tp -93.09 129.53 39.03 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.141 -179.25 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -61.82 139.23 58.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.297 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 90.2 p -158.31 163.95 36.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.452 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.721 HG12 HG21 ' A' ' 63' ' ' VAL . 43.8 t -125.16 129.53 73.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.25 144.66 48.01 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.319 -178.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 105' ' ' ASP . 41.0 p-10 -77.36 129.2 35.51 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.36 2.01 86.94 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 110.526 -1.029 . . . . 0.0 110.526 -178.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.7 tt0 -78.37 130.91 36.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 120.988 0.423 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.4 m -71.09 130.76 42.35 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.713 178.522 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.429 HG21 HD13 ' A' ' 75' ' ' ILE . 21.6 m -133.71 158.43 42.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.524 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.472 ' HG2' HD23 ' A' ' 60' ' ' LEU . 94.6 mt-10 -115.78 132.42 56.64 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.287 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -161.33 167.11 26.42 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.473 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -88.57 149.53 23.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.252 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.8 t -108.43 123.9 64.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.481 -0.488 . . . . 0.0 109.957 -179.789 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 53' ' ' LYS . 68.4 t -122.99 128.13 75.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.402 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.7 ' OE1' HD11 ' A' ' 55' ' ' ILE . 50.1 tp10 -64.99 124.87 23.18 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.946 -178.864 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -120.76 159.59 15.39 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -61.98 -40.06 94.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.709 0.29 . . . . 0.0 110.937 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -81.95 -9.3 59.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.391 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 142.7 -167.54 26.21 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.504 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.29 141.94 58.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.5 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.56 151.93 35.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.655 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.449 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -118.69 142.43 47.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.045 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.11 153.34 42.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.184 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 54.36 43.08 30.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.059 0.457 . . . . 0.0 110.174 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.05 125.39 28.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.106 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.9 p -135.67 169.43 17.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.824 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.09 177.24 45.69 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 178.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.431 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.7 Cg_endo -69.73 136.38 32.93 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 121.911 1.74 . . . . 0.0 112.188 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.68 21.53 77.87 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.07 1.79 90.41 Favored Glycine 0 CA--C 1.531 1.084 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 128' ' ' PRO . 85.5 t -63.16 140.43 97.67 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 122.853 -0.204 . . . . 0.0 110.527 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -58.06 148.53 76.75 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 121.58 1.52 . . . . 0.0 111.292 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.2 t -69.15 128.99 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.605 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -61.47 -41.85 97.88 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.435 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.83 -175.9 48.94 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -109.5 159.96 16.62 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.845 0.355 . . . . 0.0 110.53 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt -61.49 -37.81 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -63.63 -15.37 58.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.078 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.48 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . -59.78 142.52 53.14 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.451 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.626 -179.846 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.642 0 O4'-C1'-C2' 107.132 0.938 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.433 -1.146 0 O4'-C4'-C3' 103.948 -1.652 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.537 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.428 -0.721 0 O4'-C4'-C3' 103.752 -1.848 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.781 0 O4'-C1'-C2' 107.584 1.349 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.902 0 O4'-C4'-C3' 104.298 -1.302 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.189 0 C1'-O4'-C4' 106.784 -2.083 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.828 0 O4'-C1'-C2' 107.427 1.207 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 52.8 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.7 mtpp -72.04 146.97 47.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.185 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.433 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.8 tttp -63.44 134.49 55.74 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 110.926 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.8 t -97.46 101.7 12.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.334 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.64 -45.0 98.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.068 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.55 163.45 39.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.109 -178.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.545 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.1 t -98.12 -149.09 0.33 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.7 179.725 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.0 mtmt -53.92 119.31 4.85 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.449 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 57' ' ' THR . 72.2 t -131.38 131.67 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.629 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 62.2 mt -65.7 131.07 45.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.102 0.477 . . . . 0.0 109.835 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.62 176.13 24.78 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 91.8 m -129.33 135.46 48.77 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.735 0.302 . . . . 0.0 110.508 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 95.2 t -70.88 108.02 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.826 -179.228 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.54 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.7 tttt -61.66 -47.81 83.65 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.073 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.54 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 58.1 p-90 -177.1 138.94 0.26 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.602 -1.181 . . . . 0.0 109.942 178.052 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -136.07 117.57 14.8 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -100.59 119.68 38.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.004 0.43 . . . . 0.0 110.907 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.437 HG21 ' N ' ' A' ' 139' ' ' ALA . 65.3 t -62.18 -46.33 96.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.422 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.13 -46.16 90.6 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -61.41 -39.23 89.98 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.924 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.61 1.93 63.6 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.349 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -148.21 161.22 41.91 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.505 0.653 . . . . 0.0 110.062 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -159.48 -177.91 33.0 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.568 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.461 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 81.5 m-85 -129.24 143.96 51.04 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.425 HG13 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -116.93 123.42 71.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.814 178.797 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -91.11 109.12 20.37 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.933 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.423 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -63.64 130.29 43.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.083 178.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -74.99 -26.86 59.88 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.358 179.041 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -70.77 -41.78 71.27 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.905 0.383 . . . . 0.0 110.224 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.2 p -104.49 -11.14 17.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.675 -178.173 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LYS . . . . . 0.423 ' N ' ' O ' ' A' ' 77' ' ' ARG . 98.6 mttt 55.86 31.19 17.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.927 0.394 . . . . 0.0 110.043 -178.486 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -120.45 145.84 46.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.225 179.72 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -70.31 147.22 49.91 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.073 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 122' ' ' ALA . 88.3 t -130.12 132.53 65.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.816 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -66.31 138.29 57.52 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.328 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.425 HG11 HG13 ' A' ' 75' ' ' ILE . 7.7 p -151.44 149.88 13.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.232 0.539 . . . . 0.0 110.879 179.012 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -133.48 155.38 49.65 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.83 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.2 pt20 -60.9 -25.52 66.79 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 63.2 p -79.56 -13.05 59.8 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.479 178.595 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.24 1.56 55.53 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.119 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.46 HD11 HG23 ' A' ' 103' ' ' VAL . 78.8 mt -93.91 108.9 21.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.847 0.356 . . . . 0.0 111.202 -178.239 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -64.32 -43.11 95.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.318 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.85 138.98 54.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.147 -178.455 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -144.91 157.19 44.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.476 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -56.98 120.15 36.18 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.83 -32.23 94.4 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.015 1.81 . . . . 0.0 112.581 179.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -62.41 -21.79 65.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.418 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -85.62 127.59 34.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 120.693 0.282 . . . . 0.0 110.623 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -65.46 -39.47 92.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.795 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.529 HD12 ' O ' ' A' ' 140' ' ' ALA . 85.0 mt -118.3 150.32 39.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.254 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -63.15 136.8 57.97 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.7 p -159.38 163.05 35.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.495 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 54.9 t -125.72 128.39 72.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.525 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.66 138.62 38.1 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.274 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.01 135.76 38.68 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.57 3.19 90.15 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.425 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.6 tp10 -92.36 128.45 38.21 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 121.002 0.429 . . . . 0.0 110.537 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.6 m -68.16 132.99 48.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.674 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.99 158.04 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.235 -0.586 . . . . 0.0 111.394 -178.562 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -117.37 134.4 54.87 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.153 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 39.8 p90 -158.75 162.2 37.08 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.819 -0.753 . . . . 0.0 112.586 -177.61 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -88.88 144.09 26.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.25 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.3 123.78 59.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.987 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 53' ' ' LYS . 14.6 p -121.11 134.52 64.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -61.69 126.85 28.8 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.554 -0.459 . . . . 0.0 110.968 -178.512 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -109.42 167.42 12.87 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 52.6 tp10 -60.97 -43.91 98.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.719 0.295 . . . . 0.0 110.945 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -90.72 -18.19 25.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.403 -178.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 164.34 -171.54 39.88 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.506 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.96 143.65 56.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 110.437 -179.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -126.63 154.54 43.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.726 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.96 143.49 34.03 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.034 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.13 157.71 43.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.184 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 55.4 49.48 16.81 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.939 0.4 . . . . 0.0 110.07 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 86.7 t -75.8 125.17 35.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.14 -179.152 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -137.5 163.57 30.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.76 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.4 165.76 54.17 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.082 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.8 Cg_exo -59.6 136.05 68.41 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.962 1.774 . . . . 0.0 112.154 -178.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.3 19.44 79.65 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 178.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.36 1.59 90.31 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 128' ' ' PRO . 90.4 t -60.96 139.06 94.09 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-O 119.692 -0.194 . . . . 0.0 110.572 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' HG13 ' A' ' 131' ' ' VAL . 24.0 Cg_endo -60.69 149.06 89.5 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.679 1.586 . . . . 0.0 111.323 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.6 t -70.28 128.81 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.55 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 12.7 tp-100 -61.07 -39.99 91.98 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.534 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.14 -175.71 53.82 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 65.4 m -107.54 155.65 19.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.59 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -62.64 -35.52 79.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.493 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -62.11 -13.65 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.099 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.46 ' O ' ' HB2' ' A' ' 140' ' ' ALA . . . -56.79 137.97 53.9 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.468 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.529 ' O ' HD12 ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.641 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.471 0 O4'-C4'-C3' 107.037 1.437 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.822 0 O4'-C1'-C2' 107.582 1.348 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 303' ' ' ' DC' . . . . . 0.606 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.43 -1.433 0 O4'-C4'-C3' 103.428 -2.172 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.893 0 P-O3'-C3' 120.357 0.547 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.425 -0.907 0 O4'-C1'-C2' 107.218 1.017 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.31 0 C4'-C3'-C2' 104.885 1.685 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C4'-C3' 104.73 -0.87 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 79.9 t . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.457 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.0 mt -61.92 -44.21 98.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.037 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.524 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.85 159.34 43.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.117 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.557 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.8 p -107.81 -140.7 0.38 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.661 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt -50.93 102.52 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.262 -0.575 . . . . 0.0 110.505 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 57' ' ' THR . 84.3 t -128.49 130.19 69.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.712 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 87.1 mt -82.12 137.01 35.08 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.93 -179.88 22.47 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 89.8 m -127.29 136.18 51.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.792 0.329 . . . . 0.0 110.501 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 89.3 t -76.67 112.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.74 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.534 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.45 -48.15 80.93 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.534 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -178.76 143.66 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.961 177.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -138.73 118.73 13.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -98.77 120.89 39.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.987 0.422 . . . . 0.0 110.81 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.402 HG21 ' N ' ' A' ' 139' ' ' ALA . 69.9 t -64.16 -45.1 97.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.42 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.1 ttp85 -61.31 -44.46 97.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.41 -38.36 89.4 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.843 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.36 3.96 66.67 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 121.091 -0.575 . . . . 0.0 112.401 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -149.28 161.38 42.16 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.441 0.621 . . . . 0.0 110.137 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.429 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -162.75 -177.08 35.46 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 120.554 -0.831 . . . . 0.0 111.577 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -131.56 147.7 52.55 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.107 0.48 . . . . 0.0 112.233 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.2 mt -120.24 127.68 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.856 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -93.32 109.83 21.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.849 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.9 mtm180 -65.6 131.78 47.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.093 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.9 p30 -86.91 -0.21 56.13 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.278 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -100.32 -32.7 10.72 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.892 0.377 . . . . 0.0 110.098 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.75 -10.59 11.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.674 -179.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 56.9 mtmt 55.37 32.34 18.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 109.996 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -121.25 132.37 54.77 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.319 0.58 . . . . 0.0 111.222 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -67.04 146.47 54.3 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.049 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.0 p -134.03 148.03 30.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.931 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -73.45 138.46 45.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.354 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 73' ' ' GLY . 4.8 p -143.01 145.56 22.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 121.112 0.482 . . . . 0.0 110.947 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -137.4 158.85 43.52 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.868 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -61.28 -39.19 89.49 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.5 p -67.27 -15.7 63.85 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.469 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.02 0.75 54.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.496 HD11 HG23 ' A' ' 103' ' ' VAL . 83.5 mt -98.65 104.97 16.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.038 0.447 . . . . 0.0 111.136 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -62.67 -44.93 95.01 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.331 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.412 ' HB2' HG22 ' A' ' 126' ' ' THR . 75.9 mmtt -125.62 145.39 50.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.002 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -150.98 176.59 10.98 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.399 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -63.71 121.14 68.92 Favored Pre-proline 0 CA--C 1.54 0.589 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.38 -25.61 63.69 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.999 1.799 . . . . 0.0 112.535 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.0 mmm180 -69.96 -17.95 63.33 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.436 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -95.78 123.85 39.54 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.689 0.28 . . . . 0.0 110.632 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -66.02 -39.8 90.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.858 0.361 . . . . 0.0 110.752 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -103.66 136.68 42.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.219 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.1 mtm180 -65.1 137.18 57.51 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.316 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 86.1 p -160.05 164.0 33.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 59.4 t -123.43 128.37 74.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.21 145.73 44.95 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.309 -179.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -83.0 137.91 33.96 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.49 2.78 88.29 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -93.57 132.13 38.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.88 0.371 . . . . 0.0 110.465 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -69.59 133.19 47.32 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.611 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.68 159.67 40.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.522 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -120.95 131.07 54.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -160.75 167.31 27.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.507 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -100.55 138.05 38.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.284 178.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.524 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 55.4 t -95.87 124.79 48.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 120.523 -0.471 . . . . 0.0 109.863 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.1 t . . . . . 0 C--N 1.326 -0.418 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.461 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 120.918 0.39 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.7 145.83 24.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.033 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.8 155.7 39.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.159 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 54.28 50.45 16.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.999 0.428 . . . . 0.0 110.131 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -78.4 119.62 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.112 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.412 HG22 ' HB2' ' A' ' 93' ' ' LYS . 82.3 p -138.41 164.58 28.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.769 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.05 171.27 51.1 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -69.18 137.64 37.66 Favored 'Trans proline' 0 C--N 1.3 -1.994 0 C-N-CA 122.0 1.8 . . . . 0.0 112.122 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.11 19.43 79.79 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.5 0.58 89.35 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 128' ' ' PRO . 76.0 t -61.2 137.77 94.35 Favored Pre-proline 0 CA--C 1.535 0.391 0 O-C-N 122.802 -0.234 . . . . 0.0 110.51 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.15 150.3 87.86 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 121.61 1.54 . . . . 0.0 111.351 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.05 132.39 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.588 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -61.66 -40.27 94.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.616 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.01 -176.98 53.91 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 72.6 m -103.19 153.78 20.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.82 0.343 . . . . 0.0 110.56 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -59.89 -37.75 80.28 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.401 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -62.31 -15.56 48.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.12 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.402 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.331 -0.233 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.569 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.2 t . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.426 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.3 mt -62.29 -44.17 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.061 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.77 164.95 33.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.098 0.475 . . . . 0.0 111.061 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.81 ' O ' HG23 ' A' ' 59' ' ' VAL . 10.9 t -98.05 -151.4 0.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.647 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.458 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 22.5 pttp -47.03 116.0 1.24 Allowed 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.453 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.81 HG23 ' O ' ' A' ' 57' ' ' THR . 93.9 t -129.79 128.08 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.688 179.391 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.6 mt -75.18 136.5 41.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.12 0.486 . . . . 0.0 109.827 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -152.86 -175.87 24.8 Favored Glycine 0 CA--C 1.52 0.363 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.5 m -130.54 136.76 49.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.81 0.338 . . . . 0.0 110.503 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.731 HG21 HG12 ' A' ' 103' ' ' VAL . 77.5 t -73.21 115.57 14.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.752 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.43 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.2 ttpt -63.73 -47.05 82.63 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.43 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 56.5 p-90 -176.43 148.18 0.73 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 114.673 -1.148 . . . . 0.0 109.901 177.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -143.4 115.62 8.44 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -101.0 123.29 44.96 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.88 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.3 t -63.33 -46.08 96.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.461 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -60.29 -45.49 93.15 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.53 88.33 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.894 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.93 2.61 66.53 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.01 161.87 41.49 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 117.456 0.628 . . . . 0.0 110.064 179.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.443 ' O ' HG22 ' A' ' 86' ' ' VAL . . . -157.74 -177.92 31.3 Favored Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.601 -179.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -131.72 146.5 52.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.152 0.501 . . . . 0.0 112.157 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.856 HD12 HG11 ' A' ' 86' ' ' VAL . 86.8 mt -120.55 127.25 75.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.838 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -92.94 109.84 21.29 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.879 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.4 mtm180 -62.75 133.39 54.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.109 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 p30 -87.74 -0.15 56.52 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.279 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.9 -32.12 11.14 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 120.974 0.416 . . . . 0.0 110.113 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 75.2 p -113.44 -11.03 13.17 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.698 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt 57.69 31.44 20.41 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 0.0 110.007 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -120.1 142.66 48.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.356 0.598 . . . . 0.0 111.198 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.36 144.82 51.5 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.051 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 87.3 t -128.21 128.2 68.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.972 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -72.8 130.1 39.7 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.341 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.057 HG12 ' HB3' ' A' ' 122' ' ' ALA . 33.3 m -132.91 159.42 43.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.215 0.531 . . . . 0.0 110.917 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.34 155.93 47.36 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.936 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -60.86 -23.05 64.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.2 p -81.85 -11.94 58.71 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.421 178.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.22 0.9 56.98 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.156 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.4 mt -96.8 100.3 10.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.943 0.401 . . . . 0.0 111.168 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -63.36 -44.12 95.72 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.298 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -122.33 144.88 48.74 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.954 0.406 . . . . 0.0 111.031 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.5 p-10 -155.07 175.69 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.38 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -66.63 120.55 71.77 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -64.81 -25.66 60.42 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.039 1.826 . . . . 0.0 112.552 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -65.47 -20.73 66.48 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.395 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.82 128.68 40.19 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.696 0.284 . . . . 0.0 110.633 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -66.13 -38.67 88.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.754 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.9 mt -108.89 149.7 28.77 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.214 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -69.68 129.94 41.0 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.384 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 65.8 m -143.46 157.9 44.07 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.474 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.731 HG12 HG21 ' A' ' 63' ' ' VAL . 48.8 t -126.41 131.69 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.18 49.21 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.361 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.56 115.18 26.77 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 95.14 -8.42 69.85 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -72.21 156.11 39.5 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.921 0.391 . . . . 0.0 110.492 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.3 m -86.96 129.47 34.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.653 178.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.0 m -129.86 158.98 42.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.431 -177.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -119.91 129.44 54.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 50.3 p90 -158.11 161.03 37.92 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.783 -0.767 . . . . 0.0 112.567 -177.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -85.36 152.98 22.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.336 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.426 HG12 ' HB ' ' A' ' 55' ' ' ILE . 59.8 t -107.18 124.67 63.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 120.473 -0.491 . . . . 0.0 109.985 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 83.3 t . . . . . 0 C--N 1.327 -0.409 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.776 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 . . . . . 0 C--O 1.228 -0.03 0 CA-C-O 120.89 0.376 . . . . 0.0 110.621 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 1.057 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -85.33 154.66 21.74 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.034 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.36 151.9 32.38 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.297 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 53.35 46.52 26.18 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.161 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 98.9 t -70.75 124.09 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.126 -179.125 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -140.91 165.55 27.21 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.76 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.78 172.93 52.61 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 53.5 Cg_endo -70.6 136.77 31.54 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.061 1.841 . . . . 0.0 112.102 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.25 20.25 79.67 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 3.04 90.67 Favored Glycine 0 CA--C 1.532 1.146 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 75.4 t -63.68 138.09 97.28 Favored Pre-proline 0 CA--C 1.536 0.416 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.66 152.42 81.95 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.579 1.519 . . . . 0.0 111.337 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 94.7 t -68.92 131.31 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.563 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -61.11 -45.4 94.87 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.518 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.92 159.1 26.42 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -74.9 162.49 28.58 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.82 0.343 . . . . 0.0 110.581 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -72.35 -24.91 61.35 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.528 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -69.83 -15.4 63.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.052 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.481 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.268 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.433 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 98.1 t . . . . . 0 N--CA 1.452 -0.374 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.1 mt -62.43 -43.32 98.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.036 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.84 160.8 42.89 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.08 0.467 . . . . 0.0 111.107 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.651 ' O ' HG23 ' A' ' 59' ' ' VAL . 3.2 p -99.22 -146.21 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.646 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -50.06 108.01 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.451 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 57' ' ' THR . 70.1 t -126.72 129.83 71.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.721 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.3 mt -74.83 137.1 41.64 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.22 -179.42 24.17 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.8 m -128.15 135.87 50.36 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.856 0.36 . . . . 0.0 110.451 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 84.7 t -75.99 109.25 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.708 -179.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.04 -49.65 75.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 60.9 p-90 -174.72 146.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.979 178.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -142.58 121.16 12.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -103.47 123.12 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.592 -0.443 . . . . 0.0 110.868 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.0 t -63.79 -45.88 95.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.477 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.04 -44.77 96.89 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -62.2 -38.14 87.99 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 91.86 2.26 69.56 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.423 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -148.77 161.3 42.07 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-N 117.454 0.627 . . . . 0.0 110.057 179.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.5 178.36 36.55 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.536 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -126.12 143.39 51.14 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.201 0.524 . . . . 0.0 112.118 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 86.2 mt -120.02 127.23 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.828 178.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -89.0 118.08 28.48 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.2 mtm180 -72.51 131.9 43.13 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.212 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -83.36 -6.35 59.44 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.267 179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.87 -33.25 11.7 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.002 0.429 . . . . 0.0 110.086 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -114.06 -11.68 12.69 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.861 -0.608 . . . . 0.0 111.734 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.8 mttp 55.62 33.02 20.36 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.641 -0.424 . . . . 0.0 109.964 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -122.51 137.83 54.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.289 0.566 . . . . 0.0 111.248 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.24 142.27 57.8 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.046 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.478 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 80.0 t -127.79 131.16 70.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.876 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -69.08 138.8 54.62 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.328 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.21 149.31 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.163 0.506 . . . . 0.0 110.979 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -136.13 159.31 42.11 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.855 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.457 HE22 HD21 ' A' ' 100' ' ' LEU . 97.5 mt-30 -61.3 -39.49 90.65 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.2 p -66.6 -18.31 65.3 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.4 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.95 -0.79 55.48 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.095 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.463 HD11 HG23 ' A' ' 103' ' ' VAL . 84.0 mt -95.74 103.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.97 0.414 . . . . 0.0 111.091 -178.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -63.25 -43.96 96.53 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.292 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -127.27 147.38 50.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.088 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -154.44 177.55 11.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.336 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -65.6 120.8 71.32 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.09 -22.16 62.17 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.069 1.846 . . . . 0.0 112.515 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.3 mmm180 -67.46 -21.75 65.52 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -100.87 122.62 43.77 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-O 120.701 0.286 . . . . 0.0 110.534 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -61.0 -48.43 81.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.74 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.457 HD21 HE22 ' A' ' 88' ' ' GLN . 66.3 tp -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 -60.95 132.48 54.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.999 0.428 . . . . 0.0 110.37 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.8 m -148.39 159.9 43.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.547 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 52.6 t -121.33 127.8 75.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.421 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -69.2 149.53 49.02 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.403 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -85.81 134.68 33.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.56 4.02 90.13 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -91.44 130.47 37.27 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.989 0.423 . . . . 0.0 110.465 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.4 m -69.15 132.71 46.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.651 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.4 m -129.99 157.53 42.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.471 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -117.59 126.74 53.07 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 51.0 p90 -156.57 163.6 39.17 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.718 -0.793 . . . . 0.0 112.537 -177.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -88.52 149.64 23.52 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.238 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.9 t -106.86 124.93 62.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.429 -0.508 . . . . 0.0 109.964 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 97.7 t . . . . . 0 C--N 1.327 -0.402 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.346 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 C--O 1.227 -0.117 0 CA-C-O 120.928 0.394 . . . . 0.0 110.645 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.478 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -119.89 143.22 48.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.076 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.1 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.261 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 53.5 45.84 27.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.977 0.418 . . . . 0.0 110.147 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 85.4 t -72.99 120.44 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.136 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.49 164.2 30.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.877 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.54 172.46 50.57 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 52.5 Cg_endo -70.13 136.9 33.16 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 122.041 1.827 . . . . 0.0 112.162 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.33 19.68 79.78 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.03 1.26 89.73 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 71.0 t -62.0 138.06 95.66 Favored Pre-proline 0 CA--C 1.536 0.408 0 O-C-N 122.776 -0.25 . . . . 0.0 110.556 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.91 150.3 88.31 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 121.687 1.591 . . . . 0.0 111.335 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.54 133.95 30.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.561 -179.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -60.48 -41.75 94.84 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.589 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.96 179.54 52.71 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.4 m -106.03 160.88 14.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.927 0.394 . . . . 0.0 110.552 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -61.09 -37.43 82.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.535 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -65.21 -14.6 61.03 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.118 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.539 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.331 -0.233 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.479 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t . . . . . 0 N--CA 1.45 -0.432 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.447 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.1 mt -63.17 -44.78 99.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.039 -178.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.1 163.57 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.086 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.588 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.7 t -102.68 -148.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.658 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.416 ' N ' HG23 ' A' ' 57' ' ' THR . 59.1 mtmt -52.67 115.43 1.8 Allowed 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.388 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 57' ' ' THR . 75.7 t -132.3 130.38 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.755 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.1 mt -75.3 131.23 40.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.12 0.486 . . . . 0.0 109.771 178.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.66 -177.03 20.95 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.4 m -128.38 137.41 51.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.868 0.366 . . . . 0.0 110.478 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.704 HG21 HG12 ' A' ' 103' ' ' VAL . 96.1 t -73.82 115.06 14.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.536 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.4 tttt -62.88 -48.95 76.79 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 179.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.536 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 53.6 p-90 -179.31 140.28 0.15 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.99 178.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -135.96 117.26 14.59 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -102.67 123.67 46.8 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.876 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.4 t -62.84 -45.64 98.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.487 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -61.08 -45.37 95.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -62.74 -38.61 91.2 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.493 -0.483 . . . . 0.0 110.836 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.13 2.24 68.88 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.37 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -148.44 161.44 41.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.394 0.597 . . . . 0.0 110.14 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -157.22 -179.5 32.19 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.571 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -129.37 146.47 51.23 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 79.2 mt -125.7 128.22 72.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.79 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -94.26 126.22 39.38 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.857 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 95.1 mtm-85 -74.9 131.47 40.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.092 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -84.07 -0.16 50.69 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.305 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -100.79 -33.31 10.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.945 0.403 . . . . 0.0 110.112 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 81.4 p -116.5 -8.57 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.758 -0.656 . . . . 0.0 111.647 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt 56.22 30.86 17.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.397 . . . . 0.0 110.006 -179.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -117.08 137.14 52.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.21 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.5 p-10 -74.25 158.05 34.76 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.113 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.23 148.51 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.947 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -77.94 136.68 38.04 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.375 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -143.96 148.1 19.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.159 0.504 . . . . 0.0 110.976 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -133.28 159.11 41.18 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.945 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.85 -25.56 65.13 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.8 p -74.86 -16.15 60.69 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.478 179.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.24 0.46 55.33 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.142 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.436 HD11 HG23 ' A' ' 103' ' ' VAL . 80.5 mt -95.13 100.47 11.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.12 -178.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -64.65 -41.8 95.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.298 179.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.15 138.4 52.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.123 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -148.54 153.73 38.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.342 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -58.62 120.83 48.67 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.31 -19.19 61.93 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 121.92 1.746 . . . . 0.0 112.557 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.0 mmm-85 -63.31 -23.96 67.64 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.408 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -101.39 133.24 46.31 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 120.686 0.279 . . . . 0.0 110.652 -179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -68.62 -38.46 80.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.745 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.9 mt -103.92 142.8 33.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.244 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.5 mtt85 -66.87 137.98 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.303 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -156.59 153.25 28.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.471 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 63' ' ' VAL . 42.3 t -119.58 131.96 70.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -59.16 143.09 46.18 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.344 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -81.96 120.24 24.98 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.14 2.39 89.37 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.6 tp10 -81.71 137.42 35.39 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.903 0.383 . . . . 0.0 110.554 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 88.1 m -68.83 132.46 46.8 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.726 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.0 157.78 42.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.413 -178.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -117.43 126.99 53.58 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.407 ' HB3' HG22 ' A' ' 125' ' ' VAL . 48.4 p90 -154.82 162.09 41.24 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 119.807 -0.757 . . . . 0.0 112.565 -177.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -93.14 149.13 21.44 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.246 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.447 HG12 ' HB ' ' A' ' 55' ' ' ILE . 62.0 t -107.47 126.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.469 -0.492 . . . . 0.0 109.956 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 C--N 1.327 -0.407 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.945 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.226 -0.139 0 CA-C-O 120.827 0.346 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.15 152.67 29.1 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.973 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.97 157.12 43.18 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.193 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 53.4 44.88 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.436 . . . . 0.0 110.215 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.407 HG22 ' HB3' ' A' ' 111' ' ' PHE . 95.1 t -72.05 124.07 27.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.073 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.4 p -136.67 168.48 19.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.789 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.65 171.07 54.45 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -66.61 138.97 51.5 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 C-N-CA 121.929 1.753 . . . . 0.0 112.175 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.27 16.8 79.66 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.89 2.45 90.55 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.706 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -68.4 147.95 98.18 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-O 119.704 -0.189 . . . . 0.0 110.55 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . 0.706 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.6 Cg_exo -59.48 150.73 73.79 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.582 1.521 . . . . 0.0 111.309 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t -66.36 131.34 32.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.622 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -61.74 -39.97 93.45 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.497 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.47 -173.64 54.85 Favored Glycine 0 CA--C 1.524 0.623 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.66 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 71.1 m -112.5 157.96 20.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.822 0.344 . . . . 0.0 110.59 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -60.55 -37.69 82.08 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.384 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -60.87 -19.5 60.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.111 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.449 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.45 -42.94 97.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.108 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.417 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -147.11 157.32 43.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.799 ' O ' HG23 ' A' ' 59' ' ' VAL . 9.9 p -102.47 -149.99 0.4 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.609 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -48.25 104.66 0.06 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.497 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 57' ' ' THR . 96.7 t -125.04 129.37 73.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.696 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.0 mt -75.37 138.59 41.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.132 0.492 . . . . 0.0 109.762 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.39 -178.15 25.0 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -129.05 137.76 51.48 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.878 0.37 . . . . 0.0 110.491 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 92.1 t -73.11 109.86 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.754 -179.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.511 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 61.9 tttm -61.16 -50.93 71.18 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.511 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.3 p-90 -176.65 139.55 0.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.016 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -137.92 116.57 12.17 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -99.34 121.72 41.49 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.964 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.26 -45.82 97.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.426 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -62.71 -42.1 99.48 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -62.2 -39.06 91.49 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.835 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.4 2.23 65.87 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.354 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -149.56 162.19 40.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 117.464 0.632 . . . . 0.0 109.984 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.33 -179.28 35.95 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.499 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -130.33 144.9 51.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.213 0.53 . . . . 0.0 112.127 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.4 mt -120.11 126.33 75.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.839 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -93.16 119.76 32.71 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -72.85 133.79 44.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.161 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -83.23 -8.58 59.45 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.29 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -93.04 -33.18 14.2 Favored 'General case' 0 C--O 1.231 0.121 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.092 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 79.1 p -115.31 -9.13 12.23 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.75 -178.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.4 mttt 53.37 32.7 14.25 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.972 -179.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -120.39 134.74 55.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.332 0.587 . . . . 0.0 111.219 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -64.36 144.2 57.34 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.03 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 95.0 t -130.05 133.1 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.878 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -65.51 138.29 57.97 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.396 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.18 147.76 18.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.251 0.548 . . . . 0.0 110.855 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -137.73 160.2 39.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.926 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.406 ' HA ' HD12 ' A' ' 91' ' ' ILE . 97.2 mt-30 -61.73 -39.03 90.13 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -178.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.7 p -67.99 -16.07 63.88 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.453 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.84 2.41 51.48 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.406 HD12 ' HA ' ' A' ' 88' ' ' GLN . 85.0 mt -98.6 107.73 20.91 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.885 0.374 . . . . 0.0 111.245 -178.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -65.63 -42.65 91.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.349 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.038 -178.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -144.11 168.78 19.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.388 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -55.12 121.14 34.54 Favored Pre-proline 0 CA--C 1.539 0.553 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.96 -41.69 72.5 Favored 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 121.933 1.756 . . . . 0.0 112.597 -178.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -63.86 -14.63 54.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? -104.39 118.03 35.61 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 120.688 0.28 . . . . 0.0 110.616 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -77.26 -22.83 51.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.915 0.388 . . . . 0.0 110.785 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.4 tp -100.72 125.61 47.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.173 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.64 133.8 56.46 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.584 -0.447 . . . . 0.0 110.31 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.3 t -160.79 151.92 18.93 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.495 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 56.6 t -118.59 127.13 75.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.68 145.85 46.02 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.334 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -83.56 135.42 34.64 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.3 4.06 89.86 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -92.43 131.87 37.24 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 120.958 0.409 . . . . 0.0 110.461 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.6 m -69.47 133.66 47.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.64 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.8 m -131.8 158.47 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.462 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.67 130.52 55.09 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -156.57 164.12 38.57 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 119.778 -0.769 . . . . 0.0 112.541 -177.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -97.3 140.28 32.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.368 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.3 t -100.86 125.65 54.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.066 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.326 -0.44 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.673 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 . . . . . 0 C--O 1.226 -0.147 0 CA-C-O 121.008 0.432 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.531 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -105.19 145.16 30.99 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.975 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.14 162.93 39.49 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.195 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 54.06 45.23 27.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.985 0.421 . . . . 0.0 110.173 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.7 t -74.25 123.91 30.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.048 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.9 p -138.32 167.93 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.806 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.96 174.38 53.05 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.433 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -68.86 137.6 38.58 Favored 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.065 1.844 . . . . 0.0 112.121 -178.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.02 20.19 78.81 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.92 2.11 90.65 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.5 t -63.37 137.21 97.01 Favored Pre-proline 0 CA--C 1.537 0.449 0 O-C-N 122.78 -0.247 . . . . 0.0 110.56 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.94 145.42 91.32 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.561 1.507 . . . . 0.0 111.314 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.58 132.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -60.84 -43.1 98.73 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.456 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.99 -179.93 52.83 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 37.9 t -106.19 141.07 38.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.849 0.357 . . . . 0.0 110.589 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.5 ptmt -59.26 -21.88 60.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.44 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 70.1 m-85 -66.07 -22.62 66.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.139 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.199 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.47 -179.516 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.4 t . . . . . 0 N--CA 1.45 -0.473 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.438 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.4 mt -63.14 -44.28 99.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.033 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -149.01 164.08 35.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 15.0 t -101.99 -149.05 0.38 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.648 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 57' ' ' THR . 58.4 mtmt -52.3 117.01 2.52 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.431 -178.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 84.8 t -133.21 131.37 58.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.687 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.3 mt -76.01 136.07 39.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.084 0.469 . . . . 0.0 109.776 178.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.55 -179.36 24.42 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.5 m -127.06 140.67 52.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.937 0.398 . . . . 0.0 110.455 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.691 HG21 HG12 ' A' ' 103' ' ' VAL . 93.0 t -82.21 111.24 18.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.739 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 64.9 tttp -62.77 -49.93 73.03 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 63.2 p-90 -169.81 154.41 5.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.645 -1.161 . . . . 0.0 109.927 177.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -142.5 118.68 10.75 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 -98.23 112.1 24.2 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.993 0.425 . . . . 0.0 110.892 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.423 HG21 ' N ' ' A' ' 139' ' ' ALA . 73.9 t -61.75 -45.05 99.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.381 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.2 ttt85 -61.09 -44.5 97.26 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.08 -38.71 92.27 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.444 -0.503 . . . . 0.0 110.821 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.15 4.49 59.87 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.387 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -152.37 162.0 41.8 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 117.43 0.615 . . . . 0.0 110.102 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.521 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -156.04 -176.05 27.73 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.56 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -126.3 145.14 50.55 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.155 0.502 . . . . 0.0 112.138 -179.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 83.3 mt -120.12 125.45 74.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.896 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -90.66 109.59 20.76 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.479 -0.488 . . . . 0.0 110.813 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -62.87 135.32 57.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.13 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -86.37 -2.3 58.3 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.316 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -100.14 -34.05 10.2 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.973 0.416 . . . . 0.0 110.144 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.7 p -115.44 -9.25 12.13 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.679 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mmtm 55.43 29.96 14.15 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -115.18 133.62 55.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.375 0.607 . . . . 0.0 111.299 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.9 142.52 58.26 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.985 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.7 t -124.83 133.27 69.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -70.77 138.18 50.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.313 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -148.73 148.69 15.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.183 0.516 . . . . 0.0 110.954 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -132.79 155.77 48.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.886 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -60.15 -23.67 64.1 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 80.5 p -83.33 -10.41 58.5 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.591 -0.443 . . . . 0.0 110.401 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.91 3.61 55.39 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.116 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.428 HD11 HG23 ' A' ' 103' ' ' VAL . 86.1 mt -99.13 106.1 18.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-O 120.994 0.426 . . . . 0.0 111.228 -178.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -63.31 -44.78 94.02 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.327 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -122.3 141.21 51.76 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.125 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -150.23 176.34 10.95 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.349 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -64.95 120.42 66.56 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.69 -23.35 63.4 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.01 1.807 . . . . 0.0 112.578 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.9 mmm-85 -68.5 -19.62 64.54 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.412 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -98.93 129.33 45.25 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 120.678 0.275 . . . . 0.0 110.661 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -67.52 -37.86 83.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.966 0.412 . . . . 0.0 110.731 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.2 mt -105.6 141.34 37.22 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.258 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.28 138.76 57.87 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.319 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.409 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 93.8 p -156.96 162.75 39.61 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.532 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.691 HG12 HG21 ' A' ' 63' ' ' VAL . 45.6 t -125.88 130.97 72.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.38 143.8 37.94 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.294 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . 0.4 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 41.0 p-10 -75.92 132.75 40.46 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.65 4.83 89.45 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 63' ' ' VAL . 85.3 tt0 -86.93 129.48 34.86 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.007 0.432 . . . . 0.0 110.488 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 99.6 m -71.1 131.2 43.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.67 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.3 158.49 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.455 -177.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.91 129.0 54.95 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 178.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 45.9 p90 -155.68 162.82 40.5 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.582 -177.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -92.4 149.46 21.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.375 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HB ' ' A' ' 55' ' ' ILE . 60.5 t -108.19 126.35 64.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.937 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.624 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 C--O 1.226 -0.154 0 CA-C-O 120.973 0.416 . . . . 0.0 110.672 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -109.96 147.75 32.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.989 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.43 161.08 41.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.145 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 54.51 44.37 28.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.984 0.421 . . . . 0.0 110.125 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 91.8 t -72.81 122.77 26.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.092 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 62.7 p -136.91 163.79 29.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.783 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.43 168.57 54.8 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.099 -1.601 . . . . 0.0 109.099 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.426 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.5 Cg_exo -59.52 138.09 81.69 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 121.903 1.736 . . . . 0.0 112.094 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.21 19.04 75.45 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.77 4.42 90.34 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -62.63 136.94 96.35 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 122.699 -0.295 . . . . 0.0 110.484 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -58.44 146.96 88.24 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.552 1.502 . . . . 0.0 111.335 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.4 132.37 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.645 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 11.8 tp-100 -61.34 -41.41 96.99 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.549 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.23 -176.59 50.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.2 m -105.49 157.85 17.08 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.75 0.31 . . . . 0.0 110.64 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -60.84 -37.39 81.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.51 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -63.88 -17.3 63.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.055 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--O 1.233 0.202 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.435 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.6 t . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.25 -44.42 99.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.071 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.52 157.25 43.1 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.632 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.4 p -102.41 -147.42 0.37 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.668 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -51.93 107.44 0.2 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.441 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 57' ' ' THR . 76.1 t -125.11 131.24 72.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.745 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 68.8 mt -69.09 134.98 50.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.069 0.462 . . . . 0.0 109.838 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.77 178.23 30.82 Favored Glycine 0 CA--C 1.519 0.341 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m -130.77 137.77 49.62 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.866 0.365 . . . . 0.0 110.466 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -70.45 112.39 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.813 -179.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.51 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.45 -48.59 80.44 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.51 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.8 p-90 -177.32 140.06 0.27 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 114.564 -1.198 . . . . 0.0 109.95 177.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -138.14 115.28 10.96 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -100.21 124.44 45.64 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.934 -178.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -63.3 -46.08 96.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.452 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -61.19 -44.44 97.29 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.91 -39.21 93.84 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.872 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.42 4.78 65.83 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.365 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -151.75 162.59 40.77 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 117.442 0.621 . . . . 0.0 110.078 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.65 -178.4 34.6 Favored Glycine 0 CA--C 1.525 0.689 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.557 -179.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -129.64 148.67 51.56 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.124 0.488 . . . . 0.0 112.095 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.421 HG13 HG11 ' A' ' 86' ' ' VAL . 82.4 mt -118.67 126.79 75.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.428 -0.806 . . . . 0.0 109.863 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -91.54 110.24 21.55 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.876 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -65.72 130.36 43.0 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.085 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -87.54 -3.58 58.99 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.331 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -97.74 -31.5 12.22 Favored 'General case' 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.393 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.0 p -113.28 -9.89 13.38 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.686 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp 57.77 32.14 21.48 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.024 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -126.23 148.88 49.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.34 0.59 . . . . 0.0 111.168 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -82.3 158.87 23.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -142.93 150.6 17.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -78.15 135.79 37.72 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.352 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.421 HG11 HG13 ' A' ' 75' ' ' ILE . 5.5 p -146.52 147.99 17.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.104 0.478 . . . . 0.0 110.864 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -136.21 159.1 42.76 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.9 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.465 ' HA ' HD12 ' A' ' 91' ' ' ILE . 27.6 pt20 -59.19 -25.02 63.6 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -178.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -74.44 -16.05 60.88 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.468 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.461 ' HB1' ' HA ' ' A' ' 123' ' ' ALA . . . -89.32 2.96 53.63 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.155 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.465 HD12 ' HA ' ' A' ' 88' ' ' GLN . 84.5 mt -95.87 103.12 14.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.905 0.383 . . . . 0.0 111.153 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -65.19 -43.67 90.9 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.314 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -119.17 144.23 46.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.134 -178.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.0 t30 -144.1 171.18 14.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.439 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -61.07 122.87 72.6 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.64 -23.12 57.04 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 121.906 1.737 . . . . 0.0 112.522 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.4 mmm-85 -73.38 -14.06 61.21 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.399 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -114.2 142.22 46.54 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 120.746 0.308 . . . . 0.0 110.658 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.488 ' CE1' HD21 ' A' ' 100' ' ' LEU . 43.9 p90 -98.35 4.91 48.61 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.694 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.488 HD21 ' CE1' ' A' ' 99' ' ' TYR . 88.7 mt -119.42 142.4 48.25 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.156 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -81.15 125.98 30.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.416 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 87.9 p -156.38 162.44 40.05 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.507 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 39.7 t -131.53 134.63 60.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.38 147.98 50.36 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.338 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -84.91 120.82 26.91 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.25 -5.61 82.8 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.04 135.21 41.27 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-O 121.069 0.462 . . . . 0.0 110.44 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.2 m -70.88 131.46 43.79 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.636 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 19.9 m -135.93 159.38 39.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.39 -178.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -116.11 138.54 51.16 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.6 p90 -159.44 164.04 34.87 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.523 -177.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -98.59 138.49 35.71 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.218 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.0 t -107.02 127.21 62.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 120.463 -0.495 . . . . 0.0 110.033 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.326 -0.422 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.15 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 . . . . . 0 C--O 1.227 -0.128 0 CA-C-O 120.952 0.406 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.16 143.41 43.25 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.966 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.461 ' HA ' ' HB1' ' A' ' 90' ' ' ALA . . . -153.22 161.07 42.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.231 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 56.84 47.17 18.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 110.125 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.7 t -77.61 121.08 29.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.114 -179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 59.2 p -137.88 169.04 18.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.797 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.26 167.73 54.84 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 131' ' ' VAL . 34.8 Cg_exo -60.63 138.12 77.84 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.99 1.793 . . . . 0.0 112.146 -178.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.5 20.58 78.48 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 178.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.47 89.84 Favored Glycine 0 CA--C 1.532 1.108 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 128' ' ' PRO . 78.3 t -61.02 138.21 94.15 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-O 119.667 -0.206 . . . . 0.0 110.556 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -61.56 148.37 93.15 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 121.662 1.575 . . . . 0.0 111.233 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.5 t -63.81 130.77 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.653 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -62.31 -40.11 95.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.615 -179.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.77 157.42 33.15 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 81.5 p -76.19 160.2 29.93 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 120.921 0.391 . . . . 0.0 110.539 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -70.32 -23.48 62.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.513 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -80.09 -2.96 46.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.144 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.242 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.465 -179.967 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 97.0 t . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.454 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.4 mt -63.77 -45.9 95.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.002 -179.056 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -158.21 162.2 37.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.762 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.7 t -96.38 -142.86 0.28 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.57 179.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.478 ' N ' HG23 ' A' ' 57' ' ' THR . 76.0 mmtt -50.34 103.28 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.291 -0.563 . . . . 0.0 110.416 -179.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 57' ' ' THR . 95.0 t -119.28 128.59 75.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 80.0 mt -64.33 130.75 45.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.082 0.468 . . . . 0.0 109.776 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.16 174.45 23.75 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -129.22 134.31 47.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.941 0.4 . . . . 0.0 110.488 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.674 HG21 HG12 ' A' ' 103' ' ' VAL . 98.6 t -75.43 108.48 7.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.723 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 22.0 ttmm -63.2 -48.22 79.23 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 62.4 p-90 -176.14 143.82 0.55 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.616 -1.174 . . . . 0.0 109.925 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -138.53 115.65 10.98 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.412 HD22 ' ND2' ' A' ' 70' ' ' ASN . 99.5 m-20 -100.0 119.21 37.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.978 0.418 . . . . 0.0 110.922 -179.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.58 -46.7 94.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.509 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -62.46 -41.49 98.8 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.412 ' ND2' HD22 ' A' ' 67' ' ' ASN . 96.2 m-20 -62.82 -38.61 91.39 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.494 -0.482 . . . . 0.0 110.809 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.37 4.54 64.2 Favored Glycine 0 CA--C 1.531 1.042 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.382 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.404 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 40.9 p90 -148.88 160.18 43.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 117.528 0.664 . . . . 0.0 110.107 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.66 173.22 37.16 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.515 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -128.12 146.88 50.56 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.096 0.474 . . . . 0.0 112.232 -179.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.3 mt -120.61 125.86 74.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.855 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -91.4 111.15 22.53 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.509 -0.477 . . . . 0.0 110.899 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.459 ' NH1' HG11 ' A' ' 113' ' ' VAL . 88.7 mtm180 -61.5 133.35 55.62 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.113 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -86.29 -12.16 50.26 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.311 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -89.49 -29.87 18.67 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-O 121.022 0.439 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.6 p -116.46 -11.42 11.15 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.694 -178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 58.0 mtpt 57.04 32.11 21.1 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -119.77 134.04 55.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.22 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -64.72 143.19 58.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.058 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.593 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 58.0 t -127.78 130.98 70.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.829 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -70.99 130.04 40.55 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.425 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.04 149.55 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.163 0.506 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -131.14 164.99 24.28 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.889 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.64 -39.75 94.82 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -69.69 -17.2 63.46 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.443 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.36 -2.63 53.49 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.169 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.7 mt -96.77 106.48 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.949 0.404 . . . . 0.0 111.112 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.75 -43.06 97.56 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.296 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -125.11 142.42 51.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.129 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -148.88 176.18 10.63 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.437 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.5 t-20 -66.23 117.33 42.21 Favored Pre-proline 0 CA--C 1.54 0.569 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.91 -31.34 95.3 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.979 1.786 . . . . 0.0 112.588 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.8 mmm-85 -64.23 -19.96 65.71 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.294 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.482 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 76.0 mmtt -93.14 129.0 39.28 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 120.671 0.272 . . . . 0.0 110.613 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -67.68 -37.96 83.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.873 0.368 . . . . 0.0 110.785 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.1 mt -110.1 144.63 38.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.257 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -65.82 137.67 57.38 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.329 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.2 p -156.86 163.07 39.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.455 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.674 HG12 HG21 ' A' ' 63' ' ' VAL . 46.9 t -128.82 130.39 68.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.56 149.0 49.22 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.384 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -86.56 134.47 33.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.62 1.68 90.55 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -91.75 130.27 37.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-O 120.888 0.375 . . . . 0.0 110.526 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -70.16 134.36 48.05 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.69 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.93 161.2 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.433 -178.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -120.54 136.35 54.81 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 178.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.452 ' HB3' HG22 ' A' ' 125' ' ' VAL . 29.2 p90 -157.58 161.06 38.71 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.563 -178.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -83.35 122.07 27.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.21 179.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.459 HG11 ' NH1' ' A' ' 77' ' ' ARG . 61.3 t -88.83 122.26 39.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.491 -0.484 . . . . 0.0 109.998 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 59.4 t . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.546 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 . . . . . 0 C--O 1.227 -0.08 0 CA-C-O 120.822 0.344 . . . . 0.0 110.676 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.593 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -100.55 141.04 33.96 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.956 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.92 157.72 43.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.185 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 54.59 43.76 29.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.96 0.409 . . . . 0.0 110.076 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.7 t -70.18 125.43 28.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.09 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.0 p -138.92 164.76 28.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.775 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.91 164.35 54.24 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.526 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.4 Cg_exo -60.02 136.73 71.3 Favored 'Trans proline' 0 C--N 1.301 -1.942 0 C-N-CA 122.001 1.801 . . . . 0.0 112.06 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 76.89 13.64 83.42 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.96 -0.56 89.1 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.526 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.4 p -64.82 141.38 98.32 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-O 119.679 -0.2 . . . . 0.0 110.586 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . 0.409 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 18.4 Cg_endo -58.03 147.69 81.15 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.66 1.573 . . . . 0.0 111.349 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -69.9 134.46 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.585 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -60.94 -43.67 98.35 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.515 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.16 158.32 30.92 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -72.92 157.01 38.26 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.84 0.352 . . . . 0.0 110.619 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -69.3 -19.65 63.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.455 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -79.87 -7.7 58.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.128 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.482 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.33 -0.259 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.504 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 54' ' ' VAL . 7.2 p . . . . . 0 N--CA 1.45 -0.426 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.429 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.9 mt -62.06 -44.61 99.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.098 -179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.465 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.68 160.37 40.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.64 ' O ' HG23 ' A' ' 59' ' ' VAL . 14.4 p -98.02 -150.97 0.36 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.612 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -51.32 116.87 2.25 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.466 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 57' ' ' THR . 86.7 t -132.59 131.2 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.681 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.8 mt -75.33 134.71 40.96 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.043 0.449 . . . . 0.0 109.849 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.29 -179.48 23.38 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.4 m -129.11 135.86 49.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 110.483 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.709 HG21 HG12 ' A' ' 103' ' ' VAL . 85.4 t -73.54 113.1 11.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.731 -179.319 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.45 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.6 ttpt -62.34 -46.77 87.21 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.9 p-90 -176.14 146.19 0.66 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.001 177.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -140.5 115.51 9.75 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -103.02 121.44 42.57 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.936 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.3 t -63.07 -44.56 99.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.452 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.426 ' HG3' ' N ' ' A' ' 70' ' ' ASN . 17.7 ptm180 -63.08 -35.11 79.18 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.426 ' N ' ' HG3' ' A' ' 69' ' ' ARG . 97.2 m-20 -69.36 -35.15 75.58 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.822 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 90.14 0.87 76.64 Favored Glycine 0 CA--C 1.531 1.057 0 C-N-CA 121.06 -0.591 . . . . 0.0 112.361 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -150.26 161.51 42.3 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 117.544 0.672 . . . . 0.0 110.086 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -154.98 179.43 31.02 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.603 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.16 145.64 51.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.144 0.497 . . . . 0.0 112.131 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 84.9 mt -119.74 123.58 71.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.849 178.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.64 109.16 20.57 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.817 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -63.14 130.93 46.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.115 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.3 p30 -85.43 -0.08 53.79 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.406 -0.518 . . . . 0.0 111.37 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -99.07 -34.48 10.38 Favored 'General case' 0 C--O 1.231 0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.127 178.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 77.9 p -114.4 -10.95 12.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.687 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 58.09 29.99 18.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.95 0.405 . . . . 0.0 110.025 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -116.2 132.96 56.52 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 121.362 0.601 . . . . 0.0 111.247 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -62.67 142.25 58.17 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.089 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.504 HG11 ' HB2' ' A' ' 122' ' ' ALA . 76.6 t -128.1 131.01 69.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -65.92 141.12 58.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.394 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.8 p -146.92 148.45 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.182 0.515 . . . . 0.0 110.935 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.407 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 80.8 m80 -137.63 159.04 43.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.784 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -60.33 -41.93 94.58 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.5 t -64.98 -16.63 63.61 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.478 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -84.16 -2.97 57.79 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.123 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.534 HD11 HG23 ' A' ' 103' ' ' VAL . 79.9 mt -93.45 101.45 12.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.987 0.422 . . . . 0.0 111.152 -178.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -63.55 -43.31 97.44 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.305 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -120.63 140.65 51.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.151 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -149.73 156.36 41.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -60.48 121.45 60.46 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.49 -22.18 65.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 121.995 1.797 . . . . 0.0 112.478 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.52 -21.55 66.17 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.35 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -86.34 130.83 34.37 Favored 'General case' 0 N--CA 1.456 -0.127 0 CA-C-O 120.748 0.308 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 84.8 t80 -61.23 -48.5 81.2 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -116.43 139.98 49.85 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.206 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -55.71 138.01 48.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.075 0.464 . . . . 0.0 110.291 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 94.2 p -158.84 165.08 35.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.511 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.709 HG12 HG21 ' A' ' 63' ' ' VAL . 46.3 t -124.04 129.61 74.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.0 147.76 51.17 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -80.66 121.04 25.36 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.14 -0.86 88.93 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.16 135.11 41.11 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 120.941 0.401 . . . . 0.0 110.463 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 91.1 m -70.07 131.57 44.52 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.637 179.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.77 159.18 43.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.37 -0.532 . . . . 0.0 111.511 -178.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -120.74 129.87 53.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.439 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.7 p90 -157.64 163.86 37.81 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 112.549 -177.589 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -93.68 144.85 25.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.205 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.9 t -97.07 125.65 50.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.592 -0.443 . . . . 0.0 109.942 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 99.3 t . . . . . 0 C--N 1.326 -0.445 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 -179.53 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 120.985 0.421 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.504 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.45 146.73 29.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.973 -179.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.1 157.86 43.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.255 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 54.42 45.32 27.34 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.118 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.439 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.0 t -71.51 122.15 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.08 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.6 p -138.75 161.64 36.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.796 179.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 162.48 54.43 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.501 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.1 Cg_exo -58.96 138.0 83.11 Favored 'Trans proline' 0 C--N 1.301 -1.926 0 C-N-CA 122.005 1.803 . . . . 0.0 112.149 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.23 19.24 78.55 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 178.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.89 3.01 89.54 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 128' ' ' PRO . 95.0 t -60.72 137.63 93.12 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 122.811 -0.229 . . . . 0.0 110.472 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 153.06 79.84 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 121.64 1.56 . . . . 0.0 111.309 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -70.65 129.11 34.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.617 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.3 tp60 -60.72 -44.34 96.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.55 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.39 162.0 28.28 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 179.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -81.4 163.06 23.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.933 0.397 . . . . 0.0 110.56 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.51 -37.13 86.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.502 179.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -66.67 -7.63 22.0 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.137 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.462 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.278 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.495 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.1 t . . . . . 0 N--CA 1.45 -0.45 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.54 -44.13 99.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.087 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.08 43.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.736 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -104.41 -147.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.632 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.415 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 21.4 pttm -48.11 106.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.452 -179.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 57' ' ' THR . 85.2 t -127.53 130.58 70.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.718 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 93.1 mt -74.88 135.82 41.52 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 109.824 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.36 178.33 25.05 Favored Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.1 m -128.32 137.94 52.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 120.853 0.359 . . . . 0.0 110.547 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 94.0 t -77.1 109.79 12.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.689 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.5 ttpt -62.79 -46.96 85.58 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 51.5 p-90 -176.67 146.87 0.6 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.954 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -141.35 125.0 16.81 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.4 m-20 -107.48 122.53 46.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.992 0.425 . . . . 0.0 110.941 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.9 t -63.22 -46.71 95.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.462 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -62.02 -43.29 99.16 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.45 88.04 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.807 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.48 0.99 69.25 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.374 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -148.3 163.52 36.81 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 117.503 0.652 . . . . 0.0 110.076 179.16 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.21 -179.67 32.32 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.538 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -126.45 143.08 51.31 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.095 0.474 . . . . 0.0 112.111 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.431 HG13 HG11 ' A' ' 86' ' ' VAL . 87.1 mt -121.8 126.52 74.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.859 178.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -94.09 109.97 21.71 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.93 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -63.62 134.57 55.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.073 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -88.62 -9.89 50.6 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.275 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.3 p-10 -96.71 -12.9 23.17 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.146 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 55.7 p -133.84 -10.51 2.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.709 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.5 mttp 51.61 35.51 14.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.952 0.406 . . . . 0.0 109.976 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -120.11 134.11 55.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.223 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -67.81 130.03 41.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.118 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 96.2 t -119.21 131.77 70.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.52 139.49 55.63 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.293 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 HG13 ' A' ' 75' ' ' ILE . 7.5 p -148.11 148.34 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 CA-C-O 121.133 0.492 . . . . 0.0 110.948 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -131.74 155.59 47.43 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.9 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.469 ' OE1' HD11 ' A' ' 100' ' ' LEU . 26.8 pt20 -59.35 -28.46 66.87 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.8 p -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.431 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.99 0.25 55.48 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.198 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.448 HD11 HG23 ' A' ' 103' ' ' VAL . 82.2 mt -93.83 103.11 14.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.013 0.435 . . . . 0.0 111.128 -178.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -64.96 -42.22 94.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.281 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.452 ' HB3' HG22 ' A' ' 126' ' ' THR . 22.8 ttmm -125.69 136.1 52.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.074 -178.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -146.76 176.47 9.84 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.375 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -62.2 121.2 64.64 Favored Pre-proline 0 CA--C 1.539 0.54 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.31 -26.12 64.0 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 121.965 1.777 . . . . 0.0 112.65 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.1 -14.45 61.85 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.426 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 4.0 mptp? -99.34 113.93 26.52 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 120.717 0.294 . . . . 0.0 110.647 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.21 -47.83 84.3 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.889 0.376 . . . . 0.0 110.758 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.469 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.3 tp -94.09 130.83 40.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.216 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -60.5 138.46 58.01 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.256 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.532 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 93.7 p -157.97 163.37 37.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.424 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 51.9 t -129.06 131.04 68.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.64 148.01 47.7 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.303 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -86.09 134.36 33.83 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.1 2.63 90.56 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.8 tp10 -91.1 129.82 37.06 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-O 120.913 0.387 . . . . 0.0 110.517 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.9 m -70.01 133.03 46.81 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.719 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.3 m -130.61 159.09 42.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.49 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.02 130.05 55.94 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.6 p90 -156.24 162.93 40.1 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 119.774 -0.77 . . . . 0.0 112.49 -177.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -97.09 142.33 29.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.225 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.1 t -101.18 125.27 55.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.031 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.8 p . . . . . 0 C--N 1.326 -0.416 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.44 ' O ' HG12 ' A' ' 114' ' ' VAL . 89.0 tt0 . . . . . 0 C--O 1.227 -0.107 0 CA-C-O 120.885 0.374 . . . . 0.0 110.661 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -74.46 150.76 39.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.042 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.59 157.96 41.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.186 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 53.52 47.97 22.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.029 0.443 . . . . 0.0 110.131 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.5 t -73.36 123.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.084 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 93' ' ' LYS . 81.6 p -140.18 164.04 31.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.841 179.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.06 164.45 54.48 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG23 ' A' ' 131' ' ' VAL . 37.3 Cg_exo -60.79 138.33 78.64 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.995 1.797 . . . . 0.0 112.096 -179.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.14 18.78 79.37 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.69 0.74 89.98 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -59.87 137.69 90.47 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.431 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.46 150.31 87.0 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 121.588 1.525 . . . . 0.0 111.296 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.1 t -69.03 129.67 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.616 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -60.63 -44.38 96.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.507 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 88.41 164.78 40.62 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.668 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -80.62 165.35 22.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.822 0.344 . . . . 0.0 110.572 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -62.47 -39.05 92.18 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.488 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -66.26 -9.81 36.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.139 -179.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.275 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.43 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 N--CA 1.45 -0.434 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.96 -45.36 97.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.07 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -153.33 161.74 42.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.084 -179.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.694 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -97.51 -146.29 0.31 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.587 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.433 ' N ' HG23 ' A' ' 57' ' ' THR . 38.4 mtmm -52.12 113.65 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.538 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 57' ' ' THR . 93.2 t -127.49 128.55 69.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.768 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 94.7 mt -65.36 130.05 41.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.042 0.448 . . . . 0.0 109.925 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.29 170.27 25.52 Favored Glycine 0 C--O 1.228 -0.259 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.9 m -130.66 137.07 49.4 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.886 0.374 . . . . 0.0 110.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 103' ' ' VAL . 91.5 t -75.32 116.2 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.832 -179.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.2 ptpt -74.53 -35.37 63.13 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 176.7 139.49 0.07 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.987 178.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -138.98 115.97 10.9 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -100.57 118.48 36.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.014 0.435 . . . . 0.0 110.905 -178.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.92 -45.17 97.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.421 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.2 ttp85 -59.71 -45.29 92.57 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -61.38 -38.2 86.17 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.869 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.45 3.86 62.75 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.324 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -149.64 160.73 43.27 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 117.528 0.664 . . . . 0.0 110.051 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.53 179.9 33.87 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.615 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -132.67 147.27 52.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.17 0.509 . . . . 0.0 112.101 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.407 HG13 HG11 ' A' ' 86' ' ' VAL . 80.4 mt -121.56 129.06 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.846 178.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -97.33 108.26 20.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.877 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.3 mtm-85 -62.89 131.26 48.14 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.073 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.68 -9.07 57.76 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.333 179.151 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -94.03 -29.85 15.0 Favored 'General case' 0 N--CA 1.458 -0.057 0 CA-C-O 120.911 0.386 . . . . 0.0 110.134 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.5 p -116.83 -13.17 10.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.679 -178.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.7 mttt 54.22 33.79 18.89 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.066 -179.128 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -117.94 131.58 56.49 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.28 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -71.94 130.62 41.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.055 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.8 p -124.03 147.75 28.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.907 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -75.47 142.41 42.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.354 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.427 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -144.81 146.49 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.099 0.476 . . . . 0.0 111.016 179.159 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -135.19 154.58 51.56 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.848 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -61.04 -24.88 66.52 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 111.971 0.36 . . . . 0.0 111.971 -178.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 72.1 p -76.89 -13.86 59.94 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.351 179.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.69 2.56 54.64 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.091 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 103' ' ' VAL . 82.5 mt -96.23 107.31 19.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.022 0.439 . . . . 0.0 111.183 -178.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -67.99 -43.09 79.73 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.334 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.97 141.01 48.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.098 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -144.51 160.73 40.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.6 t-20 -56.29 119.91 31.26 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.28 -31.57 93.99 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.075 1.85 . . . . 0.0 112.527 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -62.59 -19.19 63.48 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.431 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -111.21 140.37 45.83 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.655 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -95.08 -13.99 24.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.889 0.376 . . . . 0.0 110.775 179.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.0 tp -106.03 125.49 51.06 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.195 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.7 mtt-85 -62.89 130.83 46.53 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.634 -0.427 . . . . 0.0 110.305 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 47.2 t -157.9 154.62 28.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.537 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 63' ' ' VAL . 45.0 t -120.88 130.57 74.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.24 144.81 45.11 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.376 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -74.93 129.88 38.43 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.27 1.45 85.88 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -178.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.468 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -76.92 132.62 39.18 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 120.9 0.381 . . . . 0.0 110.538 -179.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -74.55 129.45 37.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.711 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 14.2 m -133.57 162.46 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.417 -177.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -124.81 141.24 52.25 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.451 ' HB3' HG22 ' A' ' 125' ' ' VAL . 20.6 p90 -160.87 163.41 32.02 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 119.715 -0.794 . . . . 0.0 112.494 -177.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -90.01 124.98 35.22 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.277 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.4 t -92.62 127.04 45.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.457 -0.497 . . . . 0.0 109.974 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 C--N 1.327 -0.376 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.506 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 . . . . . 0 C--O 1.227 -0.104 0 CA-C-O 120.83 0.347 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.98 145.98 39.86 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.8 159.52 44.08 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.208 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 54.44 43.17 30.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.035 0.445 . . . . 0.0 110.185 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.451 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.1 t -72.77 121.08 22.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.098 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -138.58 171.36 14.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.795 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.47 177.28 46.78 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 131' ' ' VAL . 55.7 Cg_endo -69.95 137.67 35.45 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 121.935 1.757 . . . . 0.0 112.19 -178.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 18.93 77.24 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.02 2.14 89.55 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.4 t -61.98 137.06 95.4 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.762 -0.257 . . . . 0.0 110.553 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.41 147.68 76.39 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.568 1.512 . . . . 0.0 111.311 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.7 t -67.64 127.32 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.591 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -61.52 -41.48 97.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.535 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.01 -175.04 49.99 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.616 -0.594 . . . . 0.0 111.616 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 75.5 m -111.4 160.29 17.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.885 0.374 . . . . 0.0 110.572 -179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -59.45 -39.28 83.09 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.439 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -60.59 -15.38 27.38 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.12 179.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.23 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.526 179.978 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.1 t . . . . . 0 N--CA 1.45 -0.455 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.74 -44.12 99.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.039 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.06 158.23 43.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.593 ' O ' HG23 ' A' ' 59' ' ' VAL . 1.7 p -98.68 -153.43 0.43 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.699 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -53.97 118.28 3.88 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.407 -178.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 57' ' ' THR . 94.6 t -131.64 128.65 60.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.699 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 95.3 mt -68.28 135.88 52.62 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.097 0.475 . . . . 0.0 109.801 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.89 178.35 27.44 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 86.7 m -130.38 137.52 49.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.801 0.334 . . . . 0.0 110.535 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.698 HG21 HG12 ' A' ' 103' ' ' VAL . 77.4 t -75.75 116.19 18.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.741 -178.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 64' ' ' LYS . 9.4 ptmt -69.82 -41.75 74.56 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 60.6 p-90 178.24 138.37 0.08 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.944 177.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -132.54 115.3 15.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 178.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -94.84 117.41 30.09 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.0 t -63.9 -44.82 98.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.471 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 64.6 mtp85 -61.89 -41.41 97.84 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -63.21 -37.63 87.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.856 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.85 3.28 66.16 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.301 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -149.98 160.04 43.92 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 117.482 0.641 . . . . 0.0 110.107 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.26 179.81 36.45 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 120.499 -0.857 . . . . 0.0 111.515 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -130.7 150.59 51.81 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.192 0.52 . . . . 0.0 112.146 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.403 HG21 ' CE2' ' A' ' 111' ' ' PHE . 83.3 mt -120.05 127.06 75.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.858 178.48 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.81 110.26 21.7 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.938 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.44 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -65.9 128.9 37.88 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.101 179.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -74.39 -25.81 59.71 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.309 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -71.81 -41.66 67.96 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.151 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.5 p -108.11 -7.24 16.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.66 -176.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . 0.44 ' N ' ' O ' ' A' ' 77' ' ' ARG . 75.1 mmtt 52.29 31.16 8.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.906 0.384 . . . . 0.0 109.967 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -118.37 133.96 55.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.315 0.578 . . . . 0.0 111.274 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -64.23 146.28 54.58 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.067 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.603 HG11 ' HB2' ' A' ' 122' ' ' ALA . 86.5 t -128.24 130.46 69.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.871 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -68.07 130.37 42.75 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.9 149.12 18.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.219 0.533 . . . . 0.0 110.921 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -127.12 161.1 29.26 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.888 179.21 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.9 pt20 -61.12 -24.5 66.3 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -81.06 -11.51 59.5 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.388 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.25 -3.8 58.44 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.193 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.607 HD11 HG23 ' A' ' 103' ' ' VAL . 85.6 mt -90.62 102.15 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 111.082 -178.405 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -63.71 -43.09 97.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.293 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -120.62 140.9 50.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.076 -178.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -139.79 153.33 47.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.461 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.438 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.0 p-10 -57.65 132.9 82.45 Favored Pre-proline 0 CA--C 1.539 0.529 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.8 -13.27 31.93 Favored 'Trans proline' 0 N--CA 1.499 1.8 0 C-N-CA 121.947 1.765 . . . . 0.0 112.573 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -62.29 -29.16 70.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.284 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.425 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 97.3 mttt -123.13 147.38 46.85 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 120.646 0.26 . . . . 0.0 110.668 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -89.57 -15.6 32.49 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.908 0.385 . . . . 0.0 110.821 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.9 tp -97.63 123.92 41.73 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.229 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -65.66 131.73 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.947 0.403 . . . . 0.0 110.283 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.7 p -158.73 162.76 37.17 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.562 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.698 HG12 HG21 ' A' ' 63' ' ' VAL . 26.3 t -125.34 129.07 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.408 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.48 144.77 44.64 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.368 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . 0.41 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 39.7 p-10 -75.37 130.41 38.96 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.87 1.86 87.77 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -79.21 130.41 35.44 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.516 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 90.5 m -72.93 130.08 39.57 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.688 179.049 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.8 m -134.53 162.67 38.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.368 -177.219 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -123.19 137.69 54.83 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.43 ' HB3' HG22 ' A' ' 125' ' ' VAL . 33.1 p90 -160.81 165.42 30.29 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.607 -177.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -100.54 146.11 27.5 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.325 178.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.79 127.6 60.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.524 -0.47 . . . . 0.0 109.985 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.4 p . . . . . 0 C--N 1.326 -0.433 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.196 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 . . . . . 0 C--O 1.227 -0.107 0 CA-C-O 120.917 0.389 . . . . 0.0 110.548 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.603 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -78.6 151.17 32.5 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.02 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.18 156.44 41.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.243 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.4 t30 56.78 48.18 16.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.971 0.415 . . . . 0.0 110.14 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.43 HG22 ' HB3' ' A' ' 111' ' ' PHE . 90.3 t -76.06 124.53 34.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.044 -179.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 65.4 p -138.12 167.2 22.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.759 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.69 169.32 53.57 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 178.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.425 ' O ' HG23 ' A' ' 131' ' ' VAL . 38.9 Cg_exo -60.64 136.53 67.53 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 122.031 1.821 . . . . 0.0 112.182 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.63 20.99 77.68 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.73 0.99 90.04 Favored Glycine 0 CA--C 1.532 1.127 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -61.18 141.55 93.88 Favored Pre-proline 0 CA--C 1.536 0.436 0 O-C-N 122.805 -0.232 . . . . 0.0 110.602 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -58.17 147.6 82.8 Favored 'Trans proline' 0 N--CA 1.497 1.732 0 C-N-CA 121.651 1.567 . . . . 0.0 111.285 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 41.2 t -68.5 125.06 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.628 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 tp60 -60.26 -39.92 88.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.483 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.17 -171.83 50.68 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 66.9 m -112.93 153.36 28.1 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.847 0.356 . . . . 0.0 110.55 -179.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -58.63 -36.92 74.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -59.56 -16.77 27.37 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.112 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.425 ' HB3' ' HD3' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.331 -0.22 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.482 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.451 -0.424 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.81 -43.02 94.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.117 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.93 160.59 42.65 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.177 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.582 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -99.2 -147.18 0.33 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -54.85 117.33 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.251 -0.58 . . . . 0.0 110.507 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 57' ' ' THR . 95.7 t -130.92 132.38 63.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.0 mt -65.69 130.08 42.01 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.082 0.468 . . . . 0.0 109.816 178.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.18 172.4 26.8 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.5 m -128.11 140.52 51.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.809 0.338 . . . . 0.0 110.513 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.718 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -76.32 106.88 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.77 -179.111 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.459 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 39.1 ttpt -61.15 -45.19 95.66 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.459 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -176.88 139.39 0.29 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.926 178.026 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -137.35 115.57 11.74 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -101.27 121.39 41.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.015 0.436 . . . . 0.0 110.821 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.4 HG21 ' N ' ' A' ' 139' ' ' ALA . 74.4 t -62.98 -46.23 96.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.407 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -60.58 -44.85 95.74 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -62.23 -37.92 87.25 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.846 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.65 2.95 66.88 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.374 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -148.43 161.68 41.13 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 117.473 0.636 . . . . 0.0 110.029 178.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.424 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.01 -179.01 32.58 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.532 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -130.94 145.2 51.95 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.145 0.498 . . . . 0.0 112.19 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.412 HD13 HG21 ' A' ' 109' ' ' VAL . 82.2 mt -120.29 125.08 73.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.865 179.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -93.33 110.86 22.4 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -64.51 132.9 51.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.193 179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -88.72 -6.69 57.27 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.315 179.3 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -95.9 -31.43 13.13 Favored 'General case' 0 C--O 1.232 0.182 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.163 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.0 p -114.08 -11.67 12.67 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.772 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.9 mttp 55.83 35.38 25.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.919 0.39 . . . . 0.0 110.004 -178.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -119.04 146.49 45.01 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.386 0.613 . . . . 0.0 111.232 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -84.18 121.48 27.52 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.986 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.576 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 75.0 t -112.14 126.46 69.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.94 179.319 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -64.9 134.02 53.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.337 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -134.18 148.42 30.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.138 0.494 . . . . 0.0 110.916 179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -133.63 162.28 32.36 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.905 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.34 -39.44 93.11 Favored 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -68.05 -15.82 63.76 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.453 179.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.21 -1.33 56.8 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.181 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -97.82 104.36 15.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-O 120.997 0.427 . . . . 0.0 111.164 -178.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -65.37 -43.18 91.6 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.267 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -123.03 144.63 49.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.925 0.393 . . . . 0.0 111.035 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 p-10 -151.39 177.26 10.46 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.296 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -65.52 119.46 60.11 Favored Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.62 -33.99 98.57 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.988 1.792 . . . . 0.0 112.61 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtt85 -63.47 -21.25 66.2 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.344 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -95.41 119.79 34.52 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.668 -179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -61.34 -48.27 82.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 110.814 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 86.9 mt -95.2 145.25 25.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.232 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.18 136.02 56.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.596 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -155.41 152.72 29.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.476 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.718 HG12 HG21 ' A' ' 63' ' ' VAL . 58.4 t -124.41 130.3 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.91 140.37 45.63 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.386 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -73.11 129.21 37.57 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.4 1.01 80.64 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.578 ' O ' HG23 ' A' ' 63' ' ' VAL . 88.1 tt0 -77.13 132.28 38.75 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.841 0.353 . . . . 0.0 110.56 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.0 m -71.13 130.37 41.33 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.693 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.412 HG21 HD13 ' A' ' 75' ' ' ILE . 19.9 m -134.27 160.25 41.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.442 -177.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -119.13 136.94 53.92 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.0 p90 -158.78 164.24 35.99 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.495 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -96.65 141.17 30.22 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.291 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.8 128.2 50.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.984 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 p . . . . . 0 C--N 1.327 -0.406 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.226 -0.133 0 CA-C-O 120.852 0.358 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.576 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -104.29 144.34 31.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.972 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.35 159.55 44.18 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.246 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 57.49 47.23 16.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.024 0.44 . . . . 0.0 110.185 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 93.7 t -77.18 122.68 32.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.152 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.6 p -137.46 169.36 17.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.779 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.59 172.91 47.76 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -67.63 137.02 41.11 Favored 'Trans proline' 0 C--N 1.302 -1.891 0 C-N-CA 122.01 1.807 . . . . 0.0 112.121 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.02 16.23 80.68 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.88 90.36 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.715 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -69.4 148.76 97.26 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 122.795 -0.238 . . . . 0.0 110.508 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . 0.715 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.0 Cg_exo -60.48 148.19 91.67 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.631 1.554 . . . . 0.0 111.36 179.029 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 78.0 t -70.79 132.26 33.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.592 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -60.71 -41.24 94.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.517 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.2 49.09 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.602 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.8 m -113.24 154.92 25.98 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.831 0.348 . . . . 0.0 110.544 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.3 -35.84 78.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -61.68 -19.44 62.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.117 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.596 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.256 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.476 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.97 -44.98 99.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.045 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -151.44 163.24 39.43 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.3 t -99.91 -148.93 0.36 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.749 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.455 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 25.1 pttm -52.11 117.92 3.12 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.451 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 80.8 t -133.27 130.11 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.699 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.6 mt -73.3 135.98 44.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.164 0.507 . . . . 0.0 109.835 178.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.87 179.59 24.63 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.6 m -128.91 136.31 50.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.901 0.382 . . . . 0.0 110.359 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 103' ' ' VAL . 66.0 t -75.13 108.6 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.535 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.56 -48.32 81.49 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.535 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.3 p-90 -178.61 139.15 0.17 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.006 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -134.19 115.18 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -94.52 117.41 30.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.013 0.435 . . . . 0.0 110.897 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 139' ' ' ALA . 64.5 t -62.69 -44.78 99.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.46 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.09 -44.67 97.0 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -63.03 -38.62 91.93 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.31 2.18 64.05 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.322 179.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -148.28 160.14 43.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 117.371 0.585 . . . . 0.0 110.074 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.458 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -161.3 -177.6 34.53 Favored Glycine 0 CA--C 1.525 0.707 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.545 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -128.8 145.24 51.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.146 0.498 . . . . 0.0 112.147 -178.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 90.7 mt -116.35 125.16 73.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.881 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.99 109.84 20.85 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.977 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -62.89 133.64 54.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.106 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -86.14 -1.38 57.36 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.29 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -100.85 -32.64 10.57 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 120.914 0.388 . . . . 0.0 110.107 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.8 p -113.85 -10.49 12.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.692 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.3 mttt 56.26 31.51 18.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 120.993 0.425 . . . . 0.0 110.04 -179.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.63 141.58 49.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.252 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -67.23 145.55 55.09 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.053 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.572 HG11 ' HB2' ' A' ' 122' ' ' ALA . 91.4 t -128.48 131.77 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -69.83 138.6 52.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.297 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.9 p -147.09 148.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.18 0.514 . . . . 0.0 110.912 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.47 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 76.1 m80 -129.39 160.54 32.78 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.934 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -59.84 -40.51 88.76 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.9 p -67.85 -13.34 62.06 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.448 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -80.09 -7.68 59.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.103 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.573 HD11 HG23 ' A' ' 103' ' ' VAL . 83.2 mt -92.82 96.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.934 0.397 . . . . 0.0 111.143 -178.333 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -63.0 -42.35 99.82 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.27 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.541 ' HB2' HG22 ' A' ' 126' ' ' THR . 3.7 mptp? -119.25 132.09 55.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.059 -179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -145.53 157.72 43.95 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.483 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -57.2 119.33 30.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -68.19 -20.06 43.9 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 121.946 1.764 . . . . 0.0 112.577 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -64.5 -20.05 65.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.39 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.431 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 99.0 mttt -100.92 140.47 35.17 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.719 0.295 . . . . 0.0 110.619 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -69.51 -41.58 75.86 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.721 -178.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.6 142.8 35.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.193 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -74.27 128.12 34.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 110.304 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.514 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.9 m -146.67 165.08 30.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.515 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 47.3 t -119.7 128.42 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.101 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -60.59 140.4 48.05 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.355 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -80.11 130.1 34.99 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.07 2.87 90.68 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.9 tp10 -89.13 133.45 34.39 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 120.875 0.369 . . . . 0.0 110.496 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 86.5 m -69.38 131.31 44.6 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.682 178.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 28.1 m -129.24 159.39 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.419 -177.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -119.17 128.55 54.35 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -155.98 162.07 40.4 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.555 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -92.47 150.67 20.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.283 178.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.3 t -109.31 125.01 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.94 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.457 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.4 p . . . . . 0 C--N 1.326 -0.445 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG12 ' A' ' 114' ' ' VAL . 88.7 tt0 . . . . . 0 N--CA 1.461 0.093 0 CA-C-O 120.864 0.364 . . . . 0.0 110.653 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.572 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -76.17 150.17 37.19 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.993 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.79 157.2 41.63 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 56.18 48.68 16.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.947 0.403 . . . . 0.0 110.03 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.7 t -73.81 125.17 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.124 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.541 HG22 ' HB2' ' A' ' 93' ' ' LYS . 67.9 p -139.25 163.81 31.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.761 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.03 167.83 54.71 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 109.216 -1.553 . . . . 0.0 109.216 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.445 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.9 Cg_exo -60.14 138.43 81.59 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 121.946 1.764 . . . . 0.0 112.132 -178.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 69.88 20.79 76.36 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.48 90.54 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -62.11 139.68 96.01 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.84 -0.212 . . . . 0.0 110.504 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -58.3 148.05 81.42 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 C-N-CA 121.608 1.539 . . . . 0.0 111.286 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.0 t -67.64 129.72 32.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.619 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 26.7 mp0 -61.55 -42.37 98.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.489 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.19 -171.8 53.65 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 179.335 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 57.3 m -114.85 158.06 22.45 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 110.545 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -61.7 -37.38 83.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.518 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -64.26 -13.35 48.91 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.04 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.514 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.276 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.45 -0.435 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.8 mt -61.4 -44.33 98.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.08 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -142.94 162.11 36.34 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.055 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.699 ' O ' HG23 ' A' ' 59' ' ' VAL . 5.3 p -100.61 -151.98 0.42 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.606 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -49.44 117.58 2.28 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.487 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 57' ' ' THR . 92.7 t -132.82 130.53 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.693 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.2 mt -73.2 138.21 45.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.148 0.499 . . . . 0.0 109.811 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.15 178.81 27.38 Favored Glycine 0 N--CA 1.451 -0.363 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 88.2 m -127.56 137.17 52.52 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.502 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.685 HG21 HG12 ' A' ' 103' ' ' VAL . 90.4 t -76.28 108.57 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.749 -178.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.524 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -61.15 -48.86 79.65 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.524 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.1 p-90 -177.64 143.01 0.33 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.96 178.037 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -144.42 120.57 10.8 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 70' ' ' ASN . 79.8 m-20 -103.36 133.34 48.6 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.911 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.7 t -71.25 -38.39 69.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.436 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -58.41 -47.41 83.98 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -176.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.403 ' OD1' ' O ' ' A' ' 67' ' ' ASN . 53.1 p30 -80.62 -16.04 55.07 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.803 -178.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 70' ' ' ASN . . . 70.96 18.81 76.58 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.295 177.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -149.93 164.08 36.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 117.462 0.631 . . . . 0.0 110.181 179.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.13 -173.35 38.12 Favored Glycine 0 CA--C 1.524 0.604 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.505 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -128.75 146.74 50.81 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.108 0.48 . . . . 0.0 112.114 -178.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.5 mt -120.38 126.7 75.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.955 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -94.95 111.09 22.91 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.956 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.421 ' NH2' HG21 ' A' ' 80' ' ' THR . 84.6 mtp180 -63.09 131.6 49.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.165 179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.4 p30 -89.81 2.33 55.06 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.414 -0.515 . . . . 0.0 111.323 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -107.27 -33.53 7.38 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.993 0.425 . . . . 0.0 110.198 179.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.421 HG21 ' NH2' ' A' ' 77' ' ' ARG . 74.4 p -116.2 -9.05 11.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.711 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.4 mttm 54.11 33.49 17.93 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 -178.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -112.85 132.96 55.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.233 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -73.91 125.4 28.12 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.052 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.85 131.89 70.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.883 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -63.35 142.78 58.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.351 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -139.91 145.9 25.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-O 121.218 0.532 . . . . 0.0 110.889 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -136.62 157.4 46.86 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.911 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.455 HE22 HD21 ' A' ' 100' ' ' LEU . 97.7 mt-30 -61.31 -39.25 89.8 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -178.678 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.0 p -66.79 -17.15 64.73 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -83.45 -4.27 58.35 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.154 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.425 HD11 HG23 ' A' ' 103' ' ' VAL . 81.7 mt -96.99 97.93 6.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.995 0.426 . . . . 0.0 111.217 -179.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -64.51 -41.3 96.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.283 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.531 ' HB3' HG22 ' A' ' 126' ' ' THR . 40.3 ttmt -119.45 136.33 54.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -149.43 170.82 17.69 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.357 179.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.415 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 31.5 p-10 -65.95 125.54 90.17 Favored Pre-proline 0 CA--C 1.539 0.526 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.83 -19.62 58.8 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.035 1.823 . . . . 0.0 112.59 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -64.57 -22.97 67.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -104.69 128.25 52.71 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.648 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -69.31 -37.55 77.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.754 179.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.455 HD21 HE22 ' A' ' 88' ' ' GLN . 62.6 tp -101.98 131.56 48.32 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.141 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -59.45 136.36 57.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.028 0.442 . . . . 0.0 110.279 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.3 t -158.17 155.33 28.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.572 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.685 HG12 HG21 ' A' ' 63' ' ' VAL . 53.3 t -119.64 129.36 75.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.88 151.12 51.21 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.316 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -86.67 136.1 33.15 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.71 2.86 90.25 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.9 tp10 -92.92 128.81 38.92 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.938 0.399 . . . . 0.0 110.5 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -67.12 133.31 49.59 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.751 179.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.9 m -129.53 159.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.456 -178.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -118.66 128.83 54.9 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -157.76 161.15 38.45 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.767 -0.773 . . . . 0.0 112.538 -178.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.404 ' OD1' ' C ' ' A' ' 112' ' ' ASP . 55.8 p30 -90.32 174.53 7.53 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.281 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -127.61 127.67 68.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 C-N-CA 120.509 -0.476 . . . . 0.0 109.978 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 91.8 t . . . . . 0 C--N 1.326 -0.456 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.687 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.6 pt-20 . . . . . 0 N--CA 1.461 0.092 0 CA-C-O 120.97 0.414 . . . . 0.0 110.666 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -97.77 148.46 23.34 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.96 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.09 41.76 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.236 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.1 t30 53.35 47.92 23.13 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.141 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.7 t -75.28 125.55 34.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.069 -178.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.531 HG22 ' HB3' ' A' ' 93' ' ' LYS . 69.7 p -136.92 169.21 18.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.743 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -77.27 175.58 53.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.05 137.85 35.54 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 122.074 1.849 . . . . 0.0 112.061 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.7 19.64 79.31 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.87 1.48 90.61 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 -179.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 86.6 t -62.65 137.61 96.56 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-O 119.647 -0.216 . . . . 0.0 110.611 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -59.14 148.44 85.75 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 121.697 1.598 . . . . 0.0 111.259 179.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.415 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 43.7 t -67.59 128.17 30.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.669 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -63.58 -39.62 94.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.539 -179.146 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.91 -175.58 53.16 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 179.311 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 41.4 t -101.28 160.4 14.44 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.824 0.345 . . . . 0.0 110.554 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -61.09 -37.99 84.68 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.416 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -64.35 -14.04 53.96 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.092 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.477 -179.712 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 84.9 t . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.6 mt -63.41 -44.14 98.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.046 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.25 163.73 36.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.07 0.462 . . . . 0.0 111.067 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.643 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -98.1 -146.57 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.679 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 57' ' ' THR . 63.5 mttp -50.82 116.4 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.407 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 57' ' ' THR . 74.1 t -131.78 130.03 61.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.697 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.7 mt -73.55 137.21 44.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.055 0.455 . . . . 0.0 109.808 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.32 177.9 27.2 Favored Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.4 m -128.22 135.76 50.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.856 0.36 . . . . 0.0 110.486 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.71 HG21 HG12 ' A' ' 103' ' ' VAL . 77.2 t -76.93 109.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.765 -179.209 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.1 tttt -62.22 -48.39 80.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 62.2 p-90 -175.8 147.63 0.81 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 114.678 -1.146 . . . . 0.0 109.903 178.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -137.45 115.44 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 41.4 t-20 -93.49 110.27 21.85 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.978 0.418 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 53.4 t -61.21 -46.7 96.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.391 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.1 ttp180 -62.01 -43.76 98.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -178.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.16 -39.39 92.48 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.81 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.49 4.04 59.58 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.382 179.255 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -148.26 160.82 42.57 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.423 0.611 . . . . 0.0 110.04 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.454 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -160.53 -177.22 33.44 Favored Glycine 0 CA--C 1.525 0.71 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.573 -179.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -131.5 147.9 52.58 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.134 0.492 . . . . 0.0 112.193 -179.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.2 mt -120.77 127.36 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.843 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -91.92 110.45 21.81 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.807 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 96.4 mtm-85 -62.18 135.2 57.39 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.126 179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -82.54 -6.95 59.62 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.382 179.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -94.75 -33.07 13.04 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.959 0.409 . . . . 0.0 110.138 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 68.0 p -116.9 -10.6 10.96 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.642 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 54.44 34.51 21.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.976 0.417 . . . . 0.0 110.026 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -121.04 132.64 55.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.247 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -66.23 148.14 52.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.037 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -132.78 152.15 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.914 179.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -73.24 133.11 43.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.297 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.4 p -144.84 144.11 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.149 0.499 . . . . 0.0 110.911 178.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -136.19 157.79 45.96 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.841 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -58.46 -24.73 61.05 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -178.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.3 p -73.6 -20.49 60.59 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.421 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.24 -7.74 58.88 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.137 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.3 mt -90.0 94.9 5.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.872 0.367 . . . . 0.0 111.198 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -64.34 -38.15 90.03 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.437 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -122.94 142.86 50.35 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.101 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -153.28 177.13 11.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.35 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -63.63 118.62 46.43 Favored Pre-proline 0 CA--C 1.539 0.552 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.7 -34.66 99.07 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.056 1.838 . . . . 0.0 112.545 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.09 -19.9 66.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.467 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -97.65 114.53 26.5 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-O 120.74 0.305 . . . . 0.0 110.604 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -60.69 -47.89 84.23 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.893 0.378 . . . . 0.0 110.761 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 64.0 tp -91.18 130.67 37.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.182 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -59.76 136.73 58.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.055 0.455 . . . . 0.0 110.249 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.463 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.1 t -154.18 154.25 33.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.505 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.71 HG12 HG21 ' A' ' 63' ' ' VAL . 53.1 t -121.7 131.95 71.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.4 144.64 47.74 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.324 -178.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -83.14 118.59 23.69 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.65 -0.73 74.29 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -82.82 132.33 35.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.862 0.363 . . . . 0.0 110.532 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 85.8 m -69.04 132.48 46.7 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.648 178.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -130.01 159.77 41.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.47 -178.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -119.96 126.62 51.31 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -155.45 163.81 39.55 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.558 -177.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.31 153.33 20.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.224 178.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -110.29 125.09 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.403 -0.519 . . . . 0.0 109.983 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 75.8 t . . . . . 0 C--N 1.326 -0.423 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.941 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.227 -0.121 0 CA-C-O 120.966 0.412 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -94.14 146.59 23.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.01 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.35 157.06 40.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.135 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 58.19 47.33 14.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.977 0.418 . . . . 0.0 110.164 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.2 t -76.07 123.22 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.074 -179.025 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.2 p -134.96 159.96 39.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.813 179.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.55 162.21 53.94 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.105 -1.598 . . . . 0.0 109.105 178.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.51 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.8 Cg_exo -58.83 136.99 77.34 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.039 1.826 . . . . 0.0 112.108 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.57 83.0 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.2 1.45 90.47 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.9 p -68.89 141.66 92.58 Favored Pre-proline 0 CA--C 1.535 0.4 0 CA-C-O 119.673 -0.203 . . . . 0.0 110.501 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 20.4 Cg_endo -59.09 150.24 74.72 Favored 'Trans proline' 0 N--CA 1.497 1.721 0 C-N-CA 121.634 1.556 . . . . 0.0 111.315 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -64.42 133.58 29.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.552 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -62.43 -42.41 99.43 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.496 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.41 162.59 36.16 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 85.1 p -80.59 166.3 21.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.894 0.378 . . . . 0.0 110.496 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -63.4 -36.87 85.17 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.511 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -72.1 -5.23 33.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.121 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.463 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.329 -0.295 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.448 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t . . . . . 0 N--CA 1.45 -0.454 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.0 -44.53 97.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.069 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -155.27 163.24 40.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.056 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.547 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.4 t -96.19 -149.51 0.31 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.685 179.622 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -55.1 118.0 3.96 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.52 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 57' ' ' THR . 87.5 t -129.58 128.55 65.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.701 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.7 mt -68.98 135.31 50.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.122 0.486 . . . . 0.0 109.733 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.04 -177.82 27.0 Favored Glycine 0 CA--C 1.521 0.42 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.4 m -128.28 135.34 49.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.876 0.37 . . . . 0.0 110.391 -179.564 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.711 HG21 HG12 ' A' ' 103' ' ' VAL . 97.1 t -71.28 110.87 4.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.765 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -61.52 -48.92 78.85 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.9 p-90 -177.77 140.08 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.957 178.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -137.1 119.17 15.43 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -101.22 120.88 40.9 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.892 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.407 HG21 ' C ' ' A' ' 138' ' ' TYR . 67.3 t -62.93 -45.73 98.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.525 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -61.82 -44.68 96.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -178.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -62.09 -38.78 90.13 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.902 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.61 2.1 65.53 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.397 179.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -147.54 161.96 40.05 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 117.467 0.633 . . . . 0.0 110.112 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.55 -179.05 36.9 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.561 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -126.99 146.27 50.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.153 0.501 . . . . 0.0 112.172 -178.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.407 HG21 ' CE2' ' A' ' 111' ' ' PHE . 87.2 mt -119.31 125.34 74.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.827 178.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.77 109.88 21.32 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.836 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -65.96 134.78 53.66 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.19 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -85.06 -5.31 59.35 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.418 -0.513 . . . . 0.0 111.268 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -96.49 -33.19 11.95 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.176 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 66.5 p -115.15 -9.61 12.27 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.627 -178.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt 53.63 32.5 14.59 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 121.062 0.458 . . . . 0.0 110.147 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -119.73 131.83 55.48 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.233 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.02 142.43 58.38 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.986 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.411 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 79.0 t -126.89 132.42 70.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.899 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -66.19 138.19 57.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.312 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.79 147.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.225 0.536 . . . . 0.0 110.946 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -136.88 159.96 40.31 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.905 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.418 ' HA ' HD12 ' A' ' 91' ' ' ILE . 16.6 pm0 -59.98 -20.4 57.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 64.1 p -82.52 -12.81 57.52 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.465 179.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.05 1.36 57.24 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.132 179.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.459 HD11 HG23 ' A' ' 103' ' ' VAL . 80.7 mt -95.97 101.68 12.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.929 0.395 . . . . 0.0 111.136 -178.153 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -63.11 -45.15 93.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.365 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -115.07 136.8 52.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.04 -178.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -143.26 137.85 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.31 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.4 p-10 -58.96 138.39 87.49 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.057 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.34 -9.12 24.76 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.004 1.802 . . . . 0.0 112.499 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.55 -35.95 77.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.412 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -105.04 137.91 42.07 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-O 120.687 0.279 . . . . 0.0 110.672 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.445 ' HB2' HD22 ' A' ' 100' ' ' LEU . 98.2 m-85 -68.42 -41.95 79.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.756 -179.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.59 HD22 ' N ' ' A' ' 100' ' ' LEU . 1.3 mm? -97.98 146.41 25.53 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.31 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -67.51 128.52 36.74 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.381 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.406 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.7 m -147.51 161.74 40.47 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.477 -179.271 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.711 HG12 HG21 ' A' ' 63' ' ' VAL . 32.8 t -125.97 131.11 72.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -61.64 143.48 48.65 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.266 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -81.58 123.29 28.54 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.0 3.83 88.87 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -84.74 136.67 33.61 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.939 0.399 . . . . 0.0 110.503 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 89.6 m -70.66 130.88 42.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.607 179.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -134.91 164.82 32.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.445 -178.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -124.87 137.7 54.28 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.3 p90 -160.12 162.52 34.01 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.813 -0.755 . . . . 0.0 112.481 -177.394 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -90.65 137.34 32.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.268 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.7 t -103.83 126.22 58.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.988 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 121' ' ' GLU . 35.8 m . . . . . 0 C--N 1.327 -0.408 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG22 ' A' ' 114' ' ' VAL . 88.9 tt0 . . . . . 0 N--CA 1.461 0.091 0 CA-C-O 120.892 0.377 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.411 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -77.92 152.87 33.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.12 158.22 42.65 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.14 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 53.07 47.28 24.92 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.105 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.6 t -74.43 124.05 31.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.071 -179.048 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 50.3 p -139.78 170.06 16.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.825 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.31 164.68 54.72 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 178.378 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.444 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.3 Cg_exo -59.44 137.18 76.51 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 C-N-CA 121.977 1.785 . . . . 0.0 112.177 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.31 20.81 77.06 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.25 2.48 90.5 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -179.577 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 128' ' ' PRO . 96.6 t -60.98 141.3 93.61 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 122.777 -0.249 . . . . 0.0 110.553 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -56.28 148.06 63.09 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 121.549 1.499 . . . . 0.0 111.315 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.416 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 42.9 t -69.78 126.24 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.64 -179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 16.2 tm0? -60.9 -40.42 93.01 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.54 -178.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.41 -174.39 54.95 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -111.75 162.84 14.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.841 0.353 . . . . 0.0 110.502 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -60.84 -37.91 83.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.509 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.407 ' C ' HG21 ' A' ' 68' ' ' VAL . 96.4 m-85 -71.02 -5.77 33.84 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.067 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.406 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.331 -0.214 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.521 -179.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.87 -44.26 99.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.102 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.436 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.94 162.91 37.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 -179.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.495 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.9 t -108.84 -134.8 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.707 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.441 ' N ' HG23 ' A' ' 57' ' ' THR . 68.6 mttm -54.71 102.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.346 -0.541 . . . . 0.0 110.369 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 57' ' ' THR . 97.4 t -127.26 128.75 70.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.729 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 88.6 mt -79.66 135.99 36.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.104 0.478 . . . . 0.0 109.862 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.49 178.18 21.81 Favored Glycine 0 CA--C 1.519 0.298 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 134.76 50.67 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.852 0.358 . . . . 0.0 110.463 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.661 HG21 HG12 ' A' ' 103' ' ' VAL . 86.6 t -75.77 109.99 10.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.75 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.67 -49.19 77.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 61.4 p-90 -174.51 152.78 1.75 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.899 178.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -147.06 117.07 7.24 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.6 m-20 -97.45 120.87 38.6 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.908 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -63.18 -44.8 99.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.462 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.42 HH11 ' HD2' ' A' ' 69' ' ' ARG . 9.0 ptm85 -65.22 -34.84 79.32 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -69.3 -35.35 75.9 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.521 -0.471 . . . . 0.0 110.788 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 89.38 1.42 78.39 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.367 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -150.15 162.74 39.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.445 0.623 . . . . 0.0 110.085 179.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.73 179.85 34.09 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.493 -0.86 . . . . 0.0 111.535 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -123.49 143.52 50.11 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.133 0.492 . . . . 0.0 112.091 -178.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.992 HD12 HG11 ' A' ' 86' ' ' VAL . 88.1 mt -120.63 126.2 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.841 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.91 114.75 27.38 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.875 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -71.43 128.69 36.69 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.035 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.3 p30 -83.93 -1.59 54.85 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.337 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -101.21 -31.54 10.96 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-O 120.947 0.403 . . . . 0.0 110.176 179.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.72 -12.48 11.51 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.682 -179.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.86 32.45 19.68 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.995 -179.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.78 135.35 55.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.244 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -63.32 144.95 56.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.072 -179.421 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.35 133.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.901 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -80.98 125.19 29.84 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.325 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.079 HG12 ' HB3' ' A' ' 122' ' ' ALA . 32.6 m -131.17 159.86 42.72 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-O 121.133 0.492 . . . . 0.0 110.973 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -137.95 155.97 48.34 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.837 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -60.93 -22.98 64.92 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.531 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.9 p -80.96 -13.0 59.28 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.422 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.05 2.93 55.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.094 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 103' ' ' VAL . 78.9 mt -98.03 106.68 19.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.876 0.37 . . . . 0.0 111.171 -178.331 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -63.84 -44.35 93.45 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.327 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.03 144.13 50.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.928 0.394 . . . . 0.0 111.051 -179.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 p-10 -150.26 174.32 12.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.418 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.0 t-20 -62.67 120.2 57.79 Favored Pre-proline 0 CA--C 1.541 0.604 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.49 -23.07 58.21 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.035 1.823 . . . . 0.0 112.595 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.4 mmm-85 -67.02 -21.63 65.92 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.413 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.61 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 75.5 mmtt -91.48 136.93 32.76 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.62 -179.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.404 ' C ' HD12 ' A' ' 100' ' ' LEU . 94.4 m-85 -69.18 -39.55 78.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.753 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 99' ' ' TYR . 8.0 mp -113.5 151.52 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.173 -179.465 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.66 139.25 58.74 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.319 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.8 p -156.0 161.36 40.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.603 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.661 HG12 HG21 ' A' ' 63' ' ' VAL . 52.7 t -123.12 125.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.8 146.86 48.94 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.363 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -84.55 133.78 34.44 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.88 4.8 89.61 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.565 -1.014 . . . . 0.0 110.565 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -92.61 129.77 38.44 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.96 0.41 . . . . 0.0 110.504 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.5 m -66.81 133.55 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.576 178.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.5 m -128.89 158.15 41.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.459 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -120.0 130.11 54.59 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -160.8 165.14 30.79 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.549 -177.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -95.28 144.98 25.41 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.306 178.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.436 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -105.06 126.3 60.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.022 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.8 p . . . . . 0 C--N 1.328 -0.36 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.58 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 . . . . . 0 C--O 1.227 -0.122 0 CA-C-O 120.926 0.393 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 1.079 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -116.67 149.81 39.17 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.23 156.99 42.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.191 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 54.81 43.89 29.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.051 0.453 . . . . 0.0 110.123 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.8 t -72.45 121.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.054 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.1 p -137.88 166.23 24.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.725 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.61 175.24 49.79 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.49 138.21 38.12 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.929 1.753 . . . . 0.0 112.097 -179.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 19.99 77.94 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.79 1.12 90.56 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.03 137.52 95.58 Favored Pre-proline 0 CA--C 1.535 0.39 0 O-C-N 122.822 -0.222 . . . . 0.0 110.556 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -59.45 146.26 95.51 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.656 1.57 . . . . 0.0 111.247 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -64.96 135.27 28.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.69 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -59.51 -42.78 92.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.469 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.28 176.71 51.16 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 179.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 43.8 t -97.0 143.93 27.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.92 0.391 . . . . 0.0 110.54 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -60.14 -21.07 61.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.552 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -74.93 -12.59 60.39 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.113 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.61 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . . . . . . 0 C--N 1.331 -0.215 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.515 -179.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.5 t . . . . . 0 N--CA 1.451 -0.404 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.5 mt -62.82 -45.3 99.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.029 -178.723 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.83 167.62 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.116 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.5 t -105.66 -134.77 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.68 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.443 ' N ' HG23 ' A' ' 57' ' ' THR . 87.8 tttt -50.34 112.91 0.76 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.482 -179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 57' ' ' THR . 72.5 t -135.45 131.29 51.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.771 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.472 HD23 ' HG2' ' A' ' 110' ' ' GLU . 67.2 mt -75.01 133.75 41.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.121 0.486 . . . . 0.0 109.75 177.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.89 175.57 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 90.1 m -131.17 138.93 49.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.829 0.347 . . . . 0.0 110.432 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.721 HG21 HG12 ' A' ' 103' ' ' VAL . 97.2 t -72.62 109.18 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.78 -178.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -62.49 -48.04 81.35 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.528 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 59.0 p-90 -177.23 139.53 0.26 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.969 178.154 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -135.71 120.84 18.87 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -104.65 119.87 40.0 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.923 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.36 -45.47 98.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.482 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -60.57 -44.92 95.66 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -62.13 -38.15 87.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.813 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.1 1.47 64.97 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.34 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.5 p90 -147.5 160.16 42.91 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 117.473 0.636 . . . . 0.0 110.072 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.91 174.61 36.73 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.489 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -129.16 148.6 51.11 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.187 0.518 . . . . 0.0 112.141 -179.053 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.429 HD13 HG21 ' A' ' 109' ' ' VAL . 84.5 mt -116.55 127.18 74.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.844 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.12 109.05 19.96 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -60.38 134.99 57.6 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.159 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -84.37 -0.15 51.53 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.301 179.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -101.87 -33.04 9.94 Favored 'General case' 0 C--O 1.231 0.085 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.058 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.7 p -116.59 -9.09 11.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.693 -178.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mmtm 55.81 31.75 18.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.96 0.41 . . . . 0.0 110.037 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -117.69 133.99 55.37 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.303 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.15 144.57 56.8 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.098 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.449 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.2 t -124.14 126.94 73.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.913 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.76 129.03 38.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.318 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.93 149.76 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.186 0.517 . . . . 0.0 110.921 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.01 160.13 33.73 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.858 178.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.414 ' OE1' HD11 ' A' ' 100' ' ' LEU . 25.9 pt20 -60.24 -29.79 68.99 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -73.53 -15.66 61.29 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.385 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.19 -0.07 53.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.17 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.523 HD11 HG23 ' A' ' 103' ' ' VAL . 80.4 mt -92.98 101.3 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.967 0.413 . . . . 0.0 111.226 -178.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -62.94 -43.86 97.65 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -121.79 143.02 49.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.148 -179.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -152.77 163.79 39.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.434 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -61.76 121.15 62.81 Favored Pre-proline 0 CA--C 1.539 0.539 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.46 -21.63 66.09 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 121.967 1.778 . . . . 0.0 112.553 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.82 -22.16 66.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.326 179.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -100.89 120.67 40.49 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-O 120.751 0.31 . . . . 0.0 110.686 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 88.8 t80 -61.03 -48.3 82.41 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.703 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.414 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.5 tp -93.09 129.53 39.03 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.141 -179.25 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -61.82 139.23 58.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.297 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 90.2 p -158.31 163.95 36.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.452 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.721 HG12 HG21 ' A' ' 63' ' ' VAL . 43.8 t -125.16 129.53 73.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.25 144.66 48.01 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.319 -178.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 105' ' ' ASP . 41.0 p-10 -77.36 129.2 35.51 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.36 2.01 86.94 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 110.526 -1.029 . . . . 0.0 110.526 -178.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.7 tt0 -78.37 130.91 36.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 120.988 0.423 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.4 m -71.09 130.76 42.35 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.713 178.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.429 HG21 HD13 ' A' ' 75' ' ' ILE . 21.6 m -133.71 158.43 42.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.524 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.472 ' HG2' HD23 ' A' ' 60' ' ' LEU . 94.6 mt-10 -115.78 132.42 56.64 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -161.33 167.11 26.42 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.473 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -88.57 149.53 23.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.252 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.8 t -108.43 123.9 64.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.481 -0.488 . . . . 0.0 109.957 -179.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.4 t . . . . . 0 C--N 1.326 -0.439 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.402 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 C--O 1.226 -0.158 0 CA-C-O 120.925 0.393 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.449 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -118.69 142.43 47.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.045 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.11 153.34 42.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.184 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 54.36 43.08 30.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.059 0.457 . . . . 0.0 110.174 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.05 125.39 28.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.106 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.9 p -135.67 169.43 17.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.824 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.09 177.24 45.69 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 178.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.431 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.7 Cg_endo -69.73 136.38 32.93 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 121.911 1.74 . . . . 0.0 112.188 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.68 21.53 77.87 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.07 1.79 90.41 Favored Glycine 0 CA--C 1.531 1.084 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 128' ' ' PRO . 85.5 t -63.16 140.43 97.67 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 122.853 -0.204 . . . . 0.0 110.527 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -58.06 148.53 76.75 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 121.58 1.52 . . . . 0.0 111.292 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.2 t -69.15 128.99 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.605 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -61.47 -41.85 97.88 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.435 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.83 -175.9 48.94 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -109.5 159.96 16.62 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.845 0.355 . . . . 0.0 110.53 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt -61.49 -37.81 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -63.63 -15.37 58.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.078 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.48 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . . . . . . 0 C--N 1.33 -0.281 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.451 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.8 t . . . . . 0 N--CA 1.451 -0.401 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.64 -45.0 98.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.068 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.55 163.45 39.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.109 -178.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.545 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.1 t -98.12 -149.09 0.33 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.7 179.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.0 mtmt -53.92 119.31 4.85 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.449 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 57' ' ' THR . 72.2 t -131.38 131.67 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.629 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 62.2 mt -65.7 131.07 45.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.102 0.477 . . . . 0.0 109.835 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.62 176.13 24.78 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 91.8 m -129.33 135.46 48.77 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.735 0.302 . . . . 0.0 110.508 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 95.2 t -70.88 108.02 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.826 -179.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.54 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.7 tttt -61.66 -47.81 83.65 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.073 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.54 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 58.1 p-90 -177.1 138.94 0.26 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.602 -1.181 . . . . 0.0 109.942 178.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -136.07 117.57 14.8 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -100.59 119.68 38.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.004 0.43 . . . . 0.0 110.907 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.437 HG21 ' N ' ' A' ' 139' ' ' ALA . 65.3 t -62.18 -46.33 96.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.422 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.13 -46.16 90.6 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -61.41 -39.23 89.98 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.924 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.61 1.93 63.6 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.349 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -148.21 161.22 41.91 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.505 0.653 . . . . 0.0 110.062 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -159.48 -177.91 33.0 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.568 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -129.24 143.96 51.04 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.425 HG13 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -116.93 123.42 71.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.814 178.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -91.11 109.12 20.37 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.933 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.423 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -63.64 130.29 43.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.083 178.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -74.99 -26.86 59.88 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.358 179.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -70.77 -41.78 71.27 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.905 0.383 . . . . 0.0 110.224 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.2 p -104.49 -11.14 17.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.675 -178.173 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . 0.423 ' N ' ' O ' ' A' ' 77' ' ' ARG . 98.6 mttt 55.86 31.19 17.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.927 0.394 . . . . 0.0 110.043 -178.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -120.45 145.84 46.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.225 179.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -70.31 147.22 49.91 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.073 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 122' ' ' ALA . 88.3 t -130.12 132.53 65.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.816 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -66.31 138.29 57.52 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.328 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.425 HG11 HG13 ' A' ' 75' ' ' ILE . 7.7 p -151.44 149.88 13.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.232 0.539 . . . . 0.0 110.879 179.012 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -133.48 155.38 49.65 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.83 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.2 pt20 -60.9 -25.52 66.79 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 63.2 p -79.56 -13.05 59.8 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.479 178.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.24 1.56 55.53 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.119 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.46 HD11 HG23 ' A' ' 103' ' ' VAL . 78.8 mt -93.91 108.9 21.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.847 0.356 . . . . 0.0 111.202 -178.239 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -64.32 -43.11 95.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.318 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.85 138.98 54.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.147 -178.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -144.91 157.19 44.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.476 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -56.98 120.15 36.18 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.83 -32.23 94.4 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.015 1.81 . . . . 0.0 112.581 179.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -62.41 -21.79 65.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.418 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -85.62 127.59 34.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 120.693 0.282 . . . . 0.0 110.623 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -65.46 -39.47 92.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.795 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.3 150.32 39.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.254 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -63.15 136.8 57.97 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.7 p -159.38 163.05 35.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.495 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 54.9 t -125.72 128.39 72.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.66 138.62 38.1 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.274 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.01 135.76 38.68 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.57 3.19 90.15 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.425 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.6 tp10 -92.36 128.45 38.21 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 121.002 0.429 . . . . 0.0 110.537 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.6 m -68.16 132.99 48.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.674 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.99 158.04 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.235 -0.586 . . . . 0.0 111.394 -178.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -117.37 134.4 54.87 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.153 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 39.8 p90 -158.75 162.2 37.08 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.819 -0.753 . . . . 0.0 112.586 -177.61 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -88.88 144.09 26.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.25 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.3 123.78 59.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.987 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.325 -0.467 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.67 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 C--O 1.226 -0.145 0 CA-C-O 120.925 0.393 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.96 143.49 34.03 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.034 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.13 157.71 43.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.184 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 55.4 49.48 16.81 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.939 0.4 . . . . 0.0 110.07 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 86.7 t -75.8 125.17 35.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.14 -179.152 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -137.5 163.57 30.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.76 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.4 165.76 54.17 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.8 Cg_exo -59.6 136.05 68.41 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.962 1.774 . . . . 0.0 112.154 -178.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.3 19.44 79.65 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 178.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.36 1.59 90.31 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 128' ' ' PRO . 90.4 t -60.96 139.06 94.09 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-O 119.692 -0.194 . . . . 0.0 110.572 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' HG13 ' A' ' 131' ' ' VAL . 24.0 Cg_endo -60.69 149.06 89.5 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.679 1.586 . . . . 0.0 111.323 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.6 t -70.28 128.81 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.55 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.2 tp60 -61.07 -39.99 91.98 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.534 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.14 -175.71 53.82 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 65.4 m -107.54 155.65 19.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.59 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -62.64 -35.52 79.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.493 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -62.11 -13.65 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.099 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.437 ' N ' HG21 ' A' ' 68' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.24 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.468 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -62.71 131.41 48.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -89.96 133.04 35.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.213 0.53 . . . . 0.0 111.02 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 79.9 t -101.13 104.44 16.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.489 178.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.457 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.0 mt -61.92 -44.21 98.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.037 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.524 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.85 159.34 43.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.117 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.557 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.8 p -107.81 -140.7 0.38 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.661 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt -50.93 102.52 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.262 -0.575 . . . . 0.0 110.505 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 57' ' ' THR . 84.3 t -128.49 130.19 69.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.712 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 87.1 mt -82.12 137.01 35.08 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.93 -179.88 22.47 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 89.8 m -127.29 136.18 51.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.792 0.329 . . . . 0.0 110.501 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 89.3 t -76.67 112.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.74 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.534 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.45 -48.15 80.93 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.534 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -178.76 143.66 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.961 177.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -138.73 118.73 13.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -98.77 120.89 39.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.987 0.422 . . . . 0.0 110.81 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.402 HG21 ' N ' ' A' ' 139' ' ' ALA . 69.9 t -64.16 -45.1 97.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.42 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.1 ttp85 -61.31 -44.46 97.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.41 -38.36 89.4 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.843 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.36 3.96 66.67 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 121.091 -0.575 . . . . 0.0 112.401 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -149.28 161.38 42.16 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.441 0.621 . . . . 0.0 110.137 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.429 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -162.75 -177.08 35.46 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 120.554 -0.831 . . . . 0.0 111.577 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.456 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.6 m-85 -131.56 147.7 52.55 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.107 0.48 . . . . 0.0 112.233 -179.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.2 mt -120.24 127.68 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.856 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -93.32 109.83 21.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.849 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.9 mtm180 -65.6 131.78 47.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.093 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.9 p30 -86.91 -0.21 56.13 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.278 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -100.32 -32.7 10.72 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.892 0.377 . . . . 0.0 110.098 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.75 -10.59 11.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.674 -179.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 56.9 mtmt 55.37 32.34 18.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 109.996 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -121.25 132.37 54.77 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.319 0.58 . . . . 0.0 111.222 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -67.04 146.47 54.3 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.049 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.0 p -134.03 148.03 30.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.931 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -73.45 138.46 45.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.354 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 73' ' ' GLY . 4.8 p -143.01 145.56 22.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 121.112 0.482 . . . . 0.0 110.947 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -137.4 158.85 43.52 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.868 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -61.28 -39.19 89.49 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.5 p -67.27 -15.7 63.85 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.469 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.02 0.75 54.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.496 HD11 HG23 ' A' ' 103' ' ' VAL . 83.5 mt -98.65 104.97 16.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.038 0.447 . . . . 0.0 111.136 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -62.67 -44.93 95.01 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.331 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.412 ' HB2' HG22 ' A' ' 126' ' ' THR . 75.9 mmtt -125.62 145.39 50.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.002 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -150.98 176.59 10.98 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.399 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -63.71 121.14 68.92 Favored Pre-proline 0 CA--C 1.54 0.589 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.38 -25.61 63.69 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.999 1.799 . . . . 0.0 112.535 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.0 mmm180 -69.96 -17.95 63.33 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.436 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -95.78 123.85 39.54 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.689 0.28 . . . . 0.0 110.632 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -66.02 -39.8 90.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.858 0.361 . . . . 0.0 110.752 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -103.66 136.68 42.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.219 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.1 mtm180 -65.1 137.18 57.51 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.316 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 86.1 p -160.05 164.0 33.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 59.4 t -123.43 128.37 74.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.21 145.73 44.95 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.309 -179.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -83.0 137.91 33.96 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.49 2.78 88.29 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -93.57 132.13 38.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.88 0.371 . . . . 0.0 110.465 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -69.59 133.19 47.32 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.611 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.68 159.67 40.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.522 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -120.95 131.07 54.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -160.75 167.31 27.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.507 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -100.55 138.05 38.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.284 178.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.524 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 55.4 t -95.87 124.79 48.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 120.523 -0.471 . . . . 0.0 109.863 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 68.1 t -119.77 129.82 74.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -61.45 126.62 28.01 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.854 -178.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -117.69 160.22 13.8 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.5 mp0 -62.1 -39.58 92.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.743 0.306 . . . . 0.0 110.979 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -87.56 -5.37 58.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.372 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 141.89 -169.83 25.12 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.69 139.28 58.32 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.405 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -122.94 134.95 54.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.589 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.7 145.83 24.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.033 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.8 155.7 39.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.159 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 55.5 t-20 54.28 50.45 16.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.999 0.428 . . . . 0.0 110.131 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -78.4 119.62 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.112 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.412 HG22 ' HB2' ' A' ' 93' ' ' LYS . 82.3 p -138.41 164.58 28.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.769 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.05 171.27 51.1 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -69.18 137.64 37.66 Favored 'Trans proline' 0 C--N 1.3 -1.994 0 C-N-CA 122.0 1.8 . . . . 0.0 112.122 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.11 19.43 79.79 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.5 0.58 89.35 Favored Glycine 0 CA--C 1.531 1.054 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 128' ' ' PRO . 76.0 t -61.2 137.77 94.35 Favored Pre-proline 0 CA--C 1.535 0.391 0 O-C-N 122.802 -0.234 . . . . 0.0 110.51 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.15 150.3 87.86 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 121.61 1.54 . . . . 0.0 111.351 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.05 132.39 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.588 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -61.66 -40.27 94.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.616 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.01 -176.98 53.91 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 72.6 m -103.19 153.78 20.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.82 0.343 . . . . 0.0 110.56 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -59.89 -37.75 80.28 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.401 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -62.31 -15.56 48.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.12 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.402 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -58.32 139.98 54.25 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.569 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.659 -179.781 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.561 0 C3'-C2'-C1' 104.339 1.171 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.87 0 O4'-C4'-C3' 103.772 -1.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.537 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.429 -1.537 0 P-O3'-C3' 121.558 1.548 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -1.03 0 O4'-C4'-C3' 103.826 -1.774 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.793 0 O4'-C4'-C3' 103.859 -1.741 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.266 0 C1'-O4'-C4' 106.647 -2.181 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.849 0 O4'-C1'-C2' 107.278 1.071 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -71.0 145.54 49.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.276 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -106.98 128.59 54.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.152 0.501 . . . . 0.0 110.972 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.2 t -92.03 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.395 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.426 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.3 mt -62.29 -44.17 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.061 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.77 164.95 33.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.098 0.475 . . . . 0.0 111.061 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.81 ' O ' HG23 ' A' ' 59' ' ' VAL . 10.9 t -98.05 -151.4 0.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.647 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.458 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 22.5 pttp -47.03 116.0 1.24 Allowed 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.453 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.81 HG23 ' O ' ' A' ' 57' ' ' THR . 93.9 t -129.79 128.08 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.688 179.391 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.6 mt -75.18 136.5 41.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.12 0.486 . . . . 0.0 109.827 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -152.86 -175.87 24.8 Favored Glycine 0 CA--C 1.52 0.363 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.5 m -130.54 136.76 49.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.81 0.338 . . . . 0.0 110.503 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.731 HG21 HG12 ' A' ' 103' ' ' VAL . 77.5 t -73.21 115.57 14.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.752 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.43 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.2 ttpt -63.73 -47.05 82.63 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.43 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 56.5 p-90 -176.43 148.18 0.73 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 114.673 -1.148 . . . . 0.0 109.901 177.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -143.4 115.62 8.44 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -101.0 123.29 44.96 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.88 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.3 t -63.33 -46.08 96.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.461 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -60.29 -45.49 93.15 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.53 88.33 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.894 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.93 2.61 66.53 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 121.134 -0.555 . . . . 0.0 112.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.01 161.87 41.49 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 117.456 0.628 . . . . 0.0 110.064 179.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.443 ' O ' HG22 ' A' ' 86' ' ' VAL . . . -157.74 -177.92 31.3 Favored Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.601 -179.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.444 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 95.5 m-85 -131.72 146.5 52.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.152 0.501 . . . . 0.0 112.157 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.856 HD12 HG11 ' A' ' 86' ' ' VAL . 86.8 mt -120.55 127.25 75.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.838 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -92.94 109.84 21.29 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.879 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.4 mtm180 -62.75 133.39 54.71 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.109 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 p30 -87.74 -0.15 56.52 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.279 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.9 -32.12 11.14 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 120.974 0.416 . . . . 0.0 110.113 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 75.2 p -113.44 -11.03 13.17 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.698 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt 57.69 31.44 20.41 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 0.0 110.007 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -120.1 142.66 48.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.356 0.598 . . . . 0.0 111.198 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.36 144.82 51.5 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.051 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 87.3 t -128.21 128.2 68.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.972 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -72.8 130.1 39.7 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.341 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.057 HG12 ' HB3' ' A' ' 122' ' ' ALA . 33.3 m -132.91 159.42 43.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.215 0.531 . . . . 0.0 110.917 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.34 155.93 47.36 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.936 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -60.86 -23.05 64.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -178.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.2 p -81.85 -11.94 58.71 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.421 178.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.22 0.9 56.98 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.156 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 82.4 mt -96.8 100.3 10.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.943 0.401 . . . . 0.0 111.168 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -63.36 -44.12 95.72 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.298 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -122.33 144.88 48.74 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.954 0.406 . . . . 0.0 111.031 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.5 p-10 -155.07 175.69 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.38 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -66.63 120.55 71.77 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -64.81 -25.66 60.42 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.039 1.826 . . . . 0.0 112.552 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -65.47 -20.73 66.48 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.395 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.82 128.68 40.19 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.696 0.284 . . . . 0.0 110.633 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -66.13 -38.67 88.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.754 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.9 mt -108.89 149.7 28.77 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.214 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -69.68 129.94 41.0 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.384 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 65.8 m -143.46 157.9 44.07 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.474 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.731 HG12 HG21 ' A' ' 63' ' ' VAL . 48.8 t -126.41 131.69 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.18 49.21 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.361 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.56 115.18 26.77 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 95.14 -8.42 69.85 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -72.21 156.11 39.5 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.921 0.391 . . . . 0.0 110.492 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.3 m -86.96 129.47 34.87 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.653 178.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.0 m -129.86 158.98 42.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.431 -177.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -119.91 129.44 54.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 50.3 p90 -158.11 161.03 37.92 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.783 -0.767 . . . . 0.0 112.567 -177.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -85.36 152.98 22.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.336 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.426 HG12 ' HB ' ' A' ' 55' ' ' ILE . 59.8 t -107.18 124.67 63.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 120.473 -0.491 . . . . 0.0 109.985 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 83.3 t -121.28 129.41 75.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -67.3 125.81 27.25 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.954 -178.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -118.11 156.59 15.58 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -60.26 -45.4 93.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.729 0.3 . . . . 0.0 110.957 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.3 pttm -77.12 -18.86 57.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.368 . . . . 0.0 111.324 178.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.48 33.29 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.32 140.16 58.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.86 0.362 . . . . 0.0 110.509 179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -127.31 135.39 50.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.621 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 1.057 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -85.33 154.66 21.74 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.034 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.36 151.9 32.38 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.297 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 53.35 46.52 26.18 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.161 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 98.9 t -70.75 124.09 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.126 -179.125 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -140.91 165.55 27.21 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.76 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.78 172.93 52.61 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 53.5 Cg_endo -70.6 136.77 31.54 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.061 1.841 . . . . 0.0 112.102 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.25 20.25 79.67 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 3.04 90.67 Favored Glycine 0 CA--C 1.532 1.146 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 75.4 t -63.68 138.09 97.28 Favored Pre-proline 0 CA--C 1.536 0.416 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.66 152.42 81.95 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.579 1.519 . . . . 0.0 111.337 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 94.7 t -68.92 131.31 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.563 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -61.11 -45.4 94.87 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.518 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.92 159.1 26.42 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -74.9 162.49 28.58 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.82 0.343 . . . . 0.0 110.581 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -72.35 -24.91 61.35 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.528 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -69.83 -15.4 63.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.052 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.481 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . -58.5 140.58 53.8 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.433 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.597 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.514 -1.384 0 C4'-C3'-C2' 101.715 -1.485 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.428 -0.77 0 P-O3'-C3' 121.099 1.166 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.591 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.433 -1.162 0 O4'-C4'-C3' 103.95 -1.65 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.801 0 C3'-C2'-C1' 101.793 -0.648 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.847 0 O4'-C4'-C3' 104.28 -1.32 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.28 0 C1'-O4'-C4' 106.8 -2.072 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.433 -1.147 0 O4'-C1'-C2' 107.509 1.281 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -72.82 148.59 44.36 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.239 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -68.96 133.41 48.14 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.264 0.554 . . . . 0.0 110.969 179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 98.1 t -93.87 99.83 10.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.348 179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 95.1 mt -62.43 -43.32 98.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.036 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.84 160.8 42.89 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.08 0.467 . . . . 0.0 111.107 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.651 ' O ' HG23 ' A' ' 59' ' ' VAL . 3.2 p -99.22 -146.21 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.646 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -50.06 108.01 0.19 Allowed 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.451 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 57' ' ' THR . 70.1 t -126.72 129.83 71.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.721 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.3 mt -74.83 137.1 41.64 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.22 -179.42 24.17 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.8 m -128.15 135.87 50.36 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.856 0.36 . . . . 0.0 110.451 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 84.7 t -75.99 109.25 9.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.708 -179.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -62.04 -49.65 75.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 60.9 p-90 -174.72 146.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.979 178.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.2 t80 -142.58 121.16 12.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -103.47 123.12 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.592 -0.443 . . . . 0.0 110.868 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.0 t -63.79 -45.88 95.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.477 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.04 -44.77 96.89 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -62.2 -38.14 87.99 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 91.86 2.26 69.56 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.423 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -148.77 161.3 42.07 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-N 117.454 0.627 . . . . 0.0 110.057 179.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.5 178.36 36.55 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.536 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -126.12 143.39 51.14 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.201 0.524 . . . . 0.0 112.118 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 86.2 mt -120.02 127.23 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.828 178.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -89.0 118.08 28.48 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.2 mtm180 -72.51 131.9 43.13 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.212 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -83.36 -6.35 59.44 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.267 179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.87 -33.25 11.7 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.002 0.429 . . . . 0.0 110.086 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -114.06 -11.68 12.69 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.861 -0.608 . . . . 0.0 111.734 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.8 mttp 55.62 33.02 20.36 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.641 -0.424 . . . . 0.0 109.964 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -122.51 137.83 54.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.289 0.566 . . . . 0.0 111.248 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.24 142.27 57.8 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.046 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.478 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 80.0 t -127.79 131.16 70.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.876 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -69.08 138.8 54.62 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.328 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.21 149.31 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.163 0.506 . . . . 0.0 110.979 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -136.13 159.31 42.11 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.855 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.457 HE22 HD21 ' A' ' 100' ' ' LEU . 97.5 mt-30 -61.3 -39.49 90.65 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.2 p -66.6 -18.31 65.3 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.4 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.95 -0.79 55.48 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.095 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.463 HD11 HG23 ' A' ' 103' ' ' VAL . 84.0 mt -95.74 103.44 14.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.97 0.414 . . . . 0.0 111.091 -178.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -63.25 -43.96 96.53 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.292 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -127.27 147.38 50.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.088 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -154.44 177.55 11.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.336 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -65.6 120.8 71.32 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.09 -22.16 62.17 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.069 1.846 . . . . 0.0 112.515 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.3 mmm180 -67.46 -21.75 65.52 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -100.87 122.62 43.77 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-O 120.701 0.286 . . . . 0.0 110.534 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -61.0 -48.43 81.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.74 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.457 HD21 HE22 ' A' ' 88' ' ' GLN . 66.3 tp -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 -60.95 132.48 54.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.999 0.428 . . . . 0.0 110.37 -179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.8 m -148.39 159.9 43.56 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.547 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 52.6 t -121.33 127.8 75.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.421 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -69.2 149.53 49.02 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.403 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -85.81 134.68 33.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.56 4.02 90.13 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -91.44 130.47 37.27 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.989 0.423 . . . . 0.0 110.465 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.4 m -69.15 132.71 46.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.651 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.4 m -129.99 157.53 42.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.471 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -117.59 126.74 53.07 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.409 ' HB3' HG22 ' A' ' 125' ' ' VAL . 51.0 p90 -156.57 163.6 39.17 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.718 -0.793 . . . . 0.0 112.537 -177.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -88.52 149.64 23.52 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.238 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.9 t -106.86 124.93 62.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.429 -0.508 . . . . 0.0 109.964 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 97.7 t -117.8 129.24 74.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -61.81 124.44 20.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.027 0.441 . . . . 0.0 110.935 -178.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.7 157.85 14.72 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 179.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -63.04 -39.55 95.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.663 0.268 . . . . 0.0 110.913 -179.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -91.22 -11.62 37.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.334 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 158.29 -171.29 35.14 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -66.04 147.85 52.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -119.39 157.46 28.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.645 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.478 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -119.89 143.22 48.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.076 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.1 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.261 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 53.5 45.84 27.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.977 0.418 . . . . 0.0 110.147 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 111' ' ' PHE . 85.4 t -72.99 120.44 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.136 -179.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.49 164.2 30.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.877 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.54 172.46 50.57 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.464 ' O ' HG23 ' A' ' 131' ' ' VAL . 52.5 Cg_endo -70.13 136.9 33.16 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 122.041 1.827 . . . . 0.0 112.162 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.33 19.68 79.78 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.03 1.26 89.73 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 128' ' ' PRO . 71.0 t -62.0 138.06 95.66 Favored Pre-proline 0 CA--C 1.536 0.408 0 O-C-N 122.776 -0.25 . . . . 0.0 110.556 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.91 150.3 88.31 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 121.687 1.591 . . . . 0.0 111.335 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.54 133.95 30.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.561 -179.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -60.48 -41.75 94.84 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.589 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.96 179.54 52.71 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.4 m -106.03 160.88 14.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.927 0.394 . . . . 0.0 110.552 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -61.09 -37.43 82.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.535 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -65.21 -14.6 61.03 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.118 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.539 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -58.85 142.02 51.65 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.479 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.54 -179.792 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.613 0 O4'-C4'-C3' 107.04 1.44 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.856 0 C3'-C2'-C1' 104.542 1.316 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.444 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.427 -0.813 0 P-O3'-C3' 121.473 1.477 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.858 0 C3'-C2'-C1' 101.773 -0.662 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.887 0 O4'-C4'-C3' 104.05 -1.55 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.268 0 C1'-O4'-C4' 107.07 -1.879 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.788 0 O4'-C1'-C2' 107.069 0.881 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -71.5 145.05 49.41 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.159 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.47 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.1 tttm -66.57 134.39 52.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.183 0.516 . . . . 0.0 110.94 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t -101.8 106.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.798 . . . . 0.0 109.408 178.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.447 ' HB ' HG12 ' A' ' 113' ' ' VAL . 96.1 mt -63.17 -44.78 99.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.039 -178.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.1 163.57 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.086 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.588 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.7 t -102.68 -148.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.658 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.416 ' N ' HG23 ' A' ' 57' ' ' THR . 59.1 mtmt -52.67 115.43 1.8 Allowed 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.388 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 57' ' ' THR . 75.7 t -132.3 130.38 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.755 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.1 mt -75.3 131.23 40.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.12 0.486 . . . . 0.0 109.771 178.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.66 -177.03 20.95 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.4 m -128.38 137.41 51.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.868 0.366 . . . . 0.0 110.478 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.704 HG21 HG12 ' A' ' 103' ' ' VAL . 96.1 t -73.82 115.06 14.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.536 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.4 tttt -62.88 -48.95 76.79 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 179.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.536 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 53.6 p-90 -179.31 140.28 0.15 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.99 178.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -135.96 117.26 14.59 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -102.67 123.67 46.8 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.876 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.4 t -62.84 -45.64 98.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.487 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -61.08 -45.37 95.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -62.74 -38.61 91.2 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.493 -0.483 . . . . 0.0 110.836 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.13 2.24 68.88 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.37 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -148.44 161.44 41.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.394 0.597 . . . . 0.0 110.14 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -157.22 -179.5 32.19 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.571 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.417 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.6 m-85 -129.37 146.47 51.23 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 79.2 mt -125.7 128.22 72.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.79 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -94.26 126.22 39.38 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.857 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 95.1 mtm-85 -74.9 131.47 40.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.092 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -84.07 -0.16 50.69 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.305 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -100.79 -33.31 10.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.945 0.403 . . . . 0.0 110.112 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 81.4 p -116.5 -8.57 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.758 -0.656 . . . . 0.0 111.647 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt 56.22 30.86 17.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.397 . . . . 0.0 110.006 -179.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -117.08 137.14 52.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.21 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.5 p-10 -74.25 158.05 34.76 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.113 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.3 p -144.23 148.51 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.947 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -77.94 136.68 38.04 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.375 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -143.96 148.1 19.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.159 0.504 . . . . 0.0 110.976 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -133.28 159.11 41.18 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.945 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.85 -25.56 65.13 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.8 p -74.86 -16.15 60.69 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.478 179.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.24 0.46 55.33 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.142 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.436 HD11 HG23 ' A' ' 103' ' ' VAL . 80.5 mt -95.13 100.47 11.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.12 -178.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -64.65 -41.8 95.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.298 179.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.15 138.4 52.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.123 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -148.54 153.73 38.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.342 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -58.62 120.83 48.67 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.31 -19.19 61.93 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 121.92 1.746 . . . . 0.0 112.557 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.0 mmm-85 -63.31 -23.96 67.64 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.408 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -101.39 133.24 46.31 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 120.686 0.279 . . . . 0.0 110.652 -179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -68.62 -38.46 80.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.745 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.9 mt -103.92 142.8 33.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.244 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.5 mtt85 -66.87 137.98 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.303 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -156.59 153.25 28.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.471 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 63' ' ' VAL . 42.3 t -119.58 131.96 70.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -59.16 143.09 46.18 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.344 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -81.96 120.24 24.98 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.14 2.39 89.37 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.6 tp10 -81.71 137.42 35.39 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.903 0.383 . . . . 0.0 110.554 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 88.1 m -68.83 132.46 46.8 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.726 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.0 157.78 42.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.413 -178.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -117.43 126.99 53.58 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.407 ' HB3' HG22 ' A' ' 125' ' ' VAL . 48.4 p90 -154.82 162.09 41.24 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 119.807 -0.757 . . . . 0.0 112.565 -177.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -93.14 149.13 21.44 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.246 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.447 HG12 ' HB ' ' A' ' 55' ' ' ILE . 62.0 t -107.47 126.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.469 -0.492 . . . . 0.0 109.956 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 53' ' ' LYS . 12.5 p -133.56 142.08 42.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.421 ' HG3' HG13 ' A' ' 55' ' ' ILE . 96.7 mt-10 -63.39 134.02 55.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.988 0.423 . . . . 0.0 110.877 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -118.51 164.91 12.88 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 51.5 mp0 -62.19 -40.6 96.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.712 0.292 . . . . 0.0 110.989 -179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.85 -0.03 57.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.343 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 136.54 -168.91 24.0 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -58.31 136.67 57.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -132.43 135.33 46.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.695 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.15 152.67 29.1 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.973 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.97 157.12 43.18 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.193 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 53.4 44.88 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.436 . . . . 0.0 110.215 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.407 HG22 ' HB3' ' A' ' 111' ' ' PHE . 95.1 t -72.05 124.07 27.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.073 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.4 p -136.67 168.48 19.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.789 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.65 171.07 54.45 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -66.61 138.97 51.5 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 C-N-CA 121.929 1.753 . . . . 0.0 112.175 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 74.27 16.8 79.66 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.89 2.45 90.55 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.706 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -68.4 147.95 98.18 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-O 119.704 -0.189 . . . . 0.0 110.55 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . 0.706 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.6 Cg_exo -59.48 150.73 73.79 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.582 1.521 . . . . 0.0 111.309 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t -66.36 131.34 32.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.622 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -61.74 -39.97 93.45 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.497 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.47 -173.64 54.85 Favored Glycine 0 CA--C 1.524 0.623 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.66 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 71.1 m -112.5 157.96 20.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.822 0.344 . . . . 0.0 110.59 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -60.55 -37.69 82.08 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.384 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -60.87 -19.5 60.3 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.111 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -60.05 137.81 58.01 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.449 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.627 -179.821 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.473 0 C3'-C2'-C1' 104.964 1.617 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.938 0 O4'-C4'-C3' 102.782 -2.818 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.58 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.433 -1.19 0 O4'-C4'-C3' 103.518 -2.082 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.886 0 C3'-C2'-C1' 101.076 -1.16 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.81 0 C4'-C3'-C2' 102.403 -0.797 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.33 0 C1'-O4'-C4' 107.268 -1.737 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.83 0 C3'-C2'-C1' 104.29 1.135 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 23.1 t0 . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -71.51 145.74 48.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.225 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -62.74 133.71 55.2 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.176 0.512 . . . . 0.0 110.974 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.74 101.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.46 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.45 -42.94 97.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.108 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.417 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -147.11 157.32 43.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.799 ' O ' HG23 ' A' ' 59' ' ' VAL . 9.9 p -102.47 -149.99 0.4 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.609 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -48.25 104.66 0.06 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.497 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 57' ' ' THR . 96.7 t -125.04 129.37 73.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.696 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.0 mt -75.37 138.59 41.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.132 0.492 . . . . 0.0 109.762 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.39 -178.15 25.0 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -129.05 137.76 51.48 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.878 0.37 . . . . 0.0 110.491 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.68 HG21 HG12 ' A' ' 103' ' ' VAL . 92.1 t -73.11 109.86 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.754 -179.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.511 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 61.9 tttm -61.16 -50.93 71.18 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.511 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.3 p-90 -176.65 139.55 0.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.016 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -137.92 116.57 12.17 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -99.34 121.72 41.49 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.964 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.26 -45.82 97.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.426 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -62.71 -42.1 99.48 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -62.2 -39.06 91.49 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.835 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.4 2.23 65.87 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.354 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -149.56 162.19 40.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 117.464 0.632 . . . . 0.0 109.984 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.33 -179.28 35.95 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.499 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.444 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.9 m-85 -130.33 144.9 51.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.213 0.53 . . . . 0.0 112.127 -178.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.4 mt -120.11 126.33 75.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.839 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -93.16 119.76 32.71 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -72.85 133.79 44.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.161 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -83.23 -8.58 59.45 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.29 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -93.04 -33.18 14.2 Favored 'General case' 0 C--O 1.231 0.121 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.092 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 79.1 p -115.31 -9.13 12.23 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.75 -178.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.4 mttt 53.37 32.7 14.25 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.972 -179.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -120.39 134.74 55.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.332 0.587 . . . . 0.0 111.219 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -64.36 144.2 57.34 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.03 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 95.0 t -130.05 133.1 64.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.878 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -65.51 138.29 57.97 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.396 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.18 147.76 18.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.251 0.548 . . . . 0.0 110.855 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -137.73 160.2 39.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.293 -0.867 . . . . 0.0 109.926 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.406 ' HA ' HD12 ' A' ' 91' ' ' ILE . 97.2 mt-30 -61.73 -39.03 90.13 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -178.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.7 p -67.99 -16.07 63.88 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.453 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -87.84 2.41 51.48 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.406 HD12 ' HA ' ' A' ' 88' ' ' GLN . 85.0 mt -98.6 107.73 20.91 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.885 0.374 . . . . 0.0 111.245 -178.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -65.63 -42.65 91.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.349 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.038 -178.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -144.11 168.78 19.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.388 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -55.12 121.14 34.54 Favored Pre-proline 0 CA--C 1.539 0.553 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.96 -41.69 72.5 Favored 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 121.933 1.756 . . . . 0.0 112.597 -178.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -63.86 -14.63 54.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? -104.39 118.03 35.61 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 120.688 0.28 . . . . 0.0 110.616 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -77.26 -22.83 51.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.915 0.388 . . . . 0.0 110.785 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 65.4 tp -100.72 125.61 47.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.173 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.64 133.8 56.46 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.584 -0.447 . . . . 0.0 110.31 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.3 t -160.79 151.92 18.93 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.495 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.68 HG12 HG21 ' A' ' 63' ' ' VAL . 56.6 t -118.59 127.13 75.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.68 145.85 46.02 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.334 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -83.56 135.42 34.64 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.3 4.06 89.86 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -92.43 131.87 37.24 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 120.958 0.409 . . . . 0.0 110.461 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.6 m -69.47 133.66 47.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.64 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.8 m -131.8 158.47 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.231 -0.588 . . . . 0.0 111.462 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.67 130.52 55.09 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -156.57 164.12 38.57 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 119.778 -0.769 . . . . 0.0 112.541 -177.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -97.3 140.28 32.0 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.368 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.3 t -100.86 125.65 54.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.066 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -121.24 132.03 71.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -63.38 126.86 28.85 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.942 -178.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.07 164.15 12.18 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -61.66 -42.63 99.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.765 0.317 . . . . 0.0 111.006 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -83.39 -21.56 33.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.408 179.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 160.73 -169.24 36.38 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.729 -0.949 . . . . 0.0 110.729 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.19 143.93 57.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.887 0.375 . . . . 0.0 110.39 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -131.55 150.46 52.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.591 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.531 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -105.19 145.16 30.99 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.975 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.14 162.93 39.49 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.195 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 54.06 45.23 27.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.985 0.421 . . . . 0.0 110.173 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.7 t -74.25 123.91 30.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.048 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.9 p -138.32 167.93 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.806 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.96 174.38 53.05 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.433 ' O ' HG23 ' A' ' 131' ' ' VAL . 48.5 Cg_endo -68.86 137.6 38.58 Favored 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.065 1.844 . . . . 0.0 112.121 -178.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.02 20.19 78.81 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.92 2.11 90.65 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.5 t -63.37 137.21 97.01 Favored Pre-proline 0 CA--C 1.537 0.449 0 O-C-N 122.78 -0.247 . . . . 0.0 110.56 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.94 145.42 91.32 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.561 1.507 . . . . 0.0 111.314 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.58 132.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -60.84 -43.1 98.73 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.456 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.99 -179.93 52.83 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 37.9 t -106.19 141.07 38.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.849 0.357 . . . . 0.0 110.589 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.5 ptmt -59.26 -21.88 60.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.44 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 70.1 m-85 -66.07 -22.62 66.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.139 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -56.92 137.57 55.14 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.47 -179.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.62 -179.627 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.526 0 C3'-C2'-C1' 105.019 1.656 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.856 0 O4'-C4'-C3' 103.675 -1.925 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.575 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.432 -1.278 0 O4'-C4'-C3' 103.326 -2.274 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.943 0 C3'-C2'-C1' 100.782 -1.37 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.819 0 O4'-C1'-C2' 107.379 1.163 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.243 0 C1'-O4'-C4' 105.9 -2.714 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.818 0 O4'-C1'-C2' 107.534 1.304 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.5 t0 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -142.89 157.3 44.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.211 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.484 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.1 tttm -102.02 129.11 48.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.175 0.512 . . . . 0.0 110.969 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.4 t -96.17 102.15 13.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.399 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.438 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.4 mt -63.14 -44.28 99.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.033 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -149.01 164.08 35.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 15.0 t -101.99 -149.05 0.38 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.648 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 57' ' ' THR . 58.4 mtmt -52.3 117.01 2.52 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.431 -178.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 84.8 t -133.21 131.37 58.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.687 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.3 mt -76.01 136.07 39.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.084 0.469 . . . . 0.0 109.776 178.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.55 -179.36 24.42 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.5 m -127.06 140.67 52.12 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.937 0.398 . . . . 0.0 110.455 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.691 HG21 HG12 ' A' ' 103' ' ' VAL . 93.0 t -82.21 111.24 18.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.739 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 64.9 tttp -62.77 -49.93 73.03 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 63.2 p-90 -169.81 154.41 5.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.645 -1.161 . . . . 0.0 109.927 177.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -142.5 118.68 10.75 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 -98.23 112.1 24.2 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.993 0.425 . . . . 0.0 110.892 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.423 HG21 ' N ' ' A' ' 139' ' ' ALA . 73.9 t -61.75 -45.05 99.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.381 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 59.2 ttt85 -61.09 -44.5 97.26 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.08 -38.71 92.27 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.444 -0.503 . . . . 0.0 110.821 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.15 4.49 59.87 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.387 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -152.37 162.0 41.8 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 117.43 0.615 . . . . 0.0 110.102 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.521 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -156.04 -176.05 27.73 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.56 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.448 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 90.9 m-85 -126.3 145.14 50.55 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 121.155 0.502 . . . . 0.0 112.138 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 83.3 mt -120.12 125.45 74.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.896 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -90.66 109.59 20.76 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.479 -0.488 . . . . 0.0 110.813 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -62.87 135.32 57.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.13 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -86.37 -2.3 58.3 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.316 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -100.14 -34.05 10.2 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.973 0.416 . . . . 0.0 110.144 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 70.7 p -115.44 -9.25 12.13 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.679 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mmtm 55.43 29.96 14.15 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -115.18 133.62 55.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.375 0.607 . . . . 0.0 111.299 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.9 142.52 58.26 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.985 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.7 t -124.83 133.27 69.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -70.77 138.18 50.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.313 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -148.73 148.69 15.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.183 0.516 . . . . 0.0 110.954 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -132.79 155.77 48.33 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.886 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -60.15 -23.67 64.1 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 80.5 p -83.33 -10.41 58.5 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.591 -0.443 . . . . 0.0 110.401 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.91 3.61 55.39 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.116 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.428 HD11 HG23 ' A' ' 103' ' ' VAL . 86.1 mt -99.13 106.1 18.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-O 120.994 0.426 . . . . 0.0 111.228 -178.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -63.31 -44.78 94.02 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.327 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -122.3 141.21 51.76 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.125 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -150.23 176.34 10.95 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.349 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -64.95 120.42 66.56 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.69 -23.35 63.4 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 122.01 1.807 . . . . 0.0 112.578 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.9 mmm-85 -68.5 -19.62 64.54 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.412 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt -98.93 129.33 45.25 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 120.678 0.275 . . . . 0.0 110.661 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -67.52 -37.86 83.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.966 0.412 . . . . 0.0 110.731 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.2 mt -105.6 141.34 37.22 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.258 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.28 138.76 57.87 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.319 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.409 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 93.8 p -156.96 162.75 39.61 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.532 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.691 HG12 HG21 ' A' ' 63' ' ' VAL . 45.6 t -125.88 130.97 72.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.38 143.8 37.94 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.294 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.4 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 41.0 p-10 -75.92 132.75 40.46 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.65 4.83 89.45 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 63' ' ' VAL . 85.3 tt0 -86.93 129.48 34.86 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.007 0.432 . . . . 0.0 110.488 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 99.6 m -71.1 131.2 43.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.67 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.3 158.49 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.455 -177.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.91 129.0 54.95 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 178.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 45.9 p90 -155.68 162.82 40.5 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.582 -177.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -92.4 149.46 21.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.375 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HB ' ' A' ' 55' ' ' ILE . 60.5 t -108.19 126.35 64.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.937 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 53' ' ' LYS . 14.6 p -127.16 133.13 68.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -69.63 126.84 30.93 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.865 -178.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.47 162.88 12.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -61.19 -39.58 90.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.713 0.292 . . . . 0.0 110.95 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -85.56 -11.73 53.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.38 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 146.79 -172.84 27.2 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -63.47 140.12 58.84 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.885 0.374 . . . . 0.0 110.417 179.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.94 152.55 49.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.672 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -109.96 147.75 32.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.989 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.43 161.08 41.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.145 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 54.51 44.37 28.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.984 0.421 . . . . 0.0 110.125 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 91.8 t -72.81 122.77 26.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.092 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 62.7 p -136.91 163.79 29.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.783 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.43 168.57 54.8 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.099 -1.601 . . . . 0.0 109.099 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.426 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.5 Cg_exo -59.52 138.09 81.69 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 121.903 1.736 . . . . 0.0 112.094 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.21 19.04 75.45 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.77 4.42 90.34 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -62.63 136.94 96.35 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 122.699 -0.295 . . . . 0.0 110.484 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -58.44 146.96 88.24 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.552 1.502 . . . . 0.0 111.335 179.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.4 132.37 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.645 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 11.8 tp-100 -61.34 -41.41 96.99 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.549 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.23 -176.59 50.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.2 m -105.49 157.85 17.08 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.75 0.31 . . . . 0.0 110.64 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -60.84 -37.39 81.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.51 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -63.88 -17.3 63.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.055 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 68' ' ' VAL . . . -60.66 138.47 58.07 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.435 -179.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.41 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.63 -179.791 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.57 0 C3'-C2'-C1' 105.055 1.682 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.83 0 O4'-C4'-C3' 103.023 -2.577 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.501 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.426 -1.789 0 O4'-C4'-C3' 103.202 -2.398 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.436 -0.899 0 O4'-C4'-C3' 103.987 -1.613 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . 0.415 " H1'" ' C2 ' ' B' ' 306' ' ' ' DC' . . . . . . . . 0 C3'--C2' 1.528 0.979 0 O4'-C1'-C2' 107.033 0.848 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . 0.415 ' C2 ' " H1'" ' B' ' 305' ' ' ' DC' . . . . . . . . 0 C3'--C2' 1.532 1.353 0 C1'-O4'-C4' 106.905 -1.997 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.879 0 C4'-C3'-C2' 104.835 1.635 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -144.43 160.24 41.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.207 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -66.94 136.06 54.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.196 0.522 . . . . 0.0 110.9 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.6 t -99.04 101.91 12.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.482 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.25 -44.42 99.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.071 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.52 157.25 43.1 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.632 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.4 p -102.41 -147.42 0.37 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.668 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -51.93 107.44 0.2 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.441 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 57' ' ' THR . 76.1 t -125.11 131.24 72.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.745 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 68.8 mt -69.09 134.98 50.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.069 0.462 . . . . 0.0 109.838 178.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.77 178.23 30.82 Favored Glycine 0 CA--C 1.519 0.341 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m -130.77 137.77 49.62 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.866 0.365 . . . . 0.0 110.466 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -70.45 112.39 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.813 -179.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.51 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.45 -48.59 80.44 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.51 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.8 p-90 -177.32 140.06 0.27 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 114.564 -1.198 . . . . 0.0 109.95 177.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -138.14 115.28 10.96 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -100.21 124.44 45.64 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.934 -178.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -63.3 -46.08 96.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.452 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -61.19 -44.44 97.29 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.91 -39.21 93.84 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.872 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.42 4.78 65.83 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.365 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -151.75 162.59 40.77 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 117.442 0.621 . . . . 0.0 110.078 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.65 -178.4 34.6 Favored Glycine 0 CA--C 1.525 0.689 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.557 -179.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.442 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.7 m-85 -129.64 148.67 51.56 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.124 0.488 . . . . 0.0 112.095 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.421 HG13 HG11 ' A' ' 86' ' ' VAL . 82.4 mt -118.67 126.79 75.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.428 -0.806 . . . . 0.0 109.863 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -91.54 110.24 21.55 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.876 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -65.72 130.36 43.0 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.085 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -87.54 -3.58 58.99 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.331 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -97.74 -31.5 12.22 Favored 'General case' 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.393 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.0 p -113.28 -9.89 13.38 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.686 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp 57.77 32.14 21.48 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.024 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -126.23 148.88 49.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.34 0.59 . . . . 0.0 111.168 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -82.3 158.87 23.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.035 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 p -142.93 150.6 17.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -78.15 135.79 37.72 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.352 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.421 HG11 HG13 ' A' ' 75' ' ' ILE . 5.5 p -146.52 147.99 17.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.104 0.478 . . . . 0.0 110.864 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -136.21 159.1 42.76 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.9 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.465 ' HA ' HD12 ' A' ' 91' ' ' ILE . 27.6 pt20 -59.19 -25.02 63.6 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -178.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -74.44 -16.05 60.88 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.468 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.461 ' HB1' ' HA ' ' A' ' 123' ' ' ALA . . . -89.32 2.96 53.63 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.155 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.465 HD12 ' HA ' ' A' ' 88' ' ' GLN . 84.5 mt -95.87 103.12 14.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.905 0.383 . . . . 0.0 111.153 -178.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -65.19 -43.67 90.9 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.314 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -119.17 144.23 46.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.134 -178.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 54.0 t30 -144.1 171.18 14.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.439 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.8 t-20 -61.07 122.87 72.6 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.64 -23.12 57.04 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 121.906 1.737 . . . . 0.0 112.522 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 57.4 mmm-85 -73.38 -14.06 61.21 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.399 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -114.2 142.22 46.54 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 120.746 0.308 . . . . 0.0 110.658 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.488 ' CE1' HD21 ' A' ' 100' ' ' LEU . 43.9 p90 -98.35 4.91 48.61 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.694 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.699 ' CD1' ' HB3' ' A' ' 140' ' ' ALA . 88.7 mt -119.42 142.4 48.25 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.156 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -81.15 125.98 30.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.416 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 87.9 p -156.38 162.44 40.05 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.507 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 39.7 t -131.53 134.63 60.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.38 147.98 50.36 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.338 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -84.91 120.82 26.91 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.25 -5.61 82.8 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.04 135.21 41.27 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-O 121.069 0.462 . . . . 0.0 110.44 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.2 m -70.88 131.46 43.79 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.636 179.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 19.9 m -135.93 159.38 39.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.39 -178.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -116.11 138.54 51.16 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.6 p90 -159.44 164.04 34.87 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.523 -177.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -98.59 138.49 35.71 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.218 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 65.0 t -107.02 127.21 62.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 120.463 -0.495 . . . . 0.0 110.033 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m -119.56 156.73 21.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -89.37 118.06 28.75 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.008 0.432 . . . . 0.0 110.91 -178.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -106.91 167.91 14.1 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -61.77 -44.71 96.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.715 0.293 . . . . 0.0 110.943 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -74.9 -22.89 58.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.37 179.081 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 153.83 -164.76 31.37 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -65.59 143.16 57.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.88 0.372 . . . . 0.0 110.38 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -127.43 159.32 34.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.636 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.16 143.41 43.25 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.966 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.461 ' HA ' ' HB1' ' A' ' 90' ' ' ALA . . . -153.22 161.07 42.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.231 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 56.84 47.17 18.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.986 0.422 . . . . 0.0 110.125 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.7 t -77.61 121.08 29.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.114 -179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 59.2 p -137.88 169.04 18.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.797 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.26 167.73 54.84 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 131' ' ' VAL . 34.8 Cg_exo -60.63 138.12 77.84 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.99 1.793 . . . . 0.0 112.146 -178.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.5 20.58 78.48 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 178.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.35 0.47 89.84 Favored Glycine 0 CA--C 1.532 1.108 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 128' ' ' PRO . 78.3 t -61.02 138.21 94.15 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-O 119.667 -0.206 . . . . 0.0 110.556 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -61.56 148.37 93.15 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 121.662 1.575 . . . . 0.0 111.233 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.5 t -63.81 130.77 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.653 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -62.31 -40.11 95.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.615 -179.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.77 157.42 33.15 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 81.5 p -76.19 160.2 29.93 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 120.921 0.391 . . . . 0.0 110.539 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -70.32 -23.48 62.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.513 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -80.09 -2.96 46.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.144 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.31 138.73 56.21 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.465 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.699 ' HB3' ' CD1' ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.62 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.517 0 C3'-C2'-C1' 105.11 1.722 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.925 0 O4'-C4'-C3' 103.714 -1.886 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.574 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.429 -1.51 0 O4'-C4'-C3' 103.22 -2.38 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.899 0 C3'-C2'-C1' 101.774 -0.661 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.895 0 O4'-C1'-C2' 107.203 1.003 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.316 0 C1'-O4'-C4' 107.46 -1.6 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.832 0 O4'-C1'-C2' 106.875 0.704 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 23.4 pttp -146.92 159.44 43.54 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.165 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.42 ' O ' HG13 ' A' ' 114' ' ' VAL . 64.1 tttp -110.86 131.61 54.9 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.21 0.529 . . . . 0.0 110.996 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 97.0 t -94.68 102.95 14.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.389 178.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.454 ' HB ' HG12 ' A' ' 113' ' ' VAL . 95.4 mt -63.77 -45.9 95.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.002 -179.056 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -158.21 162.2 37.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.762 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.7 t -96.38 -142.86 0.28 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.57 179.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.478 ' N ' HG23 ' A' ' 57' ' ' THR . 76.0 mmtt -50.34 103.28 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.291 -0.563 . . . . 0.0 110.416 -179.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 57' ' ' THR . 95.0 t -119.28 128.59 75.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 80.0 mt -64.33 130.75 45.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.082 0.468 . . . . 0.0 109.776 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.16 174.45 23.75 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -129.22 134.31 47.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.941 0.4 . . . . 0.0 110.488 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.674 HG21 HG12 ' A' ' 103' ' ' VAL . 98.6 t -75.43 108.48 7.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.723 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 22.0 ttmm -63.2 -48.22 79.23 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 62.4 p-90 -176.14 143.82 0.55 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.616 -1.174 . . . . 0.0 109.925 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -138.53 115.65 10.98 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.412 HD22 ' ND2' ' A' ' 70' ' ' ASN . 99.5 m-20 -100.0 119.21 37.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.978 0.418 . . . . 0.0 110.922 -179.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.58 -46.7 94.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.509 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -62.46 -41.49 98.8 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -177.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.412 ' ND2' HD22 ' A' ' 67' ' ' ASN . 96.2 m-20 -62.82 -38.61 91.39 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.494 -0.482 . . . . 0.0 110.809 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.37 4.54 64.2 Favored Glycine 0 CA--C 1.531 1.042 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.382 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.404 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 40.9 p90 -148.88 160.18 43.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 117.528 0.664 . . . . 0.0 110.107 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -160.66 173.22 37.16 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.515 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -128.12 146.88 50.56 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.096 0.474 . . . . 0.0 112.232 -179.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 85.3 mt -120.61 125.86 74.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.855 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -91.4 111.15 22.53 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.509 -0.477 . . . . 0.0 110.899 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.459 ' NH1' HG11 ' A' ' 113' ' ' VAL . 88.7 mtm180 -61.5 133.35 55.62 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.113 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -86.29 -12.16 50.26 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.339 -0.544 . . . . 0.0 111.311 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -89.49 -29.87 18.67 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-O 121.022 0.439 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.6 p -116.46 -11.42 11.15 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.694 -178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 58.0 mtpt 57.04 32.11 21.1 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -119.77 134.04 55.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.22 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -64.72 143.19 58.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.058 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.593 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 58.0 t -127.78 130.98 70.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.829 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -70.99 130.04 40.55 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.425 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.04 149.55 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.163 0.506 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -131.14 164.99 24.28 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.889 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.64 -39.75 94.82 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -69.69 -17.2 63.46 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.443 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.36 -2.63 53.49 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.169 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.7 mt -96.77 106.48 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.949 0.404 . . . . 0.0 111.112 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.75 -43.06 97.56 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.296 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -125.11 142.42 51.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.129 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -148.88 176.18 10.63 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.437 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.5 t-20 -66.23 117.33 42.21 Favored Pre-proline 0 CA--C 1.54 0.569 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.91 -31.34 95.3 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.979 1.786 . . . . 0.0 112.588 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.8 mmm-85 -64.23 -19.96 65.71 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.294 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.482 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 76.0 mmtt -93.14 129.0 39.28 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 120.671 0.272 . . . . 0.0 110.613 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -67.68 -37.96 83.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.873 0.368 . . . . 0.0 110.785 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.1 mt -110.1 144.63 38.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.257 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -65.82 137.67 57.38 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.329 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.2 p -156.86 163.07 39.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.455 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.674 HG12 HG21 ' A' ' 63' ' ' VAL . 46.9 t -128.82 130.39 68.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.56 149.0 49.22 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.384 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -86.56 134.47 33.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.62 1.68 90.55 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.9 tp10 -91.75 130.27 37.57 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-O 120.888 0.375 . . . . 0.0 110.526 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -70.16 134.36 48.05 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.69 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.8 m -133.93 161.2 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.433 -178.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -120.54 136.35 54.81 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 178.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.452 ' HB3' HG22 ' A' ' 125' ' ' VAL . 29.2 p90 -157.58 161.06 38.71 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.563 -178.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -83.35 122.07 27.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.21 179.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.459 HG11 ' NH1' ' A' ' 77' ' ' ARG . 61.3 t -88.83 122.26 39.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.491 -0.484 . . . . 0.0 109.998 -179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.42 HG13 ' O ' ' A' ' 53' ' ' LYS . 59.4 t -122.01 129.24 75.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -67.61 127.08 31.43 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.899 -178.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -120.74 157.61 15.84 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -58.88 -47.84 83.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.026 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.5 pttm -71.58 -22.08 61.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.353 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 154.25 -168.31 32.52 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.67 140.13 58.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.942 0.401 . . . . 0.0 110.353 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -120.16 135.43 54.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.676 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.593 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -100.55 141.04 33.96 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.956 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.92 157.72 43.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.185 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 54.59 43.76 29.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.96 0.409 . . . . 0.0 110.076 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.7 t -70.18 125.43 28.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.09 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.0 p -138.92 164.76 28.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.775 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.91 164.35 54.24 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.526 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.4 Cg_exo -60.02 136.73 71.3 Favored 'Trans proline' 0 C--N 1.301 -1.942 0 C-N-CA 122.001 1.801 . . . . 0.0 112.06 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 76.89 13.64 83.42 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.96 -0.56 89.1 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.526 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.4 p -64.82 141.38 98.32 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-O 119.679 -0.2 . . . . 0.0 110.586 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . 0.409 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 18.4 Cg_endo -58.03 147.69 81.15 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.66 1.573 . . . . 0.0 111.349 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -69.9 134.46 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.585 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -60.94 -43.67 98.35 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.515 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.16 158.32 30.92 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -72.92 157.01 38.26 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.84 0.352 . . . . 0.0 110.619 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 14.9 ptmm? -69.3 -19.65 63.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.455 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -79.87 -7.7 58.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.128 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.482 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . -61.25 140.31 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.629 -0.428 . . . . 0.0 110.504 -179.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.563 -179.634 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.511 -1.664 0 N19-C1'-C2' 115.781 0.988 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.834 0 C4'-C3'-C2' 101.926 -1.274 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.466 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C4'-C3' 103.779 -1.821 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.92 0 C4'-C3'-C2' 102.199 -1.001 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.528 0.968 0 O4'-C1'-C2' 107.49 1.263 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.352 0 C1'-O4'-C4' 106.057 -2.602 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C1'-C2' 107.293 1.085 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 61.6 mtpt -123.63 146.8 47.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.189 -179.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -105.35 131.89 52.22 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.217 0.532 . . . . 0.0 110.867 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 54' ' ' VAL . 7.2 p -99.62 103.95 15.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.386 178.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.429 ' HB ' HG12 ' A' ' 113' ' ' VAL . 97.9 mt -62.06 -44.61 99.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.098 -179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.465 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.68 160.37 40.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.64 ' O ' HG23 ' A' ' 59' ' ' VAL . 14.4 p -98.02 -150.97 0.36 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.612 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -51.32 116.87 2.25 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.466 -178.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 57' ' ' THR . 86.7 t -132.59 131.2 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.681 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.8 mt -75.33 134.71 40.96 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.043 0.449 . . . . 0.0 109.849 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.29 -179.48 23.38 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.4 m -129.11 135.86 49.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 110.483 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.709 HG21 HG12 ' A' ' 103' ' ' VAL . 85.4 t -73.54 113.1 11.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.731 -179.319 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.45 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.6 ttpt -62.34 -46.77 87.21 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 55.9 p-90 -176.14 146.19 0.66 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.001 177.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -140.5 115.51 9.75 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -103.02 121.44 42.57 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.936 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.3 t -63.07 -44.56 99.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.452 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.426 ' HG3' ' N ' ' A' ' 70' ' ' ASN . 17.7 ptm180 -63.08 -35.11 79.18 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.426 ' N ' ' HG3' ' A' ' 69' ' ' ARG . 97.2 m-20 -69.36 -35.15 75.58 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.576 -0.449 . . . . 0.0 110.822 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 90.14 0.87 76.64 Favored Glycine 0 CA--C 1.531 1.057 0 C-N-CA 121.06 -0.591 . . . . 0.0 112.361 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -150.26 161.51 42.3 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 117.544 0.672 . . . . 0.0 110.086 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -154.98 179.43 31.02 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.603 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.435 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 95.9 m-85 -129.16 145.64 51.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.144 0.497 . . . . 0.0 112.131 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 84.9 mt -119.74 123.58 71.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.849 178.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.64 109.16 20.57 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.817 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -63.14 130.93 46.73 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.115 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.3 p30 -85.43 -0.08 53.79 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.406 -0.518 . . . . 0.0 111.37 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -99.07 -34.48 10.38 Favored 'General case' 0 C--O 1.231 0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.127 178.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 77.9 p -114.4 -10.95 12.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.687 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 58.09 29.99 18.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.95 0.405 . . . . 0.0 110.025 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -116.2 132.96 56.52 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 121.362 0.601 . . . . 0.0 111.247 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -62.67 142.25 58.17 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.089 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.504 HG11 ' HB2' ' A' ' 122' ' ' ALA . 76.6 t -128.1 131.01 69.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -65.92 141.12 58.34 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.394 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.8 p -146.92 148.45 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.182 0.515 . . . . 0.0 110.935 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.407 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 80.8 m80 -137.63 159.04 43.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.784 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -60.33 -41.93 94.58 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.5 t -64.98 -16.63 63.61 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.478 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -84.16 -2.97 57.79 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.123 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.534 HD11 HG23 ' A' ' 103' ' ' VAL . 79.9 mt -93.45 101.45 12.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.987 0.422 . . . . 0.0 111.152 -178.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -63.55 -43.31 97.44 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.305 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -120.63 140.65 51.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.151 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -149.73 156.36 41.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.3 t-20 -60.48 121.45 60.46 Favored Pre-proline 0 CA--C 1.539 0.549 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.49 -22.18 65.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 121.995 1.797 . . . . 0.0 112.478 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.52 -21.55 66.17 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.35 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -86.34 130.83 34.37 Favored 'General case' 0 N--CA 1.456 -0.127 0 CA-C-O 120.748 0.308 . . . . 0.0 110.629 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 84.8 t80 -61.23 -48.5 81.2 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.3 tp -116.43 139.98 49.85 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.206 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -55.71 138.01 48.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.075 0.464 . . . . 0.0 110.291 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 94.2 p -158.84 165.08 35.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.511 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.709 HG12 HG21 ' A' ' 63' ' ' VAL . 46.3 t -124.04 129.61 74.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.0 147.76 51.17 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -80.66 121.04 25.36 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.14 -0.86 88.93 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -75.16 135.11 41.11 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-O 120.941 0.401 . . . . 0.0 110.463 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 91.1 m -70.07 131.57 44.52 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.637 179.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.77 159.18 43.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.37 -0.532 . . . . 0.0 111.511 -178.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -120.74 129.87 53.81 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.439 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.7 p90 -157.64 163.86 37.81 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 112.549 -177.589 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -93.68 144.85 25.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.205 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.9 t -97.07 125.65 50.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.592 -0.443 . . . . 0.0 109.942 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 99.3 t -121.24 132.1 71.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -72.61 122.59 21.65 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.549 -0.46 . . . . 0.0 110.967 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -108.93 164.45 12.52 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 51.5 mp0 -62.69 -40.65 97.79 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.771 0.32 . . . . 0.0 110.982 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.9 mtmm -90.89 -6.45 54.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.29 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.13 -177.41 28.25 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -69.35 148.14 50.1 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.944 0.402 . . . . 0.0 110.341 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -133.79 158.91 42.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.636 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.504 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.45 146.73 29.11 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.973 -179.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.1 157.86 43.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.255 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 54.42 45.32 27.34 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.118 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.439 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.0 t -71.51 122.15 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.08 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.6 p -138.75 161.64 36.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.796 179.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 162.48 54.43 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.501 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.1 Cg_exo -58.96 138.0 83.11 Favored 'Trans proline' 0 C--N 1.301 -1.926 0 C-N-CA 122.005 1.803 . . . . 0.0 112.149 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.23 19.24 78.55 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 178.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.89 3.01 89.54 Favored Glycine 0 CA--C 1.531 1.05 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 128' ' ' PRO . 95.0 t -60.72 137.63 93.12 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 122.811 -0.229 . . . . 0.0 110.472 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 153.06 79.84 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 121.64 1.56 . . . . 0.0 111.309 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -70.65 129.11 34.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.617 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.3 tp60 -60.72 -44.34 96.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.55 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.39 162.0 28.28 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 179.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 84.0 p -81.4 163.06 23.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.933 0.397 . . . . 0.0 110.56 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.51 -37.13 86.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.502 179.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -66.67 -7.63 22.0 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.137 -178.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.505 ' O ' ' HB2' ' A' ' 140' ' ' ALA . . . -49.17 129.58 18.16 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.495 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.505 ' HB2' ' O ' ' A' ' 139' ' ' ALA . . . . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.506 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.511 0 C3'-C2'-C1' 104.824 1.517 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.806 0 O4'-C4'-C3' 102.817 -2.783 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.573 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.705 0 O4'-C4'-C3' 103.785 -1.815 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.857 0 C3'-C2'-C1' 101.798 -0.645 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.882 0 O4'-C1'-C2' 107.427 1.207 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.351 0 C4'-C3'-C2' 104.785 1.585 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.809 0 O4'-C1'-C2' 107.353 1.139 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 63.5 mtpt -69.87 146.47 51.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.317 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -63.75 135.17 56.46 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 121.212 0.529 . . . . 0.0 111.008 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.1 t -102.49 102.36 13.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.417 178.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.54 -44.13 99.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.087 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.08 43.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.736 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -104.41 -147.94 0.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.632 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.415 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 21.4 pttm -48.11 106.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.452 -179.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 57' ' ' THR . 85.2 t -127.53 130.58 70.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.718 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 93.1 mt -74.88 135.82 41.52 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.091 0.472 . . . . 0.0 109.824 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.36 178.33 25.05 Favored Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.1 m -128.32 137.94 52.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 120.853 0.359 . . . . 0.0 110.547 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.683 HG21 HG12 ' A' ' 103' ' ' VAL . 94.0 t -77.1 109.79 12.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.689 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.447 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 38.5 ttpt -62.79 -46.96 85.58 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 51.5 p-90 -176.67 146.87 0.6 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.954 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -141.35 125.0 16.81 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.4 m-20 -107.48 122.53 46.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.992 0.425 . . . . 0.0 110.941 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.9 t -63.22 -46.71 95.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.462 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -62.02 -43.29 99.16 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -61.75 -38.45 88.04 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.807 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.48 0.99 69.25 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.374 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -148.3 163.52 36.81 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 117.503 0.652 . . . . 0.0 110.076 179.16 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.21 -179.67 32.32 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.552 -0.833 . . . . 0.0 111.538 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.466 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.8 m-85 -126.45 143.08 51.31 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.095 0.474 . . . . 0.0 112.111 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.431 HG13 HG11 ' A' ' 86' ' ' VAL . 87.1 mt -121.8 126.52 74.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.859 178.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -94.09 109.97 21.71 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.93 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -63.62 134.57 55.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.073 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -88.62 -9.89 50.6 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.275 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.3 p-10 -96.71 -12.9 23.17 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.146 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 55.7 p -133.84 -10.51 2.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.709 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.5 mttp 51.61 35.51 14.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.952 0.406 . . . . 0.0 109.976 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -120.11 134.11 55.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.223 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -67.81 130.03 41.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.118 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 96.2 t -119.21 131.77 70.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.52 139.49 55.63 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.293 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.431 HG11 HG13 ' A' ' 75' ' ' ILE . 7.5 p -148.11 148.34 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 CA-C-O 121.133 0.492 . . . . 0.0 110.948 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -131.74 155.59 47.43 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.9 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.469 ' OE1' HD11 ' A' ' 100' ' ' LEU . 26.8 pt20 -59.35 -28.46 66.87 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.8 p -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.431 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.99 0.25 55.48 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.198 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.448 HD11 HG23 ' A' ' 103' ' ' VAL . 82.2 mt -93.83 103.11 14.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 121.013 0.435 . . . . 0.0 111.128 -178.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -64.96 -42.22 94.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.281 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.452 ' HB3' HG22 ' A' ' 126' ' ' THR . 22.8 ttmm -125.69 136.1 52.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.074 -178.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -146.76 176.47 9.84 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.375 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -62.2 121.2 64.64 Favored Pre-proline 0 CA--C 1.539 0.54 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.31 -26.12 64.0 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 121.965 1.777 . . . . 0.0 112.65 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -72.1 -14.45 61.85 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.426 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 4.0 mptp? -99.34 113.93 26.52 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 120.717 0.294 . . . . 0.0 110.647 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.21 -47.83 84.3 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.889 0.376 . . . . 0.0 110.758 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.469 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.3 tp -94.09 130.83 40.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.216 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -60.5 138.46 58.01 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.256 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.532 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 93.7 p -157.97 163.37 37.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.424 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.683 HG12 HG21 ' A' ' 63' ' ' VAL . 51.9 t -129.06 131.04 68.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.64 148.01 47.7 Favored Glycine 0 CA--C 1.524 0.647 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.303 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -86.09 134.36 33.83 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.1 2.63 90.56 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 51.8 tp10 -91.1 129.82 37.06 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-O 120.913 0.387 . . . . 0.0 110.517 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.9 m -70.01 133.03 46.81 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.719 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.3 m -130.61 159.09 42.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.49 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -118.02 130.05 55.94 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 125' ' ' VAL . 44.6 p90 -156.24 162.93 40.1 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 119.774 -0.77 . . . . 0.0 112.49 -177.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -97.09 142.33 29.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.225 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG1' ' HB1' ' A' ' 120' ' ' ALA . 65.1 t -101.18 125.27 55.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.031 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.8 p -118.32 138.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.3 tm-20 -63.6 128.05 34.09 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.924 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.85 162.86 12.42 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -60.69 -40.94 94.05 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.773 0.32 . . . . 0.0 111.042 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -89.56 -11.54 42.44 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.342 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.81 -173.9 30.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.465 ' HB1' ' CG1' ' A' ' 113' ' ' VAL . . . -63.39 137.53 58.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.877 0.37 . . . . 0.0 110.459 179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.44 ' O ' HG12 ' A' ' 114' ' ' VAL . 89.0 tt0 -128.83 135.38 49.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.661 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -74.46 150.76 39.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.042 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.59 157.96 41.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.186 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 53.52 47.97 22.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.029 0.443 . . . . 0.0 110.131 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.5 t -73.36 123.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.084 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 93' ' ' LYS . 81.6 p -140.18 164.04 31.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.841 179.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.06 164.45 54.48 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG23 ' A' ' 131' ' ' VAL . 37.3 Cg_exo -60.79 138.33 78.64 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.995 1.797 . . . . 0.0 112.096 -179.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.14 18.78 79.37 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.69 0.74 89.98 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -59.87 137.69 90.47 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.431 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.46 150.31 87.0 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 121.588 1.525 . . . . 0.0 111.296 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.1 t -69.03 129.67 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.616 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -60.63 -44.38 96.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.507 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 88.41 164.78 40.62 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.668 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 83.5 p -80.62 165.35 22.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.822 0.344 . . . . 0.0 110.572 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -62.47 -39.05 92.18 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.488 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -66.26 -9.81 36.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.139 -179.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.532 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . -56.45 140.35 46.17 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.43 -179.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.552 -179.894 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.52 0 C3'-C2'-C1' 104.875 1.554 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.847 0 C4'-C3'-C2' 101.443 -1.757 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.514 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.74 0 O4'-C4'-C3' 103.47 -2.13 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.435 -0.971 0 O4'-C4'-C3' 103.579 -2.021 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.855 0 O4'-C1'-C2' 107.42 1.2 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.437 0 C1'-O4'-C4' 106.869 -2.022 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.818 0 O4'-C1'-C2' 106.787 0.624 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.401 ' HE2' HG11 ' A' ' 114' ' ' VAL . 25.6 pttm -144.36 155.95 44.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.254 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -80.2 134.38 36.12 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.197 0.522 . . . . 0.0 110.987 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 77.8 t -101.49 103.34 14.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.438 178.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.96 -45.36 97.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.07 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -153.33 161.74 42.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.084 -179.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.694 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -97.51 -146.29 0.31 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.587 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.433 ' N ' HG23 ' A' ' 57' ' ' THR . 38.4 mtmm -52.12 113.65 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.538 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 57' ' ' THR . 93.2 t -127.49 128.55 69.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.768 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 94.7 mt -65.36 130.05 41.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.042 0.448 . . . . 0.0 109.925 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.29 170.27 25.52 Favored Glycine 0 C--O 1.228 -0.259 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.9 m -130.66 137.07 49.4 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.886 0.374 . . . . 0.0 110.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 103' ' ' VAL . 91.5 t -75.32 116.2 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.832 -179.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.2 ptpt -74.53 -35.37 63.13 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 176.7 139.49 0.07 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.987 178.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -138.98 115.97 10.9 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -100.57 118.48 36.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.014 0.435 . . . . 0.0 110.905 -178.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.92 -45.17 97.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.421 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.2 ttp85 -59.71 -45.29 92.57 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -178.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -61.38 -38.2 86.17 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.869 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.45 3.86 62.75 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.324 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -149.64 160.73 43.27 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 117.528 0.664 . . . . 0.0 110.051 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.53 179.9 33.87 Favored Glycine 0 CA--C 1.524 0.648 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.615 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.468 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 93.6 m-85 -132.67 147.27 52.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.17 0.509 . . . . 0.0 112.101 -179.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.407 HG13 HG11 ' A' ' 86' ' ' VAL . 80.4 mt -121.56 129.06 75.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.846 178.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -97.33 108.26 20.95 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.877 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 88.3 mtm-85 -62.89 131.26 48.14 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.073 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.68 -9.07 57.76 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.333 179.151 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -94.03 -29.85 15.0 Favored 'General case' 0 N--CA 1.458 -0.057 0 CA-C-O 120.911 0.386 . . . . 0.0 110.134 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.5 p -116.83 -13.17 10.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.679 -178.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.7 mttt 54.22 33.79 18.89 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.066 -179.128 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -117.94 131.58 56.49 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.855 -0.612 . . . . 0.0 111.28 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 62.0 t0 -71.94 130.62 41.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.055 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.8 p -124.03 147.75 28.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.907 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -75.47 142.41 42.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.354 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.427 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.2 p -144.81 146.49 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.099 0.476 . . . . 0.0 111.016 179.159 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -135.19 154.58 51.56 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.848 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -61.04 -24.88 66.52 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 111.971 0.36 . . . . 0.0 111.971 -178.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 72.1 p -76.89 -13.86 59.94 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.351 179.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.69 2.56 54.64 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.091 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 103' ' ' VAL . 82.5 mt -96.23 107.31 19.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.022 0.439 . . . . 0.0 111.183 -178.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -67.99 -43.09 79.73 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.334 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.97 141.01 48.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.098 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -144.51 160.73 40.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.6 t-20 -56.29 119.91 31.26 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.28 -31.57 93.99 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.075 1.85 . . . . 0.0 112.527 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -62.59 -19.19 63.48 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.431 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -111.21 140.37 45.83 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.655 -179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.652 ' OH ' ' HB1' ' A' ' 140' ' ' ALA . 50.0 p90 -95.08 -13.99 24.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.889 0.376 . . . . 0.0 110.775 179.731 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 66.0 tp -106.03 125.49 51.06 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.195 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.7 mtt-85 -62.89 130.83 46.53 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.634 -0.427 . . . . 0.0 110.305 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 47.2 t -157.9 154.62 28.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.537 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 63' ' ' VAL . 45.0 t -120.88 130.57 74.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.24 144.81 45.11 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.376 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -74.93 129.88 38.43 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.27 1.45 85.88 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -178.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.468 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -76.92 132.62 39.18 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 120.9 0.381 . . . . 0.0 110.538 -179.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.2 m -74.55 129.45 37.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.89 -0.595 . . . . 0.0 109.711 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 14.2 m -133.57 162.46 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 C-N-CA 120.315 -0.554 . . . . 0.0 111.417 -177.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -124.81 141.24 52.25 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.451 ' HB3' HG22 ' A' ' 125' ' ' VAL . 20.6 p90 -160.87 163.41 32.02 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 119.715 -0.794 . . . . 0.0 112.494 -177.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -90.01 124.98 35.22 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.277 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.4 t -92.62 127.04 45.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.457 -0.497 . . . . 0.0 109.974 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.401 HG11 ' HE2' ' A' ' 52' ' ' LYS . 33.3 m -125.37 157.33 34.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -93.27 119.28 32.24 Favored 'General case' 0 C--N 1.324 -0.53 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.93 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.01 165.37 13.24 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -60.18 -46.53 89.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.726 0.298 . . . . 0.0 110.994 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -74.55 -24.61 58.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.379 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 157.31 -168.39 34.13 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.57 142.17 58.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.846 0.355 . . . . 0.0 110.462 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 -129.22 156.84 43.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.673 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -112.98 145.98 39.86 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.8 159.52 44.08 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.208 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 54.44 43.17 30.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.035 0.445 . . . . 0.0 110.185 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.451 HG22 ' HB3' ' A' ' 111' ' ' PHE . 96.1 t -72.77 121.08 22.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.098 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -138.58 171.36 14.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.795 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.47 177.28 46.78 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 131' ' ' VAL . 55.7 Cg_endo -69.95 137.67 35.45 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 121.935 1.757 . . . . 0.0 112.19 -178.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 18.93 77.24 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.02 2.14 89.55 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 128' ' ' PRO . 94.4 t -61.98 137.06 95.4 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.762 -0.257 . . . . 0.0 110.553 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.41 147.68 76.39 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.568 1.512 . . . . 0.0 111.311 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.7 t -67.64 127.32 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.733 -0.387 . . . . 0.0 110.591 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -61.52 -41.48 97.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.535 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.01 -175.04 49.99 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.616 -0.594 . . . . 0.0 111.616 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 75.5 m -111.4 160.29 17.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.885 0.374 . . . . 0.0 110.572 -179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -59.45 -39.28 83.09 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.439 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -60.59 -15.38 27.38 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.12 179.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -58.33 141.63 50.54 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.526 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.652 ' HB1' ' OH ' ' A' ' 99' ' ' TYR . . . . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.615 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.471 0 C3'-C2'-C1' 104.966 1.618 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.456 0.908 0 C4'-C3'-C2' 101.321 -1.879 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.552 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.426 -1.839 0 O4'-C4'-C3' 102.968 -2.632 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.814 0 P-O3'-C3' 120.412 0.593 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.829 0 O4'-C1'-C2' 107.415 1.195 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.399 0 C1'-O4'-C4' 107.227 -1.766 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.835 0 O4'-C4'-C3' 104.384 -1.216 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 57.1 t0 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.42 ' HD3' HG21 ' A' ' 114' ' ' VAL . 17.9 ptpt -141.15 159.15 42.82 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.272 -179.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.496 ' O ' HG23 ' A' ' 114' ' ' VAL . 87.8 tttt -106.62 132.52 52.52 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.224 0.535 . . . . 0.0 110.987 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.1 t -97.76 100.13 10.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.426 -0.806 . . . . 0.0 109.469 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.74 -44.12 99.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.039 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.06 158.23 43.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.593 ' O ' HG23 ' A' ' 59' ' ' VAL . 1.7 p -98.68 -153.43 0.43 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.699 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -53.97 118.28 3.88 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.407 -178.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 57' ' ' THR . 94.6 t -131.64 128.65 60.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.699 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 95.3 mt -68.28 135.88 52.62 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.097 0.475 . . . . 0.0 109.801 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.89 178.35 27.44 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 86.7 m -130.38 137.52 49.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.801 0.334 . . . . 0.0 110.535 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.698 HG21 HG12 ' A' ' 103' ' ' VAL . 77.4 t -75.75 116.19 18.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.741 -178.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 64' ' ' LYS . 9.4 ptmt -69.82 -41.75 74.56 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 60.6 p-90 178.24 138.37 0.08 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.944 177.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -132.54 115.3 15.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 178.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -94.84 117.41 30.09 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.606 -0.438 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.41 ' H ' ' H5 ' ' B' ' 306' ' ' ' DC' . 62.0 t -63.9 -44.82 98.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.471 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 64.6 mtp85 -61.89 -41.41 97.84 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -63.21 -37.63 87.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.856 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.85 3.28 66.16 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.301 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -149.98 160.04 43.92 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 117.482 0.641 . . . . 0.0 110.107 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.26 179.81 36.45 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 120.499 -0.857 . . . . 0.0 111.515 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.408 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 68.8 m-85 -130.7 150.59 51.81 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.192 0.52 . . . . 0.0 112.146 -178.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.403 HG21 ' CE2' ' A' ' 111' ' ' PHE . 83.3 mt -120.05 127.06 75.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.858 178.48 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -92.81 110.26 21.7 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.938 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.44 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -65.9 128.9 37.88 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.101 179.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -74.39 -25.81 59.71 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.309 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -71.81 -41.66 67.96 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.151 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.5 p -108.11 -7.24 16.13 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.66 -176.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . 0.44 ' N ' ' O ' ' A' ' 77' ' ' ARG . 75.1 mmtt 52.29 31.16 8.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.906 0.384 . . . . 0.0 109.967 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -118.37 133.96 55.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.315 0.578 . . . . 0.0 111.274 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -64.23 146.28 54.58 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.067 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.603 HG11 ' HB2' ' A' ' 122' ' ' ALA . 86.5 t -128.24 130.46 69.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.871 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -68.07 130.37 42.75 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.9 149.12 18.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.219 0.533 . . . . 0.0 110.921 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -127.12 161.1 29.26 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.888 179.21 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.9 pt20 -61.12 -24.5 66.3 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -81.06 -11.51 59.5 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.388 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.25 -3.8 58.44 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.193 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.607 HD11 HG23 ' A' ' 103' ' ' VAL . 85.6 mt -90.62 102.15 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 111.082 -178.405 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -63.71 -43.09 97.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.293 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -120.62 140.9 50.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.076 -178.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -139.79 153.33 47.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.461 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.438 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.0 p-10 -57.65 132.9 82.45 Favored Pre-proline 0 CA--C 1.539 0.529 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.8 -13.27 31.93 Favored 'Trans proline' 0 N--CA 1.499 1.8 0 C-N-CA 121.947 1.765 . . . . 0.0 112.573 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -62.29 -29.16 70.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.284 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.425 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 97.3 mttt -123.13 147.38 46.85 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-O 120.646 0.26 . . . . 0.0 110.668 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -89.57 -15.6 32.49 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.908 0.385 . . . . 0.0 110.821 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.461 HD23 ' H ' ' A' ' 140' ' ' ALA . 65.9 tp -97.63 123.92 41.73 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.229 -179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -65.66 131.73 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.947 0.403 . . . . 0.0 110.283 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 94.7 p -158.73 162.76 37.17 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.562 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.698 HG12 HG21 ' A' ' 63' ' ' VAL . 26.3 t -125.34 129.07 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.408 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.48 144.77 44.64 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.368 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.41 ' N ' ' OD1' ' A' ' 105' ' ' ASP . 39.7 p-10 -75.37 130.41 38.96 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.87 1.86 87.77 Favored Glycine 0 CA--C 1.53 0.973 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.0 tt0 -79.21 130.41 35.44 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.516 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 90.5 m -72.93 130.08 39.57 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.688 179.049 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.8 m -134.53 162.67 38.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.368 -177.219 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -123.19 137.69 54.83 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.43 ' HB3' HG22 ' A' ' 125' ' ' VAL . 33.1 p90 -160.81 165.42 30.29 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.607 -177.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -100.54 146.11 27.5 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.325 178.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.79 127.6 60.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.524 -0.47 . . . . 0.0 109.985 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.496 HG23 ' O ' ' A' ' 53' ' ' LYS . 14.4 p -122.08 134.07 66.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.196 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -65.89 126.89 29.94 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.546 -0.461 . . . . 0.0 110.947 -178.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.8 166.04 12.24 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -59.64 -48.16 82.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 111.062 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 26.4 pttm -73.83 -22.82 59.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.315 179.041 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 153.72 -169.4 32.37 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.29 139.16 58.52 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.836 0.351 . . . . 0.0 110.428 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -134.97 136.02 41.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.548 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.603 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -78.6 151.17 32.5 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.02 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -150.18 156.44 41.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.243 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.4 t30 56.78 48.18 16.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.971 0.415 . . . . 0.0 110.14 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.43 HG22 ' HB3' ' A' ' 111' ' ' PHE . 90.3 t -76.06 124.53 34.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.044 -179.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 65.4 p -138.12 167.2 22.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.759 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.69 169.32 53.57 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 178.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.425 ' O ' HG23 ' A' ' 131' ' ' VAL . 38.9 Cg_exo -60.64 136.53 67.53 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 122.031 1.821 . . . . 0.0 112.182 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.63 20.99 77.68 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.73 0.99 90.04 Favored Glycine 0 CA--C 1.532 1.127 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.4 t -61.18 141.55 93.88 Favored Pre-proline 0 CA--C 1.536 0.436 0 O-C-N 122.805 -0.232 . . . . 0.0 110.602 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -58.17 147.6 82.8 Favored 'Trans proline' 0 N--CA 1.497 1.732 0 C-N-CA 121.651 1.567 . . . . 0.0 111.285 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 41.2 t -68.5 125.06 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.628 -179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 tp60 -60.26 -39.92 88.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.483 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.17 -171.83 50.68 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 66.9 m -112.93 153.36 28.1 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.847 0.356 . . . . 0.0 110.55 -179.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -58.63 -36.92 74.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -59.56 -16.77 27.37 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.112 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.425 ' HB3' ' HD3' ' A' ' 98' ' ' LYS . . . -58.95 142.09 51.92 Favored 'General case' 0 C--N 1.331 -0.22 0 C-N-CA 120.521 -0.472 . . . . 0.0 110.482 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.461 ' H ' HD23 ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.605 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.43 -1.438 0 C3'-C2'-C1' 104.425 1.232 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.888 0 C4'-C3'-C2' 101.819 -1.381 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.408 ' C2 ' ' CZ ' ' A' ' 74' ' ' PHE . . . . . . . . 0 O5'--C5' 1.43 -0.624 0 C4'-C3'-C2' 101.65 -1.55 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.796 0 C4'-C3'-C2' 101.604 -1.596 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.816 0 O4'-C4'-C3' 104.365 -1.235 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . 0.41 ' H5 ' ' H ' ' A' ' 68' ' ' VAL . . . . . . . . 0 C3'--C2' 1.532 1.406 0 C1'-O4'-C4' 105.879 -2.729 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.803 0 O4'-C1'-C2' 107.126 0.932 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.6 p-10 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -70.34 143.74 51.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.201 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -63.76 135.85 56.98 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.17 0.509 . . . . 0.0 111.008 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.38 101.23 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.373 178.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.81 -43.02 94.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.117 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -147.93 160.59 42.65 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.177 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.582 ' O ' HG23 ' A' ' 59' ' ' VAL . 4.2 p -99.2 -147.18 0.33 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -54.85 117.33 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.251 -0.58 . . . . 0.0 110.507 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 57' ' ' THR . 95.7 t -130.92 132.38 63.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.0 mt -65.69 130.08 42.01 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.082 0.468 . . . . 0.0 109.816 178.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.18 172.4 26.8 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 98.5 m -128.11 140.52 51.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.809 0.338 . . . . 0.0 110.513 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.718 HG21 HG12 ' A' ' 103' ' ' VAL . 88.1 t -76.32 106.88 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.77 -179.111 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.459 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 39.1 ttpt -61.15 -45.19 95.66 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.459 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.0 p-90 -176.88 139.39 0.29 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.926 178.026 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -137.35 115.57 11.74 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -101.27 121.39 41.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.015 0.436 . . . . 0.0 110.821 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.4 HG21 ' N ' ' A' ' 139' ' ' ALA . 74.4 t -62.98 -46.23 96.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.407 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -60.58 -44.85 95.74 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -62.23 -37.92 87.25 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.846 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 92.65 2.95 66.88 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.374 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -148.43 161.68 41.13 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 117.473 0.636 . . . . 0.0 110.029 178.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.424 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -158.01 -179.01 32.58 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.532 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.471 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 96.2 m-85 -130.94 145.2 51.95 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.145 0.498 . . . . 0.0 112.19 -179.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.412 HD13 HG21 ' A' ' 109' ' ' VAL . 82.2 mt -120.29 125.08 73.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.865 179.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -93.33 110.86 22.4 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -64.51 132.9 51.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.193 179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -88.72 -6.69 57.27 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.315 179.3 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -95.9 -31.43 13.13 Favored 'General case' 0 C--O 1.232 0.182 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.163 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.0 p -114.08 -11.67 12.67 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.772 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 63.9 mttp 55.83 35.38 25.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.919 0.39 . . . . 0.0 110.004 -178.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -119.04 146.49 45.01 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.386 0.613 . . . . 0.0 111.232 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -84.18 121.48 27.52 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.986 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.576 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 75.0 t -112.14 126.46 69.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.94 179.319 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . 0.518 ' CB ' ' HZ3' ' A' ' 118' ' ' LYS . 92.6 t80 -64.9 134.02 53.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.337 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 73' ' ' GLY . 7.5 p -134.18 148.42 30.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.138 0.494 . . . . 0.0 110.916 179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -133.63 162.28 32.36 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.905 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -62.34 -39.44 93.11 Favored 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -68.05 -15.82 63.76 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.453 179.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.21 -1.33 56.8 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.181 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 80.5 mt -97.82 104.36 15.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-O 120.997 0.427 . . . . 0.0 111.164 -178.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -65.37 -43.18 91.6 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.267 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -123.03 144.63 49.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.925 0.393 . . . . 0.0 111.035 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 p-10 -151.39 177.26 10.46 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.296 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -65.52 119.46 60.11 Favored Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.62 -33.99 98.57 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.988 1.792 . . . . 0.0 112.61 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtt85 -63.47 -21.25 66.2 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.344 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -95.41 119.79 34.52 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.668 -179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -61.34 -48.27 82.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 110.814 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 86.9 mt -95.2 145.25 25.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.232 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.18 136.02 56.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.596 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.2 t -155.41 152.72 29.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.476 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.718 HG12 HG21 ' A' ' 63' ' ' VAL . 58.4 t -124.41 130.3 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -62.91 140.37 45.63 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.386 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -73.11 129.21 37.57 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.4 1.01 80.64 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.578 ' O ' HG23 ' A' ' 63' ' ' VAL . 88.1 tt0 -77.13 132.28 38.75 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.841 0.353 . . . . 0.0 110.56 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 93.0 m -71.13 130.37 41.33 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.693 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.412 HG21 HD13 ' A' ' 75' ' ' ILE . 19.9 m -134.27 160.25 41.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.442 -177.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -119.13 136.94 53.92 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.0 p90 -158.78 164.24 35.99 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.772 -0.771 . . . . 0.0 112.495 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -96.65 141.17 30.22 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.291 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.8 128.2 50.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.984 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 p -124.34 135.27 64.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.5 tm-20 -66.33 128.95 38.14 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.89 -178.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.33 158.04 15.16 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 52.5 mp0 -59.86 -45.44 92.46 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.657 0.265 . . . . 0.0 111.025 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.518 ' HZ3' ' CB ' ' A' ' 85' ' ' PHE . 23.1 pttp -76.5 -16.89 59.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.249 178.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 150.17 -171.19 30.14 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.88 140.75 58.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.912 0.387 . . . . 0.0 110.4 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -128.14 154.45 45.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.608 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.576 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -104.29 144.34 31.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.972 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.35 159.55 44.18 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.246 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 57.49 47.23 16.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.024 0.44 . . . . 0.0 110.185 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 93.7 t -77.18 122.68 32.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.152 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.6 p -137.46 169.36 17.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.779 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.59 172.91 47.76 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -67.63 137.02 41.11 Favored 'Trans proline' 0 C--N 1.302 -1.891 0 C-N-CA 122.01 1.807 . . . . 0.0 112.121 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.02 16.23 80.68 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.88 90.36 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.715 HG22 ' HD2' ' A' ' 132' ' ' PRO . 1.3 p -69.4 148.76 97.26 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 122.795 -0.238 . . . . 0.0 110.508 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . 0.715 ' HD2' HG22 ' A' ' 131' ' ' VAL . 35.0 Cg_exo -60.48 148.19 91.67 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.631 1.554 . . . . 0.0 111.36 179.029 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 78.0 t -70.79 132.26 33.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.592 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -60.71 -41.24 94.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.517 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.2 49.09 Favored Glycine 0 CA--C 1.525 0.683 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.602 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.8 m -113.24 154.92 25.98 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.831 0.348 . . . . 0.0 110.544 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.3 -35.84 78.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -61.68 -19.44 62.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.117 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.596 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -60.1 140.78 56.66 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.476 -179.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.513 -179.617 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.514 -1.356 0 O4'-C4'-C3' 104.289 -1.311 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.877 0 P-O3'-C3' 121.031 1.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.532 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.431 -1.393 0 O4'-C4'-C3' 103.636 -1.964 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.828 0 C5'-C4'-O4' 108.417 -0.614 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.848 0 O4'-C1'-C2' 107.341 1.128 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.532 1.353 0 C1'-O4'-C4' 107.546 -1.539 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.847 0 O4'-C4'-C3' 104.767 -0.833 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 33.1 t0 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -71.02 144.78 50.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.238 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.86 134.55 56.84 Favored 'General case' 0 CA--C 1.516 -0.346 0 CA-C-O 121.249 0.547 . . . . 0.0 110.915 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 57.4 t -96.77 101.78 12.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.344 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -62.97 -44.98 99.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.045 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -151.44 163.24 39.43 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.3 t -99.91 -148.93 0.36 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.749 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.455 ' HG3' ' O ' ' A' ' 58' ' ' LYS . 25.1 pttm -52.11 117.92 3.12 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.451 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 57' ' ' THR . 80.8 t -133.27 130.11 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.699 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.6 mt -73.3 135.98 44.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.164 0.507 . . . . 0.0 109.835 178.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.87 179.59 24.63 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.6 m -128.91 136.31 50.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.901 0.382 . . . . 0.0 110.359 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 103' ' ' VAL . 66.0 t -75.13 108.6 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.535 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.56 -48.32 81.49 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.535 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.3 p-90 -178.61 139.15 0.17 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.006 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -134.19 115.18 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -94.52 117.41 30.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.013 0.435 . . . . 0.0 110.897 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 139' ' ' ALA . 64.5 t -62.69 -44.78 99.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.46 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -61.09 -44.67 97.0 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -63.03 -38.62 91.93 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.31 2.18 64.05 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.322 179.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -148.28 160.14 43.27 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 117.371 0.585 . . . . 0.0 110.074 179.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.458 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -161.3 -177.6 34.53 Favored Glycine 0 CA--C 1.525 0.707 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.545 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -128.8 145.24 51.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.146 0.498 . . . . 0.0 112.147 -178.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 90.7 mt -116.35 125.16 73.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.881 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.99 109.84 20.85 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.977 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -62.89 133.64 54.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.106 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -86.14 -1.38 57.36 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.29 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -100.85 -32.64 10.57 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 120.914 0.388 . . . . 0.0 110.107 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 76.8 p -113.85 -10.49 12.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.692 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.3 mttt 56.26 31.51 18.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 120.993 0.425 . . . . 0.0 110.04 -179.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.63 141.58 49.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.252 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -67.23 145.55 55.09 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.22 -0.9 . . . . 0.0 111.053 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.572 HG11 ' HB2' ' A' ' 122' ' ' ALA . 91.4 t -128.48 131.77 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -69.83 138.6 52.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.297 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 73' ' ' GLY . 5.9 p -147.09 148.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.18 0.514 . . . . 0.0 110.912 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.47 ' O ' ' HB3' ' A' ' 90' ' ' ALA . 76.1 m80 -129.39 160.54 32.78 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.934 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -59.84 -40.51 88.76 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.9 p -67.85 -13.34 62.06 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.448 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 87' ' ' HIS . . . -80.09 -7.68 59.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.103 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.573 HD11 HG23 ' A' ' 103' ' ' VAL . 83.2 mt -92.82 96.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.934 0.397 . . . . 0.0 111.143 -178.333 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -63.0 -42.35 99.82 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.27 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.541 ' HB2' HG22 ' A' ' 126' ' ' THR . 3.7 mptp? -119.25 132.09 55.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.059 -179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -145.53 157.72 43.95 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.483 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -57.2 119.33 30.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -68.19 -20.06 43.9 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 121.946 1.764 . . . . 0.0 112.577 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -64.5 -20.05 65.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.39 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.431 ' HD3' ' HB3' ' A' ' 139' ' ' ALA . 99.0 mttt -100.92 140.47 35.17 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.719 0.295 . . . . 0.0 110.619 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -69.51 -41.58 75.86 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.721 -178.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.6 142.8 35.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.193 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -74.27 128.12 34.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 110.304 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.514 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 66.9 m -146.67 165.08 30.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.515 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 47.3 t -119.7 128.42 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.101 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -60.59 140.4 48.05 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.355 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -80.11 130.1 34.99 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.07 2.87 90.68 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.9 tp10 -89.13 133.45 34.39 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 120.875 0.369 . . . . 0.0 110.496 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 86.5 m -69.38 131.31 44.6 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.682 178.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 28.1 m -129.24 159.39 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.419 -177.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -119.17 128.55 54.35 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.4 p90 -155.98 162.07 40.4 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.555 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -92.47 150.67 20.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.283 178.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.3 t -109.31 125.01 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.94 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.457 HG12 ' O ' ' A' ' 121' ' ' GLU . 6.4 p -123.41 140.06 48.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -83.73 111.73 19.42 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.925 -178.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -95.01 176.0 34.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -62.13 -44.56 96.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.701 0.286 . . . . 0.0 110.935 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -75.77 -23.67 55.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.364 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 152.91 -167.18 31.62 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -63.62 143.54 57.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 110.452 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG12 ' A' ' 114' ' ' VAL . 88.7 tt0 -143.75 136.24 27.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.653 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.572 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -76.17 150.17 37.19 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.993 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -151.79 157.2 41.63 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 56.18 48.68 16.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.947 0.403 . . . . 0.0 110.03 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.7 t -73.81 125.17 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.124 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.541 HG22 ' HB2' ' A' ' 93' ' ' LYS . 67.9 p -139.25 163.81 31.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.761 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.03 167.83 54.71 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 109.216 -1.553 . . . . 0.0 109.216 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.445 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.9 Cg_exo -60.14 138.43 81.59 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 121.946 1.764 . . . . 0.0 112.132 -178.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 69.88 20.79 76.36 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.63 2.48 90.54 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 128' ' ' PRO . 89.8 t -62.11 139.68 96.01 Favored Pre-proline 0 CA--C 1.535 0.374 0 O-C-N 122.84 -0.212 . . . . 0.0 110.504 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -58.3 148.05 81.42 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 C-N-CA 121.608 1.539 . . . . 0.0 111.286 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 79.0 t -67.64 129.72 32.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.619 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 26.7 mp0 -61.55 -42.37 98.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.489 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.19 -171.8 53.65 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 179.335 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 57.3 m -114.85 158.06 22.45 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 110.545 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -61.7 -37.38 83.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.518 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -64.26 -13.35 48.91 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.04 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.514 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -59.54 -39.41 83.87 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 139' ' ' ALA . . . . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.581 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.486 0 C3'-C2'-C1' 104.689 1.421 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -1.003 0 O4'-C4'-C3' 103.491 -2.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.437 -0.85 0 O4'-C4'-C3' 103.697 -1.903 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.935 0 O4'-C4'-C3' 103.677 -1.923 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.843 0 O4'-C1'-C2' 107.501 1.274 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.533 1.465 0 C1'-O4'-C4' 106.619 -2.201 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.818 0 O4'-C4'-C3' 104.199 -1.401 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.3 t0 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 58.2 mtmt -70.39 144.5 51.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.142 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -106.04 131.25 53.55 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 121.162 0.506 . . . . 0.0 111.039 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 1.5 p -96.73 103.02 14.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.36 178.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.8 mt -61.4 -44.33 98.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.08 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -142.94 162.11 36.34 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.055 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.699 ' O ' HG23 ' A' ' 59' ' ' VAL . 5.3 p -100.61 -151.98 0.42 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.606 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -49.44 117.58 2.28 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.487 -178.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 57' ' ' THR . 92.7 t -132.82 130.53 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.693 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 90.2 mt -73.2 138.21 45.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.148 0.499 . . . . 0.0 109.811 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -150.15 178.81 27.38 Favored Glycine 0 N--CA 1.451 -0.363 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 88.2 m -127.56 137.17 52.52 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.502 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.685 HG21 HG12 ' A' ' 103' ' ' VAL . 90.4 t -76.28 108.57 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.749 -178.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.524 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.9 tttt -61.15 -48.86 79.65 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.524 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.1 p-90 -177.64 143.01 0.33 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.96 178.037 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -144.42 120.57 10.8 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 70' ' ' ASN . 79.8 m-20 -103.36 133.34 48.6 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.911 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.7 t -71.25 -38.39 69.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.436 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -58.41 -47.41 83.98 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -176.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.403 ' OD1' ' O ' ' A' ' 67' ' ' ASN . 53.1 p30 -80.62 -16.04 55.07 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.803 -178.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.403 ' N ' ' OD1' ' A' ' 70' ' ' ASN . . . 70.96 18.81 76.58 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.295 177.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -149.93 164.08 36.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 117.462 0.631 . . . . 0.0 110.181 179.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.13 -173.35 38.12 Favored Glycine 0 CA--C 1.524 0.604 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.505 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.446 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 98.4 m-85 -128.75 146.74 50.81 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.108 0.48 . . . . 0.0 112.114 -178.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 88.5 mt -120.38 126.7 75.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.955 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.1 t-20 -94.95 111.09 22.91 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.956 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.421 ' NH2' HG21 ' A' ' 80' ' ' THR . 84.6 mtp180 -63.09 131.6 49.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.165 179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.4 p30 -89.81 2.33 55.06 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.414 -0.515 . . . . 0.0 111.323 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -107.27 -33.53 7.38 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.993 0.425 . . . . 0.0 110.198 179.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.421 HG21 ' NH2' ' A' ' 77' ' ' ARG . 74.4 p -116.2 -9.05 11.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.711 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.4 mttm 54.11 33.49 17.93 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 -178.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -112.85 132.96 55.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.233 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -73.91 125.4 28.12 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.052 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.85 131.89 70.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.883 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -63.35 142.78 58.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.351 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.8 p -139.91 145.9 25.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.239 0 CA-C-O 121.218 0.532 . . . . 0.0 110.889 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -136.62 157.4 46.86 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.911 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.455 HE22 HD21 ' A' ' 100' ' ' LEU . 97.7 mt-30 -61.31 -39.25 89.8 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -178.678 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.0 p -66.79 -17.15 64.73 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.381 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -83.45 -4.27 58.35 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.154 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.425 HD11 HG23 ' A' ' 103' ' ' VAL . 81.7 mt -96.99 97.93 6.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.995 0.426 . . . . 0.0 111.217 -179.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -64.51 -41.3 96.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.283 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.531 ' HB3' HG22 ' A' ' 126' ' ' THR . 40.3 ttmt -119.45 136.33 54.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -149.43 170.82 17.69 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.357 179.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.415 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 31.5 p-10 -65.95 125.54 90.17 Favored Pre-proline 0 CA--C 1.539 0.526 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.83 -19.62 58.8 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.035 1.823 . . . . 0.0 112.59 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -64.57 -22.97 67.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -104.69 128.25 52.71 Favored 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.648 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -69.31 -37.55 77.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.754 179.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.455 HD21 HE22 ' A' ' 88' ' ' GLN . 62.6 tp -101.98 131.56 48.32 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.141 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -59.45 136.36 57.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.028 0.442 . . . . 0.0 110.279 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.3 t -158.17 155.33 28.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.572 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.685 HG12 HG21 ' A' ' 63' ' ' VAL . 53.3 t -119.64 129.36 75.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -68.88 151.12 51.21 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.316 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -86.67 136.1 33.15 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.71 2.86 90.25 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.9 tp10 -92.92 128.81 38.92 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.938 0.399 . . . . 0.0 110.5 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -67.12 133.31 49.59 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.751 179.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.9 m -129.53 159.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.456 -178.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -118.66 128.83 54.9 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -157.76 161.15 38.45 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.767 -0.773 . . . . 0.0 112.538 -178.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.404 ' OD1' ' C ' ' A' ' 112' ' ' ASP . 55.8 p30 -90.32 174.53 7.53 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.281 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -127.61 127.67 68.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 C-N-CA 120.509 -0.476 . . . . 0.0 109.978 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 91.8 t -120.03 130.95 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -72.45 114.25 10.37 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.058 0.456 . . . . 0.0 110.896 -179.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -84.82 179.71 51.22 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -68.81 -29.28 67.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.702 0.287 . . . . 0.0 110.962 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -116.79 -23.25 8.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.402 -179.314 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -170.9 173.4 44.61 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -70.24 155.38 40.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.788 0.328 . . . . 0.0 110.512 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 24.6 pt-20 -136.89 158.25 44.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.666 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -97.77 148.46 23.34 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.96 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.09 41.76 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.236 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.1 t30 53.35 47.92 23.13 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.141 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.7 t -75.28 125.55 34.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.069 -178.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.531 HG22 ' HB3' ' A' ' 93' ' ' LYS . 69.7 p -136.92 169.21 18.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.743 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -77.27 175.58 53.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.05 137.85 35.54 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 122.074 1.849 . . . . 0.0 112.061 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.7 19.64 79.31 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.87 1.48 90.61 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 -179.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 86.6 t -62.65 137.61 96.56 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-O 119.647 -0.216 . . . . 0.0 110.611 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -59.14 148.44 85.75 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 121.697 1.598 . . . . 0.0 111.259 179.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.415 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 43.7 t -67.59 128.17 30.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.669 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -63.58 -39.62 94.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.539 -179.146 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.91 -175.58 53.16 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 179.311 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 41.4 t -101.28 160.4 14.44 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.824 0.345 . . . . 0.0 110.554 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -61.09 -37.99 84.68 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.416 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -64.35 -14.04 53.96 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.092 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.51 138.88 57.55 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.477 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.58 -179.807 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.491 0 O4'-C4'-C3' 104.386 -1.214 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.455 0.853 0 C4'-C3'-C2' 102.025 -1.175 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.501 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.699 0 O4'-C4'-C3' 102.897 -2.703 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.435 -0.964 0 O4'-C4'-C3' 104.121 -1.479 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.874 0 O4'-C1'-C2' 107.362 1.148 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.25 0 C1'-O4'-C4' 106.677 -2.159 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.798 0 C3'-C2'-C1' 101.948 -0.537 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -71.49 150.5 44.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -128.11 130.07 47.58 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.196 0.522 . . . . 0.0 110.937 179.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 84.9 t -91.74 100.57 11.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.397 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.741 HD11 ' OE1' ' A' ' 115' ' ' GLU . 96.6 mt -63.41 -44.14 98.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.046 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.25 163.73 36.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.07 0.462 . . . . 0.0 111.067 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.643 ' O ' HG23 ' A' ' 59' ' ' VAL . 12.6 t -98.1 -146.57 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.679 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 57' ' ' THR . 63.5 mttp -50.82 116.4 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.333 -0.547 . . . . 0.0 110.407 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 57' ' ' THR . 74.1 t -131.78 130.03 61.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.697 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 89.7 mt -73.55 137.21 44.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.055 0.455 . . . . 0.0 109.808 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.32 177.9 27.2 Favored Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.4 m -128.22 135.76 50.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.856 0.36 . . . . 0.0 110.486 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.71 HG21 HG12 ' A' ' 103' ' ' VAL . 77.2 t -76.93 109.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.765 -179.209 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.522 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.1 tttt -62.22 -48.39 80.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.522 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 62.2 p-90 -175.8 147.63 0.81 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 114.678 -1.146 . . . . 0.0 109.903 178.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -137.45 115.44 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 41.4 t-20 -93.49 110.27 21.85 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.978 0.418 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 53.4 t -61.21 -46.7 96.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.391 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.1 ttp180 -62.01 -43.76 98.16 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -178.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -62.16 -39.39 92.48 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.81 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.49 4.04 59.58 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.382 179.255 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -148.26 160.82 42.57 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.423 0.611 . . . . 0.0 110.04 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.454 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -160.53 -177.22 33.44 Favored Glycine 0 CA--C 1.525 0.71 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.573 -179.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.455 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 97.5 m-85 -131.5 147.9 52.58 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.134 0.492 . . . . 0.0 112.193 -179.338 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 87.2 mt -120.77 127.36 75.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.843 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -91.92 110.45 21.81 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.807 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 96.4 mtm-85 -62.18 135.2 57.39 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.126 179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -82.54 -6.95 59.62 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.382 179.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -94.75 -33.07 13.04 Favored 'General case' 0 C--O 1.231 0.097 0 CA-C-O 120.959 0.409 . . . . 0.0 110.138 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 68.0 p -116.9 -10.6 10.96 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.642 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 68.6 mttm 54.44 34.51 21.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.976 0.417 . . . . 0.0 110.026 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -121.04 132.64 55.01 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.247 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -66.23 148.14 52.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.037 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.1 p -132.78 152.15 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.914 179.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -73.24 133.11 43.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.297 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 73' ' ' GLY . 6.4 p -144.84 144.11 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.149 0.499 . . . . 0.0 110.911 178.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -136.19 157.79 45.96 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.841 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.4 pt20 -58.46 -24.73 61.05 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -178.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 82.3 p -73.6 -20.49 60.59 Favored 'General case' 0 C--N 1.32 -0.695 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.421 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.24 -7.74 58.88 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.137 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.3 mt -90.0 94.9 5.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 120.872 0.367 . . . . 0.0 111.198 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -64.34 -38.15 90.03 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.437 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -122.94 142.86 50.35 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.101 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -153.28 177.13 11.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.35 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -63.63 118.62 46.43 Favored Pre-proline 0 CA--C 1.539 0.552 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.7 -34.66 99.07 Favored 'Trans proline' 0 N--CA 1.497 1.712 0 C-N-CA 122.056 1.838 . . . . 0.0 112.545 179.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.09 -19.9 66.21 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.467 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -97.65 114.53 26.5 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-O 120.74 0.305 . . . . 0.0 110.604 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -60.69 -47.89 84.23 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.893 0.378 . . . . 0.0 110.761 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.625 ' HB3' ' HB3' ' A' ' 140' ' ' ALA . 64.0 tp -91.18 130.67 37.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.182 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -59.76 136.73 58.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.055 0.455 . . . . 0.0 110.249 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.463 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.1 t -154.18 154.25 33.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.505 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.71 HG12 HG21 ' A' ' 63' ' ' VAL . 53.1 t -121.7 131.95 71.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.4 144.64 47.74 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.324 -178.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -83.14 118.59 23.69 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.65 -0.73 74.29 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -82.82 132.33 35.17 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.862 0.363 . . . . 0.0 110.532 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 85.8 m -69.04 132.48 46.7 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.648 178.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -130.01 159.77 41.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.47 -178.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -119.96 126.62 51.31 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -155.45 163.81 39.55 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.558 -177.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.31 153.33 20.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.224 178.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -110.29 125.09 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.403 -0.519 . . . . 0.0 109.983 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 75.8 t -123.41 129.75 74.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.741 ' OE1' HD11 ' A' ' 55' ' ' ILE . 51.5 tp10 -70.27 127.09 31.59 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.905 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.95 159.98 13.71 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.6 mp0 -61.55 -39.51 91.38 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.741 0.305 . . . . 0.0 110.957 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -85.23 -8.38 58.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.354 179.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 144.96 -169.77 26.61 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.52 143.85 57.62 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.885 0.374 . . . . 0.0 110.52 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -129.08 136.4 50.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.668 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -94.14 146.59 23.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.01 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.35 157.06 40.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.135 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.9 t30 58.19 47.33 14.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.977 0.418 . . . . 0.0 110.164 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.2 t -76.07 123.22 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.074 -179.025 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.2 p -134.96 159.96 39.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.813 179.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.55 162.21 53.94 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.105 -1.598 . . . . 0.0 109.105 178.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.51 ' O ' HG12 ' A' ' 131' ' ' VAL . 31.8 Cg_exo -58.83 136.99 77.34 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.039 1.826 . . . . 0.0 112.108 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 78.75 13.57 83.0 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.2 1.45 90.47 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 128' ' ' PRO . 9.9 p -68.89 141.66 92.58 Favored Pre-proline 0 CA--C 1.535 0.4 0 CA-C-O 119.673 -0.203 . . . . 0.0 110.501 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 131' ' ' VAL . 20.4 Cg_endo -59.09 150.24 74.72 Favored 'Trans proline' 0 N--CA 1.497 1.721 0 C-N-CA 121.634 1.556 . . . . 0.0 111.315 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 81.5 t -64.42 133.58 29.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.552 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -62.43 -42.41 99.43 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.496 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.41 162.59 36.16 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 85.1 p -80.59 166.3 21.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.894 0.378 . . . . 0.0 110.496 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -63.4 -36.87 85.17 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.511 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -72.1 -5.23 33.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.121 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.463 ' HB2' ' CB ' ' A' ' 102' ' ' SER . . . -58.6 140.39 54.45 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.448 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.625 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.636 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.555 0 C3'-C2'-C1' 104.658 1.399 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.518 -0.992 0 C4'-C3'-C2' 101.247 -1.953 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.56 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.427 -1.77 0 O4'-C4'-C3' 103.189 -2.411 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.821 0 O4'-C1'-C2' 107.405 1.186 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.429 -1.517 0 C3'-C2'-C1' 104.482 1.273 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.432 -1.256 0 C1'-O4'-C4' 107.597 -1.502 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.882 0 C5'-C4'-O4' 108.618 -0.489 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.48 ' NZ ' HG11 ' A' ' 114' ' ' VAL . 22.6 pttp -140.89 152.07 44.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.281 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -78.05 136.56 37.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.234 0.54 . . . . 0.0 110.907 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 101.88 12.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.375 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.0 -44.53 97.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.069 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -155.27 163.24 40.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.056 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.547 ' O ' HG23 ' A' ' 59' ' ' VAL . 11.4 t -96.19 -149.51 0.31 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.685 179.622 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -55.1 118.0 3.96 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.52 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 57' ' ' THR . 87.5 t -129.58 128.55 65.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.701 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 91.7 mt -68.98 135.31 50.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.122 0.486 . . . . 0.0 109.733 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -153.04 -177.82 27.0 Favored Glycine 0 CA--C 1.521 0.42 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.4 m -128.28 135.34 49.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.876 0.37 . . . . 0.0 110.391 -179.564 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.711 HG21 HG12 ' A' ' 103' ' ' VAL . 97.1 t -71.28 110.87 4.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.765 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -61.52 -48.92 78.85 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 54.9 p-90 -177.77 140.08 0.24 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.957 178.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -137.1 119.17 15.43 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -101.22 120.88 40.9 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.892 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.407 HG21 ' C ' ' A' ' 138' ' ' TYR . 67.3 t -62.93 -45.73 98.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.525 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -61.82 -44.68 96.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -178.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -62.09 -38.78 90.13 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.902 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 93.61 2.1 65.53 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.397 179.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -147.54 161.96 40.05 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 117.467 0.633 . . . . 0.0 110.112 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -162.55 -179.05 36.9 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.534 -0.841 . . . . 0.0 111.561 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.459 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 92.3 m-85 -126.99 146.27 50.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.153 0.501 . . . . 0.0 112.172 -178.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.407 HG21 ' CE2' ' A' ' 111' ' ' PHE . 87.2 mt -119.31 125.34 74.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.827 178.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.77 109.88 21.32 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.836 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -65.96 134.78 53.66 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.19 179.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -85.06 -5.31 59.35 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.418 -0.513 . . . . 0.0 111.268 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -96.49 -33.19 11.95 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.176 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 66.5 p -115.15 -9.61 12.27 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.627 -178.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt 53.63 32.5 14.59 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 121.062 0.458 . . . . 0.0 110.147 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -119.73 131.83 55.48 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.233 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.02 142.43 58.38 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.986 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.411 ' CG1' ' HB2' ' A' ' 122' ' ' ALA . 79.0 t -126.89 132.42 70.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.899 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -66.19 138.19 57.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.312 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.79 147.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.225 0.536 . . . . 0.0 110.946 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -136.88 159.96 40.31 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.905 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.418 ' HA ' HD12 ' A' ' 91' ' ' ILE . 16.6 pm0 -59.98 -20.4 57.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 64.1 p -82.52 -12.81 57.52 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.465 179.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.05 1.36 57.24 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.132 179.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.459 HD11 HG23 ' A' ' 103' ' ' VAL . 80.7 mt -95.97 101.68 12.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.929 0.395 . . . . 0.0 111.136 -178.153 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -63.11 -45.15 93.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.365 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -115.07 136.8 52.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.04 -178.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -143.26 137.85 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.31 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 133' ' ' VAL . 34.4 p-10 -58.96 138.39 87.49 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.057 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -71.34 -9.12 24.76 Favored 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.004 1.802 . . . . 0.0 112.499 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -60.55 -35.95 77.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.412 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -105.04 137.91 42.07 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-O 120.687 0.279 . . . . 0.0 110.672 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.445 ' HB2' HD22 ' A' ' 100' ' ' LEU . 98.2 m-85 -68.42 -41.95 79.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.756 -179.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.59 HD22 ' N ' ' A' ' 100' ' ' LEU . 1.3 mm? -97.98 146.41 25.53 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.31 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -67.51 128.52 36.74 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.381 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.406 ' CB ' ' HB2' ' A' ' 139' ' ' ALA . 48.7 m -147.51 161.74 40.47 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.477 -179.271 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.711 HG12 HG21 ' A' ' 63' ' ' VAL . 32.8 t -125.97 131.11 72.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -61.64 143.48 48.65 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.266 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -81.58 123.29 28.54 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.0 3.83 88.87 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -84.74 136.67 33.61 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.939 0.399 . . . . 0.0 110.503 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 89.6 m -70.66 130.88 42.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.607 179.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -134.91 164.82 32.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.445 -178.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -124.87 137.7 54.28 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.435 ' HB3' HG22 ' A' ' 125' ' ' VAL . 31.3 p90 -160.12 162.52 34.01 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.813 -0.755 . . . . 0.0 112.481 -177.394 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -90.65 137.34 32.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.268 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.7 t -103.83 126.22 58.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.988 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.48 HG11 ' NZ ' ' A' ' 52' ' ' LYS . 35.8 m -123.97 153.33 30.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -91.72 115.07 27.75 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.082 0.468 . . . . 0.0 111.023 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -97.31 172.13 27.46 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -63.89 -39.67 94.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.675 0.274 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -85.17 -18.9 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 154.94 -171.3 33.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -66.63 143.24 57.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.883 0.373 . . . . 0.0 110.412 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.457 ' O ' HG22 ' A' ' 114' ' ' VAL . 88.9 tt0 -138.08 136.06 36.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.628 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.411 ' HB2' ' CG1' ' A' ' 84' ' ' VAL . . . -77.92 152.87 33.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -152.12 158.22 42.65 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.14 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 53.07 47.28 24.92 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.105 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 111' ' ' PHE . 97.6 t -74.43 124.05 31.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.071 -179.048 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 50.3 p -139.78 170.06 16.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.825 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.31 164.68 54.72 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 178.378 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.444 ' O ' HG23 ' A' ' 131' ' ' VAL . 31.3 Cg_exo -59.44 137.18 76.51 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 C-N-CA 121.977 1.785 . . . . 0.0 112.177 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.31 20.81 77.06 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.25 2.48 90.5 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -179.577 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 128' ' ' PRO . 96.6 t -60.98 141.3 93.61 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 122.777 -0.249 . . . . 0.0 110.553 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -56.28 148.06 63.09 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 121.549 1.499 . . . . 0.0 111.315 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.416 ' O ' ' HB3' ' A' ' 95' ' ' ASN . 42.9 t -69.78 126.24 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 C-N-CA 120.73 -0.388 . . . . 0.0 110.64 -179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 16.2 tm0? -60.9 -40.42 93.01 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.54 -178.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 80.41 -174.39 54.95 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -111.75 162.84 14.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.841 0.353 . . . . 0.0 110.502 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -60.84 -37.91 83.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.509 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.417 ' CE2' ' C2 ' ' B' ' 307' ' ' ' DT' . 96.4 m-85 -71.02 -5.77 33.84 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.067 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.501 ' O ' ' HB3' ' A' ' 140' ' ' ALA . . . -59.14 -38.92 80.82 Favored 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.521 -179.035 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 139' ' ' ALA . . . . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.578 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.43 -1.446 0 C3'-C2'-C1' 104.69 1.422 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.802 0 O4'-C4'-C3' 104.335 -1.265 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.52 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.434 -1.068 0 O4'-C4'-C3' 103.126 -2.474 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.457 0.982 0 C3'-C2'-C1' 101.34 -0.971 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.426 -0.873 0 O4'-C1'-C2' 106.98 0.8 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.236 0 C1'-O4'-C4' 107.378 -1.659 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . 0.417 ' C2 ' ' CE2' ' A' ' 138' ' ' TYR . . . . . . . . 0 O5'--C5' 1.427 -0.833 0 O4'-C1'-C2' 104.899 -1.092 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 30.3 mmmt -78.82 152.34 31.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.185 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.475 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.2 tttm -105.31 130.9 53.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.183 0.516 . . . . 0.0 110.958 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 54' ' ' VAL . 1.4 p -95.97 100.85 11.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.414 179.178 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 96.0 mt -62.87 -44.26 99.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.102 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.436 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.94 162.91 37.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 -179.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.495 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.9 t -108.84 -134.8 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.707 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.441 ' N ' HG23 ' A' ' 57' ' ' THR . 68.6 mttm -54.71 102.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.346 -0.541 . . . . 0.0 110.369 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 57' ' ' THR . 97.4 t -127.26 128.75 70.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.729 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 88.6 mt -79.66 135.99 36.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.104 0.478 . . . . 0.0 109.862 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.49 178.18 21.81 Favored Glycine 0 CA--C 1.519 0.298 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 134.76 50.67 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.852 0.358 . . . . 0.0 110.463 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.661 HG21 HG12 ' A' ' 103' ' ' VAL . 86.6 t -75.77 109.99 10.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.75 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.508 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.8 tttt -61.67 -49.19 77.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.508 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 61.4 p-90 -174.51 152.78 1.75 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.899 178.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -147.06 117.07 7.24 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.6 m-20 -97.45 120.87 38.6 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.908 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -63.18 -44.8 99.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.462 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.42 HH11 ' HD2' ' A' ' 69' ' ' ARG . 9.0 ptm85 -65.22 -34.84 79.32 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -69.3 -35.35 75.9 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.521 -0.471 . . . . 0.0 110.788 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 89.38 1.42 78.39 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.367 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -150.15 162.74 39.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.445 0.623 . . . . 0.0 110.085 179.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.73 179.85 34.09 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.493 -0.86 . . . . 0.0 111.535 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.474 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 81.9 m-85 -123.49 143.52 50.11 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.133 0.492 . . . . 0.0 112.091 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.992 HD12 HG11 ' A' ' 86' ' ' VAL . 88.1 mt -120.63 126.2 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.841 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.91 114.75 27.38 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.516 -0.474 . . . . 0.0 110.875 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -71.43 128.69 36.69 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.035 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.3 p30 -83.93 -1.59 54.85 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.375 -0.53 . . . . 0.0 111.337 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -101.21 -31.54 10.96 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-O 120.947 0.403 . . . . 0.0 110.176 179.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 73.2 p -115.72 -12.48 11.51 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.682 -179.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.86 32.45 19.68 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.995 -179.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.78 135.35 55.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.244 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -63.32 144.95 56.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.072 -179.421 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.35 133.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.901 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -80.98 125.19 29.84 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.325 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.079 HG12 ' HB3' ' A' ' 122' ' ' ALA . 32.6 m -131.17 159.86 42.72 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-O 121.133 0.492 . . . . 0.0 110.973 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -137.95 155.97 48.34 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.837 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -60.93 -22.98 64.92 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.531 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.9 p -80.96 -13.0 59.28 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.422 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.05 2.93 55.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.094 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 103' ' ' VAL . 78.9 mt -98.03 106.68 19.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.876 0.37 . . . . 0.0 111.171 -178.331 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -63.84 -44.35 93.45 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.327 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.03 144.13 50.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.928 0.394 . . . . 0.0 111.051 -179.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.5 p-10 -150.26 174.32 12.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.418 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.0 t-20 -62.67 120.2 57.79 Favored Pre-proline 0 CA--C 1.541 0.604 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.49 -23.07 58.21 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.035 1.823 . . . . 0.0 112.595 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 55.4 mmm-85 -67.02 -21.63 65.92 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.413 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.61 ' HD2' ' HB3' ' A' ' 139' ' ' ALA . 75.5 mmtt -91.48 136.93 32.76 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.62 -179.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.404 ' C ' HD12 ' A' ' 100' ' ' LEU . 94.4 m-85 -69.18 -39.55 78.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.753 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 99' ' ' TYR . 8.0 mp -113.5 151.52 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.173 -179.465 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -64.66 139.25 58.74 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.319 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.8 p -156.0 161.36 40.48 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.603 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.661 HG12 HG21 ' A' ' 63' ' ' VAL . 52.7 t -123.12 125.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -66.8 146.86 48.94 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.363 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -84.55 133.78 34.44 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.88 4.8 89.61 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.565 -1.014 . . . . 0.0 110.565 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -92.61 129.77 38.44 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.96 0.41 . . . . 0.0 110.504 -179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 92.5 m -66.81 133.55 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.576 178.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.5 m -128.89 158.15 41.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.459 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -120.0 130.11 54.59 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -160.8 165.14 30.79 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.549 -177.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -95.28 144.98 25.41 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.306 178.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.436 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -105.06 126.3 60.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.022 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 53' ' ' LYS . 13.8 p -125.15 130.91 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.96 128.89 37.79 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.941 -178.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.84 160.72 13.05 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -60.47 -42.85 97.08 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.741 0.305 . . . . 0.0 110.97 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -86.46 -14.37 43.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.334 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 156.09 -175.2 33.9 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -64.05 142.24 58.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.381 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -125.98 159.13 33.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 1.079 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -116.67 149.81 39.17 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -149.23 156.99 42.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.191 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 54.81 43.89 29.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.051 0.453 . . . . 0.0 110.123 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.8 t -72.45 121.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.054 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.1 p -137.88 166.23 24.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.725 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.61 175.24 49.79 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.49 138.21 38.12 Favored 'Trans proline' 0 C--N 1.301 -1.969 0 C-N-CA 121.929 1.753 . . . . 0.0 112.097 -179.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 71.37 19.99 77.94 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.79 1.12 90.56 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.03 137.52 95.58 Favored Pre-proline 0 CA--C 1.535 0.39 0 O-C-N 122.822 -0.222 . . . . 0.0 110.556 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -59.45 146.26 95.51 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.656 1.57 . . . . 0.0 111.247 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.4 t -64.96 135.27 28.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.69 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -59.51 -42.78 92.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.469 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 81.28 176.71 51.16 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 179.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 43.8 t -97.0 143.93 27.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.92 0.391 . . . . 0.0 110.54 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -60.14 -21.07 61.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.552 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -74.93 -12.59 60.39 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.113 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.61 ' HB3' ' HD2' ' A' ' 98' ' ' LYS . . . -58.37 141.03 52.53 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.515 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.61 -179.498 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.522 0 C3'-C2'-C1' 104.461 1.258 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.831 0 O4'-C4'-C3' 103.812 -1.788 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.521 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.425 -1.886 0 O4'-C4'-C3' 102.856 -2.744 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.81 0 P-O3'-C3' 120.438 0.615 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.526 0.776 0 C4'-C3'-C2' 102.477 -0.723 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.214 0 C1'-O4'-C4' 106.43 -2.336 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.794 0 O4'-C1'-C2' 107.356 1.142 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 60.1 mtmt -70.62 143.9 51.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.261 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.44 ' O ' HG13 ' A' ' 114' ' ' VAL . 87.5 tttt -104.9 129.37 53.28 Favored 'General case' 0 CA--C 1.516 -0.327 0 CA-C-O 121.218 0.533 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.5 t -94.09 103.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.41 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.7 HD11 ' OE1' ' A' ' 115' ' ' GLU . 96.5 mt -62.82 -45.3 99.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.029 -178.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -149.83 167.62 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.116 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 59' ' ' VAL . 7.5 t -105.66 -134.77 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.68 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.443 ' N ' HG23 ' A' ' 57' ' ' THR . 87.8 tttt -50.34 112.91 0.76 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.283 -0.567 . . . . 0.0 110.482 -179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 57' ' ' THR . 72.5 t -135.45 131.29 51.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.771 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.472 HD23 ' HG2' ' A' ' 110' ' ' GLU . 67.2 mt -75.01 133.75 41.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.121 0.486 . . . . 0.0 109.75 177.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.89 175.57 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 90.1 m -131.17 138.93 49.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.829 0.347 . . . . 0.0 110.432 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.721 HG21 HG12 ' A' ' 103' ' ' VAL . 97.2 t -72.62 109.18 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.78 -178.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 88.0 tttt -62.49 -48.04 81.35 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.528 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 59.0 p-90 -177.23 139.53 0.26 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.969 178.154 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -135.71 120.84 18.87 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -104.65 119.87 40.0 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.923 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.36 -45.47 98.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.482 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -60.57 -44.92 95.66 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -62.13 -38.15 87.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.813 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.1 1.47 64.97 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.34 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 44.5 p90 -147.5 160.16 42.91 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 117.473 0.636 . . . . 0.0 110.072 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -159.91 174.61 36.73 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.489 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -129.16 148.6 51.11 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.187 0.518 . . . . 0.0 112.141 -179.053 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.429 HD13 HG21 ' A' ' 109' ' ' VAL . 84.5 mt -116.55 127.18 74.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.844 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -89.12 109.05 19.96 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -60.38 134.99 57.6 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.159 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -84.37 -0.15 51.53 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.301 179.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -101.87 -33.04 9.94 Favored 'General case' 0 C--O 1.231 0.085 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.058 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.7 p -116.59 -9.09 11.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.693 -178.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mmtm 55.81 31.75 18.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.96 0.41 . . . . 0.0 110.037 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -117.69 133.99 55.37 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.303 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.15 144.57 56.8 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.098 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.449 HG11 ' HB2' ' A' ' 122' ' ' ALA . 99.2 t -124.14 126.94 73.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.913 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.76 129.03 38.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.318 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.93 149.76 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.186 0.517 . . . . 0.0 110.921 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.01 160.13 33.73 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.858 178.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.414 ' OE1' HD11 ' A' ' 100' ' ' LEU . 25.9 pt20 -60.24 -29.79 68.99 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.8 p -73.53 -15.66 61.29 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.385 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.19 -0.07 53.43 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.17 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.523 HD11 HG23 ' A' ' 103' ' ' VAL . 80.4 mt -92.98 101.3 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.967 0.413 . . . . 0.0 111.226 -178.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -62.94 -43.86 97.65 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -121.79 143.02 49.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.148 -179.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -152.77 163.79 39.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.434 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -61.76 121.15 62.81 Favored Pre-proline 0 CA--C 1.539 0.539 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.46 -21.63 66.09 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 121.967 1.778 . . . . 0.0 112.553 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -65.82 -22.16 66.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.326 179.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -100.89 120.67 40.49 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-O 120.751 0.31 . . . . 0.0 110.686 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 88.8 t80 -61.03 -48.3 82.41 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.703 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.414 HD11 ' OE1' ' A' ' 88' ' ' GLN . 65.5 tp -93.09 129.53 39.03 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.141 -179.25 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -61.82 139.23 58.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.297 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 139' ' ' ALA . 90.2 p -158.31 163.95 36.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.452 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.721 HG12 HG21 ' A' ' 63' ' ' VAL . 43.8 t -125.16 129.53 73.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.25 144.66 48.01 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.319 -178.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 105' ' ' ASP . 41.0 p-10 -77.36 129.2 35.51 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.36 2.01 86.94 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 110.526 -1.029 . . . . 0.0 110.526 -178.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 63' ' ' VAL . 87.7 tt0 -78.37 130.91 36.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 120.988 0.423 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.4 m -71.09 130.76 42.35 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.713 178.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.429 HG21 HD13 ' A' ' 75' ' ' ILE . 21.6 m -133.71 158.43 42.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.524 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.472 ' HG2' HD23 ' A' ' 60' ' ' LEU . 94.6 mt-10 -115.78 132.42 56.64 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -161.33 167.11 26.42 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 119.738 -0.785 . . . . 0.0 112.473 -177.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -88.57 149.53 23.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.252 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.8 t -108.43 123.9 64.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 120.481 -0.488 . . . . 0.0 109.957 -179.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 53' ' ' LYS . 68.4 t -122.99 128.13 75.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.402 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.7 ' OE1' HD11 ' A' ' 55' ' ' ILE . 50.1 tp10 -64.99 124.87 23.18 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.946 -178.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -120.76 159.59 15.39 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -61.98 -40.06 94.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.709 0.29 . . . . 0.0 110.937 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -81.95 -9.3 59.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.391 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 142.7 -167.54 26.21 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.504 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -62.29 141.94 58.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 0.0 110.5 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.56 151.93 35.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.655 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.449 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -118.69 142.43 47.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.045 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.11 153.34 42.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.184 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 54.36 43.08 30.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.059 0.457 . . . . 0.0 110.174 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.05 125.39 28.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.106 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 64.9 p -135.67 169.43 17.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.824 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.09 177.24 45.69 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 178.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.431 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.7 Cg_endo -69.73 136.38 32.93 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 121.911 1.74 . . . . 0.0 112.188 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 70.68 21.53 77.87 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.07 1.79 90.41 Favored Glycine 0 CA--C 1.531 1.084 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 128' ' ' PRO . 85.5 t -63.16 140.43 97.67 Favored Pre-proline 0 CA--C 1.535 0.4 0 O-C-N 122.853 -0.204 . . . . 0.0 110.527 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -58.06 148.53 76.75 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 121.58 1.52 . . . . 0.0 111.292 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 70.2 t -69.15 128.99 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.605 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -61.47 -41.85 97.88 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.435 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.83 -175.9 48.94 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 70.6 m -109.5 159.96 16.62 Favored 'General case' 0 N--CA 1.455 -0.194 0 CA-C-O 120.845 0.355 . . . . 0.0 110.53 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt -61.49 -37.81 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -63.63 -15.37 58.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.078 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.48 ' HB2' ' OG ' ' A' ' 102' ' ' SER . . . -59.78 142.52 53.14 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.451 -179.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.626 -179.846 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.512 -1.642 0 O4'-C1'-C2' 107.132 0.938 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.433 -1.146 0 O4'-C4'-C3' 103.948 -1.652 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.537 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O5'--C5' 1.428 -0.721 0 O4'-C4'-C3' 103.752 -1.848 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.781 0 O4'-C1'-C2' 107.584 1.349 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.527 0.902 0 O4'-C4'-C3' 104.298 -1.302 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.53 1.189 0 C1'-O4'-C4' 106.784 -2.083 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.828 0 O4'-C1'-C2' 107.427 1.207 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 52.8 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.7 mtpp -72.04 146.97 47.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.185 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.433 ' O ' HG23 ' A' ' 114' ' ' VAL . 63.8 tttp -63.44 134.49 55.74 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 110.926 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.8 t -97.46 101.7 12.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.334 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.64 -45.0 98.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.068 -179.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -152.55 163.45 39.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.109 -178.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.545 ' O ' HG23 ' A' ' 59' ' ' VAL . 13.1 t -98.12 -149.09 0.33 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.7 179.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.0 mtmt -53.92 119.31 4.85 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.449 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 57' ' ' THR . 72.2 t -131.38 131.67 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.629 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 62.2 mt -65.7 131.07 45.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.102 0.477 . . . . 0.0 109.835 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.62 176.13 24.78 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 91.8 m -129.33 135.46 48.77 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.735 0.302 . . . . 0.0 110.508 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.688 HG21 HG12 ' A' ' 103' ' ' VAL . 95.2 t -70.88 108.02 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.826 -179.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.54 ' HG2' ' HD1' ' A' ' 65' ' ' TRP . 87.7 tttt -61.66 -47.81 83.65 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.073 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.54 ' HD1' ' HG2' ' A' ' 64' ' ' LYS . 58.1 p-90 -177.1 138.94 0.26 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.602 -1.181 . . . . 0.0 109.942 178.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -136.07 117.57 14.8 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -100.59 119.68 38.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.004 0.43 . . . . 0.0 110.907 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.437 HG21 ' N ' ' A' ' 139' ' ' ALA . 65.3 t -62.18 -46.33 96.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.87 -0.604 . . . . 0.0 111.422 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.13 -46.16 90.6 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -61.41 -39.23 89.98 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.924 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 94.61 1.93 63.6 Favored Glycine 0 CA--C 1.532 1.097 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.349 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -148.21 161.22 41.91 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 117.505 0.653 . . . . 0.0 110.062 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 86' ' ' VAL . . . -159.48 -177.91 33.0 Favored Glycine 0 CA--C 1.524 0.616 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.568 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.461 ' CZ ' ' C2 ' ' B' ' 303' ' ' ' DC' . 81.5 m-85 -129.24 143.96 51.04 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.425 HG13 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -116.93 123.42 71.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.814 178.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -91.11 109.12 20.37 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.486 -0.485 . . . . 0.0 110.933 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.423 ' O ' ' N ' ' A' ' 81' ' ' LYS . 81.3 mtp180 -63.64 130.29 43.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.083 178.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -74.99 -26.86 59.88 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.358 179.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 62.8 t0 -70.77 -41.78 71.27 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-O 120.905 0.383 . . . . 0.0 110.224 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 71.2 p -104.49 -11.14 17.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.675 -178.173 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . 0.423 ' N ' ' O ' ' A' ' 77' ' ' ARG . 98.6 mttt 55.86 31.19 17.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.927 0.394 . . . . 0.0 110.043 -178.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -120.45 145.84 46.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.225 179.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -70.31 147.22 49.91 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.073 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 122' ' ' ALA . 88.3 t -130.12 132.53 65.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.816 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -66.31 138.29 57.52 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.328 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.425 HG11 HG13 ' A' ' 75' ' ' ILE . 7.7 p -151.44 149.88 13.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.232 0.539 . . . . 0.0 110.879 179.012 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -133.48 155.38 49.65 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.83 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 27.2 pt20 -60.9 -25.52 66.79 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 63.2 p -79.56 -13.05 59.8 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.479 178.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.24 1.56 55.53 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.119 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.46 HD11 HG23 ' A' ' 103' ' ' VAL . 78.8 mt -93.91 108.9 21.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.847 0.356 . . . . 0.0 111.202 -178.239 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -64.32 -43.11 95.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.318 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -123.85 138.98 54.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.147 -178.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -144.91 157.19 44.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.476 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -56.98 120.15 36.18 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.83 -32.23 94.4 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.015 1.81 . . . . 0.0 112.581 179.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -62.41 -21.79 65.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.418 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -85.62 127.59 34.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 120.693 0.282 . . . . 0.0 110.623 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -65.46 -39.47 92.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.795 -179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.529 HD12 ' O ' ' A' ' 140' ' ' ALA . 85.0 mt -118.3 150.32 39.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.254 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -63.15 136.8 57.97 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.7 p -159.38 163.05 35.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.495 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 63' ' ' VAL . 54.9 t -125.72 128.39 72.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -65.66 138.62 38.1 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.274 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.01 135.76 38.68 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 80.57 3.19 90.15 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.425 ' O ' HG23 ' A' ' 63' ' ' VAL . 51.6 tp10 -92.36 128.45 38.21 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 121.002 0.429 . . . . 0.0 110.537 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.6 m -68.16 132.99 48.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.674 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.99 158.04 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.235 -0.586 . . . . 0.0 111.394 -178.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -117.37 134.4 54.87 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.153 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.438 ' HB3' HG22 ' A' ' 125' ' ' VAL . 39.8 p90 -158.75 162.2 37.08 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.819 -0.753 . . . . 0.0 112.586 -177.61 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -88.88 144.09 26.44 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.25 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.3 123.78 59.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 C-N-CA 120.567 -0.453 . . . . 0.0 109.987 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 53' ' ' LYS . 14.6 p -121.11 134.52 64.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -61.69 126.85 28.8 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.554 -0.459 . . . . 0.0 110.968 -178.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -109.42 167.42 12.87 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 52.6 tp10 -60.97 -43.91 98.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.719 0.295 . . . . 0.0 110.945 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -90.72 -18.19 25.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.403 -178.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 164.34 -171.54 39.88 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -61.96 143.65 56.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.944 0.402 . . . . 0.0 110.437 -179.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -126.63 154.54 43.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.726 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 84' ' ' VAL . . . -105.96 143.49 34.03 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.034 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.13 157.71 43.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.184 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 55.4 49.48 16.81 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.939 0.4 . . . . 0.0 110.07 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 111' ' ' PHE . 86.7 t -75.8 125.17 35.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.14 -179.152 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.6 p -137.5 163.57 30.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.76 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.4 165.76 54.17 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 131' ' ' VAL . 32.8 Cg_exo -59.6 136.05 68.41 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.962 1.774 . . . . 0.0 112.154 -178.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 73.3 19.44 79.65 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 178.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.36 1.59 90.31 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 128' ' ' PRO . 90.4 t -60.96 139.06 94.09 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-O 119.692 -0.194 . . . . 0.0 110.572 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . 0.416 ' HD2' HG13 ' A' ' 131' ' ' VAL . 24.0 Cg_endo -60.69 149.06 89.5 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.679 1.586 . . . . 0.0 111.323 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 77.6 t -70.28 128.81 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.55 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.2 tp60 -61.07 -39.99 91.98 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.534 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.14 -175.71 53.82 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 65.4 m -107.54 155.65 19.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.59 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -62.64 -35.52 79.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.493 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -62.11 -13.65 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.099 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.46 ' O ' ' HB2' ' A' ' 140' ' ' ALA . . . -56.79 137.97 53.9 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.468 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.529 ' O ' HD12 ' A' ' 100' ' ' LEU . . . . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.641 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 301' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.513 -1.471 0 O4'-C4'-C3' 107.037 1.437 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 302' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.52 -0.822 0 O4'-C1'-C2' 107.582 1.348 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 303' ' ' ' DC' . . . . . 0.606 ' O2 ' " O4'" ' B' ' 303' ' ' ' DC' . . . . . . . . 0 O4'--C4' 1.43 -1.433 0 O4'-C4'-C3' 103.428 -2.172 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 304' ' ' ' DA' . . . . . . . . . . . . . . . . . . . . 0 C4'--C3' 1.519 -0.893 0 P-O3'-C3' 120.357 0.547 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 305' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.425 -0.907 0 O4'-C1'-C2' 107.218 1.017 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 306' ' ' ' DC' . . . . . . . . . . . . . . . . . . . . 0 C3'--C2' 1.531 1.31 0 C4'-C3'-C2' 104.885 1.685 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 307' ' ' ' DT' . . . . . . . . . . . . . . . . . . . . 0 O5'--C5' 1.427 -0.785 0 O4'-C4'-C3' 104.73 -0.87 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_